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A b s t r a c t
ABSTRACT
The cytokine IFN-y regulates the expression of numerous genes in macrophages, 
including many that are implicated in atherosclerotic processes. Studying the 
signalling mechanisms involved in the mediation of IFN-y responses may lead to the 
identification of future therapeutic targets for the treatment of atherosclerosis.
Previous work in our laboratory revealed a role for the kinase CK2 in modulating the 
expression of the LPL and ICER genes in response to IFN-y. Experiments detailed in 
this report show that the CK2 inhibitor apigenin inhibited the IFN-y-mediated 
induction of each gene in the group selected for study (ICER, MCP-1, SOCS-1, IP-10, 
Mig, l-TAC, CCR2), suggesting that there may be a common role for CK2 in the 
regulation of macrophage gene expression by the cytokine. The PI3K inhibitor 
LY294002 has also previously been found in our laboratory to prevent the IFN-y- 
mediated suppression of LPL expression. In this study LY294002 selectively 
inhibited the induction of MCP-1, IP-10, Mig, l-TAC, and CCR2 expression by IFN-y 
but not that of ICER or SOCS-1. Extension of this line of investigation through 
microarray analysis provided further evidence for a gene-specific requirement for 
PI3K in mediating IFN-y responses.
The signalling pathways involved in the regulation of MCP-1 and ICER gene 
expression by IFN-y were chosen for more detailed study. The JAK-STAT pathway is 
the most widely accepted mechanism of IFN-y signalling. However, recent studies 
have suggested the existence of potential STATl-independent pathways. The 
functions of CK2 and PI3K were investigated, in relation to a STAT1-dependent or -  
independent mechanism of IFN-y signalling, in the regulation of MCP-1 and ICER 
expression.
A role for the JAK-STAT pathway in the regulation of MCP-1 expression by IFN-y was 
revealed, in macrophages, through co-transfection studies with inactive mutant 
forms of JAK1, JAK2 and STAT1. Promoter binding analyses demonstrated that IFN- 
y induced the binding of STAT1 to a GAS site in the MCP-1 promoter. PKB was 
found to act as a downstream effector for PI3K in the IFN-y-mediated induction of 
MCP-1. Both CK2 and PI3K/PKB were found to be involved in the IFN-y-mediated 
activation of STAT1 through phosphorylation at Serine 727. Additionally, 
constitutive S p l protein binding to the MCP-1 promoter was demonstrated. Co- 
immunoprecipitation revealed an IFN-y-inducible interaction between S p l and 
STAT1 that may function in the cytokine response.
In our laboratory CK2 has previously been shown to phosphorylate CREB in 
response to IFN-y. A luciferase reporter construct containing four tandem CRE 
consensus elements, used to model the ICER promoter that contains four CRE-like 
sites, showed inducible activation by IFN-y, through CK2. The JAK2 inhibitor AG490, 
and dominant negative forms of JAK1, JAK2 and STAT1, did not attenuate increases 
in ICER expression in response to IFN-y. These findings indicate that CREs 
represent a novel class of IFN-y-responsive element and that the regulation of ICER 
expression may occur through CK2 in a JAK-STAT-independent pathway.
Together these studies have demonstrated novel roles for the kinases CK2 and 
PI3K in the regulation of macrophage gene expression by IFN^y.
xi
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CHAPTER 1. INTRODUCTION
1.1 In troduction
The rising incidence of obesity in the Western world is accompanied by an increase 
in the proportion of the population affected by coronary artery disease (CAD). There 
is therefore an ever increasing demand for new therapies for the combat of 
coronary conditions. Atherosclerosis is a primary cause of CAD, characterised by 
the formation of a lipid-filled plaque within the wall of large arteries. One of the 
major risk factors for the disease is the presence of high levels of cholesterol in the 
blood. The development of the cholesterol-lowering drugs statins, in the past ten 
years, has had a dramatic benefit in reducing the incidence of the disease in high 
risk individuals (Grundy 1998). However there is still a need for new and more 
effective treatments for atherosclerosis.
The development of the atherosclerotic lesion is a chronic inflammatory process 
and is governed by a complex network of signalling pathways. Although statins may 
have some antiinflammatory effects, the therapeutic strategies currently in place 
largely ignore the inflammatory component of the disease (Lefer 2002). The study 
of signalling mechanisms involved in the regulation of gene expression by 
inflammatory cytokines, with respect to atherosclerosis, offers the opportunity to 
uncover potential targets for therapeutic intervention in the future. The focus of this 
thesis is the mechanisms by which the proinflammatory cytokine interferon (iFN)-y 
regulates gene expression. In particular, the role of IFN-y in inducing the expression 
of the proatherogenic chemokine monocyte chemoattractant protein (MCP)-1 was 
studied in detail.
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1.2 Cytokines
Cytokines are small, regulatory proteins (most below 30kDa in size) with pleiotropic 
actions, particularly in the regulation of the immune system and the inflammatory 
response. White blood cells secrete numerous cytokines although they are also 
produced by a variety of other cells in the body. Constitutive expression of cytokines 
is usually low, a range of stimuli inducing transient production. Typically cytokines 
act over short distances by binding to specific cell surface receptors and causing 
changes in the pattern of gene expression. Cytokines exert a multitude of actions 
on a variety of cells, including regulation of cell proliferation, changes in the state of 
differentiation, chemotaxis and other effects on the inflammatory response (Vilcek 
2003).
It is possible to group cytokines into families on the basis of their structural 
features. Families include: interleukins (IL-1 to IL-26); interferons (e.g. IFN-a, IFN-(3, 
IFN-co and IFN-y); chemokines (chemotactic cytokines) (CC, CXC, C, and CX3C 
subfamilies); tumor necrosis factors (e.g. TNF-a); transforming growth factor-p 
family (e.g. TGF-p, bone morphogenetic proteins (BMPs)); and other growth factors 
(e.g. platelet-derived growth factor (PDGF), epidermal growth factor (EGF)) (Table 
1.1) (Vilcek 2003).
There is a high degree of functional redundancy among the different cytokines and 
cytokines that are structurally very distinct often exhibit similar effects (e.g. TNFa 
and IL-1 (Zhao etal. 2003, Le and Vilcek 1987)). There are also many examples of 
cytokines acting synergistically (e.g. TNF-a and IFN-y in the regulation of lipoprotein 
lipase (LPL) (Tengku-Muhammad et al. 1998) or ICAM-1 expression (Jahnke and 
Johnson 1994); IL-18 with IL-2 or IL-12 in the induction of Th l/Th2 cytokine 
expression (Rodriguez-Galan 2005)) or antagonistically (e.g. IL-4 and IFN-y in the 
regulation of iNOS expression (Jungi et al. 1997), or collagen biosynthesis 
(Sempowski et al. 1996); IL-1 and TGF-p observed over genome wide gene 
expression analysis (Takahashi et al. 2005a)). In the inflamed tissue a large 
number of cytokines are present and the network of interactions between them is 
likely to be extremely complex.
3
Ch a pter  one: In tr o d u c tio n
Table 1.1 Division of cytokines into families based on structural features
Chemokines CC subfamily (CCL1-28) 
CXC subfamily (CXCL1-16) 
C subfamily (XCL1-2) 
CX3C subfamily (CX3CL1)
IL-1 IL -la
IL-ip
IL-1 receptor antagonist 
IL-18
IL-10 IL-10
IL-19
IL-20
IL-22
IL-24 (MDA-7)
IL-17 IL-17
IL-25
IL-2/IL-4 IL-2 
IL-A 
IL-5
GM-CSF
IL-6/IL-12 IL-6
IL-12
IFNs IFN-a
IFN-P
IFN-e
IFN-k
IFN-<d
IFN-y
IFN-t
IFN-X(l-3)
TGF-P TGF-P
BMPs
Inhibins
Activins
Tumor necrosis factors TNF-a
LT-a (TNF-p) 
LT-p
Fas ligand
CD40 ligand
TRAIL
BAFF
APRIL
RANK
LIGHT
Abbreviations: APRIL apoptosis-inducing ligand; BAFF, B-cell activating factor belonging to the TNF 
family; BMP, bone morphogenetic protein; CD40, complementarity determinant 40; IL. interleukin; 
IFN, interferon; LIGHT, homologous to lymphotoxins, inducible expression, competes with HSV 
glycoprotein D for HVEM/TR2; LT, lymphotoxin; MDA-7, melanoma-differentiation associated gene-7; 
RANK, receptor activator of NF-kB; TGF, transforming growth factor; TNF, tumor necrosis factor 
TRAIL TNF-a related apoptosis inducing ligand (adapted from Vilcek 2003).
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1.3 In te r fe ro n ^
The interferon (IFN) family of cytokines is divided into Type I IFNs (IFN-a, IFN-p, IFN- 
e, IFN-k, IFN-co, IFN-i), Type II IFNs (IFN-y) and the more recently discovered Type III 
IFNs (IFN-M-3). Type I IFNs share notable sequence homology and are synthesised 
by most cell types (Meager 1998). Type II IFN, IFN-y is molecularly distinct from the 
Type I IFNs and functions through a separate receptor (IFN-yR). IFN-y is produced 
predominantly by natural killer (NK) cells and activated T-lymphocytes but can also 
be produced by monocytes/macrophages, NKT cells, B cells and dendritic cells. 
(Schroder et al. 2004, Freucht et al. 2001, Gessani and Bellardelli 1998). It is 
homodimeric, composed of two identical a-subunits, with secondary structure 
consisting mostly of a-helix with no p-sheet (Ealick et al. 1991). The biological and 
pathological roles of IFN-y are discussed in more detail in the following sections. 
Type III IFNs are relatively uncharactised but function through a distinct receptor to 
that used by either Type I or II IFNs (Bartlett et al. 2005).
1.3.1 Biological functions of IFN^y
IFN-y has a multitude of functions, displaying direct antiviral activity through the 
inhibition of several stages of viral replication, as well as a variety of 
immunomodulatory and inflammatory roles. Mice with defective IFN-y genes or 
lacking IFN-yR develop with no obvious morphological defects but display an 
increased susceptibility to bacterial and viral infection (van den Broek et al. 1995, 
Dalton et al 1993). Specific actions of IFN-y signalling in inflammation and the 
immune system include: stimulation of antigen presentation through induced
expression of Class I and II major histocompatibility complex (MHC) molecules on 
the surface of macrophages and T-lymphocytes; antigen processing; control of 
Thl/Th2 balance (primarily through inhibition of Th2 proliferation); the activation of 
macrophages, T-lymphocytes and NK cells by inducing the production of reactive 
oxygen intermediates and hydrogen peroxide to enhance the killing of intracellular 
parasites; stimulation of cytokine production in target cells; and recruitment of cells 
to the site of injury through increased expression of chemokines and adhesion 
molecules (Schroder et al. 2004, Tau and Rothman 1999, Stark et al. 1998, 
Boehm etal. 1997).
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Cellular state is also influenced by IFN-y, including regulation of the rate of 
proliferation, differentiation and apoptosis. In general IFN-y inhibits cell growth by 
modulating the expression of certain genes linked to the cell cycle (e.g. c-myc 
(Ramana et al. 2000)), and can either induce or suppress apoptosis depending on 
the cell type or state of differentiation (Schroder et al. 2004, Tau and Rothman 
1999, Stark et al. 1998, Boehm et al. 1997). Table 1.2 summarises the biological 
roles of IFN-y.
Table 1.2 Biological roles of IFN^ y
Anti-viral activity Inhibition of viral replication
Immunomodulation Stimulation of antigen presentation and processing 
Control of Thl/Th2 balance
Inflammation Recruitment of inflammatory cells 
Stimulation of cytokine production
Regulation of cellular state Inhibition of proliferation 
Regulation of differentiation 
Regulation of apoptosis
Activation of macrophages, T-lymphocytes and NK cells
1.3.2 Pathological functions of IFN-y
The pathogenesis of several autoimmune diseases is accelerated by IFN-y including 
multiple sclerosis, Typel diabetes mellitus and HIV infection (reviewed in Billau 
1996) and anti-IFN-y has been suggested as a potential treatment for these 
conditions (Skurkovich and Skurkovich 2003). Multiple sclerosis is associated with 
a systemic increase in IFN-y and adminstration of the cytokine to patients with the 
disease increases the exacerbation rate (Panitch et al. 1989, Panitch 1992, 
Navikas and Link 1996, Link etal. 1994). Patients with diabetes mellitus have also 
been shown to have elevated levels of the cytokine in blood plasma (Ozer et al. 
2003). Non-obese diabetic (NOD) mice in which the IFN-yR gene has been knocked- 
out exhibit a marked inhibition of insulitis and display no signs of diabetes (Wang et 
al. 1997). Disruption of the IFN-y gene in these mice has also been shown to delay 
the onset of diabetes (Serrez et al. 2005). Treatment of NOD mice with anti-IFN-y 
antibodies, or a nonimmunogenic form of IFN-yR that similarly binds and neutralises
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the cytokine, results in decreased insultis (Nicoletti et al. 1996, Campbell et al. 
1991). In individuals infected with HIV, raised levels of IFN-y have been found in 
the blood serum and lymph nodes and the cytokine can act as an inducer of HIV 
expression in monocytes (Boyle etal. 1993, Biswas eta/. 1992, Griffin etal. 1991).
Antitumor activity has been well documented for IFN-y. IFN-yR-null mice are highly 
susceptible to chemical carcinogenesis (Kaplan et al. 1998) and treatment with 
IFN-y has been found to result in increased survival rates in animal models of 
tumorigenesis (Peyregne et al. 2004, Gansbacher et al. 1990). The tumor 
suppressive effects of IFN-y may be due to the antiproliferative and proapoptotic 
effects of the cytokine and the promotion of the other immune responses (Ruiz de 
Almodovar et al. 2004, Wagner et al. 2004, Ikeda et al. 2002, Detjen et al. 2001, 
Dighe et al. 1994, Hawkyard et al. 1992). Several clinical studies have examined 
the use of recombinant IFN-y as an anticancer therapy. In some cases patients 
exhibited tumor regression following IFN-y treatment (Pujade-Lauraine et al. 1996, 
Boutin eta l. 1994, Ellerhorst eta l. 1994, Kurzrock etal. 1985), however, a number 
of trials have shown no significant effect (Elhilali et al. 2000, Gleave et al. 1998, 
Jett et al. 1994). The cytokine may also be associated with a cancer related 
disorder, cachexia, involving weight loss and anaemia. In this case IFN-y treatment 
of mice with the condition accelerates weight loss (Ramos et al. 2004, Mattys et al. 
1991).
The role of IFN-y in the immune system and inflammation means that it is likely to 
have a role in disorders associated with a chronic inflammatory reaction. For 
instance, differential expression of IFN-y has been linked to the pathology of 
glomerulonephritis (Kitching et al. 1999), rheumatoid arthritis (Canete et al. 2000) 
and pancreatitis (Uehara et al. 2003, Xie et al. 2001). While this report will 
concentrate on the implications for the development of atherosclerosis, several of 
the key functions contributing to disease progression may be applicable to other 
inflammatory conditions.
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1.4 Importance o f IFN-y in A therosclerosis
1.4.1 Atherosclerosis
Atherosclerosis is a chronic, progressive disorder characterised by the development 
of a complex, lipid filled plaque in the artery wall. Complications arising from 
atherosclerosis, including myocardial infarction and stroke, are the principal cause 
of death in Western societies. It is a multifactorial disease in which genetic 
predisposition, age, stress, physical inactivity, dietary habits, diabetes, infection, 
smoking, hypercholesterolemia and hypertension are some of the main risk factors 
(Glass and Witztum 2001, Libby 2000, Lusis 2000, Ross 1999).
The pathology of atherosclerosis can be broken down simplistically into three 
distinct phases: formation of fatty streaks: development of a complex lesion; and 
plaque rupture (Figure 1.1). In the course of the disease monocytes and T- 
lymphocytes migrate from the circulation into the intima of the arterial wall. The 
monocytes in the intima differentiate into macrophages, which then take up 
modified lipoproteins to transform into foam cells. Fatty streaks, often present in 
humans even from childhood, consist of an accumulation of such cholesterol-filled 
foam cells (Figure 1.1A). The more advanced, complex lesion develops as smooth 
muscle cells (SMCs) from the arterial media migrate into the intima. Here they may 
also take up lipoproteins to become foam cells (Figure 1.1B). A fibrous cap, 
consisting of SMCs and extracellular matrix (ECM), then forms, that encloses a 
necrotic core of lipid-rich debris that results from the death of accumulated foam 
cells (Glass and Witztum 2001, Libby 2000, Lusis 2000, Ross 1999). Other 
features of the complex plaque can include calcification and neovascularisation. 
Neovascularisation is thought to contribute to plaque instability and also provide a 
route by which cells can continue to enter the lesion even after the fibrous cap 
becomes impossible to penetrate (Lord and Bobryshev 2002).
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Figure 1.2A LDL is oxidised in the subendothelial space, progressing from 
minimally modified LDL (mmLDL) to oxidised LDL (oxLDL). OxLDL and 
inflammatory cytokines induce expression of cell adhesion molecules on the 
endothelial surface, mediating attachment of monocytes. Monocytes migrate 
into the subendothelial space and differentiate into macrophages. Uptake of 
oxLDL via scavenger receptors leads to foam cell formation. Within the 
macrophage oxLDL cholesterol is esterified and stored in lipid droplets, 
converted to more soluble forms, or is exported to extracellular HDL acceptors 
(adapted from Glass and Witztum 2001).
Figure 1.2B Interactions between macrophage foam cells and Th l/Th2 cells 
establish a chronic inflammatory process. Cytokines secreted by lymphocytes 
and macrophages exert both pro- and antiatherogenic effects on cells of the 
vessel wall. Smooth muscle cells (SMCs) migrate from the media, proliferate 
and secrete extracellular matrix (ECM) proteins to form a fibrous cap enclosing 
macrophage foam cells (adapted from Glass and Witztum 2001).
Figure 1.2C Necrosis of macrophage and SMC-derived foam cells leads to the 
formation of a necrotic core and accumulation of extracellular cholesterol. 
Macrophage secretion of matrix metal loproteinases (MMPs) and 
neovascularisation contribute to weakening of the fibrous plaque. Plaque 
rupture exposes blood components to tissue factor, initiating coagulation, the 
recruitment of platelets and the formation of a thrombus (adapted from Glass 
and Witztum 2001).
Abbreviations: ABCA1, ATP-binding cassette transporter A l; ACAT, acyl-CoA:cholesterol 
acyltransferase; apoE, apolipoprotein E; CCR2, CC chemokine receptor 2; CD36, 
complementarity determinant 36; CS-1, connecting segment-1; E-selectin, endothelial-selectin; 
HDL, high density lipoprotein; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; IFN, 
interferon; iNOS, inducible nitric oxide synthase; LDL, low density lipoprotein, 15-LO, 15- 
lipoxygenase; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage-colony 
stimulating factor, mmLDL, minimally modified LDL; MMP, matrix metalloproteinase; oxLDL, 
oxidised LDL; P-selectin, platelet-selectin; SR-A, scavenger recptor-A; Th, T helper; VCAM-1, 
vascular cell adhesion molecule-1.
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Growth of the lesion into the arterial lumen often leads to alterations in blood flow 
and ischemia. However it is the eventual rupture of the plaque that causes clinical 
complications as exposure to tissue factor in the necrotic core initiates the 
coagulation cascade and leads to thrombosis formation (Figure 1.2C). Vulnerable 
plaques usually have very thin fibrous caps and a higher number of inflammatory 
cells. The maintenance of the fibrous cap is dictated by the production of ECM 
components, predominantly by SMCs, and the action of matrix degrading enzymes 
(Lord and Bobryshev 2002, Lee and Libby 1997, Davies etal. 1993).
1.4.2 Response to injury hypothesis
The “response to injury” hypothesis is a widely accepted model for atherogenesis. 
The disease is currently considered as an initially protective, inflammatory response 
to the accumulation of modified lipoproteins in the artery (the “injury”) (Glass and 
Witztum 2001, Lusis 2000, Ross 1999). Although many risk factors are believed to 
influence the progression of atherosclerosis, hypercholesterolemia is undoubtedly 
the most important, being sufficient in itself to drive lesion formation (Steinberg 
2002). Hypercholesterolemia can arise due to genetic predisposition (e.g. in 
familial hypercholesterolemia) (Lusis et al. 2004) or as a result of various lifestyle 
factors including a high fat diet or lack of exercise.
Cholesterol is carried in the bloodstream by several lipoprotein particles: 
chylomicrons; very low-density lipoprotein (VLDL); low-density lipoprotein (LDL); and 
high-density lipoprotein (HDL). LDL transports the majority of serum cholesterol in 
humans. Elevated levels of serum cholesterol lead to the deposition of LDL in the 
arterial wall (Navab et al. 1996). Native LDL would not accumulate rapidly enough 
through normal transport pathways to form foam cells. It is the oxidation of LDL by 
reactive oxygen species (ROS) and oxidative enzymes in the intima that is thought to 
be the primary intiating event in atherosclerosis development (Skalen 2002, Cyrus 
et al. 1999, Navab et al. 1996, Goldstein et al. 1979). Oxidatively modified LDL 
(oxLDL) acts both as an inflammatory mediator itself; capable of stimulating the 
recruitment of inflammatory cells, and by inducing an inflammatory response in 
overlying endothelial cells (ECs) (Navab et al. 1996, McMurray et al. 1993, Yui 
1993, Quinn etal. 1987).
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1.4.3 Role of endothelial cells in atherosclerosis
In response to oxLDL and cytokines within the intima, the endothelium becomes 
more permeable and displays increased levels of cell adhesion molecules including 
vascular cell adhesion molecule-1 (VCAM-1) (Cybulsky and Gimbrone 1991), 
intercellular adhesion molecule-1 (ICAM-1) and P- and E-selectins (Collins et al. 
2000, Dong et al. 1998). The endothelium also produces a range of vasoactive 
molecules, cytokines, chemokines and growth factors. These include IL-1, IL-18, 
TNF-a, IL-8, MCP-1, macrophage-colony stimulating factor (MCSF), PDGF and TGF-p. 
This response leads to increased leukocyte adhesion to the endothelium and the 
extravasation of monocytes and T-lymphocytes into the intima, contributing to lesion 
development. The further release of cytokines, chemokines and growth factors by 
these cells enhances the endothelial response. Certain cytokines (e.g. IL-3, IL-18) 
and chemokines (e.g. IL-8, MCP-1) stimulate the proliferation of ECs and promote 
angiogenesis (Raines and Ferri 2005, Grainger 2004a, Fazio and Linton 2001, Ross 
1999).
An important regulator of EC gene expression is shear stress, controlling transcription 
through shear stress regulatory elements (SSREs) (consensus sequence: GAGACC) in 
the promoter regions of target genes. The endothelium appears to be sensitive to 
different flow forms in the artery which cause varying patterns in gene expression. 
Steady laminar flow is characterised as atheroprotective, and disturbed flow as an 
atheroprone waveform. This is important in explaining the prevalence of 
atherogenesis at particular arterial sites, such as branches or curvatures where the 
blood flow is altered. These sites display an increased accumulation of T-cells and 
NKT cells; high concentrations of inflammatory cytokines; and increased permeability 
of the endothelium to lipoprotein molecules. Plaques forming in these regions often 
have a high cellularity and are predisposed to the generation of thin fibrous caps 
prone to rupture. Gene array analysis has shown that atheroprone waveforms 
upregulate the expression of cell surface adhesion molecules (e.g. VCAM-1, ICAM-1, 
E-selectin), chemokines and chemokine receptors (e.g. MCP-1, IL-8, CXCR4), pro- and 
antioxidant enzymes (lipoxygenases, nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, superoxide dismutase (SOD), nitric oxide synthase (NOS)), and 
matrix degrading enzymes (e.g. MMP-1) in ECs (Dai et al. 2004, Vanderlaan et al. 
2004, Brooks etal. 2002, Chen etal. 2001, Gimbrone 1999).
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1.4.4 Role of monocytes and macrophages in atherosclerosis
Monocytes and macrophages are present at all stages of lesion development and 
make up about 60-70% of cells in the advanced plaque. They have a 
multifunctional role in the progression of the lesion (reviewed in Takahashi et al. 
2002). Monocytes recruited to the site of inflammation infiltrate the artery wall 
where they are propagated and differentiate into macrophages in response to 
stimulation by M-CSF (Watanabe et al. 1995). OxLDL has been shown by 
microarray analysis, to induce the expression of a number of chemokines and other 
cytokines in macrophages that contribute to inflammation within the lesion and the 
further recruitment of immune cells (Mikita et al. 2001). Initially the recruitment of 
macrophages acts as a protective mechanism through the uptake and therefore 
removal of the injurious agent, oxLDL. However macrophage uptake of modified 
lipoproteins ultimately leads to foam cell formation and atherogenesis. 
Phagocytosis of cholesterol-loaded apoptotic cells by macrophages leads to further 
accumulation of lipid within these cells (Li and Glass 2002, Kruth 2001). Mice 
carrying a mutation in the M-CSF gene (the osteopetrotic mutation) have very low 
circulating numbers of macrophages. When crossed with apoE-deficient mice (that 
rapidly develop atherosclerotic lesions on a high cholesterol diet) the offspring show 
a high resistance to the development of atherosclerotic plaques, supporting a 
proatherogenic view of macrophages (Smith etal. 1995).
1.4.4.1 Macrophage foam cell formation
The uptake of oxLDL to form foam cells is mediated predominantly through 
scavenger receptors on the macrophage surface. The most important of these in 
atherosclerosis are scavenger receptors A (SR-A) and CD36 (Yamada et al. 1998, 
Suzuki et al. 1997), both of which are upregulated by exposure to oxLDL (Nakgawa 
etal. 1998, Yoshida eta l. 1997). The LDL receptor (LDL-R) also initially contributes 
to lipid loading by binding to minimally modified LDL (mmLDL). However, LDL-R is 
downregulated by the sterol regulatory element-binding protein (SREBP) pathway as 
cholesterol accumulates, while scavenger receptors continue to take up increasing 
amounts of lipoprotein (Goldstein et al. 2002, Brown and Goldstein 1999). The 
VLDL receptor (VLDL-R) and LDL-R-like protein (LRP) are also upregulated in
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atherosclerotic lesions and may contribute to the pathogenesis of the disease as 
they have a high affinity for atherogenic remnant particles and are involved in the 
uptake of modified LDL (Schulz et al. 2003, Kosaka et al. 2001, Hiltunen et al. 
1998).
As macrophage levels of cholesterol increase, efflux mechanisms may maintain 
homeostasis for a short while largely through a process known as reverse 
cholesterol transport. One of the principal components of this system is the ATP- 
binding cassette transporter A l (ABCA1), that mediates transfer of cholesterol from 
the cell to HDL, a role that makes HDL highly atheroprotective (reviewed in Tall etal. 
2002). ApoE-null mice transplated with ABCAl-deficient bone marrow cells showed 
significantly more atherosclerosis than those given wild type bone marrow (Aiello et 
al. 2003, Aiello etal. 2002). Ultimately however, in high concentrations of modified 
LDL, the macrophage fails to maintain an adequate cholesterol balance. The 
majority of cholesterol in foam cells exists in the form of cholesterol esters. In the 
absence of a suitable acceptor (such a HDL), the enzyme acyl coenzyme A: 
acylcholesterol transferase (ACAT) catalyses the formation of cholesterol esters 
from free intracellular cholesterol and long chain fatty acids. Raised levels of 
AC ATI, the isoform principally found in macrophages, are associated with these 
cells in the atherosclerotic plaque (Miyazaki et al. 1998). It was originally thought 
that knocking out the ACAT1 gene would be beneficial to atherosclerosis but apoE- 
null mice with this deletion exhibited atherosclerosis progression to a similar extent 
to those without it. Though the lesions had a reduced cholesterol content, deposits 
were found elsewhere including the brain (Fazio et al. 2001). Partial inhibition of 
ACAT activity however has been demonstrated to have an atheroprotective effect in 
apoE-null mice (Kusunoki etal. 2001).
1.4.4.2 Plaque destabilisation
Lendon et al. (1991) showed that lesions with a high macrophage density had 
weaker fibrous caps than less cellular lesions. Macrophages may contribute to the 
destabilisation of the plaque in a number of ways. As macrophage foam cells 
undergo apoptosis themselves, their contents contribute to the necrotic core (Li and 
Glass 2002). A correlation has been found between lesional macrophages 
expressing the marker of apoptosis, caspase 3, and high levels of expression of
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tissue factor. The release of prothrombotic molecules, such as tissue factor and 
complement proteins {e.g. complement C3b) produced by macrophages, into the 
necrotic core following foam cell apoptosis increases the thrombogenic potential of 
the plaque (Hutter et al. 2004, Takahashi et al. 2002). Macrophages also produce 
proteolytic enzymes, including matrix metalloproteinases (e.g. MMP-2, MMP-9) that 
act to weaken the fibrous cap and so lead to eventual plaque rupture (Galis et al.
1994).
1.4.5 Cytokines in atherosclerosis
The inflammatory component of atherosclerosis has come to prominence in recent 
years and cytokines have emerged as key regulators in the development of the 
atherosclerotic lesion. Cell types within the atheroma include 
monocytes/macrophages, ECs, SMCs, and T-lymphocytes as well as lower numbers 
of dendritic cells (DCs) and in some cases B-cells. A variety of cytokines and 
chemokines are secreted by each of these cell types within and around the site of 
plaque formation and they are involved in all stages of atherogenesis. Cytokines 
affect the recruitment of cells to the lesion through: chemotaxis; modulation of the 
expresson of cell adhesion molecules by ECs and SMCs; and the regulation of cell 
proliferation and migration in the atheroma. Cholesterol loading of foam cells is 
modulated by the cytokine-induced regulation of genes involved in the uptake of 
oxLDL. Cytokines also contribute to the overall stability of the lesion by regulating 
the expression of effectors of ECM turnover, and to thrombosis through the 
regulation of genes involved in coagulation cascades. Recent reviews discuss in 
detail the role of cytokines in the pathogenesis of atherosclerosis and other 
cardiovascular diseases (Mehra et al. 2005, Grainger 2004a, Young et al. 2002). 
In atherosclerosis the impact of proinflammatory stimuli (e.g. TNF-a, IL-12 and IL- 
18), that are predominantly proatherogenic (Branen etal. 2004, Elhage etal. 2003, 
Bruunsgaard et al. 2000, Lee et al. 1999), appears to outweigh that of anti­
inflammatory, antiatherogenic cytokines such as TGF-p and IL-10 (Grainger 2004b, 
Zimmerman et al. 2004, Mallat et al. 1999) triggering a chronic inflammatory 
response (Frostegard et al. 1999). However, the wide range of effects induced by 
each of these mediators means that a single molecule may have both pro- and anti­
atherogenic roles (e.g. IFN-y (Section 1.4.6)).
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1.4.6 Effects of IFN-? on atherogenesis
Among the cytokines, IFN-y is emerging as a key factor in the pathogenesis of 
atherosclerosis. Immunohistochemical studies have revealed the localisation of 
IFN-y to the atherosclerotic lesion where it is secreted primarily by activated T- 
lymphocytes (CD4+ T h l cells) and possibly macrophages (Gessani and Bellardelli 
1998, Hansson et al. 1989). Plaque formation is most likely to occur at vascular 
branch ponts where blood flow is altered. T h l cells, believed to be largely 
proatherogenic, accumulate in these regions and the expression of IFN-y is induced 
(Dai et al. 2004, Daugherty and Rateri 2002, Gimbrone 1999, van der Wal et al.
1994). More recently a key role for NKT cells, which exhibit the properties of both 
NK cells and T cells and secrete high levels of IFN-y, has been identified in 
atherosclerosis. Mice with low numbers of NKT cells display less atherosclerosis 
development than the wild type counterparts (Aslanian et al. 2005, Nakai et al. 
2004). IFN-y has a range of influences on disease progression, acting on all the 
major cell types of the plaque and the overall effect is complex. A large number of 
genes are directly or indirectly regulated by IFN-y including approximately 25% of 
the macrophage transcriptome (Ehrt et al. 2001). The expression of many such 
genes impacts on several areas of lesion development. While many of the changes 
in gene expression are proatherogenic there are also a number of key genes for 
which the regulatory effects of IFN-y are antiatherogenic.
1.4.6.1 Proatherogenic roles of IFN-y
1.4.6.1.1 Recruitment of immune cells to the lesion
Growth of the atheroma occurs largely through continued recruitment of 
macrophages and T-lymphocytes, and also SMC migration and proliferation. The 
lesions of apoE- or LDL-R-null mice deficient in IFN-y or its receptor have a 
dramatically reduced cellular content, indicating an important role for IFN-y in this 
recruitment (Buono et al. 2003, Gupta et al. 1997). The secretion of chemokines 
by lesional cells has an important role in the development of atherosclerosis, 
discussed in Section 1.5. IFN-y is responsible for the induction of a number of key
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chemokines and chemokine receptors including: MCP-1, M IP -la  and -p (Valente et 
al. 2001, Martin and Dorf 1991) and the receptors CCR5, CCR1 and CCR3 
(Hariharan etal. 1999, Zella etal. 1998); the CXC chemokines IP-10, Mig, l-TAC and 
CXCL16 (Wuttge et al. 2004, Cole et al. 1998, Farber 1997); and the CX3C 
chemokine fractalkine (Imaizumi etal. 2000).
The uptake of cells into the blood vessel intima at the site of the plaque also 
requires cell adhesion molecules displayed on the luminal surface of the 
endothelium. One of the earliest events in the development of the fatty streak is 
the upregulation of members of the immunoglobulin family of adhesion molecules 
including VCAM-1 and ICAM-1 (Collins et al. 2000, Cybulsky and Gimbrone 1991). 
IFN-y is an important mediator of this response, inducing the expression of both 
VCAM-1 and ICAM-1 in ECs and SMCs (Chung et al. 2002, Cybulsky et al. 1993). 
IFN-y also increases the expression of integrins such as a-5-p -l integrin, on the 
surface of VSMCs. This allows the cells to bind to the fibronectin component of the 
extracellular matrix (ECM) and hence provides a substrate for SMC migration to the 
lesion and causes the cells to adopt a proliferative phenotype (Barillari etal. 2001).
The majority of macrophages and T-cells in the atherosclerotic lesion are in an 
activated state whereby they are primed to respond to stimuli such as bacterial 
antigens (or in the lesion, oxLDL). For both cell types this involves the increased 
secretion of proinflammatory cytokines and chemokines so contributing to the 
inflammation and growth of the plaque. IFN-y is known to stimulate both the 
differentiation of monocytes to macrophages and macrophage activation (Nathan et 
al. 1983). Activation of CD4+ T-cells by IFN-y occurs through increased antigen 
presentation by MHC Class II molecules. While both Type I and Type II IFNs cause 
upregulation of MHC Class I antigens that present antigens for the activation of 
CD8+ T-cells, IFN-y alone induces MHC Class II expression involved in the activation 
of CD4+ T-cells (Thl). IFN-y increases the expression of MHC Class II molecules on 
the surface of a variety of cell types including ECs, macrophages and SMCs (Iwata 
etal. 2001, Mach etal. 1996, Jonasson etal. 1985).
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1.4.6.1.2 Cholesterol accumulation in foam cells
The uptake of cholesterol, in the form of oxLDL, by macrophages and SMCs to form 
lipid-loaded foam cells, is a key process throughout all the stages of plaque 
development. IFN-y has a regulatory effect on the expression of several genes that 
are key players in cholesterol metabolism, including the downregulation of ABCA1, 
apolipoprotein E and cholesterol hydroxylase and upregulation of ACAT (Reiss et al. 
2001, Panousis and Zuckerman 2000a, Panousis and Zuckerman 2000b, Brand et 
al. 1993) (Section 1.4.4.1). It appears that a general effect of IFN-y may be to 
increase the lipid loading of foam cells via a downregulation of cholesterol efflux 
pathways and up-regulation of mechanisms by which cholesterol accumulates (e.g. 
esterification through ACAT). Incubation of foam cells with IFN-y decreases HDL- 
mediated cholesterol efflux by approximately 2 fold and efflux to apoAl by more 
than 4 fold (independent of apoE or SR-B1 synthesis). Overall, treatment has been 
shown to result in a redistribution of intracellular cholesterol and an increase in 
cholesterol ester accumulation (Panousis and Zuckerman 2000a, Panousis and 
Zuckerman 2000b). More recently, IFN-y has been shown to impede reverse 
cholesterol transport and promote foam cell transformation in human THP-1 
monocytes/macrophages (Reiss etal. 2004).
14.6.1.3 Complex plaque formation and thrombosis
As the disease progresses, the atherosclerotic lesion becomes increasingly complex 
and the advanced plaque may include features such as calcification and 
neovascularisation (Lord and Bobryshev 2002). Neovascularisation and 
angiogenesis may be increased by IFN-y by the upregulation of certain chemokines 
(e.g. MCP-1). The cytokine may have a role in mechanisms of calcification through 
an increase in the expression of 1-a-hydroxylase. This enzyme is responsible for 
catalysing the conversion of 25-hydroxyvitamin D to l-<x, 25-dihydroxyvitaminD, an 
active metabolite of vitamin D that contributes to calcification (Esteban et al. 2004, 
Shoi etal. 2000).
Production of ECM components by SMCs contributes to the formation of a fibrous 
cap on the luminal side of the lesion. Beneath this cap, the advanced plaque 
contains a lipid filled necrotic core, formed as foam cells in the lesion die and
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release their contents. Cell death in the atherosclerotic lesion occurs primarily 
through the process of apoptosis. The function of IFN-y in apoptosis is complex and 
the cytokine can have either a pro- or antiapoptotic effect depending on the specific 
state of the cell (Schroder et al. 2004, Tau and Rothman 1999, Stark et al. 1998, 
Boehm et al. 1997). Inagaki et al. (2002) have shown that IFN-y stimulates the 
apoptosis of macrophage foam cells. Microarray studies have revealed a number of 
IFN-stimulated genes (ISGs) with apoptotic functions including TNF-a related 
apoptosis inducing ligand (TRAIL), Fas and caspases 4 and 8 in macrophages. 
Upregulation of caspases 1 and 3 by IFN^y has also been demonstrated in 
macrophages. In SMCs and monocytes an increase in susceptibility to apotosis and 
IL-lp-converting enzyme (ICE) expression has been observed in response to IFN-y 
treatment (Inagaki etal. 2002, Tamura etal. 1996, Chawla-Sarkar etal. 2003).
Certain factors contribute to the likelihood of plaque rupture, leading to the clinical 
complications of atherosclerosis, by affecting the composition and stability of the 
fibrous cap. IFN-y producing T h l cells frequently accumulate at the sites of plaque 
rupture and there are several mechanisms by which IFN-y can contribute to 
destabilisation of the plaque (van der Wal et al. 1994). The fibrous cap is 
composed principally of ECM components synthesised by SMCs, including elastic 
filament and proteoglycans with collagens providing most of the tensile strength. 
Lesions with a high foam cell content and low ECM have been shown to be more 
likely to rupture and cause thrombosis formation (Lee and Libby 1997, Davies et al.
1993). Increased cellularity of the lesion caused by exposure to IFN-y has already 
been discussed. Additionally the expression of a number of collagen genes (e.g. 
collagens 1 and 3), as well as SMC proliferation and matrix synthesis, is inhibited by 
IFN-y (Yuan etal. 1999, Amento etal. 1991, Hansson etal. 1988).
Matrix metalloproteinases (e.g. MMP-1, 2, 3 and 9) break down the ECM and thus 
cause plaque destabilisation (Galis et al. 1994). Activated T h l cells have been 
shown to stimulate increased production of these MMPs by macrophages and 
SMCs (Schonbeck et al. 1997). Tissue factor activity is also enhanced by IFN-y 
treatment, in synergy with C-reactive protein (CRP), so increasing the likelihood or 
rate of thrombosis following plaque rupture (Nakagomi et al. 2000).
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1.4.6.2 Antiatherogenic roles of IFN-y
Despite the range of proatherogenic functions of IFN-y discussed so far, certain 
modulations in gene expression caused by this cytokine appear to be 
atheroprotective. Treatment of monocyte/macrophage cells with IFN-y in vitro has 
been demonstrated, in some cases, to reduce both the oxidation of LDL and the 
uptake of oxLDL (Folcik et al. 1997, Christen et al. 1994, Fong et al. 1994, Fong et 
al. 1990). A recent study has also found that transplantation of IFN-y-deficient bone 
marrow in LDL-R-/- mice increases the extent of atherosclerosis development, 
suggesting that IFN-y secreted by bone marrow derived cells (T-lymphocytes and 
monocytes/macrophages) has an atheroprotective effect. Notably however the 
lesions in these mice had a high collagen content suggesting that they were less 
susceptible to rupture (Niwa et al. 2004). The seemingly contradictory pro- and 
antiatherogenic roles of IFN-y can be compared to the cytokine’s similarly conflicting 
pro- and antiinflammatory effects. While IFN-y is primarily considered to be a 
proinflammatory cytokine, it induces the expression of a number of anti­
inflammatory mediators (e.g. IL-1 receptor antagonist and IL-18 binding protein) in a 
range of cell types (Muhl and Pfeilschifter 2003).
1.4.6.2.1 Reduced uptake of oxLDL
In atherosclerosis, scavenger receptors, most significantly SR-A and CD36, are the 
principal mediators of oxLDL uptake in foam cell formation (Yamada et al. 1998, 
Greaves et al. 1998, Suzuki et al. 1997). IFN-y mediates inhibition of the 
expression of SR-A and CD36 in macrophages (although it increases expression in 
SMCs) and it is primarily to this effect that reductions in macrophage foam cell 
formation are attributed (Nakagawa etal. 1998, Gengand Hansson 1992). VLDL-R 
and LRP have also been implicated in atherosclerosis development through the 
uptake of modified LDL and atherogenic remnant particles (Schulz et al. 2003, 
Hiltunen et al. 1998). The expression of these receptors is similarly repressed by 
IFN-y (Kosaka etal. 2001, LaMarre etal. 1993).
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The physiological role of LPL in lipid metabolism is to catalyse the hydrolysis of the 
triacyl glycerol component of VLDL and chylomicrons to provide non-esterified fatty 
acids and 2-monoacylglycerol for tissue utilisation (Mead et al. 2002). LPL plays a 
compelx role in atherogenesis with both pro- and antiatherogenic actions being 
reported. The enzyme expressed by adipose tissue and muscle is considered to be 
antiatherogenic because it aids the clearance of circulating lipoproteins. On the 
other hand, LPL expressed by macrophages is proatherogenic. The main evidence 
for this comes from a series of bone marrow transplantation studies (reviewed in 
Stein and Stein 2003, Mead and Ramji 2002, Mead et al. 1999). For example, 
mice transplanted with LPL-null bone marrow (therefore producing LPL-deficient 
macrophages) exhibit decreased macrophage foam cell development in 
atherosclerosis (Babaev et al. 1999). It is believed that the lipolysis of VLDL and 
chylomicrons by LPL increases the formation of atherogenic lipoprotein remnants. 
Additionally, the enzyme on the surface of macrophages acts as a molecular bridge, 
assisting the uptake of oxLDL to form foam cells (Stein and Stein 2003, Mead and 
Ramji 2002, Mead et al. 1999, Zilversmit 1973). We have shown previously that 
IFN-y reduces LPL gene expression in macrophages at the transcriptional level, and 
this represents an atheroprotective effect (Hughes etal. 2002, Tengku-Muhammed 
etal. 1999a, Tengku-Muhammad 1996).
1.4.6.2.2 Effects on oxidative stress in the vascular wall
In certain studies, IFN-y has been found to inhibit macrophage-mediated LDL 
oxidation, a crucial step in the development of atherosclerosis (Folcik et al. 1997, 
Christen et al. 1994, Fong et al. 1994). IFN-y has various effects that may 
contribute to changes in oxidative stress in the vascular wall and thus affect the 
oxidation of LDL (Madamanchi 2005). Of particular importance is the regulation of 
nitric oxide (NO) production. Signalling by IFN-y, in particular in synergy with 
lipopolysaccharide (LPS) or other cytokines (e.g. TNF-a, IL-2, TGF-0, IL-4), leads to an 
upregulation of inducible NOS (iNOS) gene expression in a wide variety of cell types, 
including ECs, SMCs and macrophages (Yokoyama et al. 1996, Hukkanen et al.
1995). The subsequent increase in NO plays a role in mediating many of the 
antiviral and antimicrobial effects of IFN-y, participating directly in the killing of 
parasitic cells (Bogdan 2001).
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antiviral and antimicrobial effects of IFN-y, participating directly in the killing of 
parasitic cells (Bogdan 2001).
Increased generation of NO, which acts as a potent antioxidant, in response to IFN-y 
may be responsible for observations that the cytokine counteracts the oxidation of 
LDL (Jessup and Dean 1993). Indeed, iNOS-deficient mouse macrophages disclose 
a prooxidant effect of IFN-y on LDL oxidation (Niu et al. 2000). NO also has a 
number of other antiatherogenic effects, including: inhibition of immune cell 
recruitment to the lesion by counteracting the increase in VCAM-1 expression on 
ECs; blocking nuclear factor-kappa B (NF-kB) signalling which is important for many 
proinflammatory pathways; and decreasing the proliferation of VSMCs and both T- 
cell activation and proliferation, leading to reduced cytokine production (including 
IFN-y) (Gewaltigand Kojda 2002, Bodgan 2001, De Catarina etal. 1995, Peng etal.
1995). Knock-out of endothelial NOS (eNOS) in mice has been shown to increase 
atherosclerotic lesion formation (Knowles etal. 2000). It should, however, be noted 
that at high vascular concentrations of NO (appr. > lpM ), a reaction is promoted 
with superoxide to form peroxynitrite, an oxidant stronger than superoxide itself 
(Beckman and Koppenol 1996). In fact, where eNOS is overexpressed it has been 
shown to accelerate atherosclerotic lesion formation in apoE-deficient mice 
(Kawashima and Yokoyama 2004, Ozaki et al. 2002, O’Donnell and Freeman
2001). It has also been suggested that graft arteriosclerosis is promoted by IFN-y 
through the induction of iNOS expression leading to excessive production of NO 
(Mitchell and Lichtman 2004).
IFN-y also regulates the expression of a number of other genes implicated in the 
control of oxidative stress and the oxidation of LDL. A consensus on the action of 
such gene regulation has, however, not emerged as some effects are 
atheroprotective whereas others are proatherogenic. For example, IFN-y induces 
the expression of extracellular (EC)-SOD, which protects cells from oxidative stress 
via the removal of reactive oxygen species (ROS) (Stralin and Marklund 2000, 
Takahashi et al. 1998, Marklund 1992). In addition, the expression of 
myeloperoxidase, implicated in the development of atherosclerosis through the 
production of ROS, is suppressed by IFN-y (Zhang et al. 2001, Podrez et al. 2000,
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Kawano et al. 1993). Furthermore, IFN-y decreases the expression of 15- 
lipoxygenase, which has been linked to the oxidation of LDL (Li et al. 2005, 
Takahashi et al. 2005b, Fong et al. 1994, Conrad et al. 1992). On the other hand, 
the cytokine has been demonstrated to stimulate the secretion of ROS by 
macrophages, ECs and neutrophils (Tennenberg et al. 1993, Matsubara and Ziff 
1986, Murray et al. 1985). This may be because of the induced expression of 
vascular enzymes such as NADPH oxidase (Lopez et al. 2003, Obermeier et al. 
1995, Pfefferkorn etal. 1990) and xanthine oxidase (Ghezzi etal. 1984).
1.4.6.3 Mouse models
Compound-deficient mice in apoE and IFN-y or IFN-yR exhibit significant reductions 
in diet-induced atherosclerosis compared with apoE-null mice (Whitman et al. 
2002a, Gupta eta l. 1997). Recently, compound-deficient mice in LDL-R and IFN-y 
have also been shown to exhibit decreased atherosclerosis compared to LDL-R-null 
mice (Buono et al. 2003). Furthermore, administration of exogenous IFN-y 
enhances atherosclerosis in apoE-deficient mice and IL-18 has also been shown to 
enhance atherosclerosis in these mice through the release of IFN-y (Whitman et al. 
2002b, Whitman et al. 2000). Interestingly, IFN-y has been found to elicit 
arteriosclerosis in the absence of leukocytes, suggesting that a proatherogenic 
effect may be mediated through actions on VSMCs (Tellides et al. 2000). As 
mentioned previously, T h l and NKT cells, both of which secrete large amounts of 
IFN-y and localise to sites of lesion formation, have been shown through mouse 
models to be proatherogenic (Aslanian et al. 2005, Nakai et al. 2004, Daugherty 
and Rateri 2002). Inhibition of T h l polarization leading to decreased IFN-y 
secretion is also atheroprotective (Laurat et al. 2001). In a directly clinically 
relevant situation, there is a reduced incidence and severity of transplant 
arteriosclerosis following heart grafts in IFN-y-deficient mice (Raisanen-Sokolowski 
etal. 1998, Nagano eta l. 1997)
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Table 1.3 Pro- and antiatherogenic effects of IFN^ y
------------------- -
___________ ___________
Cell adhesion 
molecules (+)
(e.g. VCAM-1, ICAM-1)
EC
SMC
Recruitment 
inflammatory cells
Cybulsky et al. 1993  
Chung etal. 2002
SRs (-) 
(e.g. SR-A, 
CD36)
Macrophage Reduced uptake oxLDL Gengand 
Hansson 1992
Chemokines (+)
(e.g. MCP-1, M IP-la,
Macrophage
EC
Recruitment 
inflammatory cells
Valente etal. 1998  
Martin and Dorf
LRP (-) Macrophage Reduced uptake oxLDL Kosaka etal. 
2001
M IP-13) 1991
MHC-II (+) Macrophage
EC
SMC
Antigen presentation 
T cell activation
Iwata et al. 2001  
Jonasson etal. 1985  
Mach et al. 1996
VLDLR (-) Macrophage Reduced uptake oxLDL LaMarre etal. 
1993
ABCA1 (-) Macrophage Reduced cholesterol 
efflux
Panousis and 
Zuckerman 2000a
LPL (-) Macrophage Reduced uptake oxLDL 
Reduced production of 
proatherogenic remnants
Hughes etal. 
2002
ApoE(-) Macrophage Reduced cholesterol 
efflux
Brand etal. 1993 iNOS (+) Macrophage
EC
SMC
Reduced oxidation LDL Yokoyama etal. 
1996
ACAT (+) Macrophage Increased
cholesterol
esterification
Panousis and 
Zuckerman 2000b
Cholesterol 
hydroxylase (-)
Macrophage
EC
Reduced cholesterol 
metabolism
Reiss et al. 2001
MMPs (+)
(e.g. 1, 2, 3, 9)
Macrophage
SMC
Plaque instability Schonbeck et al. 
1997
Collagens (-) 
(e.g.-l, -3 )
Macrophage
SMC
Plaque instability Amento et al 1991  
Yuan et al. 1999
Abbreviations: ABCA1, ATP-binding cassette transporter-Al; apoE, apolipoprotein E; CD36, complementarity determinant 36; EC, endothelial cell; ICAM-1, intercellular 
adhesion molecule-1; iNOS, inducible nitric oxide synthase; LDL, low-density lipoprotein; LPL, lipoprotein lipase; LRP, low density lipoprotein-receptor related protein; MCP-1, 
monocyte chemoattractant protein-1; MHC-II, major histocompatibility antigen class-ll; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; oxLDL, 
oxidised-LDL; SMC, smooth muscle cell; SR-A, scavenger recptor-A; VCAM-1, vascular cell adhesion molecule-1; VLDL-R, very low density-1 ipoprotein-receptor
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In contrast to these findings, a recent study by Niwa et al. (2004) suggested that 
IFN-y produced by bone marrow-derived cells delayed the progression of 
atherosclerosis. The results in relation to changes in lipoprotein levels have also 
been controversial. For example, exogenous administration of IFN-y in apoE- 
deficient mice decreases serum cholesterol levels but enhances atherosclerosis 
formation (Whitman et al. 2000). Another study observed a gender specific effect 
whereby IFN-Y-deficiency in male, but not female, apoE-null mice was associated 
with reduced atherosclerosis development (Whitman et al. 2002). Table 1.4 
summarises the findings from studies into the effect of IFN-y on atherosclerotic 
lesion formation in mice.
The role of IFN-y in the pathology of atherosclerosis is undeniably complex and the 
proatherogenic versus antiatherogenic nature of the cytokine has long been a 
subject for debate. While it is still not currently possible to reconcile all the 
conflicting evidence, the majority of research from mouse models of the disease 
that are deficient in IFN-y signalling points towards a largely proatherogenic role. 
However, such a plethora of genes are regulated by IFN-y that it is hard to 
determine the impact of each of these on the disease. Substantial evidence exists 
that some of these gene regulatory events are antiatherogenic. It is possible that 
the role of IFN-y may depend on the stage of the pathology and the presence of 
other factors in the atheroma, and mice that are deficient in IFN-y signalling 
represent an extreme situation. Further research is, therefore, clearly needed into 
the phenotypic effects of this cytokine on various areas of complex plaque growth 
{e.g. foam cell formation, angiogenesis, calcification, plaque rupture) and into the 
specific signalling pathways involved in the regulation of individual genes, with the 
hope of identifying potential therapeutic targets in order to combat this disease.
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Table 1.4 Effects of IFN-y on atherosclerotic lesion formation in mice
Im S i
Gupta etal. 
1997
IFN-yR/
ApoE
High fat Decreased lesional area
Decreased lipid content
Decreased cellularity
Increased collagen content
Increased apoAIV rich particles in plasma
Proatherogenic
Nagano et al. 
1997
IFN-y Heart transplant in 
i m m u no-su ppressed 
mice
Decreased intimal thickening Promotes graft 
arteriosclerosis
Raisanen- 
Sokolowski et al. 
1998
IFN-y Heart transplant in 
im m u no-su ppressed 
mice
Decreased intimal thickening 
Increased cellularity
Promotes graft 
arteriosclerosis but may 
increase plaque stability 
in atherosclerosis
Tellideset al. 
2000
IFN-y
injection (3
times
weekly)
Transplant 
pi^human arteries 
in immuno-deficient 
mice
Thickening of intima 
Accumulation VSMCs in intima
Can induce
arteriosclerotic changes 
through action on VSMCs
Whitman etal. 
2000
ApoE IFN-y
injection
(daily)
Increased lesional area 
Increased cellularity 
Decreased collagen content 
Decreased serum cholesterol
Proatherogenic but may 
decrease serum 
cholesterol levels
Whitman et al. 
2002
IFN-y/
ApoE
IL-18
injection
(daily)
IL-18 induced atherogenesis not observed in 
compound knock-out mice
Proatherogenic
Whitman et al. 
2002
IFN-y/
ApoE
Normal/ 
high fat
Decreased lesional area in males only 
Decreased cellularity in males only
Proatherogenic in male 
mice
Buono et al. 
2003
IFN-y/
LDLR
High fat Decreased lesional area 
Decreased lipid content 
Decreased cellularity at 8 weeks
Proatherogenic
Niwa et al. 2004 IFN-y
(BMT)/
LDLR
BMT High fat Increased lesional area at 6 weeks 
Decreased cellularity 
Increased collagen content
IFN-y produced by BM- 
derived cells anti­
atherogenic but may 
decrease plaque stability
Abbreviations: BMT, bone marrow transplant; IFN-y, interferon-y; IL-18, interleukin-18; LDL-R, low density-lipoprotein-receptor; VSMC, vascular smooth muscle cell.
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1.5 Chemokines
As discussed previously, chemokines have an important role in the progression of 
atherosclerosis. IFN-y alters the expression of a number of chemokines and 
chemokine receptors and these responses are likely to impact on the development 
of the disease.
1.5.1 Structure and classification
Chemokines are a class of cytokines best characterised with respect to their role in 
the recruitment of immune cells to the site of inflammation. They are small (most 8- 
lOkDa) disulphide linked polypeptides classified according to the arrangement of a 
conserved N-terminal cysteine motif. Disulphide bonds link the first and third and 
the second and fourth cysteine residues in the motif. The largest chemokine family 
is the CC chemokines in which the first two cysteine residues are adjacent; in CXC 
chemokines they are separated by one amino acid; and in CX3C chemokines, of 
which there is only one known at present (fractalkine), they are separated by three 
amino acids. The C chemokines, of which two have been identified at present 
(lymphotactin and SCM-lp), have only one pair of cysteine residues linked by a 
disulphide bond. The majority of chemokines function as dimers although one, 
platelet factor (PF) 4 (CXCL4) is a tetramer (IUIS/WHO Subcommitte on Chemokine 
Nomenclature 2003, Mantovani 1999, Rollins 1997).
1.5.2 Biological functions of chemokines
Chemokines are produced by the majority of somatic cells including 
monocytes/macrophages, ECs, SMCs and T-cells in the atherosclerotic lesion. They 
are mostly secreted although there are two membrane bound chemokines; 
fractalkine (CX3CL1) and CXCL16. Chemokine signalling is mediated through 
binding to 7-transmembrane G-coupled receptors. Downstream signalling cascades 
are usually calcium-dependent and often involve the activation of PI3K (Curnock et 
al. 2002, Sozzani et al. 1993). Chemokine receptors are classified according to the 
class of ligand to which they bind and so fall into CC, CXC, CX3C and C receptor 
families (IUIS/WHO Subcommitte on Chemokine Nomenclature 2003, Murphy
2002). Each receptor may be activated by a number of different ligands (see Table 
1.5).
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Table 1.5 Human chemokine receptors and their ligands
Abbreviations: BCA-1, B lymphocyte chemoattractant; CTACK, cutaneous T-cell-attracting 
chemokine: DC, dendritic cell; EC, endothelial cell; ENA-78, epithelial neutrophil-activating 
peptide 78; GCP-2, granulocyte chemotactic protein-2; GRO, growth related oncogene; HCC, 
human CC chemokine; IL-8, interleukin 8; IP-10, interferon-y-inducible protein 10; l-TAC, 
interferon-l inducible T-cell a  chemoattractant; MCP, monocyte chemoattractant protein; MDC, 
macrophage-derived chemokine; MEC, mammary-enriched chemokine; Mig monokine induced 
by interferon y; MIP, macrophage inflammatory protein; MPIF-1, myeloid progenitor inhibitory 
factor 1; NAP-2, neutrophil-activating peptide 2; NK cell, natural killer cell; PMN, 
polymorphonuclear leukocyte (eosinphil, neutrophil, basophil, mast cell); RANTES, regulated on 
activation normal T cell-expressed and secreted; SCM-lp, single cystein motif-ip; SDF-1, 
stromal-cell-derived factor 1; SLC, secondary lymphoid tissue chemokine; SMC, smooth muscle 
cell; TARC, thymus and activation-regulated chemokine; TECK, thymus-expressed chemokine 
(adapted from Lucas and Greaves 2001, Mantovani 1999).
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u
CC family
CCR1
M IP-la
MIP-ip
RANTES
MCP-3
HCC-1
HCC-2
HCC-4
MPIF-1
CCL3
CCL4
CCL5
CCL7
CCL14
CCL15
CCL16
CCL23
+ + + +
DC 
B cell 
SMC
CCR2
MCP-1
MCP-3
MCP-2
MCP-4
HCC-4
CCL2
CCL7
CCL8
CCL13
CCL16
+ + + +
DC
EC
Fibroblast
SMC
CCR3
RANTES
MCP-3
MCP-2
Eotaxin
MCP-4
HCC-2
Eotaxin-2
Eotaxin-3
MEC
CCL5
CCL7
CCL8
CCL11
CCL13
CCL15
CCL24
CCL26
CCL28
+ + Epithelial
cell
CCR4 TARCMDC
CCL17
CCL22
+ + + DC
CCR5
M IP-la
MIP-ip
RANTES
HCC-1
CCL3
CCL4
CCL5
CCL14
+ + + DC
CCR6 MIP-3a CCL20 + + +
DC 
B cell
CCR7 MIP-30
SLC
CCL19
CCL21
+ + DC 
B cell
CCR8 1-309 CCL1 + + + +
CCR9 TECK CCL25 +
CCR10 CTACKMEC
CCL27
CCL28
+ + B cell
CXCR1 GCP-2IL-8
CXCL6
CXCL8
+ + + EC
GRO-a CXCL1
CXCR2
GRO-p
GRO-y
ENA-78
GCP-2
NAP-2
IL-8
CXCL2
CXCL3
CXCL5
CXCL6
CXCL7
CXCL8
+ + EC
CXCR3
Mig
IP-10
l-TAC
CXCL9
CXCL10
CXCL11
+ + + EC
CXCR4 SDF-1 CXCL12 + + + + DC
CXCR5 BCA-1 CXCL13 + + Bcell
CXCR6 CXCL16 + +
CX3C family
CX3CR1 Fractalkine CX3CL1 + + + SMC
C family
XCR1 Lymphotactin
SCM-13
XCL1
XCL2
+
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Traditionally, chemokines have been viewed as effectors of immune cell function, 
however receptors are also present on other cell types including ECs and SMCs (see 
Table 1.5) (Mantovani 1999, Rollins 1997). Similarly, while research has focused 
on the role of chemokines in immune cell recruitment in inflammation, it is now 
recognised that they also have important functions in the regulation of cellular state 
{e.g. proliferation, activation, differentiation), discussed separately below.
1.5.2.1 Role of chemokines in immune cell recruitment
Leukocyte extravasation occurs in three stages: leukocyte rolling: firm adhesion to 
the endothelium: and migration into the arterial intima. At the site of inflammation 
chemokines present at the endothelial surface provide a cue for the firm binding of 
leukocytes and a chemokine gradient spanning the endothelium directs 
extravasation into the intima. Chemokines both upregulate the expression of 
adhesion molecules on the surface of the endothelium and promote the activation 
of integrins to increase binding affinity. They also stimulate the secretion of other 
inflammatory mediators to further increase immune cell recruitment (Cybulsky et al. 
2004, Montavani 1999, Rollins 1997). The CX3C chemokine, fractalkine, is able to 
act as an adhesion molecule itself. Fractalkine is unusual in that the chemokine 
domain is anchored to the cell membrane by a mucin-rich stalk attached to a 
transmembrane domain. The chemokine is presented on the surface of ECs in 
inflammation and mediates the adhesion of monocytes, T-lymphocytes, NK cells 
and dendritic cells (DCs) by interacting with CX3CR1 on the target cell. The 
chemokine domain can also be shed through proteolytic cleavage by the enzymes 
ADAM17 (TNF-a converting enzyme) or ADAM10 (disintegrin-like MMP). The 
secreted chemokine can induce chemotaxis, activate monocytes and enhance the 
binding affinity of integrins (Haskell et al. 1999, Fong et al. 1998, Bazan et al. 
1997, Imai etal. 1997).
1.5.2.2 Role of chemokines in the regulation of cellular state
Chemokines have a role in the regulation of both immune cell activation and 
cellular proliferation in inflammation (Mantovani 1999, Rollins 1997). Enhanced 
proliferation of ECs in response to a subset of chemokines stimulates angiogenesis.
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The family of CXC chemokines is further divided into two groups based on the 
presence or absence of an ELR (glutamate-leucine-arginine) motif in the N-terminal 
domain. ELR-containing chemokines (e.g. IL-8, ENA-78 and GCP-2) are generally 
angiogenic while non-ELR CXC chemokines (e.g. IP-10 and Mig) are found to inhibit 
angiogenesis (Strieter et al. 1995). Some CC chemokines also stimulate 
angiogenesis including MCP-1 and eotaxin (Salcedo et al. 2001, Salcedo et al.
2000, Weber et al. 1999a). Chemokines have a role in hematopoiesis (the 
generation of new blood cells from myeloid progenitors) through the inhibition of 
proliferation, regulation of survival and promotion of chemotaxis. A large number of 
chemokines have the ability to suppress the proliferation of progenitor cells 
including M IP-la, GRO-p, GRO-y, PF4, IL-8 and MCP-1. Those that do not exert this 
effect, and in some cases counteract the suppressive effect of other chemokines, 
include MIP-lp, GRO-a, GRO-y and RANTES (Broxmeyer 2001, Youn et 2000, 
Broxmeyer and Kim 1999).
1.5.3 Chemokines and atherosclerosis
As an inflammatory disease, the overall expression of chemokines in the 
atherosclerotic lesion is high, stimulated by the cocktail of cytokines and oxidised 
lipids present. The role of chemokines in the pathogenesis of atherosclerosis is 
currently of particular interest. A number of studies have suggested a pro- 
atherogenic impact and broad-spectrum chemokine inhibitors offer a promising 
thereapeutic strategy for the treatment of the disease (Grainger and Reckless
2003, Johnson et al. 2004). Several recent reviews discuss the various functions of 
chemokines in atherosclerosis in detail (Quehenberger 2005, Charo and Taubman
2004, Sheikine and Hansson 2004, Burke-Gaffney et al. 2002, Lucas and Greaves
2001, Reape and Groot 1999) and the effects are summarised in Table 1.6.
Particular interest in the role of chemokines in atherosclerosis has been generated 
due to important studies involving the CC chemokine MCP-1, which have shown a 
beneficial effect to deficiency in either the chemokine or its receptor CCR2 in mouse 
models of atherosclerosis (Dawson et al. 1999, Gosling et al. 1999, Boring et al. 
1998, Gu eta l. 1998). This chemokine is discussed in detail in Section 1.6. Other 
chemokines that have been shown to be present in the atheroma, in either humans
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or mouse models of the disease, are listed in Table 1.6. Each chemokine displays a 
differential pattern of expression and localisation within the lesion and this is likely 
to vary over the course of the disease.
Knock-out mouse models (summarised in Table 1.6) have revealed the function and 
importance of specific chemokines and receptors in atherosclerosis and also the 
degree of functional redundancy in the chemokine system. For instance, the 
receptors CCR1 and CCR5 both bind to the chemokines RANTES, M IP -la  and MIP- 
ip , all of which have been localised to the lesion (Pattison etal. 1996, Wilcox etal.
1994). While knock-out of the CCR5 receptor in apoE-null mice does not confer an 
atheroprotective effect (Kuziel etal. 2003), blocking both CCR1 and CCR5 signalling 
using the inhibitor Met-RANTES decreases atherosclerosis development in apoE- 
and LDL-R-deficient mice (Veillard et al. 2004, Schober et al. 2002). It is also 
noticeable that while MCP-1- or CCR2-deficiency in mouse models of the disease 
significantly reduces the number of monocytes/macrophages within the lesion, 
these cells are still present, indicating the existence of alternative mechanisms of 
recruitment (Dawson et al. 1999, Gosling et al. 1999, Boring et al. 1998, Gu et al.
1998).
The membrane bound chemokines fractalkine and CXCL16 are of particular interest 
in atherosclerosis. As discussed previously, in addition to its role as a 
chemoattractant, fractalkine can also act as a cellular adhesion molecule in the 
recruitment of monocytes/macrophages and T-cells. A knock-out mouse model 
deficient in fractalkine and apoE has recently been generated that exhibits reduced 
atherosclerosis in comparison to the apoE-null mouse (Teupser et al. 2004). Mice 
lacking the receptor CX3CR display a similar phenotype (Combadiere et al. 2003, 
Lesnik et al. 2003). The chemokine CXCL16 has similar domain organisation to 
fractalkine; including a chemokine domain anchored to the membrane by a mucin- 
rich stalk, which may be released by enzymatic cleavage (Wilbanks et al. 2001). 
CXCL16 also has a dual role in atherosclerosis, functioning as both a 
chemoattractant for activated T-cells, and as a scavenger receptor contributing to 
the uptake of oxLDL in macrophage-foam cell formation (Wuttge et al. 2004, 
Minami et al. 2001).
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Table 1.6 Chemokines in the atherosclerotic lesion
MCP-1 Monocyte chemoattractant 
T-cell chemoattractant 
Adhesion of leukocytes to EC 
SMC migration and proliferation 
Angi ogenesis
Rayner et al. 2000  
Seino etal. 1995  
Takeya etal. 1993
Gu et al. 1998 (MCP LDLR -/-) 
Boring etal. 1998  
(CCR2-A. apoE -A)
Gosling etal. 1999
(MCP -A, overexpression apoB)
Aiello et al. 1999  
(Overexpression MCP-1 BMT, 
apoE-A)
Dawson et al. 1999  
(CCR2-A, apoE-A)_________
MCP-4 Monocyte chemoattractant 
Activated T-cell chemoattractant
Berkhout et al. 1997
M IP-la Monocyte chemoattractant 
Activated T-cell chemoattractant
Wilcox etal. 1994 Schober et al. 2002  
(Inhibition CCR1/5 signalling with 
Met-RANTES, apoE-A)
M IP-10 Monocyte chemoattractant Veillard etal. 2004
T-cell chemoattractant (Inhibition CCR1/5 signalling with 
Met-RANTES, LDLR-A)
RANTES Monocyte chemoattractant 
Activated T-cell chemoattractant 
Activation of macrophages 
Activation of T-cells
Pattison et al. 1996  
Wilcox etal. 1994
PARC Naive T-cell chemoattractant Reape etal. 1999
M IP-30 T-cell chemoattractant
Adhesion of T-cells to EC
TARC Activated T-cell chemoattractant 
Platelet activation and aggregation
Greaves et al. 2001
MDC Activated T-cell chemoattractant 
Platelet activation and aggregation
IL-8 Monocyte chemoattractant Boisvert et al. 1998 Boisvert et al. 1998
Activated T-cell chemoattractant 
Angiogenesis
SMC migration and proliferation 
Adhesion of monocytes to EC
(CXCR2)
Wang etal. 1996a 
Apostolopoulos et al. 
1996
(CXCR2-A BMT, LDLR-A)
GRCkx Monocyte chemoattractant 
Activated T-cell chemoattractant 
Angiogenesis
SMC migration and proliferation
Boisvert et al. 1998  
(CXCR2)
CXCL16 Scavenger receptor 
Activated T-cell chemoattractant
Minami et al. 2001  
Wuttge et al. 2004
Eotaxin SMC migration Haley et al. 2000 Veillard etal. 2005  
(CXCR3-A, apoE-A)
Fractalkine Cell-adhesion molecule 
Monocyte chemoattractant 
T-cell chemoattractant 
Adhesion of monocytes to EC 
SMC migration 
Platelet activation
Wong et al. 2002  
Lucas et al. 2003
Teupser et al. 2004 (Fractalkine 
-A. apoE-A and LDLR-A)
Lesnik et al. 2003  
(CXC3R-A, apoE-A)
Combadiere et al. 2003  
(CXC3R-A, apoE-A)
IP-10 Activated T-cell chemoattractant 
SMC migration
Mach etal. 1999
Mig Activated T-cell chemoattractant
ITAC Activated T-cell chemoattractant
SDF-la T-cell chemoattractant Abi-Younes etal.
Platelet activation and aggregation 2000
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In general, chemokines increase the cellularity of the lesion through: increased 
recruitment of monocytes/macrophages, T-cells and SMCs; enhanced proliferation 
of SMCs; immune cell activation; and stimulation of the secretion of 
proinflammatory mediators. In inflammation and atherosclerosis, the recruitment 
of monocytes/macrophages appears to be largely regulated by the CC chemokines 
{e.g. MCP-1 and -4, M IP -la  and -1(3, RANTES) although CXC chemokines such as IL- 
8 and the CX3C chemokine fractalkine have also been shown to recruit monocytes. 
The CXC chemokines predominantly recruit activated T-cells {e.g. IL-8, GRO-a, IP-10, 
Mig, ITAC) (Quehenberger 2005, Charo and Taubman 2004, Sheikine and Hansson 
2004, Burke-Gaffney et al. 2002, Lucas and Greaves 2001, Reape and Groot
1999). The CC chemokine PARC preferentially attracts naive T-cells (Adema et al.
1997) that are activated within the lesion by inflammatory cytokines and 
chemokines such as the CC-chemokines RANTES, M IP -la  and MCP-1 (Taub et al. 
1996, Bacon et al. 1995). The chemokine receptors CCR1, CCR2, CCR3, CCR5, 
CXCR4 and CX3CR have been shown to be present on the surface of SMCs and the 
migration and proliferation of these cells can be regulated by chemokines in the 
lesion {e.g. IP-10, IL-8, MCP-1, fractalkine, eotaxin) (Kodali eta l. 2004, Lucas eta l. 
2003, Schecter et al. 2003, Schecter et al. 2000, Hayes et al. 1998, Wang et al. 
1996b). Eotaxin is known primarily for the recruitment of eosinophils but is 
associated with SMC-rich areas of the atherosclerotic plaque and is thought to 
function in the recruitment of these cells in the disease (Kodali etal. 2004, Haley et 
al. 2000).
In the advanced plaque chemokines are likely to have a role in neovascularisation. 
As previously discussed, ELR-containg CXC chemokines (e.g. IL-8) and CC 
chemokines (e.g. MCP-1) stimulate angiogenesis. Non-ELR CXC chemokines (e.g. 
IP-10, Mig) however inhibit this process so that the overall role of chemokines in 
neovascularisation is uncertain (Strieter et al. 1995). Additionally, particular 
chemokines increase the thrombogenic potential of the plaque as they are known 
to cause platelet activation and clotting. These include SDF, TARC, MDF and 
fractalkine (Schafer etal. 2004, Abi-Younes etal. 2001, Abi-Younes etal. 2000).
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1.6 Monocyte C hem oattractant P rote in -1
Of the chemokines discussed above, the CC chemokine MCP (monocyte 
chemoattractant protein)-l (CCL2) has attracted the most interest in relation to its 
role in atherosclerosis and has been shown in several independent studies to be a 
proatherogenic factor (Harrington 2000, Rollins 1996). The regulation of MCP-1 is 
of particular interest as it presents a potential therapeutic target for atherosclerosis. 
Transfection of a N-terminal deletion mutant of the MCP-1 gene (7ND) in apoE-null 
mice has been shown to inhibit both lesion formation and the progression of 
existing lesions, as well as increasing plaque stability (Inoue et al. 2002, Ni et al.
2001).
1.6.1 Biological roles of MCP-1
There are four functional MCP chemokines in humans (MCP 1-4) and three in mice 
(MCP 1, 3 and 5) (Berkhout et al. 1997, Sarafi et al. 1997, Proost et al. 1996). A 
variety of cell types produce MCP-1 including monocytes/macrophages, ECs, 
VSMCs, fibroblasts, chondrocytes, astrocytes and epithelial cells as well as certain 
cancerous cells (Proost et al. 1998, Zhang et al. 1996). MCP-1 functions as a 
dimer and is structurally similar to MIP-lp. The murine protein (also known as JE) 
shares considerable sequence homology with human MCP-1 but has an additional 
O-linked carbohydrate at the C-terminus, the function of which is unclear 
(Lubkowski et al. 1997, Zhang et al. 1996a). The action of MCP-1 is mediated by 
binding to the G-protein linked CC chemokine receptor, CCR2, on the cell surface 
(Section 1.5) (IUIS/WHO Subcommitte on Chemokine Nomenclature 2003, Boring 
etal. 1997).
The major biological function of MCP-1 is to promote the chemotaxis of monocytes 
to the site of inflammation, although it has also been shown to be involved in the 
recruitment of T-lymphocytes, NK cells and in the migration of VMSCs (Proost et al. 
1998). Other actions of this chemokine include: increasing monocyte adhesion to 
the endothelium through the activation of cell adhesion molecules (Gerszten 1999); 
modulating T h l and Th2 responses and the expression of inflammatory mediators 
(e.g. IFN-y, IL-4 and IL-5) (Gu et al. 2000, Peters et al. 2000, Lu et al. 1998);
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increasing the proliferation SMCs (Seltzman et al. 2002); and stimulation of 
angiogenesis (Salcedo et al. 2001, Weber et al. 1999a). Knock-out mice deficient 
in MCP-1 show an impaired ability to recruit monocytes in models of inflammation 
and exhibit decreased expression of cytokines including IL-4, IL-5 and IFN-y. Other 
responses are unaffected in these mice such as the ability to clear infection with 
Mycobacterium tuberculosis (Lu et al. 1998). Deletion of the CCR2 gene (that also 
functions as receptor for MCP-2, -3, -4 and HCC-4) in mice leads to similar defects 
in monocyte/macrophage recruitment in response to inflammatory stimuli. These 
mice exhibited a dramatic reduction in the production of IFN-y as well as the 
cytokines IL-4, IL-5 and IL-12 (Boringetal. 1997).
MCP-1 has been linked to several pathological processes characterised by the 
infiltration of monocytes, including: inflammatory skin diseases (e.g. cutaneous 
sclerosis) (Yamamoto 2003); allergic asthma (Ross et al. 2003); autoimmune 
diseases such as multiple sclerosis (Mahad and Ransohoff 2003, Simpson et al.
1998) and autoimmune encephalomyelitis (Mahad and Ransohoff 2003, 
Ransofhoff etal. 1993), as well as atherosclerosis.
1.6.2 Role of MCP-1 in atherosclerosis
A proatherogenic role has been well established for MCP-1, characterised 
predominantly by an increased accumulation of macrophage- and SMC-derived 
foam cells (Harrington 2000, Rollins 1996). As well as the role of MCP-1 in the 
chemoattraction of monocytes/macrophages, T-cells and VSMCs, the pro- 
inflammatory effects on the expression of other cytokines and enhanced 
angiogenesis stimulated by the chemokine, all contribute to atherogenesis and 
destablisation of the plaque. High levels of expression of MCP-1 have been 
detected in the atherosclerotic lesion by antibody detection and in situ 
hybridisation, and elevated levels have been found in patients in association with 
risk factors for atherosclerosis (de Lemos et al. 2003, Rayner et al. 2000, Seino et 
al. 1995, Takeya et al. 1993). Knock-out of the MCP-1 gene in apoE- and LDL-R- 
null mice significantly reduces cellularity and lesion area without affecting plasma 
lipid or lipoprotein levels (Gosling et al. 1999, Gu et al. 1998). Conversely 
increased expression of MCP-1 enhances atherosclerosis formation in apoE-null
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mice (Aiello etal. 1999). Local overexpression of MCP-1 at the blood vessel wall in 
rabbits was not sufficient by itself to induce atherosclerosis formation but acted in 
synergy with hypercholesterolemia to promote atherosclerotic changes (Namiki et 
al. 2002). Knock-out of the MCP-1 receptor, CCR2 in apoE-null mice has a similarly 
atheroprotective effect (Dawson et al. 1999, Boring et al. 1998). Expression of 
CCR2 on monocytes has been found to be increased in patients with 
hypercholesterolemia and is upregulated by high levels of LDL (Han and 
Quehenberger 2000, Han et al. 1999, Han et al. 1998). Studies have shown 
however that, in contrast to native LDL, oxLDL has an inhibitory effect on monocyte 
CCR2 expression (Han et al. 2000, Han et al. 1998). This has been explained by a 
model in which monocytes are recruited to the lesion through CCR2 signalling and 
retained at the site by downregulation of CCR2 in the presence of high levels of 
oxidised lipid. Another study has demonstrated the opposite effect, whereby oxLDL 
increased the expression of CCR2 in monocytes (Weber et al. 1999b).
1.6.3 Regulation of MCP-1 expression by inflammatory mediators
A number of inflammatory cytokines regulate the expression of MCP-1 in a variety of 
cells types, including IFN^y, IL-ip, IL-4, TNF-a , TGF-p, GM-CSF and PDGF (reviewed 
in Proost et al. 1998). Pro inflammatory cytokines generally induce MCP-1 
expression {e.g. IFN-y (Valente et al. 1998), IL-lp and TNF-a (Bian et al. 2004)) 
while antiinflammatory cytokines suppress MCP-1 gene expression {e.g. IL-10 and 
IL-13 (Kucharzik et al. 1998)). For some cytokines there is conflicting data about 
the regulatory role in MCP-1 expression and this is potentially dependent on cell 
type (e.g. TGF-p upregulates MCP-1 in ECs and mesangial cells (Chengeta l. 2005, 
Matagrano et al. 2004) but downregulates expression in macrophages (Feinberg et 
al. 2004); IL-4 induces expression in ECs (Lee eta l. 2003) but downregulates MCP- 
1 in epithelial cells (Kucharzik etal. 1998)).
Transcriptional regulation of human MCP-1 appears to be controlled largely through 
specific distal (-2500/-2300) and proximal promoter regions (-300/+1). Binding 
sites for NF-kB have been identified in both regions while the proximal region also 
contains a putative GAS site, a GC-box, AP-1 (TPA-responsive element (TRE)) sites 
and possible C/EBP binding sites. Inducible and constitutive binding to these sites
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has been demonstrated in various combinations in different cell lines and in 
response to particular mediators, as summarised in Table 1.7. Shear stress, 
thought to promote atherosclerotic plaque formation at particular arterial sites, has 
also been demonstrated to either stimulate the production of MCP-1 by ECs (Bao et 
al. 1999, Shyy et al. 1995) or to downregulate MCP-1 gene expression (Chiu et al.
2002), potentially in response to varying flow forms (Vanderlaan et al. 2004, Bao et 
al. 1999).
Table. 1.7 Regulation of MCP-1 gene expression; promoter binding studies1
IL-IP (+) Endothelial AP-1 Human Bian etal. 2004
Endothelial NFkB Human Choi et al. 2004
Mast NFkB Human Lee et al. 2004
Endothelial AP-1 (-6 8 ), NFkB (-90) Human Martin et al. 1997
IFN-y (+) Astrocyte STAT1 (-212), S p l (-124) Human Zhou et al. 2001
Astrocyte STAT1 (-212), S p l (-124) Human Zhou et al. 1998
Osteoblast STAT1 (-212), IRIS 2 (-227) Human Valente e ta l. 1998
IL-4 (+) Endothelial STAT1 (-212) Human Lee et al. 2003
Insulin (+) VSMC C/EBP-p (-2589, -3116) Rat Sekine et al. 2002
VSMC C/EBP-P (-2589, -3116) Rat Kodama etal. 2005
Glucose (+) Mesangjai AP-1 Human Lee et al. 2001
LPS (+) Macrophage C/EBP-P Mouse Hu etal. 2000
Macrophage kB3  binding site (-169) Mouse Ueno et al. 2 0 0 0
Epithelial N FkB(-2287,-2261), 
A P-l(-54)/Spl(-51)
Rat Wang etal. 2000b
Macrophage C/EBP-3 Mouse Bretz et al. 1994
PDGF BB (+) Fibroblast Sp l. Sp3 (-51) Mouse Ping etal. 1999
Fibroblast Sp3 2 (-1468, -1434) Mouse Sridhar etal. 1999
ROS (+) Endothelial NFkB. AP-1 Dog Lakshminarayanan etal. 2001
Shear stress (+) Endothelial NFkB Human Bao et al. 1999
Endothelial AP-1 (-60) Human Shyy et al. 1995
Shear stress (-) Endothelial AP-1 Human Chiu etal. 2002
Tat (HIV) (+) Astrocyte Spl(-124), AP-K-128), NFkB(-150) Human Lim and Garzino-Demo 2000
Astrocyte C/EBP-3 (0 //-200 ). Smad3 2 Human Abraham etal. 2005
TGF-p (-) Macrophage AP-1, Smad3 2 (-122 human) Mouse Feinberg et al. 2004
TNF-a (+) Endothelial AP-1 Human Bian et al. 2004
Fibroblast NFkB (-2378, 2352), S p l (-51) Mouse Boekhoudt et al. 2003
Endothelial NFkB (-2378, 2352), S p l (-51) Mouse Ping etal. 2000
Mesangial NFkB (-2378, 2352), S p l (-51) Mouse Ping etal. 1999
Fibroblast NFkB (-2378, 2352), S p l (-51) Mouse Ping etal. 1996
1 Where transcription factor binding has been localised to a particular site in the MCP-1 promoter, the position of the 
site upstream of the transcriptional start site (+1) is given in parentheses. In other cases increased DNA binding has 
been shown to a consensus element for that transcription factor.
2Transcriptional repression
Abbreviations: AP-1, activating protein-1; C/EBP-p, CCAAT/enhancer binding protein-P; HIV, human immunodeficiency 
virus; IFN-y, interferon-y; IL-ip, interieukin-lp; LPS, lipopolysaccharide; NFkB, nuclear factor kB; PDGF BB, platelet- 
derived growth factor BB; ROS, reactive oxygen species; STAT1, signal transducer and activator of transcription 1; 
TGF-p, transforming growth factor-p; TNF-a, tumor necrosis factor-a.
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Although studies in astrocytes have demonstrated the presence of a functional 
STATl-binding site, that is involved in promoter activation by IFN-y (Table 1.7), a 
study of gene expression in STATl-null bone marrow-derived macrophages (BMMs) 
showed MCP-1 induction by IFN-y in both wild type and STAT1-deficient cells, 
suggesting that a STATl-independent pathway may also exist (Gil et al. 2001, 
Ramana et at. 2002). In the following sections potential STAT1-dependent and -  
independent mechanisms of IFN-y signalling are discussed.
1.7 Role of the JAK-STAT Pathway in IFN-^ Signalling
Cytokines mediate signalling through binding to specific receptors at the cell 
surface. The association of the cytokine with its receptor generally leads to 
alterations in receptor confirmation and initiates a specific signalling cascade 
resulting in changes in transcription, translation or post-translational modifications. 
The key components of the majority of signalling pathways are protein kinases, 
which control the activation of downstream effectors through the phosphorylation of 
particular residues.
1.7.1 JAK-STAT signalling
JAK-STAT signalling is involved in the mediation of responses to a number of 
cytokines (e.g. IFN-a, IFN-p, IFN-y, IL-4, IL-6, IL-13). JAKs (including tyrosine kinase 
2 (Tyk2) and JAK1-3) are receptor-associated tyrosine kinases that are activated by 
cytokine binding to the receptor. STATs (including STAT1-4, -5a, -5b and -6) are 
SH2-domain containing transcription factors that bind to DNA as a homo- or 
heterodimer. Various JAK-STAT components are associated with the mediation of 
signalling in response to different cytokines. For instance: IL-6 treatment can lead 
to the activation of JAK1, JAK2 or Tyk2 and STAT1 and STAT3; Type 1 IFNs activate 
Tyk2, JAK1, STAT1 and STAT2 (that also associate with IRF-9 to form the 
transcription factor ISGF3); while IFN-y signalling involves JAK1, JAK2 and STAT1 
(Kerr et al. 2003, Aaronson and Horvath 2002, Schindler and Darnell 1995). The 
“JAK-STAT pathway”, as associated with IFN-y signalling, has been extensively 
studied and is discussed in detail below.
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1.7.2 JAK-STAT signalling in the IFN^y response
The cellular response to IFN-y is mediated via interaction of the cytokine with its 
receptor, IFN-yR. IFN-yR is a heterodimeric receptor with a  and p chains (IFN-yRl 
and IFN-yR2), both of which are required in order for the receptor to function in the 
transduction of the IFN^ y signal (Tau and Rothman 1999, Marsters etal. 1995).
The most widely accepted signalling mechanism for the mediation of the IFN-y 
response is the JAK-STAT pathway, elucidated through studies of mutant cell lines 
lacking specific components of the pathway (reviewed in Stark et al. 1998, 
Schindler and Darnell 1995). JAK1 is bound to the intracellular domain of IFN-yRl 
while JAK2 binds IFN-yR2. In the absence of IFN-y stimulation, receptor subunits 
are not strongly associated with one another. Ligand binding to IFN-yR causes 
assembly of the active receptor complex in which the intracellular domains of the 
receptor subunits are brought together. This allows activation of JAK1 and JAK2 by 
auto- and trans-phosphorylation. Subsequent phosphorylation of a specific tyrosine 
containing sequence on the IFN-yRl subunit provides a docking site for STAT1 
through a SH2 domain. Receptor associated STAT1 is phosphorylated by the JAK 
proteins (at tyrosine 701) causing it to dissociate from the receptor and form 
homodimers. Phosphorylation of STAT1 at Serine 727 is also required for maximal 
activation although the mechanisms involved in this are less clear (Decker and 
Kovarik 2000, Wen et al. 1995).
STAT1 homodimers translocate to the nucleus and regulate transcription of the 
majority of IFN-y-responsive genes through gamma-activated sequence (GAS) 
promoter elements (consensus sequence: TTNCNNNAA). However other elements 
have also been found to be necessary for the transcription of certain genes by IFN-y, 
including the interferon-stimulated response element (ISRE) (more commonly 
associated with Type I IFN-signalling), palindrome IFN-response element (pIRE) and 
gamma-1 FN-activated transcriptional element (GATE). The signalling mechanisms 
involved in the JAK-STAT pathway are reviewed in a number of articles (Kalvakolanu 
2003, Kerr et al. 2003, Aaronson and Horvath 2002, Stark et al. 1998, Schindler 
and Darnell 1995) and illustrated in Figure 1.2.
38
Ch apter  one : In tr o d u c tio n
A.
6 a  -  a  6I
B.
•  •
I
D.
NUCLEUS
Active Statl 
Homodimer
Assembly of the active 
receptor complex
JAK activation and Statl 
docking site formation
Statl recruitment, activation, 
and homodimer formation
Statl nuclear translocation, 
and initiation of gene 
transcription
IFN-y- responsive genes
Figure 1.2 The JAK-STAT pathway
A. Binding of IFN-y to IFN-yRl causes assembly of the receptor complex and auto- and trans­
phosphorylation of JAK1 and JAK2.
B. Activated JAKs phosphorylate IFN-yRl to provide a docking site for STAT1.
C. STAT1 is recruited to the active receptor complex where it is activated and forms a 
homodimer.
D. The STAT1 homodimer translocates to the nucleus and binds to GAS elements in the 
promoter of IFN-y responsive genes to initiate transcription (adapted from Stark et al. 1998).
Abbreviations: IFN-y, interferon-y; JAK, Janus kinase; P, phosphorylated residue; STAT1, signal transducer and 
activator of transcription.
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Other proteins also interact with JAK1, JAK2 and STAT1 that help to modulate the 
IFN-y response (reviewed in Kalvakolanu 2003, Platanias and Fish 1999). The 
mitogen activated protein kinase (MAPK), Pyk2, has been found to be constitutively 
associated with JAK2 in mouse embryonic fibroblasts (MEFs) and is activated upon 
binding of IFN-y to IFN-yRl. A dominant negative form of the protein inhibits 
phosphorylation of STAT1 at Serine 727 and also the activation of extracellular 
signalling related kinase (ERK) 1 /2  (Takaoka et al. 1999). It is not certain if ERKs 
are involved in the regulation of STAT1 or an alternative pathway (Hu et al. 2001, 
David et al. 1995) (see Section 1.8).
The GTPase Racl has also been shown to be rapidly activated in astrocytes 
stimulated with IFN-y and to associate with IFN-yR. A dominant negative form of 
Racl inhibits the phosphorylation of both STAT1 and STAT3 at Tyrosine 701 in 
response to IFN-y, without affecting the phosphorylation of JAK1. Expression of a 
GAS-regulated reporter gene was also reduced in the presence of dominant negative 
Racl (Park et al. 2004). A requirement for Racl has been demonstrated for the 
regulation of GAS activity following the activation of G-protein coupled receptors in 
VSMCs. In this case both the Rho family GTPases RhoA and Racl are required for 
maximal activation of STAT1. The expression of an activated mutant of Racl was 
found to be sufficient for the activation of JAK2 and to initiate STATl-dependent 
transcription. On the other hand the action of RhoA is unclear as a dominant negative 
form of this GTPase did not affect the activity of JAK2 or the phosphorylation of 
STAT1 (Pelletier et al. 2003). Phosphorylation of the proto-oncogene Vav in 
macrophages stimulated with IFN-y has been demonstrated and Vav may act as a 
guanine nuclear exchange factor for Racl in this system (Abe et al. 2000, English et 
al. 1997). Another GTPase, Ran, also appears to be necessary for the nuclear 
translocation of STAT1 in response to IFN-y (Sekimoto etal. 1996).
The SH2-domain containing tyrosine phosphatases (SHP)-l and SHP-2 both 
contribute to the regulation of STAT1 activity. These proteins are potentially recruited 
to IFN-yR through the SH2-domain, allowing the regulation of both JAK and STAT1 
phosphorylation. The two phosphatases appear to have opposing effects whereby 
SHP-1 functions as a positive regulator of JAK-STAT signalling while SHP-2 has a 
negative role (You et al. 1999, You and Zhao 1997).
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The expression of RNA-dependent protein kinase (PKR), activated by the 
accumulation of double-stranded RNA (dsRNA) in viral replication, is induced by IFN-y 
and mediates many of the anti-viral and anti-proliferative actions of the cytokine. 
IFN-y has also been shown to promote the phosphorylation of PKR and it may have a 
direct role in IFN-y-induced signalling. Experiments in PKR-null MEFs indicate that 
PKR is necessary for the activation of the IRF1 promoter by the cytokine (Der et al. 
1997, Kumar etal. 1997). Although the study by Kumar etal. (1997) did not support 
a role for STAT1 in the PKR-mediated regulation of IRF1, it has been found by 
Ramana et al. (2000), that in PKR-null cells, STAT1 was not properly phosphorylated 
on Serine 727 and that the expression of a reporter gene driven by GAS promoter 
elements was suppressed.
In the nucleus, several additional proteins associate with the STAT1 homodimer and 
regulate its transcriptional activity. These include CREB-binding protein (CBP/p300) 
(Zhang et al. 1996), mini chromosomal maintenance protein (MCM5) (Zhang et al. 
1998b) and breast cancer susceptibility gene 1 (BRCA1) (Ouchi et al. 2000). The 
interaction of STAT1 with MCM5 and BRCA1 is thought to require the phosphorylation 
of STAT1 at Serine 727.
1 .8  Alternative IFN-y S ignalling Pathways
The importance of the JAK-STAT pathway in IFN-y responses is clear from studies of 
STATl-null mice and mice deficient in JAK1 or JAK2. Disruption of JAK genes causes 
perinatal (JAK1) and embryonic lethality (JAK2) while STAT1-knock-out mice develop 
a phenotype similar to those deficient in IFN-y, showing an increased susceptibility to 
viral and microbial infections (Parganas et al. 1998, Rodig et al. 1998, Neubauer et 
al. 1998, Durbin et al. 1996, Meraz et al. 1996). However several recent studies 
have suggested the existence of alternative IFN-y signalling pathways independent of 
JAK-STAT.
1.8.1 Regulation of gene expression by IFN-y in STATl-deficient cells
BMMs and MEFs deficient in STAT1 exhibit enhanced proliferation in response to IFN- 
y while cell growth in wild type cells is inhibited. STATl-null mice are also more 
resistant to infection with murine cytomegalovirus (MCMV) and Sindbis virus than
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those lacking the IFN-y receptor indicating the involvement of IFN-y-dependent, 
STATl-independent pathways in the response to these viruses. Analysis of gene 
expression in STATl-deficient macrophages through representational difference 
analysis showed that IFN-y induced the expression of certain genes, including MIP- 
la ,  M IP-lp and MCP-1, and repressed that of others, such as CXCR4, in both wild 
type and STATl-null cells. IL-lp and arginase genes were upregulated by IFN-y only 
in cells lacking STAT1 (Gil et al. 2001). In these cases a STATl-dependent pathway 
may be inhibiting gene expression while opposing, STATl-independent, signals 
stimulate expression. MCP-1 was also found, by RNAase protection analysis, to be 
regulated in both STATl-deficient and wild type fibroblasts although in this case MIP- 
l a  was only induced in STATl-null cells, while the induction of MIP-lp occurred only 
in wild type cells (Ramana et al. 2001). A study by Klampfer et al. (2004) found that 
siRNA against STAT1 inhibited the induction of certan genes by IFN-y (e.g. IRF-1) but 
not that of others (e.g. caspase-7).
Microarray experiments have similarly indicated a large range of genes regulated 
independently of STAT1 (Table 1.8). IFN^ y was found to regulate 216 genes in wild 
type BMMs (187 upregulated and 29 down regulated) and 150 genes in STATl- 
deficient BMMs (51 upregulated and 99 downregulated). As with IL-ip and arginase 
genes, a significant number of genes were differentially expressed in response to 
IFN-y in STATl-deficient cells only, and not in the wild type (Ramana et al. 2002, Gil 
etal. 2001). A parallel study in STATl-null MEFs revealed 28 genes induced by more 
than 3.5 fold in response to IFN-y, approximately a third of which were also regulated 
in wild type cells. These include several cell cycle regulating genes such as c-myc 
and c-jun that are suppressed in wild type fibroblasts and may be responsible for 
altered proliferative responses in these cells (Ramana et al. 2002, Ramana et al. 
2001). The induction of c-myc expression in STATl-null fibroblasts has been found to 
involve the oncogenic protein kinase R afl (Ramana et al. 2000). A study by 
Kortylewski et al. (2004) also implicated STATl-independent pathways in altered 
growth responses to IFN-y. Their results indicate that STAT1 is crucial for the 
antiproliferative effect of IFN-y in tumor suppression and suggest the presence of 
alternative, STATl-independent, pathways that counteract the inhibitory effects of 
IFN-y on cell growth (Kortylewski etal. 2004).
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Table 1.8 Genes regulated by IFN-y in wild type and STATl-null macophages
Wild type SOCS-1 123 Cytoplasimic; regulation
M IP-13 32 Secreted; chemokine
MCP-1 22 Secreted; chemokine
Zyxin 22 Cell motility
MIG 20 Secreted; chemokine
IP-10 20 Secreted; chemokine
SOCS-3 13 Cytoplasmic regulation
IRF-1 11 Transcription
IRG-47 9.8 G-protein; regulation
LRG-47 9.5 G-protein; regulation
Ro RNP 9.4 Cell metabolism (suggested)
p204 9.4 Cell-cycle regulation
p203 9.0 Cell-cycle regulation
M IP-la receptor 8.7 Chemokine receptor
GARG-39 7.6 Cell communication (suggested)
Talin 7.1 Adhesion
IGTP 6.7 Antimicrobial resistance
TGTP 6.5 Antiviral resistance
p2 0 2 6.4 Cell cycle regulation
Tissue factor (mtf) 5.1 Coagulation
TPL-2/Cot 4.7 Proto-oncogene; kinase
Fibronectin 4.5 Extracellular matrix
ICH-3 4.4 Apoptosis
PIM-1 4.3 Proto-oncogene; cell proliferation
GRO/KC -21 Secreted; chemokine
c-fos -13 Oncogene; cell proliferation
Mel-Nl -9.0 RNA-binding protein
FAH -6.7 Metabolism
MKP-1 -5.5 Regulation; phosphatase
MIP-2 -5.4 Secreted; chemokine
TGIF -4.4 Transcriptional co-repressor
CXCR4 -4.0 Chemokine receptor
STAT1 -/- MCP-1 2 0 Secreted; chemokine
TDAG-51 12 Apoptosis
Lice2 cysteine protease 7.6 Apoptosis
IL-13 6.9 Secreted; chemokine
PRP-8 5.0 Splicing factor
PIM-1 5.0 Proto-oncogene; cell proliferation
Fibronectin 4.1 Extracellular matrix
SOCS-3 4.0 Cytoplasmic; regulation
A-X actin -33 Cell motility; inhibits metastasis
TI-227 -9.1 Metastasis
Melanoma X actin -8.0 Cell motility; inhibits metastasis
MgluR8 -5.1 Receptor
Zfx -4.5 Transcription
Rb -4.2 Tumor suppressor
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Soler et al. (2003) showed that nucleoside transporter activity is differentially 
regulated by IFN-y in STATl-null macrophages. STAT1 was required for the inhibiton 
of equilibrative nucleoside transporter (ENT) activity through posttranscriptional 
actions and for the inhibition of cell growth by IFN^y. However, the activity and 
expression of concentrative nucleoside transporters (CNT) was regulated by IFN-y 
independently of STAT1, as was the downregulation of ENT mRNA expression (Soler 
et al. 2003).
1.8.2 Potential pathways for STATl-independent regulation of IFN^y-modulated gene 
expression
Inhibition of JAK1 using a dominant negative mutant has shown certain antiviral 
responses that require the presence of functional JAK1 in addition to active STAT1, 
indicating that JAK1 has a role in the activation of other signalling molecules 
(Briscoe et al. 1996). Many genes regulated independently of STAT1 may still 
require the involvment of JAKs for IFN-y-induced stimulation of transcription. In 
support of this hypothesis, the expression of M IP-la, IL-ip and arginase genes 
(shown to be STATl-independently regulated) was not induced by IFN-y in JAK1- 
deficient BMMs (Gil etal. 2001).
Activated JAKs interact with a range of SH2 domain-containing proteins and IFN-y- 
induced tyrosine phosphorylation at certain sites in the Kinase domain may provide 
binding sites for other proteins. The Src-family Kinase Fyn, for example, has been 
shown to bind to JAK2 via a SH2 domain, although the downstream targets of this 
Kinase in IFN-y-dependent signalling are unKnown (Uddin et al. 1997). Other sites 
on IFN-yR are also phosphorylated by JAKs, in addition to the STAT1 binding site. 
These could provide docKing sites for other signalling molecules (Ramana et al. 
2002, Rane and Reddy 2000, Aringer et al. 1999). More detailed studies involving 
inhibition of JAK1 and JAK2 are required to fully understand the roles of these 
proteins in STAT-independent signalling.
The adapter molecules c-Cbl, CrKL, and CrKII are recruited by IFN-yR upon ligand 
binding. Alsayed etal. (2000) demonstrated that treatment of cells with IFN-y leads
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to tyrosine phosphorylation of c-Cbl, which in turn provides a binding site for CrkL. 
Phosphorylated CrkL then activates C3G, a guanine nucleotide exchange factor and 
Rapl. Rapl is small G protein known to mediate some growth inhibitory responses. 
This pathway occurs in response to IFN-y without the formation of CrkL-STAT 
complexes induced in IFN-a and p signalling, and so may be STAT-independent 
although receptor phosphorylation by JAK proteins may still be required (Alsayed et 
al. 2000, Platanias et al. 1999).
1.8.2.1 Transcription factors potentially involved in STATl-independent signalling
1 .8 .2 .1 .1  NF-kB
The NF-kB family of transcription factors are dimeric complexes composed from a 
collection of subunits related by a conserved DNA-binding and dimerisation region, 
the Rel homology (RH) domain. Certain members are inactive (p l0 5 /5 0  and 
plOO/52) and only function as transcriptional activators when they form 
heterodimers with proteins from a second subset (p65 (RelA), Rel (c-Rel) and RelB). 
The original NF-kB transcription factor characterised was the p50-p65 heterodimer. 
In unstimulated cells, NF-kB dimers are sequestered in the cytoplasm by an IkB 
inhibitory protein that blocks the nuclear localisation sequence. Activating stimuli 
cause the phosphorylation of an IkB kinase (IKK) complex (consisting of IKK-a, IKK- 
P and IKK-y subunits) that specifically phosphorylates IkBs targeting them for 
ubiquitination and degradation. The removal of IkB exposes the nuclear 
localisation sequence and various phosphorylation sites required for the activation 
and translocation of NF-kB to the nucleus. Active NF-kB binds to a decameric DNA 
sequence (consensus sequence: GGG[A/G]NN[C/T][C/T]CC) in the promoter of 
target genes to regulate transcription (Delhalle etal. 2004, Li and Stark 2002).
Activation of NF-kB has been implicated in a number of inflammatory responses 
and it may be an important transcriptional regulator in atherosclerosis (Monaco and 
Paleolog 2004, Collins and Cybulsky 2001). NF-kB is activated by several 
proinflammatory cytokines, most notably TNFa and IL-1 (Sizemore etal. 2002, Koul 
et al. 2001, Wang and Baldwin 1996). The transcriptional potential of NF-kB may 
be regulated at a number of stages (e.g. by phosphorylation of IkB, IKK or the
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p65/p50 subunits). The Kinase CK2 and downstream Kinases of PI3K (discussed 
further in Sections 1.10 and 1.9 respectively) have been shown to phosphorylate 
components of the NF-kB signalling pathway. For instance CK2 can phosphorylate 
and induce the degradation of IkB (Kato etal. 2003, Meggio and Pinna 2003). The 
activation of protein Kinase B (PKB) by PI3K leads to the phosphorylation of p65 in 
a pathway that is dependent on IKK-a and -p activity but not the degradation of IkB. 
PKB has been shown to associate with IKK-a in response to IL-1 and may 
phosphorylate the Kinase directly (Sizemore etal. 1999, Madrid etal. 2000, Koul et 
al. 2001, Sizemore et al. 2002).
Hwang et al. (2004) have demonstrated PI3K-dependent stimulation of NF-kB DNA 
binding and expression from a reporter construct regulated by NF-kB, in response to 
IFN-y. This study demonstrated that the induction of iNOS expression by IFN-y 
occurred in a PI3K-dependent pathway and that PI3K also regulated the 
phosphorylation of STAT1 in microglial cells. NF-kB may then function in synergy 
with, or independent of, STAT1 in the IFN-y-mediated regulation of iNOS expression 
(Hwang et al. 2004). A study by Sizemore et al. (2004) indicated that the 
expression of a subset of IFN-y-stimulated genes in MEFs is dependent on the 
presence of functional IKK but without a requirement for NF-kB. In this case IFN-y 
has no effect on the activity of a NF-kB reporter construct (Sizemore et al. 2004). 
NF-kB binding sites have been found alongside GAS/ISRE sites in the promoter of 
several genes for which the transcription factor may function in synergy with STATs 
(Hiroi and Ohmori 2003, Liu et al. 2001, Ohmori and Hamilton 1995, Ohmori and 
Hamilton 1993). Alternatively Deb et al. (2001) have suggested that PKR (also 
linKed to the activation of STAT1 in response to IFN-y (Section 1.7)) may activate NF­
kB through the phosphorylation of IkB in a JAKl-mediated, but STATl-independent 
mechanism (Deb et al 2001, Kumar et al. 1997, Yang et al. 1995).
1.8.2.1.2 AP-1
The AP-1 family of transcription factors are characterised by a highly conserved 
basic-leucine zipper domain at the C-terminus. AP-1 transcription factors are homo- 
or heterodimers composed of members of the Fos (c-Fos, FosB, Fral, Fra2) and Jun 
(c-Jun, JunB, JunD) protein families. Signalling is mediated through binding to an
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AP-1 site, also known as a TRE (consensus sequence: TGA[C/G]TCA), in the 
promoter of target genes. They are often involved in constitutive gene expression 
but are also regulated transcriptionally and by post-translational modifications in 
response to a number of cytokines and growth factors (e.g. IL-lp, TNF-a, EGF, 
PDGF) (Granger et al. 2000, Karin et al. 1997, Angel and Karin 1991). AP-1 
transcription factors are commonly regulated by MAPKs including ERKs and c-Jun 
amino-terminal protein kinase (JNK) (Karin 1995) but other kinases also regulate 
transcriptional activity including CK2 (Lin et al. 1992) and downstream effectors of 
PI3K independent of JNK or the MAPKs, MEK and p38 (Bian et al. 2004).
AP-1 transcription factors regulate the expression of many inflammatory genes and 
often function in synergy with N F-k B (Allport et al. 2 0 0 0 ,  Ahmad et al. 1998, Martin 
et al. 1997). Regulation of gene expression by AP-1 plays an important role in the 
pathogenesis of glomerular inflammatory disease (Granger etal. 2 0 0 0 ,  Sakurai and 
Sugita 1998) and it is possible that it may also be involved in other inflammatory 
disease processes, including atherosclerosis.
The promoter of the interferon-inducible HIN-200 family gene IF I16 has been found 
to contain a functional binding site for AP-1 transcription factors, in a region critical 
for constitutive expression of the gene. DNA binding for AP-1 was increased by IFN- 
y treatment as was the induction of AP-1 driven reporter genes. This activation of 
AP-1 appeared to be a primary effect of IFN-y treatment as increased binding 
activity was observed after only 10 minutes. Activation of AP-1 binding has 
therefore been proposed as a STAT-independent mechanism for expression of IFN-y 
inducible genes. Other signalling molecules involved in this pathway are unknown 
and again there may be a requirement for JAKs (Clarke etal. 2003).
1.8.2.1.3 C/EBPs
CCAAT/enhancer binding proteins (C/EBPs) are a family of transcription factors that 
contain a conserved basic-leucine zipper (bZIP) domain at the C-terminus. There 
are six C/EBP isoforms (C/EBP-a, -p, -y, -6, -e, and -Q all of which mediate 
transcription through an optimal C/EBP binding element (consensus sequence: 
[A/G]TTGCG[C/T]AA[C/T]). C/EBPs have important roles in the regulation of cellular 
differentiation and proliferation, metabolism and inflammation. The gene
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expression of C/EBP family members is regulated by a number of inflammatory 
mediators including LPS, IL-1, IL-6, IFN-y and TNF-a. The C/EBP-p isoform is the 
most highly regulated by posttranslational modifications and its activity is controlled 
by two central regulatory domains (reviewed in Ramji and Foka 2002, Poli et al. 
1998). The cytokines IL-6 (Poli et al. 1990), TGF-a (Buck et al. 1999) and TNF-a 
(Yin et al. 1996), as well as IFN-y (see below), have been shown to alter the 
transcriptional activity of C/EBP-p. Kinases that have been shown to phosphorylate 
C/EBP-p include protein kinase C (PKC) (Trautwein etal. 1993) and protein kinase A 
(PKA) (Trautwein etal. 1994).
IFN-y has been shown to enhance both the DNA binding activity and expression of 
C/EBP-p (Roy et al. 2005, Esteban et al. 2004, Salmenpera et al. 2003, Xiao et al. 
2001, Roy et al. 2000). C/EBP-p expression has also been shown to be induced by 
IFN-y in STATl-null fibroblasts (Ramana eta l. 2001). ERK1 and ERK2, activated by 
IFN-y through Pyk2, have been described in relation to a novel IFN-y activated 
pathway that appears to be independent of JAK1 activation. C/EBP-p is activated 
through ERKs following stimulation by IFN-y and induces gene expression via 
binding to a novel promoter element, GATE, characterised in the IRF9 (p48) 
promoter (Roy 2002, Hu et al. 2001, Xiao et al. 2001, Roy et al. 2000). This 
pathway appears to be dependent on STAT1 as neither the activation of ERKs or 
GATE-binding is induced in STATl-deficient cells. However, the response is 
unaffected by deficiency of JAK1 (Hu etal. 2001). A separate study has also shown 
that the activation of C/EBP-p is not attenuated by inhibitors of tyrosine 
phosphorylation and may therefore be independent of JAK1/JAK2 signalling. In this 
study, C/EBP-p DNA binding activity was found to be induced by IFN^y prior to an 
increase in gene expression (Salmanpera et al. 2003). The activity of C/EBP-p has 
also been shown to be regulated by IFN-y through mixed lineage kinases (MLK), 
independent of ERK activation (Roy et al. 2005). C/EBP-p may regulate the IFN-y- 
stimulated expression of IRF-9 in synergy with the transactivating factor GATE- 
binding factor (GBF)-l, the expresson of which is induced by IFN-y (Meng et al. 
2005, Hu et al. 2002). C/EBPs may also operate in synergy with STATs as a 
complex of IRF and C/EBP has been found to be induced by IFN-y in the regulation
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of IL-18BP gene expression (Hurgin et al. 2002). Stat3 and C/EBP-a have been 
shown to cooperatively regulate gene expression in response to GM-CSF (Numata et 
al. 2005).
1.8.2.1.4 S p l/S p3
The Sp family of transcription factors are characterised by three zinc finger motifs at 
the C-terminus. There are four Sp proteins (Spl-4) and several closely related 
transcription factors including BTEB1, TIEG1, TIEG2 and the Kruppel-like factors 
(XKLFs). Sp l, Sp3 and Sp4 are the most closely related proteins and of these S p l 
and Sp3 are ubiquitously expressed while the expression of Sp4 appears to be 
confined to specific cell types, particularly in the brain (reviewed in Philipsen and 
Suske 1999, Suske 1999, Lania et al. 1997). S p l acts predominantly as a 
transcriptional activator while Sp3 may act as a repressor or as a transcriptional 
activator in the context of the promoter (Ross et al. 2002, Noti 1997, Dennig et al. 
1995, Hagen et al. 1994). Sp transcription factors regulate gene expression 
through binding to a GC-box element (consensus sequence: CACCC) in the promoter 
of target genes. S p l has been found to be important for the constitutive expression 
of a number of housekeeping genes and those involved in cellular processes such 
as cell growth, proliferation and apoptosis (Black etal. 2001, Black etal. 1999), but 
inducible regulation has also been demonstrated: for example in response to EGF 
(Merchant et al. 1995); TNF-a (Ryuto et al. 1996, Giraudo et al. 1998); PDGF 
(Finkenzeller et al. 1997); IL-l-p (Tanaka et al. 2000); and IL-2 (Too 1997). 
Constitutive gene expression controlled by GC elements is often downregulated in 
response to stimuli by the phosphorylation of Spl/Sp3, so reducing their DNA 
binding activity {e.g. Meissner et al. 2004, Ye and Liu 2002, Zhang and Kim 1997). 
Spl/S p3 have been shown to be phosphorylated by kinases including PKA (Rohlff 
et al. 1997), PKB (Pore et al. 2004) and CK2 (Armstrong et al. 1997, Zhang and 
Kim 1997)
The GC box is often located near binding sites for other transcription factors 
suggesting that Sp proteins may act to regulate gene expression in conjunction with 
other proteins such as NF-kB (Neish etal. 1995, Sanceau etal. 1995, Perkins etal. 
1993), Smads (Pardali et al. 2000), and C/EBPs (Lee et al. 1997), as well as STATs
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(Yangetal. 2005, Ward and Samuel 2003, Cantwell etal. 1998, Too 1997, Look et 
al. 1995, Sanceau et al. 1995)
Studies in our laboratory have shown the suppression of macrophage LPL 
expression by IFN-y (Tengku-Muhammed et al. 1999a, Tengku-Muhammed et al. 
1998, Tengku-Muhammed et al. 1996). Promoter analysis and electrophoretic 
mobility shift assays (EMSA) revealed that the IFN-y response was mediated through 
a reduction in the binding of S p l and Sp3 to specific regulatory sequences in the 
gene promoter. IFN-y treatment reduced protein levels of Sp3 while the DNA- 
binding activity of S p l was inhibited without a change in protein level. CK2 was 
found to be responsible for these changes through the phosphorylation of S p l and 
Sp3 (Hughes et al. 2002).
I.8 .2 .3 .5 CREB
Transcriptional regulation coupled to cAMP-dependent signalling pathways is 
mediated through a family of DNA binding proteins comprising the cAMP response 
element binding protein (CREB), cAMP response element modulator protein (CREM), 
and activating transcription factors (ATF). These proteins belong to the bZIP class of 
transcription factors and bind to cAMP-responsive elements (CRE) (consensus 
sequence: TGACGTCA) in the promoter and enhancer regions of target genes (Antoni 
2000).
The activity of CREB has been shown to be both positively and negatively regulated 
by cytokines (including IFN-y (Liu etal. 2004, Mead etal. 2003)) and growth factors 
(Zhang et al. 2004, Jambal et al. 2003, Shaywitz and Greenburg 1999). Several 
kinases are able to phosphorylate CREB including PKA, PKC, CK2 (Meggio and 
Pinna 2003, Xie and Rothstein 1995, Gonzalez et al. 1989) and potentially PKB 
(Pugazhenthi et al. 2000, Du and Montminy 1998). In a previous study, our 
laboratory demonstrated that the phosphorylation of CREB at Ser-133 was 
increased by IFN-y and that this response was inhibited by the CK2 inhibitor 
apigenin. The activation of CREB was coupled to the upregulation of the inducible 
cAMP early repressor (ICER) gene expression, mediated by IFN-y through CRE-like 
elements known to bind CREB. This reponse was not inhibited by the JAK2 inhibitor 
AG490 and is potentially JAK-STAT independent (Mead etal. 2003) (Section 1.11).
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1.8.2.2 Functional redundancy in JAK-STAT signalling
The possibility remains that IFN-y responsive signalling in STAT1- and JAK1/2- 
deficient cells is mediated, in the absence of these factors, by other family 
members. Ramana et al. (2005) have recently shown that the regulation of SOCS-3 
in STATl-null BMMs occurs through STAT3 binding to the GAS element. Kotenko et 
al. (1996) have demonstrated that other JAKs can function in place of JAK2 when 
recruited to the IFN-yR complex. Chimeric receptors were generated in which the 
extracellular domain of human IFN-yR2 was fused to the intracellular domain of 
other receptors. Hamster cells expressing the chimeric receptor and human IFN- 
yR l were able to support STAT1 dimerisation in response to human IFN-y (Kotenko 
et al. 1996).
Studies in our laboratory have revealed potential roles for the kinases PI3K and 
CK2 in the regulation of the genes LPL and inducible cAMP early repressor (ICER) by 
IFN-y (Tengku-Muhammad et al. 1999b, Hughes et al. 2002, Mead et al. 2003). 
Additionally, the findings from a review of the current literature, suggest that these 
kinases may be important mediators in IFN-y signalling. The potential roles of PI3K 
and CK2 in the regulation of gene expression by IFN-y are presented in more detail 
in the following sections (Section 1.9 and 1.10 respectively).
1 .9  Role of Phosphoinositide 3-Kinase in IFN-y Signalling
1.9.1 Biological and pathological roles of PI3K-dependent signalling
PI3K is a member of a family of lipid kinases involved in multiple cellular processes 
including cell growth, proliferation, differentiation, motility, platelet function and 
cytoskeletal remodelling (Krasilnikov 2000, Ramey and Cantley 1999, Fruman et al. 
1998). PI3K-dependent signalling is implicated in a number of disease processes: 
mutations resulting in activation of PI3K signalling pathways lead to tumor 
formation (Stokoe 2005, Brader and Eccles 2004, Fruman 2004a, Xu et al. 2004, 
Vivanco and Sawyers 2002, Philp et al. 2001); while diabetes can be caused by 
defects in PI3K signalling (Shepherd etal. 1998, Cho etal. 2001).
In the immune response PI3K may be activated by a variety of stimuli including 
cytokines (e.g. IL-2, IL-3, IL-4, IL-5), chemokines (e.g. MCP-1, IL-8) and growth
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factors (e.g. PDGF, EGF) (Fruman 2004b, Fruman and Cantley 2002, Deane and 
Fruman 2004). Roles for PI3K have been proposed In pulmonary inflammation and 
asthma (Condliffe et al. 2000), and in macrophage accumulation in the 
inflammatory response (Navarro et al. 2003, Gerszten et al. 2001, Hirsch et al. 
2000). A proatherogenic role for PI3K is indicated by the finding that LDL-R- 
deficient mice receiving bone marrow transplantation with p l00 5  Knock-out bone 
marrow display reduced atherosclerosis formation in comparison to those receiving 
wild type bone marrow (Pinderski et al. 2005). This is potentially due to an 
increased accumulation of macrophage foam cells mediated by the 
proinflammatory effects of PI3K-dependent signalling. Additionally, proliferation 
and migration of VSMCs in pulmonary tissue has been demonstrated to require 
PI3K activation (Goncharova et al. 2002). OxLDL has also been shown to increase 
the activity of PKB in these cells and may contribute to the accumulation of SMCs in 
the atherosclerotic lesion (Chien et al. 2003). Recent reviews discuss the function 
of PI3K in cardiovascular disease (Alloatti et al. 2004, Oudit et al. 2004).
1.9.2 Isoforms of PI3K
There are three classes of PI3K in mammalian cells (referred to as Class I, II and III). 
Class I PI3Ks are the most extensively studied and are generally activated in 
response to extracellular stimuli. Class IA PI3K are composed of a p llO  catalytic 
subunit (a ,(3 and 5) and a regulatory subunit (p85a, p85p, p85y and p55, p50 that 
are generated from alternative splicing of the p85a transcript) while Class IB PI3K 
(PI3Ky) consists of a p llO y  catalytic subunit and a p lO l regulatory subunit. There 
are three Class II isoforms (PI3K-C2a, (3 and y), all of which are monomeric enzymes 
that preferentially phosphorylate phosphoinositol (PI) and PI(4)P, the functions of 
which are unclear at present. Class III PI3K are heterodimeric, composed of a 
Vps34P catalytic subunit and a p l5 0  regulatory subunit. They utilise only PI as a 
substrate and are responsible mostly for the regulation of intracellular vesicular 
trafficking processes (Hawkins et al. 2004, Cantrell 2001, Rameh and Cantley 
1999, Fruman et al. 1998).
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1.9.3 Activation and enzymatic activity of PI3K
In cells of the immune system the activity of PI3K is regulated by a variety of 
cytokine receptors. Activation of Class IA PI3K occurs in response to a range of 
cytokines and growth factors through phosphorylation by receptor-associated 
tyrosine kinases (e.g. IL2 and GM-CSF receptors) or receptors with intrinsic tyrosine 
kinase activity (e.g. PDGF, insulin and EGF receptors) (Deane etal. 2004, Fruman et 
a/. 2004, Fruman and Cantley 2002). PI3Ky is activated primarily through G-protein 
coupled receptors often in response to stimulation by chemokines (Curnock et al. 
2002, Hirsch etal. 2000).
Active PI3K catalyzes the formation of 3-phosphorylated phosphatidylinositols (by 
phosphorylation of the inositol ring of PI) that then serves to activate downstream 
signalling targets. The most common reaction is the conversion of PI(4,5)P2 to 
PI(3,4,5)P3 by Class I PI3Ks. Downstream protein kinases are subsequently 
recruited to the membrane through the binding of pleckstrin homology (PH) 
domains to PI(3,4,5)P3, where they are brought into proximity with their targets 
(Hawkins et al. 2004, Neri et al. 2002, Cantrell et al. 2001). The most widely 
studied of these are 3'-phosphoinositide-dependent protein kinase (PDK)-1 and its 
substrate PKB (often referred to as Akt), which regulates the activity of a number of 
downstream effectors including GSK-3, mTOR, IkB and the transcription factor 
forkhead (FRKD). PDK-1 also activates the kinases p70(S6K) and isoforms of PKC 
(Bjornsti and Houghton 2004, Yang et al. 2004, Cantley et al. 2002, 
Vanhaesenbroeck and Alessi 2000). Negative regulation of PI3K signalling is 
mediated largely by the protein phosphatases PTEN and SHIP (Hawkins et al. 2004, 
Neri et al. 2002, Cantrell et al. 2001). These signalling mechanisms are 
summarised in Figure 1.3. A less well-characterised aspect of PI3K is its function 
as a protein kinase. For example class I PI3K can phosphorylate serine residues of 
protein substrates such as insulin receptor substrate (IRS)-l in response to insulin 
signalling (Foukas and Shepherd 2004, Lam etal. 1994).
1.9.4 PI3K and the JAK-STAT pathway
Several studies have linked PI3K signalling to the JAK-STAT pathway. Stimulation of 
cells with IFN-y has been shown to cause the activation of PI3K and increased 
phosphorylation and activation of its downstream effector PKB (Hwang et al. 2004,
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Navarro 2003, Nguyen et al. 2001). Studies have indicated that, in certain cell 
lines, the phosphorylation of STAT1 at Serine 727 in response to IFN-y is dependent 
on the activation of PI3K and downstream effectors such as PKB (Choudhury et al. 
2004, Kristof et al. 2003, Nguyen et al. 2001). While most of the work carried out 
suggests that PI3K is not necessary for the IFN-y-stimulated phosphorylation of 
STAT1 at Tyrosine 701, Hwang et al. (2004) have found inhibition of 
phosphorylation at this site by the specific PI3K inhibitor LY294002 in microglial 
cells. Other work has suggested a negative role for PI3K in the regulation of STAT1 
transcriptional activity, whereby PI3K signals inhibit tyrosine phosphorylation of 
JAKs or STATs (Krasilnikov et al. 2003). JAK1 and JAK2 have both been found to be 
associated with the p85 regulatory subunit of PI3K in response to stimulation by 
LPS, leukaemia inhibitory factor (LIF), growth hormone (GH) and prolactin (PRL) 
(Okugawa et al. 2003, Oh et al. 1998, Yamauchi et al. 1998). IFN-aR also 
associates with PI3K following stimulation with IFN-a leading to activation of the 
kinase (Thyrell et al. 2004, Uddin et al. 2000, Pfeffer et al. 1997). Recruitment of 
PI3K to the IFN-yR complex upon treatment with IFN-y may lead to its activation 
through JAKs (Rane and Reddy 2000, Aringer et al. 1999). However Nguyen et al. 
(2001) have found that the activation of PI3K in response to IFN-y is not attenuated 
in JAK1- or JAK2-deficient cells. It is therefore possible that, in addition to its role in 
the regulation of STAT1, it may also take part in JAK-STAT-independent signalling 
pathways through the phosphorylation of other mediators.
A potential PI3K-dependent, STAT1-independent pathway has been proposed by 
Navarro etal. (2003) in the IFN-y-mediated adhesion of monocytes in inflammation. 
IFN-y stimulates the adhesion of both wild type and STATl-deficient macrophages 
and this is abrogated by inhibitors of PI3K activity. These inhibitors were not found 
to affect the STATl-dependent expression of guanylate binding protein (GBP) 
(Navarro et al. 2003). The adapter molecule c-Cbl, discussed previously in relation 
to STAT1-independent mediation of IFN-responses (Section 1.8), is also recruited to 
the membrane in response to PI3K activation (Beckwith et al. 1996). Activation of 
PI3K has been shown to lead to the regulation of a number of transcription factors 
that modulate inflammatory genes, including NFkB and AP-1 (see Section 1.8).
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These factors could potentially be involved in STATl-independent gene expression 
in response to IFN-y or function in synergy with STAT1.
PI(4,5)P2 PI(3,4,5)P3 PI(3,4)P2
Receptor
SHIP
Downstream effectors 
e.g. PKB, PDK-1, PKC, mTOR, 
GSK3, S6K, IkB
Transcription factors 
e.g. FRKD, STAT1, NFkB
PTEN
(\
Downstream effectors of PI3K
The conversion of PIP2 to PIP3 is catalysed by PI3K, providing a docking site for 
downstream kinases such as PDK-1 and PKB. PTEN and SHIP antagonise PI3K 
signalling by converting PIP3 to PI(4,5)P2 and PI(3,4)P2 respectively. PKB is 
activated by phosphorylation by PDK-1 and these kinases regulate a number of 
other signalling molecules including PKCs, GSK-3 and mTOR (which subsequently 
activates S6K). This leads, either directly or indirectly, to the regulation of 
transcription factors and gene expression.
Abbreviations: FRKD, forkhead; GSK3, glycogen synthase kinase 3; IkB, inhibitor of kB; mTOR, 
mammalian target of rapamycin; NFkB, nuclear factor kB; PDK1, 3'-phosphoinositide-dependent 
protein kinase; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidyl inositol bisphosphate; PIP3, 
phosphatidyl inositol triphosphate; PKB, protein kinase B; PKC, protein kinase C; PTEN, phosphatase 
and tensin homologue on chromosome 10; S6 K, S6  kinase (p70); SHIP, src homology 2-containing 
inositol phosphatase; STAT, signal transducer and activator of transcripton.
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1.10 Role of Casein Kinase 2 in IFN-y Signalling
1.10.1 Structure and regulation of CK2
Casein kinase 2 (CK2) is a multifunctional protein kinase found ubiquitously in 
eukaryotic organisms. In the cell CK2 has been found in both the nucleus and the 
cytoplasm and in association with the plasma membrane, golgi and endoplasmic 
reticulum (ER) (Filhol et al. 2003, Faust et al. 2002, Faust et al. 2001). The 
structure is generally tetrameric, consisting of two catalytic a  subunits and two 
regulatory p subunits (Figure 1.4). Three catalytic isoforms have been identified in 
humans, CK2a, CK2a’ and CK2a”, the latter being identified fairly recently and 
therefore less well characterised than the other two. Only one regulatory subunit 
(CK2P) has been found in humans although additional isoforms appear to be 
present in the yeast Saccharomyces cerevisiae (reviewed in Litchfield 2003, Pinna 
2003, Pinna 2002, Pinna 1997).
CK2 is unusual in that it is constitutively active despite having a quaternary 
structure, which usually suggests tight regulation of activity. Both catalytic isoforms 
are active in isolation and as part of the holoenzyme. While they are structurally 
similar, a  and a ’ do demonstrate some differential functions (Litchfield 2003, Pinna 
2003, Pinna 2002, Pinna 1997). The precise role of the p subunit is unclear as it is 
not essential for the activation of the enzyme although it does have both positive 
and negative regulatory roles in the holoenzyme. It may act as a docking platform 
for the recruitment of substrates and the subunit interacts with a variety of different 
proteins. CK2p has also been suggested to have functions independent of CK2a 
subunits and is found in cellular locations where CK2a is not present (Bibby and 
Litchfield 2005). The ability of CK2 to phosphorylate its substrates is dependent 
upon either ATP or, unusually, GTP binding to the a  subunit. Crystallographic 
studies have shown that the ATP binding pocket of only one of the a  subunits of the 
holoenzyme is occupied at any one time but the physiological relevance of this is 
not known (Litchfield 2003, Pinna 2003, Pinna 2002, Pinna 1997).
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A.
C-tcrminus of CK2a —
N-terminus of CK2u
C-terminus of 
CK2B
ATP Binding SiteAMPPNP
i
N-terminus of CK2p
B.
Positive and negative regulation
Responsiveness to stimulators 
Interaction with cellular partners
Catalytic activity 
Site recognition 
ATP/GTP binding
Figure 1.4 Structure of the CK2 tetramer
A. CK2 has a tetrameric structure composed of two catalytic a-subunits (magenta) and 
two regulatory p-subunits (yellow and blue). The non hydrolysable ATP analogue 
adenosine 5 ’-[P.Y-imido]triphosphate (AMPPNP) is present in the ATP binding site of only 
one of the catalytic CK2a subunits within the CK2 tetramer. The significance of this 
observation is unknown (adapted from Litchfield 2003).
B. Schematic representation of the CK2 holoenzyme detailing the functional sites 
(adapted from Pinna 1997)
Abbreviations: ATP, adenosine triphosphate; CK2, casein kinase 2; GTP, guanidine triphosphate.
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While CK2 is found in all eukaryotic cells, tissue specific regulation of CK2 
expression is evident, with high levels of expression in the brain and low levels in 
the heart and lung (Litchfield 2003, Pinna 2003, Pinna 2002, Pinna 1997). 
Expression is also increased during certain stages of embryogenesis and in rapidly 
proliferating cells (Issinger 1993). Despite constitutive activity the kinase is subject 
to inducible regulation by a variety of stimuli, including IFN-y (Mead et al. 2003), 
EGF (Peppercock eta l. 1991), TNF-a (Sayed et al. 2000) and ultraviolet (UV) B light 
(Brenneisen et al. 2002) although the processes by which this occurs are largely 
unknown. Evidence suggests roles for phosphorylation, regulated assembly and 
regulatory interactions (reviewed in Litchfield 2003). CK2 appears to be acidophilic 
in nature and phosphorylates serine or threonine residues in the region of acidic 
amino acids (in particular asparate and glutamate) although studies have shown 
that it may also phosphorylate certain tyrosine residues (Wilson etal. 1997, Meggio 
et al. 1994).
1.10.2 Biological Roles of CK2
Both a  and p subunits of CK2 have been found to be essential for viability and are 
highly conserved between different species (homology of CK2a between humans 
and plants is 73%, between humans and mice is 98-99%, CK2P is particularly well 
conserved with 100% homology between birds and humans) (Xu et al. 1998, 
Maridor et al. 1991, Litchfield et al. 1990, Lozeman et al. 1990). So far over three 
hundred potential physiological targets of CK2 have been identified, consistent with 
the pleiotropic nature and constitutive activity of this kinase. These include proteins 
involved in a diverse range of cellular functions although a large proportion are 
involved in mechanisms for gene expression and protein synthesis, including: 
transcription factors (e.g. CREB, CREM, c-Jun, IRF-1 and IRF-2); translational 
elements (e.g. elF2p); and effectors of DNA/RNA structure (e.g. RNA binding protein 
L5); while only a few are enzymes involved in metabolic pathways (e.g. glycogen 
synthase) (Meggio and Pinna 2003).
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CK2 is involved in the regulation of basic transcriptional apparatus and substrates 
include all three RNA polymerases (Pol I, II and III) and TFIIIB-TBP and CK2 activity 
has been shown to be necessary for synthesis of certain tRNA and 5S rRNA 
(Cabrejos et al. 2004, Hu et al. 2003, Johnston et al. 2002). A number of studies 
have implicated CK2 in cellular processes such as modulation of proliferation, 
apoptosis, regulation of cell morphology and the cell cycle (Canton and Litchfield 
2005, Ahmed et al. 2002, Sayed et al. 2002, Lebrin et al. 2000, Pinna and Meggio 
1997, Pepperkok etal. 1994).
1.10.3 Role of CK2 in disease
Many viral proteins are also substrates of CK2. The constitutive activity of this 
enzyme may have lead to its adoption as a method for the phosphorylation of 
proteins essential to the life cycle of certain viruses (e.g. latent membrane protein 
(LMP)-l and ZEBRA protein of the Epstein-Barr virus (Chi et al. 2002, Kolman et al. 
1993), IE63 protein of the herpes simplex virus (Wadd etal. 1999) and the HIV rev 
protein (Marin et al. 2000)). CK2 is also found in increased levels in certain 
tumours and has been suggested to impart oncogenic potential on cells through 
promotion of cell survival and increased proliferation (Romieu-Mourez et al. 2002, 
Landesman-Bollag et al. 2001a, Landesman-Bollag et al. 2001b, Faust et al. 1996, 
Stalter et al. 1994). Inhibition of CK2 with dominant negative constructs has been 
demonstrated to lead to the apoptosis of cancer cells (Wang et al. 2001). 
Increased proliferation through CK2 signalling may also have a role in lesion 
progression in atherosclerosis. Yamada et al. (2005) have shown through 
microarray analysis that CK2a expression is upregulated in proliferative glomerular 
lesions in a rat model of the inflammatory disease glomerulonephritis. They 
subsequently found that expression of antisense CK2a prevented the progression 
of renal pathology in the disease (Yamada et al. 2005). Similar pathways may have 
a role in the pathology of atherosclerosis.
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1.10.4 CK2 and the JAK-STAT pathway
Few studies have addressed the potential role of CK2 in IFN-y signalling. Our 
laboratory has shown that CK2 activity is induced by IFN-y and that this is not 
inhibited by the JAK2 inhibitor AG490 (Mead et al. 2003, Evans, S., personal 
communication). Use of the pharmacological inhibitor of CK2, apigenin, implicated 
CK2 in the regulation of LPL and ICER in response to IFN-y, through the 
phosphorylation of S p l/S p3 and CREB respectively (see Sections 1.8 and 1.11) 
(Mead et al. 2003, Hughes et al. 2002). Other transcription factors may also be 
regulated by CK2 (e.g. NFkB) (see Section 1.8). Higashi et al. (2003) have shown 
that CK2 is involved in the IFN-y-mediated suppression of a2(l) procollagen gene 
expression through the regulation of Y-box binding protein (YB)-l in a potential JAK- 
STAT-independent pathway. They found that apigenin did not affect the 
phosphorylation (at Tyrosine 701) or nuclear translocation of STAT1 while inhibiting 
the effect of IFN-y on the translocation of YB-1. This response was also unaffected 
by AG490 while the inhibitor prevented the IFN-y-mediated phosphorylation and 
nuclear translocation of STAT1 (Higashi etal. 2003).
l . i i  Inducible cAMP E arly  Repressor
IFN-y has been found to stimulate a dramatic, transient increase in ICER expression 
in the murine macrophage cell line J774.2. This induction was found to be 
mediated through the phosphorylation and activation of CREB by CK2 (Mead et al.
2003). ICER may be potentially responsible for suppressing the expression of 
several genes regulated in response to IFN-y through CREs. The LPL gene for 
example, the expression of which is down-regulated in response to IFN-y and also in 
synergy with cAMP, has promoter sites potentially able to bind ICER (Enerback and 
Gimble 1993). Another study has demonstrated the ability of IFN-y to suppress 
CRE- or bZIP containing AP-1 regulated promoters (Saavedra etal. 2001).
1.11.1 Structure of ICER
ICER is a member of a family of DNA-binding proteins that mediate transcriptional 
regulation in response to cAMP. The action of these proteins is mediated through 
binding to CREs in the promoter of target genes. While CREB, CREM and ATF up-
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regulate the expression of target genes, ICER lacks a trans-activation domain and 
hence inhibits transcription either by competing for DNA-binding or by 
heterodimerisation with other family members (De Cesare and Sassone-Corsi 2000, 
Shaywitz and Greenburg 1999, Della-Fazia etal. 1997, Molina etal. 1993).
The CREM gene contains two promoters, Pi and an internal promoter, P2. Isoforms 
of CREM are produced following activation of the Pi promoter. The alternative 
promoter (P2), containing tandem CRE-like elements known as cAMP-autoregulatory 
elements (CAREs), regulates the expression of ICER. Thus ICER expression can be 
regulated by CREB/CREM/ATF and by ICER itself. Four isoforms of ICER (ICER I, 
ICER ly, ICER II and ICER lly), that appear to be functionally indistinct, result from 
alternative splicing of the ICER transcript (illustrated in Figure 1.5) (Shaywitz and 
Greenburg 1999, De Cesare and Sassone-Corsi 2000, Molina etal. 1993).
Primer 1 Primer 3
DBD2ICER DBD1
ATG TAA TAG
(STOP) (STOP)
ICER I
ICER \y
ICER II
ICER lly
Figure 1.5 Domain structure of the four isoforms of ICER
Boxes represent the different exons (ICER, y, H, DBD1 and DBD2) of the ICER- 
encoding region of the CREM gene. Transcription of ICER occurs from promoter P2. 
ICER I, ICER ly, ICER II and ICER lly represent the four mRNA isoforms resulting from 
alternative mRNA splicing. The ATG initiation codon and stop codons are also 
indicated. Use of primers 1 and 2 in RT-PCR leads to amplification of mRNA 
encoding all four ICER isoforms. Primers 1 and 3 are specific for ICER I and ICER ly 
(see Table 2.5).
Abbreviations: DBD, DNA-binding domain; ICER, inducible cAMP early repressor
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1.11.2 Biological roles of ICER
The ICER transcript is expressed in a number of cell types including the brain, liver, 
T cells and macrophages (Mead etal. 2003, Mioduszewska etal. 2003, Bodor etal. 
2001, Servillo et al. 1997). Negative feedback regulation of ICER means that, in 
most cases, mRNA expression is transient and allows for cyclic expression of cAMP- 
responsive genes upregulated by CREB and attenuated by ICER. Rhythmic 
expression in the pineal gland has implicated ICER in establishing mammalian 
circadian rhythms through regulation of the hormone melatonin (Link et al. 2004, 
Maronde et al. 1999, Foulkes et al. 1997). Other roles for ICER include: the 
regulation of cellular proliferation and the cell cycle; mediation of the stress 
response; and in the molecular basis of memory (Della Fazia et al. 1998, Razavi et 
al. 1998). ICER has also been associated with disease processes such as diabetes 
(Inada eta l. 2005, Hussain eta l. 2000) and viral infection (Barnabas eta l. 1997) 
and has been shown to act as a tumor suppressor in mouse pituitary tumor cells 
and human choriocarcinoma cells (Razavi etal. 1998).
While transcriptional repression by ICER is usually achieved through binding to 
promoter CRE sites, binding to NFAT/AP-1 elements has also been demonstrated in 
the regulation of the expression of certain cytokines (e.g. IL-2, IL-4, GM-CSF, TNF-a 
and IFN-y) (Bodor and Habener 1998). The action of ICER is believed to be 
responsible for decreased expression of cytokines and chemokines in T- 
lymphocytes in response to cAMP. Genes affected include IFN-y (suggesting a 
possible negative feedback mechanism) and MIP-lp (Bodor etal. 2001).
1.11.3 Inducible regulation of ICER
ICER is the only inducible transcript of the CREM gene and the expression of ICER 
has been shown to be stimulated by a range of factors in addition to IFN-y. These 
include neuronal growth factor (NGF), follicle-stimulating hormone (FSH), thyroid- 
stimulating hormone (TSH), glucagon, norepinephrine, prostaglandin and 
neurotransmitters (e.g. glutamate) (Inada et al. 2005, Hussain et al. 2000, Storvik 
et al. 2000, Kameda et al. 1999, Uyttersprot et al. 1999Mao et al. 1998, Monaco 
et al. 1995). While some of these agents act through the cAMP pathway, others 
mediate their effects via unrelated pathways.
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1.12 Biological Significance o f JAK-STAT-Independent Pathways
While the IFN-y-mediated regulation of a large number of genes appears to be 
dependent on the JAK-STAT pathway, a growing body of evidence suggests that 
independent mechanisms may also be involved in the regulation of certain genes. 
A summary of the potential pathways involved in the regulation of gene expression 
by IFN-y is illustrated in Figure 1.6 and the individual components of these pathways 
are listed in Table 1.9.
There are likely to be certain survival advantages that support the presence of an 
alternative, JAK-STAT-independent, system for the regulation of gene expression by 
IFN-y. For instance, due to the pleiotropic effects of IFN-y on viral replication, 
several viruses are known to target IFN-y signalling largely through inhibition of the 
JAK-STAT pathway (Hegde et al. 2003). Where this occurs, JAK-STAT-independent 
pathways could provide the host with a mechanism by which key IFN-y responses 
can remain active. Studies on STATl-null mice have revealed that anti-viral 
responses to certain viruses (Sindbis virus and MCMV) have been higher in these 
mice than IFN-yR deficient animals, and almost as strong as the wild type response, 
indicating the utilisation of a STATl-independent pathway (Gil etal. 2001).
STATl-independent pathways may be involved in stimulating cell growth. Mice 
lacking STAT1 display increased tumorigenesis, probably due to the increased 
proliferative response of cells to IFN-y (Ramana etal. 2002). The growth response 
of human melanoma cells to IFN-y may also involve conflicting STATl-dependent 
(inhibitory) and -independent (stimulatory) signals (Kortylewski etal. 2004).
Many STATl-independently regulated genes have been found to be immunologically 
important proteins, including chemokines and their receptors (Gil et al. 2001). 
STATl-independent pathways may therefore play a role in directing cellular 
migration and inflammation. Recruitment of cells and cellular proliferation within 
the lesion are important processes in atherogenesis and inhibition of these 
pathways could be of potential benefit in treating the disease. Conversely STATl- 
independent pathways could potentially be linked to atheroprotective processes 
such as the down-regulation of LPL expression by IFN-y. It is important now to
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identify the signalling molecules and transcription factors involved in JAK-STAT- 
independent signalling with the aim of identifying potential therapeutic targets for 
the treatment of disease.
Figure 1.6 Potential signalling pathways involved in modulation of macrophage gene 
expression by IFN^ y
Binding of IFN-y to its receptor activates JAKs and mediators such as phosphatases (SHP- 
1, SHP-2), GTP binding proteins (Racl, Rapl), adapter proteins (c-Cbl, CrkL), guanine 
nucleotide exchange factors (Vav, C3G), coactivators (CBP/p300, BRCA1, MCM5), and 
kinases (CK2, PI3K, PKR, Pyk2, ERKs, Fyn). Some of these mediators are involved in the 
regulation of JAK-STAT signalling while others potentially regulate the activity of alternative 
transcription factors such as NFkB, AP-1, C/EBPs, Spl/Sp3 and CREB. Activation of CREB 
by CK2, in response to IFN-y, leads to the upregulation of the transcription repressor ICER 
that may be responsible for IFN-y-mediated suppression of gene expression.
Abbreviations: AP-1, activator protein-1; BRCA1, breast cancer 1; C3G, Crk SH3-binding GEF; CBP, CREB- 
binding protein; o-Cbl, cancer-causing-Casitas-B-lineage lymphoma; C/EBP, CAAT/enhancer binding protein; 
CK2, casein kinase 2; ERK, extracellular signalling related kinase; Fyn, src/yes-related novel protein tyrosine 
kinase; ICER, inducible cAMP early repressor; IFN-y, interferon-?; JAK, Janus kinase; MCM5, mini- 
chromosomal maintenance protein 5; NFkB, nuclear factor kB; P, phosphorylated residue; PI3K, 
phospoinositide 3-kinase; PKR, RNA-dependent protein kinase; Pyk, proline-rich tyrosine kinase; Rac, ras- 
related C3-botulinum toxin substrate; Rap, receptor association protein; SHP, Sro-homology 2 domain 
containing protein tyrosine phosphatase; STAT, signal transducer and activator of transcription.
ALTERh
PATHV
JAK-STAT
Rac1
VavPI3KCK2
CBP/p300
BRCA1
MCM5
NFkB
AP-1
C/EBP
Sp1
CREB
ICER
IFNy- responsive genes
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Table 1.9 Proteins involved in IFN y^ signalling pathways
JAK-STAT JAK1 Tyrosine kinase Stark etal. 1998
JAK2 Tyrosine kinase Stark etal. 1998
Pyk2 Tyrosine kinase Takaoka 1999
SHP-1 Tyrosine phosphatase You and Zhao 1997, You etal. 1999
SHP-2 Tyrosine phosphatase You and Zhao 1997, You etal. 1999
PKR Serine/Threonine kinase Der 1997, Ramana etal. 2000
PI3K Lipid kinase Nguyen et al. 2001
BRCA1 Transcriptional co-activator Ouchi et al. 2000
MCM5 Transcriptional co-activator Zhang etal. 1998
CBP/p300 Transcriptional co-activator Zhang etal. 1996
Racl GTP binding protein Park et al. 2004
Vav Guanine nucleotide exchange factor English etal. 1997
Potentially STAT- AP-1 Transcription factor Clarke etal. 2003
independent C/EBP-P Transcription factor Hu et al. 2001, Roy et al. 2000
S p l Transcription factor Hughes et al. 2002
Sp3 Transcription factor Hughes et al. 2002
CREB Transcription factor Mead et al. 2003
NFkB Transcription factor Deb etal. 2001
CK2 Serine/Threonine kinase Mead etal. 2003
R afl Serine/Threonine kinase Ramana et al. 2000
ERK l 3 Serine/Threonine kinase David etal. 1995, Hu etal. 2001
ERK23 Serine/Threonine kinase David etal. 1995, Hu etal. 20011*1 \l\fc
PKR
Fyn
PI3K
c-Cbl2
CrkL2
Crkll2
R apl2
C3G2
Serine/Threonine kinase Deb et al. 2001
Tyrosine kinase Uddin et al. 1997
Lipid kinase Nguyen etal. 2001
Adapter protein Alsayed etal. 2000, Platanias 1999
Adapter protein Alsayed etal. 2000, Platanias 1999
Adapter protein Alsayed etal. 2000, Platanias 1999
GTP binding protein Alsayed etal. 2000, Platanias 1999
Guanine nucleotide exchange factor Alsayed etal. 2000, Platanias 1999
1Proteins may also potentially be involved in both JAK-STAT-independent and - 
dependent pathways that are uncharacterised at present.
Potential dependence on JAKs is undetermined for the CrkL/C3G pathway 
(involving c-Cblr CrkL, Crkll, C3G, Rapl) and for Rafl and AP-1 activation.
3ERK proteins may also be involved in the regulation of STAT1.
Abbreviations: AP-1, activator protein-1; BRCA1, breast cancer 1; CBP, CREB-binding protein; C/EBP- 
P. CCAAT-enhancer binding protein-P; c-Cbl, cancer-causing-Casitas-B-lineage lymphoma,; C3G, Crk 
SH3-binding GEF; CK2, casein kinase 2; CREB, CRE-binding protein; ERK, extracellular signalling 
related kinase; Fyn, src/yes-related novel protein tyrosine kinase; JAK, Janus kinase; MCM5, mini- 
chromosomal maintenance protein 5; NFk B, nuclear factor k B; PI3K, phosphoinositide 3-kinase; 
PKR, RNA-dependent protein kinase; Pyk, proline-rich tyrosine kinase; Rac, ras-related C3-botulinum 
toxin substrate; Raf, Rous sarcoma associated factor; Rap, receptor association protein; SHP, Src- 
homolo^ 2 domain containing protein tyrosine phosphatase.
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1.13 Aims of the Study
Atherosclerosis is a major cause of morbidity and mortality in the Western world. 
The study of signalling mechanisms involved in the regulation of gene expression, in 
the progression of the disease, is vital in order to identify new targets for 
therapeutic intervention. IFN-y is a key inflammatory mediator in the development 
of atherosclerosis, and as such, the signalling cascades activated by the cytokine 
are an important area for scientific research.
The initial aims of the work presented in this thesis were to:
• Identify novel mediators of the IFN-y response with respect to the regulation 
of the expression of a selection of genes
• Analyse the role of the protein kinases PI3K and CK2, implicated by our 
laboratory in novel regulatory pathways for the expression of two genes (LPL 
and ICER), in IFN-y-mediated regulation of gene expression
. Investigate the function of potential JAK-STAT-independent pathways in IFN-y 
signalling
This was to be achieved through the use of RT-PCR and Western blotting, to analyse 
changes in mRNA and protein levels respectively, combined with the use of specific 
pharmacological inhibitors and dominant negative mutants to determine the role of 
particular mediators.
Initial investigations led to the identification of a novel gene-specific role for PI3K in 
the IFN-y-mediated regulation of the expression of the proatherogenic chemokine 
MCP-1. The aims were then extended to include:
• Detailed analysis of the pathways involved in the regulation of MCP-1 
expression by IFN-y
• Analysis of factors involved in MCP-1 promoter activation in response to IFN- 
y treatment
• Extension of findings regarding the selective function of PI3K in the IFN-y- 
mediated regulation of MCP-1 expression to the regulation of other genes 
associated with the progression of atherosclerosis
66
Ch a pte r  o n e : In tr o d u c tio n
Coupled with the continued use of pharmacological inhibitors and dominant 
negative mutants, these aims were to be achieved by assessing changes in the 
phosphorylation and activity of downstream effectors in response to IFN-y 
treatment, and by analysing promoter binding through EMSA, chromatin 
immunoprecipitation (ChIP) and the transfection of promoter-reporter constructs. 
The extension of this work to the regulation of additional genes was achieved using 
a combination of microarray analysis and RT-PCR.
Following previous studies in which CK2 was implicated in the regulation of ICER 
expression by IFN-y, in a mechanism potentially mediated by the CREB/CREM/ATF 
family of transcription factors, additional aims were to:
• Carry out a detailed analysis of the pathways involved in the regulation of 
ICER expression by IFN-y
• Investigate CREs as a potential novel IFN-y-responsive element
These aims were to be achieved predominantly through transfection-based 
approaches involving dominant negative mutants and promoter-reporter constructs.
Overall, it was hoped to contribute to the understanding of the signal transduction 
pathways activated by IFN-y and leading to alterations in gene expression, 
particularly with respect to mechanisms that impact on the process of 
atherogenesis. Such studies will hopefully contribute to the eventual development 
of novel therapies for the combat of atherosclerosis and CAD.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Suppliers
Table 2.1 details chemical reagents and other materials used and the suppliers 
from which they were purchased.
2.2 Preparation of Glass and Plasticware
Glass or plasticware for the isolation and manipulation of DNA, RNA or protein 
was autoclaved for 20min at 121°C and at a pressure of 975kPa. Solutions were 
also autoclaved under the same conditions.
2.3 Tissue Culture and Cytokine Treatment
2.3.1 Cell lines
The cell lines utilised for the work detailed in this study were: the mouse 
macrophage cell line, J774.2; the human monocytic cell line, U937; the human 
hepatoma cell line, Hep3B; and the human endothelial cell line, EA.hy926. 
J774.2 cells are fully differentiated macrophages with adherent properties. The 
cell line was re-cloned from the original J774.1 cell line, adapted from the ascites 
form of a murine reticulum cell sarcoma (J774) (Ralph and Nakoinz 1977, Ralph 
and Nakoinz 1975, Ralph et al. 1975). U937 cells are undifferentiated
monocytes grown in suspension, derived from a human histiocytic lymphoma 
(Ralph etal. 1976, Sundstrom and Nilsson 1976). Hep3B cells are fully adherent 
hepatocytes derived from a human carcinoma (Knowles et al. 1980, Aden et al. 
1979). The EA.hy926 cell line was a generous gift from Dr C S Edgell (University 
of North Carolina). EA.hy926 cells were derived from human umbilical-vein 
endothelial cells (HUVECs) fused with the human epithelioma cell line A549 
(Rieber etal. 1993, Edgell etal. 1983).
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Table 2.1 SuDDliers of chemical reagents and other materials
ChlP-IT™ kit Active Motif, Rixensart, Belgium
SP600125 Affiniti Research Products, Exeter, UK
SH-6 Alexis Biochemicals, Nottinghamshire, UK
a 32P-dCTP Amersham Biosciences, Buckinghamshire, UK
ECL Western Blotting Detection Reagent 
Megaprime DNA Labelling Kit 
Nick Columns
Rainbow Protein Size Markers 
Random Hexamers (PdN6)
X-ray Rim____________________________
Acrylamide: Bisacrylamide (29:1) 
Acrylamide: Bisacrylamide (37.5:1)
Anachem, Luton, UK
DM EM Tissue Culture Medium 
RPMI 1640 Tissue Culture Medium
Autogen Bioclear, Wiltshire, UK
Endothelial Growth Medium BD Biosciences, Oxford, UK
Agarose
Magnesium Chloride
Taq Polymerase (and lOx Buffer)
Bioline, London, UK
AG490
LY294002
Rapamycin
Calbiochem, Nottingham, UK
LB Agar Capsules 
LB Medium Capsules
DIFCO Laboratories, Surrey, UK
Hep3B Cell Line European Collection of Animal Cell Cultures
J774.2  Cell Une 
U937 Cell Line
(ECACC), Salisbury, UK
EDTA
Ethanol
Hydrochloric Acid
Industrial Methylated Spirits
Isopropanol
Sodium Chloride
Sodium Dodecyl Sulphate
Sodium Hydroxide
Tris
Tri-Sodium Citrate 
Other General Chemicals
Fisher Scientific, Loughborough, UK
Saran Wrap Genetic Research Instrumentation, Essex, UK
Ammonium Persulphate Gibco BRL, Paisley, UK
Fetal Calf Serum 
2-Merca ptoetha nol 
Trypsin/EDTA
Cell Scrapers Helena Biosciences, Sunderland, UK
Tissue Culture Flasks
High Purity Plasmid Maxi Prep System Marligen Biosciences, High Wycombe, UK
PVDF membrane Millipore Ltd., Gloucestershire, UK
DNA Molecular Weight Markers New England Biolabs, Hertfordshire, UK
Restriction Endonucleases 
Anti-PKB
Anti-PKB pThr308 
Anti-PKB pSer473 
Akt Kinase Assay Kit_____
Lymphoprep™_________________________________Nycomed Pharma, Bridport, UK
Phosphate Buffered Saline Tablets Oxoid Ltd., Basingstoke, UK
Micro BCA Protein Assay Kit Pierce, Chester, UK
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dNTPs
Luciferase Substrate
MMLV Reverse Transcriptase (and MMLV lOx 
Buffer)
Passive Lysis Buffer (5x)
RNasin™
Wizard SV™ Miniprep Kit
Promega, Southampton, UK
QIAquick™ Gel Extraction Kit Qiagen, Crawley, UK
Rneasy™ Total RNA Isolation Kit
Su perfect™ Transfection Reagent
Biotinylated-dUTP Roche, Hertfordshire, UK
Protein A/G Agarose Santa-Cruz Biotechnology Inc., California, USA
Anti-STAT 1 p 89 /9 4
Anti-Spl X
Anti-CK2 a, a ’ and (3
Anti-MCP-1
Tissue Culture Filters (0.2nm) Schleicher and Schuell, London, UK
DNA Oligonucleotides Sigma Genosys, Cambridgeshire, UK
Anti-p-Actin Sigma, Poole, UK
Ampicillin
Apigenin
Aproptonin
Benzamidine
Bovine Serum Albumin
Bromophenol Blue
Ethidium Bromide
Ficoll (Type 400)
Formaldehyde
Formamide
Glycerol
Leupeptin
Mineral Oil
Molecular Biology Grade Water
PEI
Penicillin/Streptomycin
PMA
PMSF
lOxTBE
TEMED
Tissue Culture Grade Water
Tissue Culture Grade DMSO
Trypan Blue Solution
Tween 20
Wortmannin
Interferon-y (Mouse) Totam Biologicals (Tebu Bio), Cambridgeshire,
Interferon-y (Human) UK
SuperArray GEArray™ kit
Mouse Atherosclerosis Microarray
Anti-STAT 1 pSer727 Upstate Biotechnology, Dundee, UK
Anti-STAT 1 pTyr701
Anti-JAK2
Anti-p85
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2.3.2 Maintenance of cell lines in culture
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (J774.2, 
Hep3B, EA.hy926) or Roswell Park Memorial Institute (RPMI) 1640 medium 
(U937) supplemented with 10% (v/v) heat-inactivated (45min, 56°C) fetal calf 
serum (HI-FCS) and penicillin (100U/ml)/streptomycin (lOOU/ml) (pen/strep). Hl- 
FCS and pen/strep were filtered through a 0.2pm sterile filter before addition to 
the culture medium. Cells were incubated in a humid environment of 5% (v/v) 
CO2 at 37°C. Culture medium was replaced every two days.
2.3.3 Subculturing of cell lines
Cells were pelleted by centrifugation (800g, 5min), washed once with DMEM 
(preheated to 37°C) (J774.2, Hep3B, EA.hy926) or RPMI 1640 (U937), and then 
suspended into fresh medium (10% (v/v) HI-FCS, 1% (v/v) pen/strep) and plated 
into new flasks at a ratio of 1:4 (i.e. cells from one flask were plated into four 
flasks of the same size). For adherent cells, resuspension was achieved using 
sterile disposable cell scrapers in the case of J774.2 cells, and by trypsinisation of 
the extracellular matrix for Hep3B and EA.hy926 cells. Trypsinisation involved the 
incubation of cells at 37°C (Hep3B, lOmin; EA.hy926, 2min) with a volume of 
trypsin/EDTA adequate to cover the cell monolayer. Trypsin was subsequently 
inactivated by washing in the presence of FCS.
2.3.4 Human primary monocyte-derived macrophage cell culture
Human blood buffy coats were obtained from the National Blood Service Wales. 
Buffy coat was underlayered with Lymphoprep™ (Nycomed Pharma) (2:1 (v/v) 
supernatant:Lymphoprep™) (containing dextran and sodium diatrizoate that 
cause erythrocyte aggregation) and subjected to centrifugation (800g, 20min) to 
allow sedimination of erythrocytes. The resulting interface was collected and 
washed with an equal volume of PBS-0.4% (w/v) tri-sodium citrate. Cells were 
pelleted by centrifugation (800g, 5min), resuspended in 0.2% (v/v) saline solution 
and incubated on ice (30s). An equal volume of 1.6% (v/v) saline solution was 
added and cells pelleted immediately by centrifugation (800g, 5min). The pellet 
was then washed 6-8 times in PBS-0.4% (w/v) tri-sodium citrate to remove
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contaminating platelets. Remaining cells were plated in RPMI 1640 (1% (v/v) 
pen/strep) and incubated at 37°C, 5% (v/v) CO2 for 6h in order to allow the 
adherence of monocytes. After this time, the cells were washed twice with PBS 
and given fresh medium supplemented with 5% (v/v) human serum. Serum was 
obtained by centrifugation of clotted human blood (30ml) (1400g, 15min). Culture 
medium was replaced every 24h for 7-10 days, over which time the cells 
differentiated from monocytes to macrophages.
2.3.5 Human umbilical vein-endothelial cell culture
HUVECs were extracted from human tissue and kindly donated by Karolina Taylor 
(Heath Hospital, Cardiff). Confluent cells were obtained at passage 3, in 
Endothelial Cell Growth Medium (BD Biosciences), and harvested the same day.
2.3.6 Treatment of cells with IFN^ y
All cells were between passage 2 and 9. J774.2 cells were grown to
approximately 60% confluence before treatment, Hep3B and EA.hy926 cells to 
approximately 80% and U937s were plated at a density of 3 x 105/m l. Human or 
mouse IFN-y, as appropriate, was added to the culture medium at lOOOU/ml 
following a 4h pre-incubation period in fresh culture medium (10% (v/v) HI-FCS) or 
following transfection procedures (Section 2.4). Treated cells were incubated as 
before at 37°C, for the appropriate time, after which the relevant extraction 
procedures were carried out.
2.3.7 Treatment of cells with inhibitors
Inhibitors were added to the cell culture medium for a pre-treatment period of lh  
prior to the addition of IFN-y. Control cells were treated with an appropriate 
volume of a vehicle control, typically DMSO. Table 2.2 details the 
pharmacological inhibitors used and their mode of action.
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Table 2.2 Action of pharmacological inhibitors used
Actinomycin D 8-amino-N-(2-amino-4,6-dimethyl-3-oxo-phenoxazin-l-yl)carbonyl-N'- 
[8-a m i no-4,6-d i methyl-7-oxo-9-[[3,6 ,10-tri methyl-7,14-bis( 1- 
methylethyl)-215,8,12,15-pentaoxo-9-oxa-3,6,13,16- 
tetrazabicyclo[14.3.0]nonadec-ll-yl]carbamoyl]phenoxazin-l- 
yl]ca rbonyl-4,6<J i methyl-7-oxo-N, N -bis[3,6 ,10-tri methyl-7,14-bis( 1- 
methylethyl)-2,5 ,8,12,15-pentaoxo-9-oxa-3,6,13,16- 
tetrazabicyclo[14.3.0]nonadec-ll-yl]-l,9-bis[[3,6,10-trimethyl-7,14- 
bis( 1-methylethyl )-2,5 ,8,12,15-pentaoxo-9-oxa-3,6,13,16- 
tetrazabicyclo[14.3.0]nonadec-ll-yl]carbamoyl]phenoxazine-l,9- 
dicarboxamide
C62H86Ni20l6 RNA
polymerase
Reversible competitor of DNA 
binding
Goldberg et al. 
1962
AG490 a-Cyano-(3,4-dihydroxy )-N-benzylcinnamide C17H14N2O3 JAK2 Reversible competitor of 
substrate binding
Meydan et al. 
1996
Apigenin 4', 5,7-Tirihydroxyflavone C15H10O5 CK2 Reversible ATP/GTP- 
competitive inhibitor of CK2
Critchfield et al, 
1997
LY294002 2-(4~Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one C19H17NO3 PI3K Reversible ATP-competitive 
inhibitor of PI3K
Vlahos et al, 
1994
Rapamycin 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-
hexadeca hyd ro-9,27-d ihyd roxy-3-(2-(4-hydroxy-3-methoxycyclohexyl y
l-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-
epoxy-3H-pyrido(2,l-c)(l,4)oxaazacyclohentricontine-
1,5,11,28,29(4H,6H,31H)-pentone
C51H79NO13 mTOR Complex formation with FKBP- 
12 inhibits mTOR activity
Chen et al. 1995
SH-6 D-2,3-Dideoxy-myo-inositol l-[(R)-2-methoxy-3-(octadecyloxy)propyl 
hydrogen phosphate
C28H57O9P PKB Reversible competitor of PH- 
domain binding
Kozikowski et al. 
2003
SP600125 1,9-Pyrazoloanthrone C14H8N2O JNK/SAPK Reversible ATP-competitive 
inhibitor of JNK1, -2 and -3
Bennett etal, 
2001
Wortmannin KY12420 C23H24O8 PI3K Irreversible covalent binding to 
the ATP-binding site of the 
p llO  catalytic subunit
Arcaro and 
Wyman n 1996
1Further information on each of these inhibitors can be found on the manufacturer’s website.
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2.3.8 Trypan blue exclusion assay
Trypan blue solution (0.4% (w/v)) was added to the cell culture medium at a ratio 
of 1:100 (v/v) and incubated at 37°C (lOmin). The number of cells taking up the 
blue stain was estimated for adherent cells by counting those in a representative 
area. The approximate proportion of dead cells was calculated from this. For 
suspension cells a haemocytometer was used to create a monolayer and the 
same procedure was carried out.
2.4 DNA Transfection of Cell Lines
All cells were between passage 2 and 7. U937 cells were plated at a density of
7.5 x 105/m l in RPMI 1640 (3% (v/v) HI-FCS), 4h prior to transfection. At the time 
of transfection the differentiating agent phorbol 12-myristate 13-acetate (PMA) 
(lp M ) was also added to these cells. Hep3B cells were grown to approximately 
60% confluence and fresh medium (DMEM 10% (v/v) HI-FCS) was added 4h 
before transfection.
2.4.1 SuperFect™ transfection
The transfection method was carried out as described by the manufacturers 
(Qiagen). The DNA/SuperFect™ complex was prepared by diluting DNA (l-2pg) to 
a concentration of 20ng/pl in RPMI 1640. SuperFect™ solution (4pl/pg DNA) was 
added and the mixture was vortexed and incubated at room temperature (lOmin). 
The complex was then suspended in RPMI 1640 (200pl/pg DNA) and added 
dropwise to the cells. Cells were treated with mediators immediately following 
transfection.
2.4.2 Polyethylenimine transfection
Plasmid DNA (5-10ug) was diluted to a volume of lOpl in 5% (w/v) glucose. 
Polyethylenimine (PEI) solution (5.625mg/ml, pH 7.2) (1.5pl) was added to the 
DNA and the resulting complex immediately suspended in DMEM (10% (v/v) HI- 
FCS) (1ml) and added dropwise to cells. Cells were incubated at 37°C (24h), 
washed twice in DMEM and treated with mediators as usual.
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2.4.3 Preparation of cell extracts for determination of reporter gene activity
Transfected cells washed once with phosphate buffered saline (PBS), and 
resuspended in lx  Passive Lysis Buffer (Promega). After vortexing, the lysate was 
incubated for lOmin at room temperature. Cell debris was pelleted by 
microcentrifugation (ll,0 0 0 rp m , 2min) (in all cases microcentrifugation was 
carried out using a Heraeus Biofuge Pico) and the supernatant retained and used 
to assay reporter gene activity.
2.4.4 Luciferase assay
Extracts from transfected cells (60pl) were mixed with a luciferase substrate 
(Promega) (lOOpI) and the fluorescent intensity (counts) was determined using a 
Turner Designs 5 0 /5 0  Luminometer set at a sensitivity value of 70% with a 2s 
delay period and 20s integrate period. The recorded number of counts is relative 
to the amount of luciferase expressed by the reporter plasmid and hence the 
activity of the promoter sequence of interest. Counts were normalised to the 
amount of protein (pg/ml) in each lysate, determined as described in Section 
2.6.4.
2.4.5 Plasmid constructs used for transfection based assays
Plasmid maps for all expression and reporter vectors can be found in Appendix I. 
Table 2.3 details the restriction endonuclease digestion used to verify the identity 
of each plasmid (Section 2.5.11)
2.4.5.1 pCRELuc
The pCRELuc plasmid was purchased from Stratagene and is based on the pLuc- 
MCS expression vector. Transcription is regulated by a TATA box and four 
upstream CRE consensus enhancer elements ((AGCCTGACGTCAGAGU).
2A .5 .2  MCP-lLuc
The luciferase reporter construct MCP[213]Luc was donated by Dr R M Ransohoff 
(Cleveland Clinic Foundation). A region of the human MCP-1 promoter 213bp 
upstream of the transcriptional start site is inserted into the pGL2-Basic luciferase 
reporter vector (Promega) (Zhou et al. 1998).
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2.4.5.3 pC/EBPx4Luc
The pC/EBPx4Luc plasmid was created by Dr T Hughes (Cardiff University) and is 
based on the pGL2-Promoter luciferase reporter vector (Promega). Transcription 
is regulated by a SV40 promoter and four upstream C/EBP consensus enhancer 
elements.
2.4.5.4 p NFkBLuc
The plasmid pNFkBLuc was obtained from Dr D Leeke (University of Reading) and 
is based on the luciferase expression vector pTALLuc (Clontech) containing an 
insert of four NFkB consensus enhancer elements.
2.4.5.5 3xly6e
The construct 3xly6e was donated by Prof J E Darnell (Rockefeller University, New 
York). The promoter contains 3 tandem STAT1 consensus sites (GAS) regulating 
the expression of a luciferase reporter gene in the pZLuc-TK vector.
Further information can be found at: 
httD ://www.rockefeller.edu/labteach/darnell/reauest.phD.
2A .5 .6  JAK1/JAK2 and STAT1
Plasmid constructs for dominant negative JAK1, JAK2 and STAT1, were donated 
by Prof J E Darnell (Rockefeller University, New York). Dominant negative JAK1 
and JAK2 are present as inserts in the pRK5 vector. A three amino acid change 
(FWYAPE to CIYAPV) in the conserved region VIII of the kinase domain of JAK1 
impairs the catalytic function (pRK5-JAKl). Dominant negative JAK2 contains a 
single amino acid mutation (Lysine to Arginine) at the ATP-binding site, resulting in 
reduced ATP-binding and catalytic activity (pRK5-JAK2) (Zong et al. 2000). Wild 
type and mutant STAT1 expression plasmids utilise the pRC/CMV vector 
(Invitrogen). STAT1 constructs include: STATl-a FLAG, expressing the wild type 
protein: STAT1 S727A, a partially active mutant with a serine to alanine change at 
the phosphorylation site Serine 727; STATl-p FLAG, a truncated form of STATl-a 
with reduced function; and STAT1 701F FLAG, a dominant negative mutant 
containing a tyrosine to phenylalanine change at the JAK kinase phosphorylation 
site (Tyrosine 701) (Osaki etal. 2003).
Further information about these plasmids can be found at: 
http.y/www.rockefeller.edu/labteach/darnell/reauest.Dhp.
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2A .5 .7  CK2
The CK2 dominant negative plasmid construct, pSG-CK2a-K68A, was a generous 
gift from Drs E M Chamburg and C Cochet (INSERM, Grenoble, France). This 
construct contains a kinase inactive mutant (lysine to alanine change at residue 
68 within the ATP-binding domain) of the CK2a catalytic subunit in the pSG 
plasmid vector (Stratagene) (Lebrin etal. 2001).
2A .5 .8  PKB
The plasmid pcDNA3 HA-PKB AAA was donated by Dr B Hemmings (Basel). An 
inactive form of PKBa, with a mutation to alanine at residue 179K in the ATP- 
binding site and residues 308T and 473S that must be phosphorylated in the 
active kinase, is inserted into the pcDNA3 expression vector (Invitrogen).
2A .5 .9  \kB
The plasmid pcDNA3 IkB was donated by Dr D Krappman (Berlin). Expression of 
the endogenous super-repressor IkBcx (human) from the pcDNA3 expression 
vector (Invitrogen) acts to inhibit NF-kB signalling in a dominant negative manner 
(Krappmann etal. 1996).
2A .5 .10  LIP
The plasmid pCS2+ LIP was created by Dr S Kousteni (Cardiff University). cDNA 
encoding Xenopus LIP was cloned into the pCS2+ expression vector (Kousteni et 
a/. 1998). LIP is an isoform of C/EBP-p that lacks the trans-activation domain and 
thereby inhibits the expression of promoters regulated by C/EBP-p by competing 
for promoter binding.
2A .5 .11  ICER
The plasmid pcDNA3 ICER was created by Dr J Mead (Cardiff University). cDNA 
(522bp) encoding murine ICER I was inserted into the pcDNA3 expression vector 
(Promega).
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Table 2.3 Restriction endonuclease digestion of plasmid constructs
pCRE Luc pLuc BamHI 2.7, 3.1
MCP-1 Luc[213] pGL2-Basic Xhol, Kpnl 5.7, 0.3
C/EBPX4 Luc pGL2-Promoter Xmal, Xhol 5.8,
NFkBx4 Luc pTAL Xbal, Hindlll 3.3, 1.7
3xly6e Luc pZluc-TK Smal 6.0
JAK1 Dominant
negative
pRK5 EcoRI, BamHI 4.7, 1.6, 0.6, 1.2
JAK2 Dominant
negative
pRK5 EcoRI, BamHI 4.7, 2.4, 0.6, 0.2
STAT1 a-FLAG pRC/CM V Hind III 6.0, 1.7
3-FLAG pRC/CM V Hind III 6.0, 1.7
Dominant pRC/CMV Hind III 6.1, 1.7
negative
(q-S727A)
Dominant 
negative 
(aY701F FLAG)
pRC/CMV Hind III 6.0, 1.7
CK2 Dominant
negative
pSG5 EcoRI 1.5, 6.0
PKB Dominant
negative
pcDNA3 Nhel, Kpnl 6.2, 0.4, 0.3
LIP - pcS2+ Xbal 4.7
IkB - pcDNA3 - -
ICER 1 - pcDNA3 BamHI, EcoRI 5.4, 0.5
Abbreviations: A, alanine; C/EBP, CCAAT/enhancer binding protein; CK2, casein kinase 2; CRE, 
cAMP responsive element; IkB, inhibitor of k B; ICER, inducible cAMP early repressor; F, 
phenylalanine; JAK, janus kinase; Luc, luciferase; MCP-1, monocyte chemoattractant protein-1; 
NFkB. nuclear factor kB; p, plasmid; PKB, protein kinase B; S, serine; STAT, signal transducer and 
activator of transcription; Y, tyrosine.
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2.5 RNA/DNA re la te d  Techniques
2.5.1 Stock solutions
Table 2.4 Composition of stock solutions used for electrophoresis of DNA/RNA
5x DNA loading dye 0.5x TBE
40%  (v/v) glycerol
0.25%  (w/v) bromophenol blue
All solutions were prepared with sterile double distilled water (ddH20)
2.5.2 RNA isolation
Extraction of RNA from cells was carried out using the RNeasy™ kit according to 
the instructions supplied by the manufacturer (Qiagen). Where RNA was 
extracted for use in microarray analysis a DNasel step was included, carried out 
as specified in the manufacturer’s protocol (Qiagen). The purity and 
concentration of RNA obtained was calculated by measuring the absorption of 
light at wavelengths of 260nm and 280nm with a Hitachi U-1800 
spectrophotometer. The quality of RNA was also analysed by resolving lp g  on a 
1% (w/v) agarose gel (Section 2.5.4).
2.5.3 Reverse transcriptase-polymerase chain reaction (RT-PCR)
RT-PCR involves two stages: firstly the synthesis of cDNA from RNA using the 
enzyme reverse transcriptase; and secondly a standard PCR reaction using this 
cDNA to obtain a specific product.
2.5.3.1 Synthesis ofcDNA (RT)
Total RNA (lpg) was incubated with random hexamers (PdN6) (200pmol) diluted 
to a volume of 14pl with tissue culture grade water at 70°C (5min). Following this 
the reactions were placed immediately on ice (5min). Molony murine leukaemia 
virus (MMLV) reverse transcriptase (200U), MMLV 5x Buffer and dNTPs (lp l, 
lOmM) were added to give a final reaction volume of 20pl which was incubated 
at 37°C (lh ). Solutions were subsequently diluted at a ratio of 1:5 in tissue 
culture grade water.
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2.5 .3 .2  PCR
PCR reactions contained lx  Buffer (Bioline), dNTPs (lOOpM), Taq polymerase (1U) 
and Forward and Reverse primers (lpM ). Concentration of magnesium chloride 
(MgCh) and cDNA was varied and for some primer sets DMSO was required. 
Cycles included a denaturation step of 95°C for 30 sec; primer annealing for lmin 
at a variable temperature; and an extension period at 72°C for 2min. An initial 
denaturation step of 95°C for 5min and a final extension at 72°C for lOmin was 
also included. The number of cycles was selected so that final products were 
generated in the exponential phase of amplification. Primer sequences, MgCh 
concentration, cDNA volume, DMSO requirement, annealing temperature and 
number of cycles are listed in Table 2.5. Primer sequences were either taken 
from the sources referenced or generated using Primer 3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/Drimer3.cgn. Temperature cycling was 
carried out on either a Biometra TRIO Thermoblock (for which reactions were 
overlayed with mineral oil) or a Peltier Thermal Cycler (PTC-200).
2.5.4 Agarose gel electrophoresis
PCR products were resolved on 1-2% (w/v) agarose gels and the fragment size 
determined by comparison to standard DNA molecular weight markers (Appendix 
II). Gels were made using 0.25x TBE and contained ethidium bromide (0.5pg/ml). 
Electrophoresis was carried out on a Fisherbrand Horizontal Gel Unit at 85V, with 
0.25x TBE as running buffer. Samples were mixed with DNA loading dye (lx) 
before adding to the wells. DNA bands were visualised under UV using a Syngene 
Gel Documentation System.
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PCR primer sequences and reaction conditions
28S rRNA 
(Kong et al. 
1999
For: 5 ’-TGA ACT ATG CTT GGG 
CAG GG -3’
513 k 1 57 11
Rev: 5 ’-AGC GCC ATC CAT TTT 
CAG GGG -3 ’
o JL
ABCA1 
(Klucken et 
al.)
For: 5'-GTT GGA AAG ATT CTC
TAT ACA CCT GA -3 ’
690 10 1 60 27Rev: 5 ’-CGT CAG CAC TCT
1
GAT GAT GGC CTG -3'
hp-Actin 
(Sabatakos 
et al. 1998)
For: 5 ’-ATG ATA TCG CCG 
CGC TCG-3'
580 10 1.5 57 18
Rev: 5 ’-CGC TCG GTG AGG 
ATC TTC A-3'
mP-Actin 
(Sabatakos 
et al. 1998)
For: 5 ’-TGG AGA AGA GCT
ATG AGC TGC CTG-3’
Rev: 5 ’-GTG CCA CCA GAC
204 10 1 5 58 18
AGC ACT GTG TTG-3'
m C C Lll 
(Michalec et 
al. 2002)
For: 5 ’- GCT CCA CAG CGC 
TTC TAT TC-3'
248 10 1.5 60 40
Rev: 5'-TTG TGG CAT CCT 
GGA CC -3’-
mCCL20 
(Shirane et 
al. 2004)
For: 5 ’-TGC TCT TCC TTG CTT 
TGG CAT GGG TA-3'
365 10 1.5 60 35
Rev: 5'-TCT GTG CAG TGA
TGT GCA GGT GAA GC -3’
mCCR2 
(Fife et al. 
2001)
For: 5 ’-GGT CAT GAT CCC TAT 
GTG G -3'
253 10 1.5 60 30
Rev: 5 ’-CTG GGC ACC TGA 
TTT AAA GG -3 ’
mCCR2 
(Schadde et 
al. 2000)
For: 5'-AAA GGA AAT GGA
AGA CAA TAA TAT G-3’
Rev: 5 ’-AAA GGC AAA CTG 1149 10 1.5
- 56 30
TCA CTT ACT TTA C-3*
mCD36 
(Yoshida et 
al. 1997)
For: 5 ‘-CAG CCC AAT GGA 
GCC ATC-3'
4 87 10 1.5 56 26
Rev: 5-CAG CGT AGA TAG 
ACC TGC-3'
mCD44 
(Kimura et 
al. 2002)
For: 5 ’-GTA CAT CAG TCA CAG 
ACC TAC-3'
598 10 1.5 56 30Rev: 5 ’-CAC CAT TTC CTG 
AGA CTT GCT-3’
GAPDH 
(Sabatakos 
et al. 1998)
For: 5'-CCC TTC ATT GAC CTC
AAC TAC ATG G-3’
4 55 5 2 60 18Rev: 5 ’nAGT CTT CTG GGT 
GGC AGT GAT GG-3'
mlCAMl 
(Sano et al. 
2005)
For: 5'-GTC CGC TTC CGC TAC 
CAT CA-3’
508 10 1.5 60 30Rev: 5 ’-ACT GCT GTT TGT 
GCT CTC CT-3’
hICER I/ll For: 5'-CTG ATG AGG AAA 657
(Peri et al. CTG AAC TTG-3' (ICERI) K 1.5 56 302001, Peri Rev: TCG GCT CTC CAG ACA 257
sJ
et al. 2002) TTT TAC-3’ (ICER II)
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mICER 1 
(Hussain et 
al. 2000)
For: 5'-CAA AAG CCC AAC ATG 
GCT G-3’ 522 1.5 65 28
Rev: 5 ’-CCA ATT CAC ACT CTA 
CAG CAG-3’
(ICER 1)
mICER I/ll 
(Storvik et 
al. 2000)
For: 5 ’-ATG GCT GTA ACT 657
GGA GAT GAA ACT-3’ (ICER 1) R 1.5 65 28Rev: 5 ’-CTA ATC TGT TTT GGG 257
AGA GCA AAT GTC-3’ (ICER II)
mlL-10 
(Moore et 
al. 1990)
For: 5 ’-TCC H A  ATG CAG GAC 
TTT AAG GGT TAC TTG-3’
257 10 1.5 60 38
Rev: 5-GAC ACC TTG GTC
TTG GAG CTT ATT AAA ATC-3’
miNOS 
(Hwang et 
al. 2004)
For: 5 ’-CAA GAG TTT GAC CAG 
AGG ACC-3’
656 10 1.5 60 28
Rev: 5-TGG AAC CAC TCG 
TAC TTG GGA-3’
m IP-10 
(Sgadari et 
al. 1996)
For: 5 ’-ACC ATG AAC CCA AGT 
GCT GCC GTC -3 ’
312 10 1.5 64 26
Rev: 5 ’-GCT TCA CTC CAG TTA 
AGG AGC CCT -3 ’
mITAC
(Hamilton et 
al. 2002)
For: 5 ’-GAA CAG GAA GGT
CAC AGC CAT AGC-3 ’
Rev: 5-ATG AGG CGA GCC
252 10 1.5 - 66 26
TGC TTG GAT CTG-3’
For: 5 ’-GAC GAC CTG CAC
mJun-B AAG ATG AA-3’ 225 10 1.5 59 27
Rev: 5 ’-ATG TGG GAG GTA 
GCT GAT GG-3’
mLPL
(Irvine et al. 
2005)
For: 5 ’-CAT TTA CCA GGG 
GGT CAC-3 ’
278 10 2 60 26Rev: 5 ’-AGG CAG AGC CCT 
TTC TCA-3’
For: 5 ’-CTT CTG TGC CTG CTG
30
/ 2 5 1hMCP-1 CTC ATA GCA-3’ 219 10 1.5 - 65
Rev: as mouse
For: 5 ’-CTT CTA TGC CTC CTG
m MCP-1
CTC ATA GCT-3’
219 10 1.5 65 25
Rev: 5 ’-CTT GGG GTC AGC 
ACA GAT CTC CTT-3’
mMig
(Sgadari et 
al. 1996)
For: 5 ’-ACT CAG CTC TGC CAT
GAA GTCCGC -3 ’
4 79 10 1.5 66 26
Rev: 5-AAA GGC TGC TCT
GCC AGG GAA GGC-3’
mMIP-ip  
(Kawakami 
eta l. 1999)
For: 5 ’-GGA ATT CTG CAG TCC
CAG CTC TGT GCAA-3’
Rev: 5 ’-GGA ATT CCA CAG 582
10 1.5 - 62 28
TCA TAT CCA CAA TAG-3’
m M IP-la  
(Sgadari et 
al. 1996)
For: 5 ’-CTC AAC ATC ATG AAG 
GTC -3 ’
285 10 1.5 57 30
Rev: 5 ’-GGC ATT CAG TTC 
CAG GTC -3 ’
mMMP9 
(Chen et al. 
2005)
For: 5-GCG CCA CCA CAG 
CCA ACT ATG-3’
3 79 10 1.5 64 30
Rev: 5 ’-TGG ATG CCG TCT
ATG TCG TCT TTA-3’
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itiNFkB 
(Sano et al. 
2005)
For: 5'-AGC AGA CTC CAC TCC 
ACT TG-3'
398 10 1.5 60 30Rev: 5'-GAC ATC AGC CCC
ACATTTCA-3’
mRANTES 
(Sgadari et 
al. 1996)
For: 5-GTA CCA TGA AGA TCT 
CTGCA-3'
287 10 1.5 60 30Rev: 5 ’-TCT ATC CTA GCT CAT 
CTCCA-3’
mSOCS-1 
(Egwuagu et 
al. 2002)
For: 5'-CTC GAG TAG GAT 
GGT AGC ACG C-3’
372 5 1.5 5 60 28
Rev: 5-CAT CTT CAC GCT
GAG CGC GAA GA-3’
mSR-Bl
(Srivastava
2003)
For: 5'-TTT CAG CAG GAT CCA 
TCT GGT GGA-3'
4 80 10 1.5 60 28
Rev: 5 ’-AGT TCA TGG GGA
TCC CAG TGA C-31
mTNF-a For: 5 ’-ATG AGC ACA GAA
(Fox and AGC ATG ATC-3’ 910 10 1.5 56 26Danska Rev: 5-CCA AAG TAG ACC
1997) TGC CCG GAC-3’
pGL2
GL1: 5 ’-TGT ATC TTA TGG TAC 
TGT AAC TGA-3’ For empty 
vector 
135
2 55 30(Promega) GL2: 5-AAG AAA TAC AAA
AAG CGC AGA AGG T-3’
hGAPDH- 
ChlP (Active 
Motif)
For: 5-TAC TAG CGG TTT TAC 
GGG CG -3 ‘
166 5 (ChIP) 2.5 59 4 0
Rev: 5'-TGC CAA AGC CTA
GGG CAG AG-3’
hMCP-ChIP
(-288-
-95)
For: 5 ’-CCC ATT TGC TCA TTT 
GGT CT -3'
194 5 (ChIP) 1.5 59 40Rev: 5 ’-CTT ATT GAA AGC 
GGG CAG AG -3'
hNegative- For: 5 ’-ATG GTT GCC ACT
ChlP GGG GAT CT-3'
174 5 (ChIP) 2 .5 59 40(Active Rev: 5 ’-TGC CAA AGC CTA
Motif) GGG GAA GA-3*
1Hepatocytes, 30 cycles; Macrophages/Endothelial cells, 25 cycles
Abbreviations: ChIP, chromatin immunoprecipitation; For, forward primer sequence; h, human; m, 
mouse; Rev, reverse primer sequence.
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2.5.5 Densitometric analysis
The intensity of bands from agarose gels was analysed using GeneTools™ 
(Syngene) software.
2.5.6 Bacterial strains and vectors
Table 2.6 indicates the genotype of the Escherichia Coli (E. Coli) strains used in 
this work. Plasmid vector maps can be found in Appendix I.
Table 2.6 Genotype of E.Coli strains used
DH5-a supE44AlacU169( t/80lacZAM15)hsdl7 
recAlendAlgyrA96thi-lrecAl
Hanahan 1983a, 
Hanahan 1983b
JM109 recAl supE44 endAl hsdR17 gyrA96 re lA l thi 
A(lac-proAB) F[traD36 proAB* lacfi lacZDM15\
Yanisch-Perron et al. 
1985
2.5.7 Preparation of competent cells
The protocol used in the preparation of competent cells is a modified version of 
Mandel and Higa (1970). LB medium (5ml) (pre-heated to 37°C) was inoculated 
with a single colony of E. Coli and incubated at 37°C (12-18h) while shaking. 
Fresh LB medium (9.9ml) was inoculated with 0.1ml of this culture and incubated 
for a further 2h under the same conditions. Cells were pelleted by centifugation 
(3000g, 5min at 4°C) and then resuspended in ice cold calcium chloride (CaCb) 
(5ml, 50mM). After incubation on ice (25min) the cells were pelleted as before 
and resuspended in ice cold CaCb (1ml, 50mM). Competent cells were either 
kept on ice or mixed with sterile glycerol (40% v/v) and stored at -80°C.
2.5.8 Transformation of competent cells
Plasmid DNA (l-5pl) was added to 200pl of competent cells and incubated on ice 
(40min). After being heat shocked at 42°C for 90s cells were immediately placed 
on ice (2min). LB medium (800pl) (pre-warmed to 37°C) was added to the cells 
and incubated at 37°C (lh ) while shaking. Transformed bacteria (200pl) were 
spread onto agar plates containing ampicillin (lOOpg/ml) (filter sterilised using
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0.2pm filters). Remaining cells were pelleted by microcentrifugation (13,000  
rpm, 3min), resuspended in LB medium (lOOpI) and spread onto separate plates. 
Colonies of transformed bacteria (ampicillin resistant) were grown overnight at 
37°C.
2.5.9 Small-scale preparation of plasmid DNA (Miniprep)
LB medium (10ml) containing ampicillin (lOOpg/ml) was inoculated with a single 
colony of transformed E.Coli and incubated at 37°C (16h) while constantly 
shaking. Preparation of plasmid DNA from the bacterial culture was carried out 
using the Wizard SV™ Miniprep Kit according to the manufacturer’s instructions. 
The concentration of DNA was calculated by measuring the absorption of light at 
wavelengths of 260nm and 280nm using a Hitachi U-1800 spectrophotometer.
2.5.10 Large-scale preparation of plasmid DNA (Maxiprep)
LB medium (12ml) containing ampicillin (lOOpg/ml) was inoculated with a single 
colony of transformed E.Coli and incubated at 37°C (7h) while constantly shaking. 
This was used to inoculate fresh LB medium/ampicillin (200ml) and grown 
overnight at 37°C while shaking. Plasmid DNA was prepared using the High Purity 
Plasmid Maxi Prep System according to the manufacturer’s instructions (Marligen 
Biosciences). The concentration of DNA was calculated by measuring the 
absorption of light at wavelengths of 260nm and 280nm using a Hitachi U-1800 
spectrophotometer.
2.5.11 Restriction endonuclease digestion of recombinant plasmid DNA
DNA (5pl) was mixed with the restriction endonuclease (8U) and its appropriate 
buffer in a total volume of 20pl. BSA (lx ) was added where required. Buffers 
used in single and double digests were as recommended by the enzyme supplier 
(NEB). The reaction was incubated at 37°C (2h) for all enzymes used except Smal 
for which the incubation temperature was 25°C. DNA fragments were analysed by 
agarose gel electrophoresis (Section 2.5.4).
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2.5.12 Cloning of DNA oligonucleotides
2.5.12.1 Restriction endonuclease digestion of oligonucleotides
DNA oligonucleotides to be cloned into plasmid vectors were designed with the 
restriction sites for Xhol and Xma at the 5 ’ and 3 ’ ends respectively. Following 
annealing (Section 2.7.1.2.1) the oligonucleotides were digested with these 
restriction endonucleases (Section 2.5.11) to create ‘sticky ends’ and the 
products subjected to agarose gel electrophoresis (Section 2.5.4). The plasmid 
vector was also digested with the same endonucleases and subjected to agarose 
gel electrophoresis.
2.5.12.2 Gel extraction
DNA bands were excised from ethidium bromide stained agarose gels and 
purified using the QIAquick™ gel extraction kit according to the manufacturer’s 
instructions (Qiagen). The efficiency of purification was assessed by 
electrophoresis on a 1% (w/v) agarose gel (Section 2.5.4).
2.5.12.3 Ligation
Vector (lp l) and insert DNA (l-7pl) was digested to create sticky ends (Section 
2.5.12.1), gel purified (Section 2.4.12.2) and incubated at 16°C overnight, with 
T4 DNA ligase (lp l) and lx  T4 Ligase Buffer in a total volume of lOpl.
2.5.12.4 PCR screening of plated colonies
A single transformed bacterial colony was picked and added to a PCR mix 
containing GL1 and GL2 primers (composition as specified in Section 2.5.3 and 
Table 2.5), specific to regions either side of the multiple cloning site of pGL2 
plasmids. The PCR reaction was carried out using a Peltier Thermal Cycler (PTC- 
200). Positive colonies were identified by resolving PCR products on a 1% (w/v) 
agarose gel (Section 2.5.4) and noting those of the correct size.
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2.5.12.5 Automated DNA sequencing
Plasmid DNA was sequenced by Lark by automated fluorescent dye termination 
sequencing using the universal primers GL1 and GL2. For more information see 
http://www.lark.com.
2.6 Protein Analysis
2.6.1 Stock solutions
Table 2.7 Stock solutions for protein analysis
Whole cell extraction buffer lOmM HEPES (pH 7.9), 400m M NaCI, 0.5mM DTT, 5% (v/v) glycerol, 
0.5mM PMSF, 10pg/ml aprotinin, 0.5M benzamidine, O.lmM EDTA
Phosphatase-free whole cell lOmM Tris-HCI (pH 7.05), 50mM NaCI, 50mM NaF. 1% (v/v) Triton X-
extraction buffer 100, 30mM Na4P207 (sodium pyrophosphate), 5p.M ZnCh, IOOjaM 
Na3V04 (sodium orthovanadate), Im M  DTT, 2.8^ig/ml aprotinin, 
2.5jig/m l each of Ieupeptin and pepstatin, 0.5mM benzamidine, 
0.5mM PMSF
Nuclei extraction buffer A lOmM HEPES (pH 7.9), 1.5mM MgCI2, lOmM KCI, 0.5mM DTT, 
0.5mM PMSF, l|jg /m l pepstatin A  lOpg/m l aprotinin, lO^g/ml 
Ieupeptin, lOpg/m l type l-S soybean trypsin inhibitor
Nuclear extraction buffer C 25% (v/v) glycerol, 20mM HEPES (pH 7.9), 60mM KCI, 420mM NaCI.
1.5mM MgCte, 0.5mM PMSF in isopropanol, lO^g/m l type l-S 
soybean trypsin inhibitor 10 0.2mM EDTA 0.5mM DTT, 10}jg/ml 
aprotinin, 10ng/ml ieupeptin________________________________
SDS-PAGE lower gel buffer_________1.5M Tris-HCI (pH 8.8), 10% (w/v) SDS
SDS-PAGE upper gel buffer 1M Tris-HCI (pH 6.8), 10% (w/v) SDS
SDS-PAGE gel loading buffer 50mM Tris-HCI (pH 6.8), lOOmM DTT, 2% (w/v) SDS, 0.1% (w/v)
(reducing) bromophenol blue, 10% (v/v) glycerol
SDS-PAGE running buffer 25mM Tris, 250m M glycine, 0.1% (w/v) SDS
Western blot transfer buffer 25mM Tris, 192mM glycine, 20% (v/v) methanol
lOx Tris-buffered saline (TBS) lOmM Tris-HCI, 20mM NaCI, pH 7.4
2.6.2 Preparation of phosphatase-free whole cell protein extracts
Cells were washed once with PBS containing NaF (lOmM) and Na3V04 (sodium 
orthovanadate) (lOOpM) and subsequently resuspended in phosphatase-free 
whole cell extraction buffer (300-800pl) (described by Hipskind et al. (1994)). 
Cell suspensions were vortexed (45s) and debris was pelleted by 
microcentrifugation (lO.OOOrpm, lOmin) at 4°C. The supernatant was retained 
and stored at -80°C.
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2.6.3 Preparation of nuclear protein extracts
Cells were pelleted by centrifugation (lOOOg, 5min) and washed three times by 
resuspension in ice-cold PBS and microcentrifugation (lO.OOOrpm, lmin). After 
the final washing step, the supernatant was discarded and the pellet 
resuspended in ice-cold buffer A (50pl) (Table 2.7) and incubated on ice (5min). 
The cells were lysed by drawing 5 times through a Hamilton syringe and subjected 
to centrifugation (lO.OOOrpm, 20s) at 4°C. The resulting nuclear pellet was gently 
resuspended in ice-cold buffer C (60pl) (Table 2.7) and incubated on ice (30min). 
After microcentrifugation at 4°C (lO.OOOrpm, 5min) the supernatant was removed 
and stored at -80°C.
2.6.4 Determination of protein concentration
The concentration of total protein in whole cell extracts was determined using the 
Micro BCA Protein Assay Reagent Kit (Pierce) in accordance with the 
manufacturer’s instructions. Briefly, protein samples were diluted in PBS and the 
concentration determined by a spectrophotometric reaction that occurs upon 
mixing with an equal volume of protein assay reagent (carried out in a 96-well 
micro-titre plate). The absorbance of each sample was read at 595nm using a 
Dynex Technologies MRX microplate reader and compared to a series of bovine 
serum albumin (BSA) standard dilutions in order to calculate the concentration.
2.6.5 Protein kinase B Activity Assay
PKB activity was determined using reagents provided in the Akt Kinase Assay Kit 
(non-radioactive) (Cell Signaling Technology). Whole cell extracts (250pg) were 
incubated with immobilised Akt antibody beads (20pl) overnight at 4°C. Beads 
were pelleted by microcentrifugation (13,000 rpm, 30s) and washed twice with lx  
Cell Lysis Buffer (500pl) and twice with lx  Kinase Buffer (500pl). Beads were 
then resuspended in Kinase Buffer (50pl) supplemented with ATP (0.2mM) and 
GSK-3 Fusion Protein (Ipg) The GSK-3 Fusion Protein contains residues 
corresponding to the peptide region surrounding the PKB phosphorylation site of
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GSK-3a/p, Ser21/9, and acts as an artificial substrate. The Kinase reaction was 
terminated by the addition of reducing solubilising solution (20pl). SDS-PAGE and 
western blot analysis was carried out on the supernatant fraction (Sections 2.6.7- 
2.6.9).
2.6.6 Immunoprecipitation
Whole cell extracts (150-300|ig) were pre-cleared by the addition of Protein A/G 
Agarose beads (Santa-Cruz Biotechnology) (20pl) and incubation with gentle 
rolling at 4°C (lh), followed by microcentrifugation (13,000rpm, 3min) to remove 
the beads. The pre-cleared supernatant was mixed with an antibody raised 
against the desired protein (2pg/ml) and incubated overnight at 4°C with gentle 
rolling. The resulting protein-antibody complex was captured by the addition of 
Protein A/G Agarose (20|il) with gentle rotary mixing at 4°C (2h). The beads 
containing the captured immunocomplex were collected by microcentrifugation 
(13,000rpm, 3min) at 4°C and washed twice with phosphatase-free extraction 
buffer (without Triton X-100) (Table 2.7). They were then resuspended in 0.1M 
glycine (pH 2.5) (50-100pl) and incubated, with gentle rolling, at 4°C (lOmin) in 
order to displace the protein from the A/G Agarose. Beads were removed by 
microcentrifugation (9000rpm, 2min) and the immunoprecipate used 
immediately for SDS-PAGE and western blot analysis (Sections 2.6.7-2.6.9).
2.6.7 Sodium dodecyl-sulphate- polyacrylamide gel electrophoresis (SDS-PAGE)
Table 2.8 Composition of SDS-PAGE gels for western blot analysis
Upper buffer - - 2.5ml
Lower buffer 5ml 5ml -
Acrylamide:bisacrylamide (37.5:1) 5ml 7.5ml 1.25ml
ddH20 9.78ml 7.28ml 6.14ml
10% (w/v) APS 200pJ 200pJ lOOpI
TEMED 20pJ 2 0 jjJ lOpI
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SDS-PAGE was performed under reducing conditions following the method of 
Laemmli (1970). SDS-PAGE gels were prepared from stock solutions (Table 2.7) 
in the compositions shown in Table 2.8, using Mini-PROTEAN II™ slab 
electrophoresis cell apparatus (Bio-Rad Laboratories), assembled as described by 
the manufacturer, lx  Running Buffer was prepared containing 0.1% (w/v) SDS 
(Table 2.7). Whole cell protein extracts (10-lOOpg) or immunoprecipated lysates 
were separated by elecrophoresis on a 10% separating gel (for western blots with 
all antibodies with the exception of MCP-1 for which a 15% separating gel was 
used) after running through approximately 1cm of stacking gel (5%). Prior to 
loading, protein samples were mixed with reducing solubilising solution (in a ratio 
of 5:1) and boiled (3min).
2.6.8 Western Blotting
The separating gel and PVDF membrane (an appropriate size to fit the gel), 
previously activated in methanol, were equilibrated in transfer buffer (Table 2.7) 
at room temperature (15min). Electrophoretic transfer of proteins from the gel to 
the PVDF membrane was carried out using a TransBlot Electrophoretic transfer 
cell (BioRad Laboratories). The gel was placed in a blotting cassette adjacent to 
the PVDF membrane, between Whatman 3MM paper and the sponge pads of the 
transfer apparatus (pre-soaked in transfer buffer). This assembly was subjected to 
electroblotting in transfer buffer at 4°C, at a constant voltage of 15V for 12-18h or 
at 150V for lh . Protein transferred to the PVDF membranes was 
immunodetected as described in Section 2.6.9.
2.6.9 Immunodetection of proteins
Blotted PVDF membranes were probed immunochemically in three stages: 
incubation with a blocking solution of lx  TBS containing 1-10% (w/v) skimmed 
milk and 0.05-0.2% (v/v) Tween-20; incubation with the primary antibody in lx  
TBS, 1-5% (w/v) skimmed milk, 0.05-0.2% (v/v) Tween; and incubation with an 
appropriate HRP-conjugated secondary antibody in lxTBS, 1-5% (w/v) skimmed 
milk, 0.05-0.1% (v/v) Tween. Membranes were washed three times after each 
incubation step with lx  TBS containing 0.05-0.1% (v/v) Tween. Conditions
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relevant to each primary antibody are specified in Table 2.9. Detection of 
membrane bound antigen-antibody complexes was carried out using enhanced 
chemiluminescence (ECL) reagent as described in the manufacturer’s instructions 
(Amersham Biosciences). Membranes were exposed to Kodak X-Ray film in a light 
proof cassette (Genetic Research Instrumentation) for varying exposure periods 
(3s-5min). X-ray films were developed using a Gevamatic 60 automatic developer 
(Agfa-Gevaert). The expected protein size was validated by comparison to 
standard Rainbow markers (Appendix II).
Table 2.9 Primary antibody binding conditions
1
STATl p 84 /91 1 /1 0 0 0 5 - 1 8 4 /9 1
Phospho STATl Ser727 1/1000 5 - Overnight1 8 4 /9 1
Phospho STATl Tyr701 1/1000 5 - Overnight1 8 4 /9 1
p85 1/2000 3 - Overnight1 85
CK2a 1/1000 5 - 1 42
CK2a’ 1/1000 5 - 1 45
CK2(3 1/1000 5 - 1 35
S p l 1/1000 3 - Overnight1 9 5 /1 0 6
MCP-1 1 /5 0 0 5 - 3 11
P-Actin 1 /8 0 0 0 1 - 1 42
PKB 1/1000 - 5 1 60
Phospho PKB Thr 308 1/1000 - 5 Overnight1 60
Phospho PKB Ser 473 1/1000 - 5 Overnight1 60
Phospho GSK3 (Akt Assay) 1/1000 - 5 Overnight1 30
Overnight incubations carried out at 4°C
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2.7 Prom oter Binding Analysis
2.7.1 Electrophoretic Mobility Shift Assay (EMSA)
2.7.1.1 Stock solutions
Table 2.10 Stock solutions involved in EMSA analysis
Dilution buffer 40mM KCI, O .lm M  EDTA
10x Binding buffer 340mM KCI, 50mM MgCI2, Im M  DTT
2.7.1.2 Preparation of radiolabelled oligonucleotide probe DNA
2.7.1.2.1 Annealing of oligonucleotides
The sequences of the oligonucleotides used for EMSA analysis are shown in Table 
2.11. Forward and reverse sequences were designed to leave 5 ’ overhangs 
containing at least one G residue following annealing to allow for complementary 
binding of [a-32P]-dCTP during radiolabelling.
Forward and reverse oligonucleotides (200ng of each) were incubated together at 
100°C (lOmin) in the presence of a medium salt buffer (lx  NEB Buffer 3) in a 
final volume of lOOpl. The mixture was then allowed to cool to room temperature. 
Double stranded oligonucleotides prepared in this way were either radiolabelled 
immediately or stored at -20°C.
Table 2.11 Seqences of oligonucleotide probes for EMSA analysis
MCP-GC (-66/-33) 5 ’ G GCA CCC TGC CTG ACT CCA CCC CCC TGG CTT A 3 ’
3' GGG ACG GAC TGA GGT GGG GGG ACC GAA T GTT G 5'
MCP-GAS (-166/-137) 5 ’ GGCTTC CAC TTC CTG GAA ACA CCC GAG GG 3'
3' AAG GTG AAG GAC CTT TGT GGG CTC CC GAG 5’
S p l 5' TAG ATT CGA TCG GGG CGG GGC GAG 3'
3 ’ TAA GCT AGC CCC GCC CCG CTC CCG 5 ’
STATl 5 ’ CTT TTC CTG GAA TC 3 ’ 
3' GAA AAG GAC CTT AG 5'
NFk B 5 ’ AGT TGA GGG GAC TTT CCC AGG C 3' 
3' TCA ACT CCC CTG AAA GGG TCC G 5 ’
AP-1 5 ’ GAT CCT TCG TGA CTC AGC GGG ATC CTT CGT GAC T 3 ’
3 ’ A AGC ACT GAG TCG CCC TAG GAA GCA CTG AGT CGC C 5'
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2.7.1.2.2 Radiolabelling of double-stranded oligonucleotides
Radiolabelling was carried out using the reagents supplied in the Megaprime™ 
Labelling Kit (Amersham Pharmacia Biotech) according the manufacturer’s 
protocol. Double-stranded oligonucleotide (5ul, diluted to 35p.l with ddhbO) was 
incubated with lx  Labelling buffer, [a-32P]-dCTP (3pl) and Klenow polymerase 
(2pl) at 37°C (30min). The reaction was stopped by the addition of lx  TE buffer 
(50pl) and separation of the radiolabelled probe from unincorporated nucleotides 
was carried out using a Sephadex G50 nick column. The column was equilibrated 
with lx  TE (9ml) and the reaction mix (IO O jliI) loaded onto the column and eluted 
in lx  TE buffer (300pl) which was then discarded. The column was then further 
eluted with lx  TE (400pl) and the eluate collected and stored at -20°C.
2.7.1.3 DNA-protein binding reactions
Binding of radiolabelled double-stranded oligonucleotides to proteins present in 
phosphatase-free whole cell extracts (Section 2.6.2) was carried out according to 
Ramji et al. (1993). Briefly, phosphatase-free whole cell extracts (5pg) were 
diluted to a final volume of 13pl with dilution buffer (Table 2.7) and incubated 
with lx  binding buffer (Table 2.7) and lp g /m l poly(dl-dC) (3pl) on ice (lOmin), to 
allow non-specific DNA binding to occur. Radiolabelled oligonucleotide (2pl) was 
then added and the reaction mixture was incubated at room temperature 
(20min).
2.7.1.4 Antibody supershift and competition binding studies
For supershift experiments antibody (2jag) was added to the DNA binding reaction. 
In competition binding studies, prior to addition of the radiolabelled probe, the 
binding reaction mixture (Section 2.7.1.3) was incubated with unlabelled probe 
(20min on ice) in molar excess of the radiolabelled probe by 250 fold.
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2.7.1.5 Electrophoresis of DNA-protein complexes
Table 2.12 Composition of non-denaturing polyacrylamide gels for EMSA analysis
Acrylamide: Bisacrylamide (29:1) 6ml 5ml
lOxTBE 5ml 4ml
ddhteO 42.5ml 30.5ml
10% APS 500^1 400^1
TEMED 50|jJ 40|il
Prior to electrophoresis 20% (w/v) Ficoll (5pl) was added to facilitate gel loading. 
DNA-protein complexes were resolved by electrophoresis on 4-6% (v/v) non­
denaturing polyacrylamide gels (Table 2.12). Electrophoresis was carried out for 
3-4h at 150V at 4°C using vertical gel apparatus (Scotlab) with 0.5x TBE as 
running buffer. Following electrophoresis, the gel was transferred to Whatmann 
3MM paper and dried under vacuum using a Gel Dryer (Model 583, BioRad) at 
80°C (lh). The dried gel was exposed to Kodak X-Ray film in a light proof cassette 
(Genetic Research Instrumentation) at -80°C  for varying exposure periods (12- 
72h). X-ray films were developed using a Gevamatic 60 automatic developer 
(Agfa-Gevaert).
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2.7.2 Chromatin immunoprecipitation (ChIP) assay
2.7.2.1 Stock solutions
ChIP analysis was carried out using reagents supplied in the ChlP-IT™ kit (Active 
Motif) according to the manufacturer’s instructions with minor modifications as 
detailed. Solutions were made up as listed in Table 2.12.
Table 2.13 Solutions used for ChIP Assay
PBS/PMSF lx  PBS; 0.5mM PMSF
Glycine Stop-Fix Solution lx  Glycine Buffer, lxPBS
Lysis Buffer lx  Lysis Buffer; 5pJ Phosphatase Inhibitor 
Cocktail (PIC)/ml); 0.5mM PMSF
Shearing Buffer lx  Shearing Buffer; 5^1 PIC/ml)
ChIP IP Buffer lx  IP Buffer, 5pl PIC/ml)
Wash Buffer 1 lx  Wash Buffer 1; lp l PIC/ml)
Wash Buffer 2 lx  Wash Buffer 1; 1^1 PIC/ml)
ChIP Elution Buffer 1% SDS; 5 0 pM NaHCOs
2.7.2.2 Formaldehyde crosslinking
Cells (approximately 3 x 105 in a 75cm2 flask) were fixed by the addition of 37% 
(v/v) formaldehyde to the culture medium (27pl 37% (v/v) formaldehyde/ml 
medium) followed by incubation at room temperature (lOmin) while rocking 
gently. Cells were washed in PBS/PMSF (5ml) and incubated in Glycine Stop-Fix 
Solution (30ml) (5min) while rocking gently. Following this cells were washed 
once in PBS/PMSF (5ml), resuspendend in ice-cold Lysis Buffer (0.75ml) and 
incubated on ice (30min). The cell suspension was drawn ten times through a 
Hamilton syringe and the nuclei pelleted by microcentrifugation (5000rpm, 
lOmin) at 4°C. Nuclei were resuspended in Shearing Buffer (0.5ml) and 
subjected to sonication as described below.
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2.7.2.3 Chromatin shearing
Chromatin shearing was achieved through sonication using a Sonics Vibracell™ 
Ultrasonic Processor with a 3mm microtip. Sonication was carried out on ice 
using optimised shearing conditions (determined in Section 4.4.2.2) consisting of 
twelve pulses of 30s at 24% power, separated by 30s pauses. Following 
microcentrifugation (13,000rpm, 12min) at 4°C the supernatant fraction, 
containing sheared chromatin, was retained. Shearing efficiency was analysed by 
electrophoresis of sheared DNA through a 2% (w/v) agarose gel subsequent to 
the reversal of cross-links (Section 2.7.2.5).
2.7.2.4 Chromatin immunoprecipitation
Sheared chromatin (50pl/reaction) was diluted in ChIP IP Buffer (60pl) and 
precleared by incubation with Protein G beads (lOOpl) (lh ) with rotation at 4°C. 
Following microcentrifugation (4000rpm, 2min) the precleared supernatant was 
incubated with the relevant antibody (4pg) overnight at 4°C. An aliquot (lOpI) of 
precleared chromatin was retained for use as an “Input” sample. Protein G beads 
(lOOpl) were added to the antibody/chromatin and incubated at 4°C (1.5h). The 
beads were then washed once with ChIP IP Buffer; four times with Wash Buffer 1; 
once with Wash Buffer 2; and twice with Wash Buffer 3 (supplied ready-to-use). 
For each wash, beads were pelleted by centrifugation (4000rpm, 2min) and 
incubated with Wash Buffer for 2min with rotation. DNA was collected from the 
Protein G beads by incubation in ChIP Elution buffer (50pl) (15min) with rotation. 
This step was performed twice and aliquots pooled to give a final elution volume 
of lOOpl.
2.7.2.5 Reversal of crosslin king and DNA purification
ChIP elutions (lOOpl) and Input DNA (diluted to lOOpl in ddhbO) were incubated 
overnight at 65°C in the presence of NaCI (0.2M) and RNaseA (O.lpg/pl). 
Subsequently, the samples were treated with Proteinase K (O.lpg/pl) at 42°C 
(1.5h) in the presence of EDTA (lOmM) and Tris-CI (pH6.5) (20mM). DNA was
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purified according to the Active Motif protocol using the mini-columns provided 
and eluted in a final volume of lOOpl ddH20.
2.7.2.6 PCR analysis
PCR analysis was carried out using conditions and primers as specified in Table
2.5 and products were separated by agarose gel electrophoresis on a 2% (w/v) 
agarose gel (Section 2.5.4).
2.8 M icroarray
2.8.1 SuperArray Oligo GEArray DNA Microarrays
Microarray experiments were performed using Oligo GEArray™ Mouse 
Atherosclerosis Microarrays supplied by SuperArray Bioscience Corporation. The 
arrays are based on a Nylon matrix platform containing gene-specific 
oligonucleotides (60bp) (Appendix V). In brief, a RNA sample is converted to 
labelled cRNA that is hydrised to the array membrane and detected by a 
chemiluminescent method. Procedures were carried out using the reagents 
supplied in the Oligo GEArray™ Reagent Kit according to the relevant protocols.
2.8.2 Stock solutions
Table 2.14 Stock solutions used for microarray based experiments
20x SSC 3M NaCI; 0.3M sodium citrate; HCI pH 7.0
Wash Solution 1 2x SSC; 1% (w/v) SDS
Wash Solution 2 O.lx SSC; 0.5% (w/v) SDS
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2.8.3 Synthesis of labelled cRNA
Total RNA (3pg) (Section 2.5.2) was converted to a labelled target cRNA probe using the 
TrueLabeling-AMP™ Linear RNA Amplification Kit (SuperArray Bioscience Corporation) 
according to the manufacturer’s protocol. Briefly this involved a cDNA synthesis reaction 
followed by an overnight cRNA synthesis and amplification reaction incorporating 
biotinylated-dUTP. Labelled cRNA was purified using the ArrayGrade cRNA Cleanup™ Kit 
(SuperArray Bioscience Corporation) according to the instructions provided by the 
manufacturer. The quality and concentration of cRNA obtained was calculated by 
measuring the absorption of light at wavelengths of 260nm and 280nm with a Hitachi LI- 
1800 spectrophotometer. Labelled cRNA was also analysed by resolving lp g  on a 1% (w/v) 
agarose gel (Section 2.5.4) and by dot blot (Section 2.8.4).
2.8.4 Dot blot to analyse cRNA labelling efficiency
Serial dilutions of labelled cRNA were prepared in the ratios: 1 /20; 1 /80; 1/320; 1/1280; 
1/5120. Dilutions (lp l) were dotted onto nitrocellulose membrane (preactivated in 
methanol) and allowed to dry. Chemiluminescent detection was carried as described in 
Section 2.8.6. The detection of a signal at a dilution of 1 /1 2 8 0  was considered to be 
sufficient for microarray analysis.
2.8.5 Hybridisation
Hybridisation procedures were carried out in a Hybaid™ rotary oven at a rotation speed of 
20rpm. Array membranes were prehybridised in GEAhyb™ Hybridisation solution (2ml) with 
continuous rotation at 60°C (2h). Following this, biotin-labelled cRNA target (6pg) was 
added to GEAhyb™ Hybridisation solution (0.75ml) and incubated with the array membrane 
overnight with continuous rotation at 60°C. Membranes were washed once with Wash 
Solution 1 (Table 2.14) (15min) and once with Wash Solution 2 (Table 2.14) (15 min), both 
at 60°C with continuous agitation.
2.8.6 Chemiluminescent detection
Chemiluminscent detection was performed using the Chemiluminescent Detection Kit 
according to the manufacturer’s protocol (SuperArray Bioscience Corporation). Membranes 
were exposed to Kodak X-Ray film in a light proof cassette (Genetic Research
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Instrumentation) for varying exposure periods (3s-15min). X-ray films were developed using 
a Gevamatic 60 automatic developer (Agfa-Gevaert).
2.8.7 Data analysis
The data analysis protocol is summarised in Figure 2.1. Microarray images were scanned 
from X-ray film using a HP Scanjet 5470c and saved as files in TIFF format. The average 
spot density for each gene, taken as the expression value (E) for that gene (E; gene), was 
measured using GEArray™ Expression Analysis Software (SuperArray Bioscience 
Corporation) accessible at httD://GEASuite.superarrav.com. As few genes were detectable 
at low exposures, yet the signal for others became saturated at high exposures, it was 
necessary to use data over a range of exposure times and normalise data between the 
signals (Section 2.8.7.2). Between 7-10 images obtained from a range of membrane 
exposure times were analysed to create a dataset that was exported to Microsoft Excel for 
analysis.
2.8.7.1 Background subtraction
A background reading (B) for each array was determined by taking the mean value of E for 
the dataset, excluding control genes, which was subtracted from E; gene. An exposure was 
selected for each gene whereby E was above the background level but below the saturation 
point (S) for that array. S was defined as the value of E at which increasing exposure times 
did not increase the value measured.
2.8.7.2 Data normalisation
In order to normalise data between different arrays in the same experiment, the relative 
value of E; GAPDH was compared between arrays, at an exposure time for which S was not 
reached in any array. As E; GAPDH reached saturation at exposures in which only a small 
number of other genes showed measurable expression, a second gene (C) was selected in 
the array representing the “Untreated” (UT) sample, for which E spanned all exposures 
without reaching S. E for all other genes was normalised to this gene at the relevant 
exposures. Where other arrays (“Treated”, T) were compared to array UT, C values were 
multiplied by the ratio: T; (E-B) GAPDH: UT; (E-B) GAPDH, to give C2 to which genes in array T 
were normalised. This gives values of E(norm) for each gene that can then be compared.
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2.8.7.3 Statistical analysis
The fold induction (F), expressed by: [T: E(norm); gene]/[UT: E(norm); gene], was calculated 
for each gene. The log2 F was calculated so that genes for which there was no change in 
expression were given a value of zero; those for which expression was reduced by half were 
given a value o f-1; and for a two-fold induction, +1. The mean log2 F was taken from three 
independent experiments and the standard deviation (SD) of log2 F calculated. A t-test was 
carried out on this data (Appendix IV) to determine whether there was a significant change in 
expression between T and UT. A P-value of < 0.05 was accepted as significant. A change in 
expression for which P < 0.1 was accepted as significant subject to PCR validation (denoted 
by *). Unchanged expression was reported where 0.5 < F < 1.5 with SD > 1.
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Figure 2.1 Microarray data normalisation
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CHAPTER 3. ROLE OF CK2 AND PI3K IN THE REGULATION OF 
MACROPHAGE GENE EXPRESSION BY IFN-y
3.1 Introduction
The cytokine IFN-y modulates the expression of numerous genes, many of which 
are involved in the progression of the atherosclerotic lesion. Studying the 
signalling pathways through which IFN-y regulates the expression of these genes 
could be of benefit in the search for therapeutic targets for the disease.
3.1.1 Experimental strategy
It was decided that the work presented here would be carried out predominantly 
in macrophages as these cells, known to be responsive to IFN-y, are a key cellular 
component of the atherosclerotic plaque (Section 1.4.4). The transformed murine 
macrophage cell line, J774.2 (Section 2.3.1), was selected as a model system. Of 
the commercially available monocyte/macrophage cell lines, cells of the J774.2 
line most closely represent differentiated macrophages (Ralph and Nakoinz 1977, 
Ralph etal. 1975, Ralph and Nakoinz 1975). In comparison to primary monocyte- 
derived macrophages, the cell line provides a more homogeneous system and 
allows for the extraction of a greater yield of RNA or protein. The J774.2 cell line 
has been used successfully to model macrophage responses to IFN-y in our 
laboratory, giving data that has subsequently been replicated in primary cells and 
other macropahge systems (Mead et al. 2003, Hughes et al. 2002, Tengku- 
Muhammad et al. 1998, Tengku-Muhammad et al. 1996). Studying signalling 
mechanisms in a murine cell line not only allows comparison to the common 
mammalian model for atherosclerosis development, the apoE-null mouse, but 
patterns in gene expression are also well-conserved with human responses. 
Additionally, key findings were to be studied in human primary macrophages to 
rule out the possibility that observations were a peculiar property of the 
transformed cell line.
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Having previously established, in our laboratory, a role for the protein kinases CK2 
and PI3K in the IFN-y-mediated regulation of LPL and ICER gene expression (Mead 
et al. 2003, Hughes et al. 2002, Tengku-Muhammad et al. 1999b, Evans, S., 
personal communication), the primary aim of the research presented in this 
chapter was to further analyse the function of these kinases in IFN-y signalling. 
This was to be achieved initially by studying the effect of specific pharmacological 
inhibitors of these mediators on the induction of a selection of genes by IFN-y. By 
this we hoped to gain information about the role of PI3K and CK2 in alternative 
pathways controlling the regulation of gene expression by the cytokine. Data from 
these experiments would then be confirmed with the use of dominant negative 
mutants and the mechanisms involved in promoter activation studied in more 
detail (see Figure 3.1 for overall strategy).
3.1.2 Selection of genes for study
In order to achieve the aims detailed above it was first necessary to select genes 
of interest for further study. We looked for a range of genes, that have previously 
been found to be inducible by IFN^y in at least one cellular system, that were 
potentially regulated by the cytokine through distinct signalling mechanisms.
The JAK-STAT pathway is the most widely accepted signalling mechanism 
activated by IFN-y (Section 1.7). However, studies by Ramana etal. (2001, 2002) 
have highlighted the existence of potential STATl-independent pathways in the 
regulation of gene expression by IFN-y. They have shown that STATl-deficient 
cells are able to support the regulation of a number of genes in response to IFN-y 
treatment (Ramana et al. 2002, Gil et al. 2001, Ramana et al. 2001) (Section 
1.8.1). Among these is the proatherogenic chemokine MCP-1, discussed in more 
detail in Section 1.6.
The induction of other genes by IFN-y, including suppressor of cytokine signalling 
(SOCS)-l, was found to be possible in wild type cells only (Ramana et al. 2002). 
SOCS-1 acts as a negative regulator of several cytokine pathways, in particular the 
JAK-STAT pathway. Knock-out of the SOCS-1 gene in mice results in neonatal 
lethality due to a complex inflammatory disease resulting in fatty degeneration of
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the liver. This pathology is thought to be caused by tissue hypersensitivity to IFN-y 
as SOCS-l/IFN-y double knock-out mice do not suffer from neonatal disease 
(Cornish et al. 2003, Alexander 2002, Alexander et al. 1999). SOCS-1 has also 
been shown to localise to the atherosclerotic lesion in apoE-null mice (Tang et al. 
2005) and is likely to modulate the inflammatory component of the disease.
As discussed previously, a recent study in our laboratory has demonstrated that 
the expression of the transcriptional repressor ICER is upregulated in response to 
IFN-y through the activation of the CREB family of transcription factors by CK2 
(Mead et al. 2003) (Sections 1.10 and 1.11). While transcriptional activation by 
IFN-y has been extensively studied, far less is known about the repression of gene 
expression by this cytokine. The upregulation of ICER may represent a novel 
mechanism for transcriptional repression in macrophages by IFN-y. Several genes 
that are implicated in atherosclerosis development are downregulated in 
response to IFN-y {e.g. SR-A, VLDL-R, and LRP (Schulz et al. 2003, Kosaka et al. 
2001, LaMarre et al. 1993, Geng and Hansson 1992) and the signalling 
pathways involved are of potential therapeutic interest. The induction of ICER 
mRNA expression by IFN-y was not found to be attenuated in the presence of the 
pharmacological inhibitor of JAK2, AG490, indicating that a novel JAK- 
independent pathway may be involved that leads to the regulation of 
CREB/CREM/ATF binding activity.
Due to the potentially differential mechanisms involved in the regulation of MCP- 
1, SOCS-1 and ICER expression by IFN-y, these three genes were selected for 
further study.
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ANALYSE THE ROLE OF 
PI3K AND CK2 IN THE 
REGULATION OF 
MACROPHAGE GENE 
EXPRESSION BY IFN-y
:
J774.2
macrophages
PHASE 1
Pretreatment with 
pharmacological 
inhibitor
PHASE 2
IFN-y treatment
RT-PCR: Analyse 
changes in mRNA 
levels
IDENTIFY POTENTIALLY 
NOVEL SIGNALLING 
MECHANISMS
T
Confirm and 
expand on previous 
findings
Experimental strategy
The aim of Phase 1 of the experimental strategy was to analyse the role of the kinases PI3K and 
CK2 in the regulation of the expression of a selection of genes by IFN-y using specific 
pharmacological inhibitors. The data from this set of experiments were to be used to identify 
potentially novel signalling mechanisms in the regulation of one or several of the selected genes. 
Phase 2 of the strategy involved the confirmation and expansion of previous findings.
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3.2 E ffe c t o f IFN^y on the Expression o f MCP-1, SOCS-1 and ICER
The effect of IFN-y on the expression of MCP-1, SOCS-1 and ICER over a 24h time 
course was analysed using RT-PCR (Section 2.5.3). Cells of the macrophage cell 
line J774.2 were stimulated with murine IFN-y for periods of 0, 1, 3, 6, 12 and 
24h (Section 2.3.6) after which RNA was extracted (Section 2.5.2). The quality of 
RNA can be seen in Figure 3.2A. As expected for total RNA, the relative intensity 
of the 28s rRNA band was approximately twice that of the 18s rRNA band, for 
each sample. For subsequent work involving RNA the quality was consistently of 
this standard although the data is not shown. RT-PCR was carried out for each 
gene using the primers and conditions detailed in Table 2.5, generating products 
of the appropriate size as determined by comparison to standard DNA molecular 
weight markers (Appendix II).
Figure 3.2 summarises the change in mRNA levels for each species in response to 
IFN-y over the duration of the time course. Figure 3.2B illustrates the PCR 
products fractionated by agarose gel electrophoresis (Section 2.5.4). 
Densitometric analysis (Section 2.5.5) was carried out and the relative intensity of 
the bands at each time point (in the case of ICER, the highest molecular weight 
band, representing ICER I, was used) was calculated in relation to the intensity of 
a PCR product band for a control gene (P-actin) to ensure equal cDNA input. The 
fold induction in comparison to the mRNA expression at Oh (assigned as 1) was 
plotted in relation to time (h) (Figure 3.2C).
Gene expression levels for ICER were highest following stimulation with IFN-y for 
3h, after which point there was a marginal decrease (Figures 3.2B and 3.2C). It is 
also clear from these results that ICER I is the major mRNA expressed in these 
cells following exposure to IFN-y. Similar to ICER, the expression of MCP-1 was 
highest after a 3h treatment period. In this case however, the level of expression 
did not decrease for subsequent time points (Figures 3.2B and 3.2C). SOCS-1 
shows a similar expression profile in response to IFN-y with mRNA levels reaching 
a maximum after 3h treatment and remaining at this level for the duration of the 
time course (Figures 3.2B and 3.2C).
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A negative (-)RT reaction (for which reverse transcriptase was not included in the 
cDNA synthesis step) gave no product, indicating that the samples were free from 
DNA contamination. A standard statistical t-test (Appendix IV) was carried out for 
this data, and for all subsequent densitometry, and changes in expression were 
significant to the degree indicated.
A comparison of the mRNA levels at the time point for which maximal gene 
expression was observed for both treated and untreated control samples 
confirmed in all cases that the increase in expression was due to the effect of IFN- 
y and not the status of the cells at that time point (Figure 3.3).
M
IFN-y - +
ICER I 
ICER ly
ICER II 
ICER lly
MCP-1 
SOCS-1
28S
Figure 3.3 IFN-y-mediated induction in mRNA expression for MCP-1, SOCS-1 and 
ICER at time point for which maximal expression was observed
J774.2 cells were cultured in the presence or absence of IFN-y for 3h. Total RNA 
was isolated and subjected to RT-PCR using primers ICER I/ll; MCP-1; SOCS-1; 
28S. The amplification products were analysed by agarose gel electrophoresis. 
The position of the appropriate product and the size of the DNA markers are 
indicated.
500/517
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3.3. Effect of Pharmacological Inhibitors on IFN-y-Stimulated Gene 
Expression
The profile of induction for MCP-1, SOCS-1 and ICER by IFN-y over time 
established an optimal treatment time of 3h for which maximal levels of mRNA 
were observed for each of these genes. Further studies aiming to determine 
components of the signalling pathways involved in this response were carried out 
with cells stimulated with IFN-y for this time. Specific pharmacological inhibitors 
were employed to study the role of various signalling mediators at concentrations 
widely used in published literature (Table 2.2).
3.3.1 Effect of pharmacological inhibition of CK2 on IFN-y-stimulated gene 
expression
Work in our laboratory has shown that IFN-y stimulates the activity of CK2 and 
indicated the involvement of this kinase in the IFN-y-mediated regulation of ICER 
and LPL gene expression in macrophages (Section 1.10) (Mead et al. 2003, 
Hughes et al. 2002). These experiments utilised the selective CK2 inhibitor 
apigenin, that functions by competing with ATP binding (Critchfield et al. 1997) 
(Table 2.2). To determine whether CK2 has a role in the IFN-y-inducible regulation 
of any of the other genes being investigated, the effect of apigenin on IFN-y 
stimulated expression was studied using ICER as a positive control.
J774.2 cells were pretreated with apigenin (lOpM) or DMSO as a vehicle control 
(Section 2.3.7). They were then cultured in the presence or absence of IFN-y for 
3h, the time at which MCP-1, SOCS-1 and ICER exhibit maximal induction. 
Following treatment, RNA was extracted and RT-PCR analysis carried out for each 
gene as before. Figure 3.4 shows the PCR products for each gene resolved by 
agarose gel electrophoresis (Figure 3.4A) and the band densities normalised to 
the expression of the control gene (3-actin (Figure 3.4B). For each of the selected 
genes IFN-y can be seen to have stimulated an increase in mRNA levels as 
expected. When combined with IFN-y treatment, apigenin reduced gene 
expression levels, suggesting that CK2 is involved in the IFN-y-induced signalling 
pathways for all of these genes.
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Figure 3.4 Effect of apigenin on the induction of ICER, MCP-1 and SOCS-1 by IFN-y
J774.2 cells were pretreated with apigenin (10pM) or DMSO as a vehicle control. 
They were then cultured in the presence or absence of IFN-y for 3h. Total RNA 
was isolated and subjected to RT-PCR using primers: ICER I/ll; MCP-1; SOCS-1; p- 
actin. The amplification products were analysed by agarose gel electrophoresis 
(A). The position of the appropriate product and the size of the DNA markers are 
indicated. Panel B shows the relative expression (mean ±SD) of the appropriate 
gene normalised to the expression of p-actin as determined by densitometric 
analysis from three independent experiments. -RT denotes a reaction in which 
no reverse transcriptase was included for the cDNA synthesis step (using vehicle- 
treated RNA). **P<0.01; ***P < 0 .0 0 1
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The constant expression of p-actin mRNA shows that apigenin at this concentration 
is not having a global effect on cellular gene expression. However in order to 
confirm that the downregulation in expression observed for these IFN-y-regulated 
genes was not due to a toxic effect of the inhibitor, a trypan blue exclusion assay 
(Section 2.3.8) was carried out. It was found that this was not the case, with a 
negligible proportion of cells dying under all treatment conditions (data not shown).
3.3.2 Effect of pharmacological inhibition of PI3K on IFN^y-stimulated gene 
expression
PI3K is a member of a family of lipid kinases involved in many cellular processes. 
PI3K and the downstream effector PKB have been linked to the activation of STAT1 
in response to IFN-y and may also be involved in the mediation of JAK-STAT- 
independent signalling pathways (Section 1.9). The pharmacological inhibitor 
LY294002 specifically acts to prevent PI3K function by acting as a competitor for 
the ATP-binding site (Walker et al. 2000, Vlahos et al. 1994) (Table 2.2). 
LY294002 has been shown in our laboratory to prevent the IFN-y-mediated 
suppression of the proatherogenic molecule LPL in macrophages (Tengku- 
Muhammad etal. 1999b, Evans, S., personal communication). The downregulation 
of LPL gene expression is also dependent on the activation of CK2 by IFN-y (Hughes 
et al. 2002). A number of other studies have also demonstrated a role for PI3K in 
the IFN-y-mediated regulation of certain responses as discussed in Section 1.9. 
The effect of PI3K inhibition by LY294002 on the IFN-y-mediated induction of MCP- 
1, SOCS-1 and ICER was therefore investigated. Hwang et al. (2004) have 
previously demonstrated that the IFN-y-mediated induction of iNOS expression was 
attenuated in the presence of LY294002. The efficacy of the inhibitor was 
determined by reproducing the effect on the induction of iNOS expression by IFN-y.
J774.2 cells were pre-treated with LY294002 (5pM and 20pM) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 3h, 
after which RNA was extracted. RT-PCR was carried out for each gene as before 
and for iNOS using the primers specified in Table 2.5.
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Figure 3.5 Effect of LY294002 on the induction of ICER, MCP-1 and SOCS-1 
expression by IFN^ y
J774.2 cells were pretreated with LY294002 (5pM and 20pM) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN^ y for 
3h. Total RNA was isolated and subjected to RT-PCR using primers: ICER I/ll; 
MCP-1; SOCS-1; iNOS, p-actin. The amplification products were analysed by 
agarose gel electrophoresis (A). The position of the appropriate product and the 
size of the DNA markers are indicated. Panel B shows the relative expression 
(mean ±SD) of the appropriate gene normalised to the expression of p-actin as 
determined by densitometric analysis from three independent experiments. -RT 
denotes a reaction in which no reverse transcriptase was included for the cDNA 
synthesis step (using vehicle-treated RNA). **P<0.01
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Figure 3.5 shows the PCR products using primers specific to each mRNA species 
(Figure 3.5A) and the band intensities in relation to p-actin expression (Figure 
3.5B). As expected the response in iNOS gene expression to IFN-y was attenuated 
by treatment with LY294002. For ICER I and SOCS-1 no difference was displayed 
between the induction with IFN-y alone and when treatment was combined with 
LY294002 (at low or high concentration) indicating that PI3K is not involved in the 
regulation of these genes in response to IFN-y. In contrast stimulation of MCP-1 
gene expression following IFN-y treatment is inhibited by LY294002 in a 
concentration dependent manner as illustrated in Figure 3.5.
3.4 Role o f PI3K and PKB in the  IFN-y-Mediated Induction o f MCP-1
While the CK2 inhibitor apigenin attenuated the induction of all three of the 
selected genes by IFN-y, the genes were differentially responsive to the PI3K 
inhibitor LY294002. Only the stimulation of MCP-1 gene expression by IFN-y was 
inhibited in a dose-dependent manner while the induction of SOCS-1 and ICER 
was unaffected. This suggests the existence of a novel and selective role for PI3K 
in the regulation of macrophage gene expression by IFN-y. Further studies were 
therefore carried out to investigate the function of PI3K in the induction of MCP-1 
expression by IFN-y.
3.4.1 Effect of LY294002 and apigenin on IFN^y-induced MCP-1 expression in 
primary human macrophages
To rule out the possibility that the results obtained are a peculiar property of the 
transformed J774.2 cell line, the effects of IFN-y and the inhibitors LY294002 and 
apigenin on MCP-1 gene expression in human primary monocyte-derived 
macrophages were investigated. Primary monocytes were isolated from human 
blood and allowed to differentiate in culture over seven days (Section 2.3.4). 
Macrophages were pretreated with apigenin (20pM), LY294002 (20pM) or DMSO 
as a vehicle control. They were then cultured in the presence or absence of 
human IFN-y for 3h, after which RNA was extracted. RT-PCR was carried out using 
primers specific for human MCP-1 and P-actin (Table 2.5) and products resolved 
by agarose gel electrophoresis (Figure 3.6A). The density of the product bands as
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determined by densitometric analysis was normalised to those for p-actin as 
illustrated in Figure 3.6B. As shown in J774.2 cells (Figure 3.4-3.5), apigenin and 
LY294002 both inhibited the induction of MCP-1 expression by IFN-y in human 
monocyte-derived macrophages.
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Figure 3.6 Inhibition of IFN^mediated induction of MCP-1 mRNA expression by 
LY294002 and apigenin in primary monocyte-derived macrophages
Primary monocyte-derived macrophages were pre-treated with apigenin (20pM), 
LY294002 (20pM) or DMSO as a vehicle control. They were then cultured in the 
presence or absence of human IFN^y for 3h. Total RNA was isolated and 
subjected to RT-PCR using primers against hMCP-1 and p-actin. The amplification 
products were analysed by agarose gel electrophoresis (A). The position of hMCP- 
1 and the size of the DNA markers are indicated. Panel B shows the relative 
expression (mean ±SD) normalised to the expression of p-actin as determined by 
densitometric analysis. -RT denotes a reaction in which no reverse transcriptase 
was included for the cDNA synthesis step (using vehicle-treated RNA). Results are 
representative of two independent experiments. **P<0.01; ***P <0.001.
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3.4.2 Effect of wortmannin and rapamycin on the IFISky-mediated induction of MCP-1 
gene expression
The inhibitor LY294002 has been demonstrated previously to inhibit the Kinase 
mammalian target of rapamycin (mTOR) independently of PI3K activity. The 
induction of iNOS was found to be inhibited by LY294002 and a dominant negative 
construct specifying for a mutant form of mTOR, but not by an alternative PI3K 
inhibitor, wortmannin (Kristof et al. 2003). In relation to the induction of MCP-1 
expression by IFN-y, LY294002 has been found to inhibit the response in endothelial 
cells, while wortmanin did not, and the effect of LY294002 was concluded to be 
independent of PI3K inhibition (Choi et al. 2004). The inhibitors wortmannin and 
rapamycin were therefore used in order to confirm that the IFN-y-mediated induction 
of MCP-1 was dependent on PI3K and not mTOR. A second possibility is that mTOR 
acts as a downstream effector of PI3K in the regulation of MCP-1 expression. 
Previous studies have shown that mTOR is activated by PKB and that it may have a 
role in the activation of STAT1 (Bjournsti and Houghton 2004). Wortmannin is an 
antibiotic originally isolated in Penlcillium wortmannii that irreversibly binds to the 
ATP binding pocket of the p llO  subunit of PI3K (Arcaro and Wymann 1993). 
Rapamycin is an antibiotic produced by Streptomyces hygroscopicus that forms a 
complex with the FK506-binding protein (FKBP)-12 which then binds and prevents 
the activation of mTOR (Chen et al. 1995) (Table 2.2).
J774.2 cells were pretreated with LY294002 (5pM and 20pM), wortmannin (5pM 
and 20pM), rapamycin (200nM and lp M ) or DMSO as a vehicle control. They were 
then cultured in the presence or absence of IFN-y for 3h after which RNA was 
extracted. RT-PCR was carried out as before using primers specifying for murine 
MCP-1 and p-actin (Table 2.5). Figure 3.7 shows the PCR products resolved by 
agarose gel electrophoresis (Figure 3.7A) and band densities normalised to p-actin 
expression (Figure 3.7B). Wortmannin was found to inhibit IFN-y-induced MCP-1 
expression in a dose-dependent manner comparable to the inhibition with 
LY294002. Rapamycin however, reduced the stimulation of MCP-1 expression by a 
minimal degree in comparison with the effect of LY294002 or wortmannin, and only 
at a high concentration. The inhibition observed upon treatment with wortmannin 
supports the theory that activation of PI3K is necessary for the induction of MCP-1 by 
IFN-y and that this is prevented by the action of LY294002.
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3.4.3 Induction of MCP-1 protein levels by IFN-y
In order to confirm that the changes shown at the mRNA level for MCP-1 
correspond to changes at the protein level, western blot analysis was carried out. 
Cells of the J774.2 cell line were stimulated with IFN-y for periods of 0 ,1 ,3 ,  6 ,1 2  
and 24h after which whole cell protein extracts were prepared with buffers 
containing phosphatase inhibitors (Section 2.6.2). Western blot analysis was 
carried out on whole cell extracts (60pg) immunoblotting with a specific antibody 
raised against MCP-1 (Section 2.6.7-2.6.9) (Table 2.9). Bands for murine MCP-1 
were seen in the range of 14-30kDa corresponding to various glycosylation 
products (Zhang et al. 1996). Cellular protein levels of MCP-1 were found to be 
maximal following 3h stimulation with IFN-y and subsequently decreased (Figure 
3.8A.i). Membranes were re-probed with anti-P-actin to ensure equal loading 
(Table 2.9). To determine whether this decrease in cellular protein was due to 
enhanced secretion of the MCP-1 protein, western blot analysis was performed on 
aliquots of extracellular growth medium collected over the same time course. 
Bands were seen in the range of 25-30kDa. The loss of the smaller sized 
products seen with cellular extracts is likely to be due to the secretion of fully 
glycosylated forms only. An increase in this product was observed after 12h and 
24h IFN-y treatment correlating with the decrease in cellular protein levels (Figure 
3.8A.ii). Densitometric analysis of the data was carried out and presented in 
Figure 3.8B.
3.4.4 Inhibition of IFN-y-mediated induction of MCP-1 protein levels by LY294002 
and apigenin
J774.2 cells were pretreated with LY294002 (20pM), apigenin (20pM) or DMSO 
as a vehicle control. They were then cultured in the presence or absence of IFN-y 
for 3h after which phosphatase-free whole cell protein extracts were prepared. 
Western blot analysis was carried out on whole cell extracts as before, 
immunoblotting with specific antibodies raised against MCP-1 and p-actin. As 
shown in Figure 3.9, both LY294002 and apigenin attenuated the IFN-y-mediated 
induction in MCP-1 protein levels. Densitometric analysis of the data was carried 
out and presented in Figure 3.9B.
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Figure 3.8 Induction of MCP-1 protein levels and secretion by IFISPy
J774.2 cells were treated with IFN-y for the times indicated and phosphatase-free 
whole cell protein extracts were prepared. Western blot analysis was carried out 
using antibodies specific for MCP-1 and (3-actin as shown. Results are 
representative of four independent experimental series (A.i). Western blot 
analysis was also carried out on aliquots of growth medium obtained over the 
same time course. Results are representative of two independent experiments 
(A.ii). Densitometric analysis was carried out on the data and presented as the 
mean fold induction (±SD) as shown (B). *P<0.05; **P<0.01.
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Effect of LY294002 and apigenin on IFN-y-mediated induction of MCP-1 
protein levels
J774.2 macrophages were pretreated with LY294002 (20pM), apigenin (20pM) or 
DMSO as a vehicle control. They were then cultured in the presence or absence of IFN- 
y for 3h. Phosphatase-free whole cell protein extracts were prepared and western blot 
analysis was carried out using an antibody specific for MCP-1 and p-actin (A). 
Densitometric analysis was carried out on the data from independent experiments 
(mean ±SD) (B). ***P < 0 .0 0 1
3.4.5 Inhibition of IFN^y-mediated induction of MCP-1 gene expression by the 
pharmacological inhibitor of PKB activity SH-6
PKB is a well-characterised effector of PI3K signalling, downstream targets of which 
include GSK-3 and mTOR (Section 1.8.3). Previous studies have found that PKB is 
activated by IFN-y in primary monocytes, THP-1 cells and fibroblasts (Navarro et al. 
2003, Nguyen et al. 2001). The small molecule inhibitor SH-6 has been shown to be 
an effective and specific inhibitor of PKB activity, without altering the activation of the 
upstream kinase PDK-1. SH-6 is a phosphatidylinositol analog the action of which is
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mediated by binding to the PH-domain of PKB (Kozikowski et al. 2003). SH-6 was used 
to determine whether PKB acts as a downstream mediator of PI3K signalling in the 
regulation of MCP-1 gene expression by IFN-y.
J774.2 cells were pretreated with SH-6 at a concentration of 20pM (Puduvalli et al. 
2005, Chong et al. 2005) or with DMSO as a vehicle control. They were then cultured 
in the presence or absence of IFN-y for 3h after which RNA was extracted. RT-PCR was 
carried out as before using primers specifying for murine MCP-1 and p-actin. Figure 
3.10 shows the PCR products resolved by agarose gel electrophoresis (Figure 3.10A) 
and band densities normalised to p-actin (Figure 3.10B). Pretreatment with SH-6 was 
found to decrease the induction of MCP-1 expression by IFN-y indicating that PKB may 
act downstream of PI3K in this pathway.
A.
M SH-6 -RT
IFN-y + _ j;_____ +
SH-6
Figure 3.10 Inhibition of IFN^y-mediated induction of MCP-1 expression by SH-6
J774.2 macrophages were pretreated with SH-6 (20pM) or DMSO as a vehicle control. They 
were then cultured in the presence or absence of IFN-y for 3h. Total RNA was isolated and 
subjected to RT-PCR using primers against MCP-1 and p-actin. The amplification products were 
analysed by agarose gel electrophoresis (A). The size of the DNA markers are indicated. Panel 
B shows the relative expression (mean ±SD) normalised to the expression of p-actin as 
determined by densitometric analysis from three independent experiments. -RT denotes a 
reaction in which no reverse transcriptase was included for the cDNA synthesis step (using 
vehicle-treated RNA). ***P < 0 .001 .
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3.5 Activation of the MCP-1 Promoter by IFN^y
The expression of the MCP-1 gene is thought to be regulated by key distal and 
proximal promoter regions as discussed in Section 1.6.3. Figure 3.11 details the 
functional elements of the MCP-1 promoter. Previous studies in astrocytes have 
mapped IFN-y-inducibility to a region of the proximal promoter of the human MCP- 
1 gene 213bp upstream of the transcriptional start site (Zhou et al. 2001, Valente 
et al. 1998, Zhou et al. 1998). The MCP-l[213]Luc construct contains this 
region, cloned into the pGL2-Basic luciferase reporter vector (Section 2.4.5).
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Figure 3.11 Functional elements in the distal and proximal promoter regions of human and 
mouse MCP-1
Schematic representation of the functional elements in the murine MCP-1 promoter (A). 
Sequence of the murine proximal MCP-1 promoter region (functional elements are 
highlighted) (adapted from Kodama et al. 2005, Lim et al. 2000, Valente et al. 1998, Zhou et 
al. 1998) (B). Sequence of the human proximal MCP-1 promoter region (functional elements 
are highlighted (adapted from Ueno et al. 2000, Valente et al. 1998, Ping et al. 1996) (C). 
Other functional C/EBP-binding elements may be present in the proximal promoter regions for 
which a specific site has not been determined (Abraham et al. 2005). Elements depicted in a 
lighter shade have been characterised in the rat MCP-1 promoter and the corresponding site 
in the mouse promoter highlighted.
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3.5.1 IFN-y-mediated upregulation of MCP-1 mRNA levels in macrophages is 
dependent on transcriptional activity but not mRNA stability
Although previous experiments in other cell types have demonstrated 
transcriptional activation of the MCP-1 promoter by IFN-y (Zhou et al. 2001, 
Valente et al. 1998, Zhou et al. 1998), the chemical inhibitor of transcription, 
actinomycin D, was used to establish that IFN-y increased the transcription of 
MCP-1 in the macrophage system and that the increase in mRNA levels was not 
mediated by a change in mRNA stability. Actinomycin D is an antibiotic that 
inhibits that action of DNA-primed RNA polymerase by complexing with DNA via 
deoxyguanosine residues (Goldberg et al. 1962) (Table 2.2). J774.2 cells were 
pretreated with actinomycin D (5pg/ml) or with DMSO as a vehicle control. They 
were then cultured in the presence or absence of IFN-y for 3h after which RNA 
was extracted. RT-PCR analysis was carried out using murine MCP-1 and p-actin 
primers as before. As shown in Figure 3.12, the presence of actinomycin D 
prevented the increase of MCP-1 mRNA by IFN-y, demonstrating a requirement for 
increased transcriptional activity as opposed to enhanced mRNA stability in 
response to the cytokine.
M Actinomycin D -RT
1000
500/517
500/517
p-Actin
Effect of actinomycin D on the induction of MCP-1 mRNA levels by
IFN-y
J774.2 cells were pretreated with actinomycin D (5pg/ml) or with DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h. Total RNA was isolated and subjected to RT-PCR using primers against MCP-1 
and p-actin. The amplification products were analysed by agarose gel 
electrophoresis. The size of the DNA markers are indicated. -RT denotes a 
reaction in which no reverse transcriptase was included for the cDNA synthesis 
step (using vehicle-treated RNA). Results shown are representative of two 
independent experiments.
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3.5.2 Preparation of plasmid constructs for transfection based assays
Plasmid DNA was used to transform the bacterial E. Coli strain DH5a and 
extracted from a single colony by the Miniprep method (Section 2.5.9). Digestion 
with restriction endonucleases was carried out to establish that the identity of the 
plasmid was as expected (Section 2.5.11). Table 2.3 gives the restriction 
endonucleases used for the digestion of each plasmid and the fragment sizes 
expected. The same bacterial colony was subsequently used to prepare glycerol 
stocks and for further extraction of plasmid DNA by the Maxiprep method (Section 
2.5.10). Dominant negative and luciferase reporter plasmid constructs are 
described in Section 2.4.5.
3.5.3 IFN-y induces the activation of the MCP-1 promoter in a macrophage 
transfection system
The promoter construct MCP[213]Luc contains the human sequence for the MCP- 
1 promoter 213bp upstream of the transcriptional start site. As detailed in Figure 
3.11, the proximal promoter of the murine MCP-1 gene is directly comparable and 
contains similar binding sites. MCP[213]Luc was therefore considered to be a 
suitable model to study the activation of the MCP-1 promoter in order to give data 
relevant to the regulation of gene expression in both species. Later studies 
(Section 4.4) will aim to confirm protein binding to corresponding regulatory 
elements in J774.2 cells. The transfection of MCP[213]Luc was carried out in 
cells of the human monocytic U937 cell line, differentiated in the presence of 
PMA. This system has been used successfully in previous transfection-based 
experiments in our laboratory for the study of macrophage gene expression (Irvine 
et al. 2005, Hughes et al. 2002). This approach also avoids difficulties, 
experienced within our laboratory and others, with the efficient transfection of 
J774.2 macrophages with exogenous DNA (Hughes etal. 2002, Hill etal. 1995).
U937 cells were transfected with MCP[213]Luc using the SuperFect™ 
Transfection method (Qiagen), following differentiation in the presence of PMA 
(Section 2.4.1). Transfected cells were treated with human IFN-y for 12h 
(identified as optimal from a time-course analysis (data not shown)). Cells were
124
C h ap ter th re e :  R o le  o f  CK2 and  PI3K in th e  R e g u la tio n  o f  M acrop hag e  G ene Expression by IFN-y
then harvested and extracts prepared for luciferase assay (Section 2.4.3-2.4.4). 
All transfections were carried out with samples in triplicate for at least three 
independent experiments. Results are presented as the mean fold induction 
(basal level assigned as 1) (±SD). A standard statistical t-test (Appendix IV) was 
performed on the data and changes in expression were found to be significant to 
the level indicated. Figure 3.13. shows an upregulation of MCP-1 promoter 
activity of approximately four fold in response to IFN-y.
MCP[213]Luc: U937
IFN-y - +
Figure 3.13 Stimulation of MCP-1 promoter activity by IFN^ y in macrophages
Cells were transfected with MCP[213]Luc and treated with IFN-y for 12h. Relative 
counts were normalised to protein concentration and presented as the fold 
induction in response to IFN-y, in relation to basal expression (assigned as 1). 
Results are presented as mean ±SD of three independent experiments. 
***p < 0 .001 .
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3.5.4 Validation of a hepatocyte transfection system for studies of MCP-1 promoter 
activity
The transfection efficiency of U937 cells was sufficient to observe a reproducible 
induction in reporter gene expression in response to IFN-y treatment (Figure 
3.13). However, the efficiency of co-transfection assays utilising dominant 
negative expression plasmids was not adequate in this system to observe the 
effect of dominant negative mutants. Indeed, several laboratories have shown 
that macrophages cannot be transfected at high efficiency with exogenous DNA 
(Dokka et al. 2000, Kusumawati et al. 1999, Hill et al. 1995). Due to the 
difficulty of transfection in monocyte/macrophage cells with the required 
efficiency, transfection based studies were subsequently carried out in the human 
hepatocyte cell line, Hep3B (Section 2.3.1), using the PEI method (Section 2.4.2). 
Experiments within our laboratory have demonstrated that this cell line can be 
transfected at high efficiency with exogenous DNA. We have also shown that 
Hep3B cells provide a good model for cytokine regulated gene expression and 
responses to IFN-y (Irvine et al. 2005, Foka et al. 2003, Irvine, S., personal 
communication, AM, S., personal communication). In order to further validate the 
use of this system for comparison to the IFN-y response in macrophages, RT-PCR 
analysis was carried out to demonstrate the induction of MCP-1 by IFN-y, and the 
effect of LY294002 and apigenin on this, in Hep3B cells. The activation of the 
MCP-1 promoter by IFN-y was also compared by transfection of the MCP[213]Luc 
reporter plasmid in U937 cells and Hep3B cells.
Hep3B cells were pre-treated with LY294002 (20pM), apigenin (20jnM) or DMSO 
as a vehicle control. They were then cultured in the presence or absence of 
human IFN-y for 3h after which RNA was extracted. RT-PCR was carried out as 
before using primers specifying for human MCP-1 and (3-actin (Table 2.5). Figure 
3.14A shows the PCR products resolved by agarose gel electrophoresis. Both 
LY294002 and apigenin attenuated the IFN-y-mediated induction in MCP-1 mRNA 
levels.
Hep3B cells were transfected with MCP[213]Luc using the PEI method (Section 
2.4.2). Transfected cells were treated with human IFN-y for 6h (identified as
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optimal from a time-course analysis (data not shown)). Cells were then harvested 
and extracts prepared for luciferase assay. Results are presented as the mean 
fold induction (basal level assigned as 1) (±SD). A standard statistical t-test was 
performed on the data and changes in expression were found to be significant to 
the level indicated. Figure 3.14B. shows an upregulation of MCP-1 promoter 
activity of approximately four-fold in response to IFN-y, comparable to the level of 
induction in U937 cells.
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Figure 3.14 Stimulation of MCP-1 gene expression and promoter activity by IFN^ y 
in hepatocytes
Hep3B cells were pretreated with LY294002 (20pM), apigenin (20pM) or DMSO 
as a vehicle control. They were then cultured in the presence or absence of 
human IFN-y for 3h. Total RNA was isolated and subjected to RT-PCR using 
primers against hMCP-1 and p-actin. The amplification products were analysed by 
agarose gel electrophoresis. The size of the DNA markers are indicated. -RT 
denotes a reaction in which no reverse transcriptase was included for the cDNA 
synthesis step (using vehicle-treated RNA). Results shown are representative of 
two independent experimental series (A). Cells were transfected with 
MCP[213]Luc and treated with IFN-y for 6h. Relative counts were normalised to 
protein concentration and presented as the fold induction in response to IFN-y, in 
relation to basal expression (assigned as 1). Results are presented as mean ±SD 
of six independent experiments (B). ***P < 0 .001 .
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3.6 Effect o f Dominant Negative Inhibitors of PKB and CK2 on the 
Activation of the MCP-1 Promoter by IFN^y
The inhibitor studies detailed previously implicated CK2, PI3K and the 
downstream effector PKB in the induction of MCP-1 expression by IFN^ y. In order 
to confirm this role co-transfection experiments were performed using dominant 
negative inhibitor constructs for the downstream effector of PI3K, PKB, and for 
CK2 (Section 2.4.5)
3.6.1 Co-transfection of the MCP-1 promoter and a dominant negative mutant of 
PKB
As described in Section 3.5.4, Hep3B cells were transfected with the luciferase 
reporter construct MCP[213]Luc and the response to IFN-y treatment (6h) 
analysed. The reporter construct was co-transfected with a plasmid specifying for 
a dominant negative mutant of PKB or with the empty plasmid vector pcDNA3. 
Results are presented in Figure 3 .15 as the mean fold induction (basal level 
assigned as 1) (±SD) except where stated otherwise A standard statistical t-test 
was performed on the data and changes in expression were found to be 
significant to the level indicated. The response to IFN-y treatment was decreased 
by approximately 46.9% in comparison to that in cells co-transfected with the 
empty plasmid expression vector (pcDNA3). This supports the proposed role of 
PKB as a potential downstream effector for PI3K in the regulation of MCP-1 gene 
expression by IFN-y. The lack of a complete inhibition of the IFN-y response 
suggests that additional pathways may also be involved in the mediation of this 
response that do not require PI3K/PKB.
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Figure 3.15 Effect of a dominant negative inhibitor of PKB on the stimulation of 
MCP-1 promoter activity by IFN-y
Hep3B cells were transfected with MCP[213]Luc and a plasmid construct 
specifying for a dominant negative mutant form of PKB or the vector pcDNA3. 
Transfected cells were treated with IFN-y for 6h after which cell extracts were 
prepared for luciferase reporter activity assay. Relative counts were normalised 
to protein concentration and presented as the fold induction in response to IFN-y, 
in relation to basal expression (assigned as 1). Results are presented as mean 
±SD of five independent experiments. ***P < 0 .001 .
3.6.2 Co-transfection of the MCP-1 promoter and a dominant negative mutant of 
CK2
As described in Section 3.5.4, Hep3B cells were transfected with the luciferase 
reporter construct MCP[213]Luc and the response to IFN-y treatment (6h) 
analysed. The reporter construct was co-transfected with a plasmid specifying for 
a dominant negative mutant of CK2 (CK2aK68A) or with the empty plasmid 
vector pSG5. Co-transfection of dominant negative CK2 with MCP[213]Luc did 
not lead to a decrease in the relative fold induction in reporter gene expression 
upon stimulation with IFN-y but caused a reduction in basal expression of 
approximately 45% in comparison with cells transfected with the empty 
expression vector (pSG5) only (Figure 3.16). Results are presented as the mean 
fold induction in comparison to the basal level for co-transfection with pSG5 
(assigned as 1) (±SD). A standard statistical t-test was performed on the data and 
changes in promoter activity were found to be significant to the level indicated. 
This suggests that CK2 does have role in the regulation of MCP-1 expression but it 
is uncertain whether the kinase is involved in the regulation of constitutive 
promoter activity, as a mediator of IFN-y-signalling, or possibly both.
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Figure 3.16 Effect of a dominant negative inhibitor of CK2 on the stimulation of 
MCP-1 promoter activity by IFN^
Hep3B cells were transfected with MCP[213]Luc and a plasmid construct 
specifying for a dominant negative mutant form of CK2 or the vector pSG5. 
Transfected cells were treated with IFN-y for 6h after which cell extracts were 
prepared for luciferase reporter activity assay. Relative counts were normalised 
to protein concentration. Results are presented as the fold induction with IFN-y 
in relation to cells transfected with MCP[213]Luc and pSG5. Results are 
presented as mean ±SD of five independent experiments. ***P<0.001; 
**P<0.01.
3.6.3 RT-PCR analysis of the effect of dominant negative CK2 on the induction of 
MCP-1 gene expression by IFN^y
In order to further address the role of CK2 in the induction of MCP-1 expression by 
IFN-y, the effect of dominant negative inhibition of CK2 on endogenous MCP-1 
mRNA expression in Hep3B cells was also assessed. Hep3B cells were 
transfected by the PEI method with a plasmid encoding a dominant negative 
mutant of CK2 or the empty plasmid vector pSG5. Cells were then stimulated 
with human IFN-y for 3h after which RNA was extracted. RT-PCR was carried out 
using primers specific for human MCP-1 and p-actin as before. The products were 
resolved by agarose gel electrophoresis (Figure 3.17A) and band densities 
normalised to p-actin (Figure 3.17B). Dominant negative CK2 inhibited the 
induction of MCP-1, confirming the effect of apigenin.
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Figure 3.17 Effect of a dominant negative inhibitor of CK2 on the induction of 
MCP-1 mRNA expression by IFN-y
Hep3B cells were transfected with a plasmid specifying for a dominant negative 
mutant form of CK2 or the vector pSG5. Transfected cells were incubated in the 
presence or absence of human IFN-y for 3h. Total RNA was isolated and 
subjected to RT-PCR using primers against hMCP-1 and p-actin. The amplification 
products were analysed by agarose gel electrophoresis (A). The size of DNA 
markers are indicated. Panel B shows the relative expression (mean ±SD) 
normalised to the expression of p-actin as determined by densitometric analysis. 
-RT denotes a reaction in which no reverse transcriptase was included for the 
cDNA synthesis step (using untreated RNA). Results are representative of three 
independent experiments. **P <0.01 .
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3.7 D iscussion
Macrophages have an important role in the progression of atherosclerosis 
(Section 1.4.4). The inflammatory cytokine IFN-y regulates the expression of 
numerous genes in these cells and studies of the mechanisms involved in such 
responses may provide potential therapeutic targets for the treatment of 
atherosclerosis and other inflammatory diseases. Regulation of gene expression 
by IFN^y has been attributed largely to signalling through the JAK-STAT pathway. 
Alternative pathways however are now being considered to contribute to the 
modulation of gene expression by this cytokine. The three genes MCP-1, SOCS-1 
and ICER were selected for study as they are potentially regulated by three 
distinct mechanisms. MCP-1 and SOCS-1 are both traditionally recognised as IFN- 
y-stimulated genes regulated through the action of STAT1 (Cornish et al. 2003, 
Alexander 2002, Zhou et al. 2001, Valente et al. 1998, Zhou et al. 1998). 
However, recent findings by Gil et al. (2001) have suggested that while SOCS-1 
expression is not inducible by IFN-y in STATl-null macrophages, MCP-1 expression 
is upregulated by IFN-y in both wild type and STATl-deficient cells (Ramana etal. 
2002, Gil etal. 2001). The induction of ICER expression in response to IFN-y has 
been studied previously in our laboratory and represents a potentially novel CK2- 
dependent mechanism of gene regulation (Mead etal. 2003).
RT-PCR analysis of the time-dependent induction of MCP-1, SOCS-1 and ICER in 
J774.2 macrophages found the expression of all three genes to be maximally 
induced at a 3h time point (Figure 3.2). While MCP-1 and SOCS-1 expression 
remained at the same level for the duration of the time course, levels of ICER 
mRNA were reduced at subsequent time points suggesting that further signalling 
events are induced that inhibit ICER expression. ICER itself is likely to be 
responsible for this inhibition in a negative feedback mechanism, or other genes 
regulated in response to IFN-y may act to suppress the transcription of ICER. It is 
clear from Figure 3.2 that the ICER I transcript is preferentially expressed in 
response to IFN- y in macrophages.
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3.7.1 Role of CK2 in the regulation of macrophage gene expression by IFN^y
The protein kinase CK2 has been found in our laboratory to be involved in the 
suppression of LPL gene transcription and in the induction of ICER expression by 
IFN-y through potentially novel pathways (Mead eta l. 2003, Hughes etal. 2002). 
Previous work in our laboratory has also shown that IFN-y induces CK2 activity in 
macrophages, and that this is inhibited, as expected, by the CK2 inhibitor, 
apigenin. Maximal activation of CK2 was observed following 2h stimulation with 
IFN-y that would be consistent with a role for this kinase in the regulation of the 
genes selected, that are maximally induced after 3h cytokine treatment (Mead et 
al. 2003). Apigenin was used to determine whether CK2 has a role in the IFN-y 
induced regulation of MCP-1 and SOCS-1 in macrophages.
Pretreatment of IFN-y stimulated cells with apigenin resulted in the inhibition of 
IFN-y induced upregulation of gene expression for all the genes studied (Figure
3.4). While implicating CK2 in the regulation of these genes, these findings also 
raise the possibility of a global role for CK2 in the IFN-y-mediated modulation of 
macrophage gene expression. The SOCS-1 gene is known to be regulated through 
JAK-STAT signalling (Cornish et al. 2003) while ICER and MCP-1 have been 
suggested to be regulated by independent pathways (Mead et al. 2003, Gil et al. 
2001). A CK2-dependent pathway may prove to be independent of JAK-STAT 
signalling, with both pathways being involved in the regulation of certain genes, or 
it may be a novel component of the JAK-STAT signalling pathway. This was a 
subject that was to be investigated further during the course of this study.
3.7.2 Selective role of PI3K in the regulation of MCP-1 by IFN^y
The inhibitor LY294002 has been shown in our laboratory to prevent the IFN-y- 
mediated suppression of LPL gene expression in macrophages (also dependent 
on CK2 activity), implicating PI3K in the IFN^y-mediated regulation of this gene 
(Tengku-Muhammad et al. 1999b, Evans, S., personal communication). A 
number of other studies have also demonstrated dependence of IFN-y signalling 
pathways on the activation of PI3K as discussed in Section 1.9. The effect of
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PI3K inhibition by LY294002 on the IFN-y-mediated induction of MCP-1, SOCS-1 
and ICER was therefore investigated.
Initial work on the regulation of ICER was carried out in relation to a potential 
involvement in the suppresion of LPL gene expression in macrophages by IFN-y. 
Transfection of cells with a plasmid construct for ICER was found to result in 
reduced LPL expression (Mead 2002). Possibly ICER represses the transcription 
of Sp3 (that regulates LPL promoter activity), so accounting for the reduced levels 
of this protein observed following stimulation with IFN-y (Hughes etal. 2002). If 
ICER is acting upstream in the regulation of LPL it is conceivable that the role of 
CK2 is in the upregulation of ICER expression and that PI3K is necessary for this. 
However, the IFN-y-mediated induction in ICER expression was not affected by the 
inhibitor LY294002, indicating that PI3K is not involved in its regulation (Figure
3.5). This does not rule out the possibility that ICER is involved in the suppression 
of LPL, with a dual role for CK2, in the PI3K-independent upregulation of ICER and 
subsequently the PI3K-dependent downregulation of LPL. Similarly, LY294002 
did not affect IFN-y-mediated induction of SOCS-1 expression (Figure 3.5). 
However MCP-1 expression following stimulation with IFN-y for 3h was reduced by 
LY294002 in a concentration dependent manner (Figure 3.5). PI3K therefore, in 
addition to CK2, appears to be selectively involved in the IFN-y-mediated 
regulation of this gene. A study by Bian et al (2004). has previously demonstrated 
a similarly selective role for PI3K in the the regulation of MCP-1 expression in 
response to the cytokines IL-lp and TNF-a. In this case LY294002 was found to 
attenuate the induction of MCP-1 gene expression by the cytokines but not that of 
IL-8 (Bian et al. 2004). Hwang et al. (2004) also showed that PI3K was required 
for the induction of iNOS mRNA expression in microglial cells through the 
activation of STAT1 but that IFN-y-stimulated expression of IRF-1 and IP-10 was 
unaffected by the presence of the inhibitor.
Activation of PI3K in response to IFN-y has been suggested to function in both 
JAK-STAT-dependent and -independent pathways (Section 1.9). It is tempting to 
speculate that the differential dependence of the regulation of MCP-1 and SOCS-1 
expression by IFN-y on PI3K is linked to the differential dependence on STAT1
134
C h a p t e r  t h r e e : R o l e  o f  CK2 a n d  P I3K  in  t h e  R e g u l a t io n  o f  M a c r o p h a g e  G e n e  Ex p r e s s io n  b y  IFN-y
shown by Gil et al. (2001). In order to further investigate the role of PI3K in IFN-y- 
signalling, the regulation of MCP-1 expression by the cytokine was studied in more 
detail.
The inhibition of MCP-1 gene expression by LY294002 and apigenin, as seen in 
macrophages of the J774.2 cell line, was similarly demonstrated in primary 
human monocyte-derived macrophages, indicating the relevance of these studies 
to conditions in vivo and ruling out cell line-specific effects (Figure 3.6). The 
induction of MCP-1 protein expression by IFN-y and the effect of these inhibitors 
on this response was also determined by western blot analysis. IFN-y was found 
to mediate a similar effect on the level of MCP-1 protein within the cell, maximal 
levels being reached following 3h stimulation with the cytokine. A decrease in 
cellular protein at subsequent time points correlated with increased MCP-1 
secretion (Figure 3.8). The inhibitors LY294002 and apigenin also prevented the 
stimulation of MCP-1 protein expression by IFN-y indicating that the observations 
of MCP-1 expression at the mRNA level are also relevant at the protein level 
(Figure 3.9).
In order to confirm that the inhibitory effect of LY294002 was specific to the 
inhibition of PI3K, a second inhibitor, wortmannin was utilised. As LY294002 has 
also been reported to inhibit mTOR and because this molecule has been 
implicated as a downstream effector of PI3K in the regulation of STAT1, the effect 
of treatment with the mTOR inhibitor, rapamycin, on the response of MCP-1 
expression to IFN-y was also analysed. Wortmannin was found to inhibit the IFN-y 
response in a similar manner to LY294002 while rapamycin only had a minimal 
effect at high dose (Figure 3.7). This suggests that LY294002 is affecting the IFN- 
y induced expression of MCP-1 through the inhibition of PI3K and that mTOR is 
unlikely to be acting as a downstream effector in this signalling pathway.
Previous experiments have demonstrated transcriptional activation of the MCP-1 
promoter by IFN-y in astrocytes and osteoblasts but to our knowledge conclusive 
studies have not been carried out in macrophages (Zhou et al. 2001, Valente et 
al. 1998, Zhou et al. 1998). The chemical inhibitor of transcription, actinomycin
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D, was used to confirm that IFN-y increased the transcription of MCP-1 in the 
macrophage system and that the response is not mediated by an increase in 
mRNA stability. The expression of the MCP-1 gene is thought to be regulated by 
key distal and proximal promoter regions as discussed in Section 1.6.3. 
Functional elements in the proximal MCP-1 promoter include putative sites for 
Spl, STAT1, AP-1, NF-kB and C/EBP binding (Figure 3.11). Previous studies, in 
other cell lines, have mapped IFN-y-inducibility to a region of the proximal 
promoter of human MCP-1 213bp upstream of the transcriptional start site (Zhou 
et al. 2001, Valente et al. 1998, Zhou et al. 1998).
A luciferase reporter construct containing this promoter region (MCP[213]Luc) 
was used to show this response in macrophages. As this construct contains the 
human sequence for the MCP-1 promoter, and to avoid difficulties associated 
with the transfection of J774.2 macrophages, transfections were carried out in 
human cells. U937 monocytes differentiated in the presence of PMA have been 
successfully used in previous transfection-based experiments in our laboratory 
(Hughes et al. 2002, Irvine et al. 2005). Activation of reporter expression from 
MCP[213]Luc in U937 cells was demonstrated in response to stimulation with 
IFN-y. However, the efficiency of co-transfection assays utilising dominant 
negative plasmids was not adequate in this system to observe the dominant 
negative effect. Due to the difficulty of transfection in monocyte/macrophage 
cells with the required efficiency, transfection based studies were subsequently 
carried out in the human hepatocyte cell line, Hep3B, using the PEI method. In 
order to validate the use of this system, RT-PCR analysis was carried out 
demonstrating the induction of MCP-1 expression by IFN-y and the inhibition of 
this response by LY294002 and apigenin. The IFN-y-mediated activation of 
MCP[213]Luc was also compared in U937 cells and Hep3B cells and found to be 
of a similar level (Figure 3 .13 and 3.14).
A number of signalling effectors function downstream of PI3K (Figure 1.3). PKB 
has been well characterised as a mediator of PI3K signalling and its activity has 
been shown in various studies to be inducible by IFN-y (Navarro et al. 2003, 
Nguyen et al. 2001). Data from the laboratory of Nguyen et al. (2001) has also
136
C h a p t e r  t h r e e : R o l e  o f  CK2 a n d  PI3K in  t h e  R e g u l a t io n  o f  M a c r o p h a g e  G e n e  Ex p r e s s io n  b y  IFN-y
implicated PKB in the phosphorylation of STAT1 on Serine727. The IFN-y- 
mediated induction of MCP-1 expression was found, by RT-PCR analysis, to be 
attenuated by the small molecule inhibitor of PKB activity, SH-6 (Figure 3.10). Co­
transfection of a dominant negative construct specifying for a mutant form of PKB 
with MCP[213]Luc inhibited the induction by IFN-y by approximately 46.9% (Figure 
3.15). Together these results implicate PKB as a likely downstream effector of 
PI3K in the IFN-y-mediated regulation of MCP-1 gene expression. A previous study 
by Murao etal. (2000), that investigated the role of PI3K and PKB in the induction 
of MCP-1 expression by TNF-a in ECs, also found that a constitutively active form 
of PKB was capable of mediating an increase in MCP-1 expression, providing 
further support for the role of PKB in the activation of the MCP-1 promoter (Murao 
etal. 2000).
3.7.3 Role of CK2 in the induction of MCP-1 expression by IFN^y
The role of CK2 in the regulation of MCP-1 expression by IFN-y, identified using 
the inhibitor apigenin, was supported by transfection of a dominant negative form 
of the kinase (CK2aK68A) in Hep3B cells. The induction of MCP-1 mRNA 
expression by IFN-y was inhibited in cells transfected with the dominant negative 
mutant compared to transfection with the empty vector (pSG5). The effect of 
apigenin on IFN-y-mediated regulation of MCP-1 expression was also 
demonstrated in human primary macrophages.
Co-transfection of dominant negative CK2 with MCP[213]Luc resulted in a 
decrease in both the basal and IFN-y-induced reporter gene expression. This 
observation suggests the possibility that CK2 may function in the constitutive 
expression of MCP-1 and potentially the other genes studied. A role for CK2 in 
constitutive gene expression would be fitting with the known properties of the 
kinase. CK2 is unusual in that it is a constitutively active kinase, although the 
activity has been shown by work in our laboratory to be increased by IFN-y 
treatment (Mead etal. 2003). Other laboratories have also shown an induction in 
CK2 activity in certain contexts (Peppercock et al. 1991, Sayed et al. 2000, 
Brenneisen et al. 2002). It is possible therefore, that CK2 may have dual roles in
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both the constitutive expression of the genes studied and in the IFN-y response. 
CK2 has been shown to be involved in regulating the transcriptional activity of 
RNA polymerase III, responsible for the expression of tRNA and small ribosomal 
RNAs, and in the regulation of transcription of mRNA transcripts by RNA 
polymerase II (Cabrejos etal. 2004, Llorens etal. 2003, Hu etal. 2003, Johnston 
et al. 2002).
The low basal level of mRNA expression for the genes studied makes the function 
of CK2 in the regulation of constitutive promoter activity difficult to ascertain from 
RT-PCR experiments. It is possible that the effect of dominant negative CK2 on 
the basal activity of the MCP[213]Luc promoter may be due to the non-chromatin 
context of the promoter or alternatively, a property of the cellular system, with a 
differential response between Hep3B hepatocytes and J774.2 macrophages. 
Further studies of the function of CK2 in the regulation of MCP-1 gene expression 
may help to establish this. It also remains to be determined whether PI3K and 
CK2 are functioning in a linear signalling pathway or in two distinct regulatory 
systems.
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CHAPTER 4. MECHANISMS IN THE REGULATION OF MCP-1 GENE 
EXPRESSION BY IFN-y
4.1 Introduction
As discussed in Section 1.6, MCP-1 has an important role in the progression of 
atherosclerosis. Knock-out of the MCP-1 gene, or its receptor CCR2, in apoE- and 
LDL-R-deficient mice dramatically inhibits lesion development (Dawson et al. 
1999, Gosling et al. 1999, Boring et al. 1998, Gu et al. 1998). The regulation of 
this chemokine by inflammatory mediators is therefore of particular therapeutic 
interest. Further investigations of the mechanisms involved in the regulation of 
MCP-1 gene expression by IFN-y were carried out with the aim of elucidating a 
novel pathway involved in IFN-y-induced signalling and identifying potential targets 
for pharmacological inhibiton of MCP-1 function in atherosclerosis.
4 .1 .1  JAK-STAT signalling in the regulation of MCP-1 expression by IFN-y
Previous studies have implicated STAT1 in the regulation of MCP-1 expression in 
response to IFN-y stimulation. A GAS site present in the proximal promoter of the 
human MCP-1 gene has been found to be necessary for the stimulation of 
promoter activity by IFN-y in astrocytes (Zhou et al. 2001, Valente et al. 1998, 
Zhou et al. 1998). However the analysis of STATl-knock out BMMs in an 
independent study by Gil et al. (2001), suggested that STAT1 is not essential for 
the upregulation of MCP-1 by IFN-y and that a STATl-independent signalling 
mechanism may have a role. In this study, the presence of JAK1 in addition to 
IFN-yR was required for the induction of other genes regulated independently of 
STAT1.
The kinases PI3K (and the downstream effector PKB) and CK2 were shown in 
Chapter 3 to be necessary for the maximal induction of MCP-1 by IFN-y. These 
kinases may potentially be involved in either STATl-dependent or -independent 
mechanisms. Work in other laboratories has linked PI3K to the JAK-STAT pathway 
(Section 1.9.4) although the activation of PI3K by IFN-y has also been observed in
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JAK1- and JAK2-deficient cells (Nguyen et al. 2001). Our laboratory has shown 
that CK2 activity is induced by IFN-y and that this is not inhibited by the JAK2 
inhibitor AG490 (Mead et al. 2003, Evans, S., personal communication). This is 
consistent with our previous finding that the specific JAK2 inhibitor, AG490, does 
not suppress the stimulation of ICER gene expression by IFN-y, in contrast to the 
effect of the CK2 inhibitor apigenin (Mead etal. 2003).
4.2.2 Experimental strategy
Work in this chapter was carried out with the aim of determining the role of JAK- 
STAT signalling in the regulation of MCP-1 gene expression by IFN-y and the 
function of CK2 and PI3K either in relation to the JAK-STAT pathway or an 
independent mechanism. This was to be achieved through the continuing use of 
pharmacological inhibitors and dominant negative mutants in order to establish a 
requirement for certain mediators, in particular, the components of the JAK-STAT 
pathway JAK1, JAK2 and STAT1.
The function of CK2 and PI3K in the IFN-y response was studied by analysing 
changes in the activity of these kinases in response to cytokine treatment. An 
IFN-y-mediated induction in CK2 activity has been demonstrated previously in the 
laboratory (Mead et al. 2003, Evans, S., personal communication) so the data 
presented concentrates on changes in the activation of the downstream effector 
of PI3K, PKB. The potential requirement for these kinases in the regulation of 
STAT1 activity was determined by assessing the effect of pharmacological 
inhibitors and dominant negative mutants for CK2 and PKB on IFN-y-mediated 
phosphorylation of STAT1 and the activation of a STATl-regulated promoter.
Further studies of the factors required for the activation of the MCP-1 promoter 
were to be carried out by EMSA and ChIP analyses of promoter binding combined 
with the use of dominant negative mutants. Co-immunoprecipitation was also 
employed in order to study the interaction of particular mediators both 
constitutively and in response to IFN-y treatment. Figure 4.1 illustrates the overall 
experimental strategy for the work covered in this chapter.
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Figure 4.1 Experimental strategy
Further analysis of the signalling mechanisms involved in the induction of MCP-1 gene 
expression by IFN-y will focus on determining the role of the JAK-STAT pathway, CK2 and 
PI3K in this response. Aims were to be achieved with the continuing use of pharmacological 
inhibitors and dominant negative mutants combined with analyses of alterations in kinase 
activity, promoter binding and the interactions between various mediators.
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4.2 Role o f JAK-STAT Signalling in the Regulation o f MCP-1 Gene 
Expression by IFN-y
Investigations into the role of JAK-STAT signalling in the regulation of the IFN-y- 
mediation induction of MCP-1 expression, primarily aimed to establish whether 
there was a requirement for any of the components of the classical JAK-STAT 
pathway, principally JAK1, JAK2 or STAT1. Initial studies utilised the JAK2 
inhibitor AG490 and findings were subsequently confirmed by the transfection of 
dominant negative mutants for these components with the MCP-1 promoter 
reporter construct MCP[213]Luc.
4.2.1 Inhibition of IFN-y-mediated induction of MCP-1 gene expression by the 
JAK2 inhibitor AG490
AG490 is a member of the tyrphostin family of tyrosine kinase inhibitors that act 
as substrate competitors without affecting the binding of ATP (Meydan et al. 
1996, Levitzki 1990) (Table 2.2). In order to assess the role of JAKs in the 
regulation of MCP-1 expression in macrophages, the effect of AG490 on mRNA 
levels was determined by RT-PCR. The effect on the IFN-y-mediated induction of 
SOCS-1 and ICER expression was also studied as a positive and negative control 
respectively.
4.2.1.1 Inhibition of IFN-y-mediated induction of MCP-1 mRNA levels by the JAK2 
inhibitor AG490
J774.2 cells were pretreated with AG490 (50pM) or DMSO as a vehicle control. 
They were then cultured in the presence or absence of IFN-y for 3h, after which 
RNA was extracted. RT-PCR was carried out as before for MCP-1, ICER I/ll and 
SOCS-1. Figure 4.2A shows the PCR products resolved by agarose gel 
electrophoresis and band densities normalised to p-actin (Figure 4.2B). For ICER 
I/ll the level of mRNA did not differ between IFN-y stimulated samples and those 
treated with AG490 in addition to IFN-y, suggesting that JAK2 is not involved in 
the regulation of ICER expression. IFN-y-mediated induction of SOCS-1 expression 
was reduced by AG490 as expected. MCP-1 expression was also inhibited by
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pretreatment with AG490 so implicating JAK2 in the regulation of this gene by 
IFN-y.
M AG490 -RT
IFN-y + - +
1000 ■ 
500/517'
P-actin
IFN-r + + IFN -y + + IFN-y + - +
AG490 AG490 AG490
Figure 4.2 Inhibition of IFN-y-mediated induction of MCP-1 mRNA expression by AG490
J774.2 macrophages were pretreated with AG490 (50pM) or DMSO as a vehicle 
control. They were then incubated in the presence or absence of IFN-y for 3h. Total 
RNA was isolated and subjected to RT-PCR using primers against: MCP-1; SOCS-1; 
ICER I; p-actin. The amplification products were analysed by agarose gel 
electrophoresis (A). The sizes of DNA markers are indicated. Panel B shows the 
relative expression (mean ±SD) normalised to the experssion of p-actin as determined 
by densitometric analysis from four independent experiments. -RT denotes a reaction 
in which no reverse transcriptase was included for the cDNA synthesis step (using 
vehicle-treated RNA). **P<0.01; ***P <0 .001.
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4.2.1.2 Inhibition of iFN-y-mediated induction of MCP-1 protein levels by the JAK2 
inhibitor AG490
Western blot analysis was also carried out in order to confirm that the effect of 
AG490 on the IFN-y-response is also observed at the protein level. J774.2 cells 
were pre-treated with AG490 (50jiM) or DMSO as a vehicle control. They were 
then cultured in the presence or absence of IFN-y for 3h, after which 
phosphatase-free whole cell extracts were prepared. Western blot analysis was 
carried out on whole cell extracts as before, immunoblotting with a specific 
antibody raised against MCP-1. The results showed a marked inhibition of the 
IFN-y-stimulated induction of MCP-1 expression by AG490. Following 
immunoblotting, membranes were re-probed with anti-p-actin to ensure equal 
loading of samples (Figure 4.3A). Densitometric analysis was carried out as 
presented in Figure 4.3B.
AG490
IFN-y + - +
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MCP-1
P-actin
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Figure 4.3 Inhibition of IFN-^mediated induction of MCP-1 protein levels by 
AG490
J774.2 cells were pre-treated with AG490 (50pM) or DMSO as a vehicle control. 
They were then cultured in the presence or absence of IFN-y for 3h. Phosphatase- 
free whole cell protein extracts were prepared and western blot analysis was 
carried out using antibodies specific for MCP-1 and p-actin (A). Densitometric 
analysis was carried out on the data (mean ±SD) from three independent 
experiments (B). ***P <0 .001 .
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4.2.2 Effect of dominant negative inhibitors of JAK1, JAK2 and STAT1 on the 
activation of the MCP-1 promoter by IFN^y
The luciferase reporter construct MCP[213]Luc, containing a 213bp region of the 
proximal human MCP-1 promoter, was previously shown to be responsive to IFN-y 
stimulation in macrophages and in a Hep3B transfection system (Section 3.5). In 
order to confirm the role of JAKs in the regulation of MCP-1 gene expression by 
IFN-y and to ascertain whether there is a requirement for STAT1, dominant 
negative constructs specifying for inactive mutants of JAK1, JAK2 and STAT1 
(Section 2.4.5) were co-transfected with MCP[213]Luc. Co-transfections were 
also carried out using the GAS-regulated reporter plasmid, 3xly6e, as a positive 
control for the action of the dominant negative inhibitors.
As described previously in Section 3.5.4, Hep3B cells were transfected with the 
luciferase reporter construct MCP[213]Luc and the response to IFN-y treatment 
(6h) analysed. The reporter construct was co-transfected with a plasmid 
specifying for dominant negative mutants of JAK1 and JAK2 and dominant 
negative forms of STAT1 mutated at the phosphorylation sites Tyrosine 701 or 
Serine 727. Due to the unavailability of the empty plasmid vectors used in these 
constructs (pRK5 and pRC/CMV), pcDNA3 (a similar plasmid containing a CMV 
promoter region) was co-transfected in control cells. All transfections were carried 
out with samples in triplicate for at least three independent experiments. Results 
are presented as the mean fold induction (basal level assigned as 1) (±SD) except 
where stated otherwise. A standard statistical t-test (Appendix IV) was performed 
on the data and changes in expression were found to be significant to the level 
indicated.
Co-transfection of dominant negative JAK1 and JAK2 with MCP[213]Luc resulted 
in a decrease in the induction by IFN-y of 75.8% and 92.6% respectively. The 
repression for the induction of the 3xly6e construct was 82% and 88.2%  
respectively. The STAT1 (Y701F) dominant negative plasmid inhibited expression 
from the 3xly6e promoter by approximately 89% but from the MCP[213]Luc 
promoter by only 46.5% suggesting that other mechanisms may also exist for the 
regulation of MCP-1 by IFN-y. The STAT1 (S727A) plasmid reduced the IFN-y 
mediated induction of MCP[213]Luc by 36.5% and 3xly6e by 42.8% (Figure 4.4).
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4.3 Role o f PI3K and CK2 in the Regulation o f JAK-STAT Signalling in 
Response to  IFN-y
4.3.1 Effect of dominant negative inhibitors of CK2 and PKB on the activation of 
the 3xly6e promoter by IFN^y
In order to investigate whether CK2 or the downstream effector of PI3K, PKB, has 
a role in the promoter binding of STAT1 in response to IFN-y treatment, dominant 
negative plasmids for each kinase were co-transfected with the GAS-regulated 
luciferase reporter construct, 3xly6e. Hep3B cells were transfected with 3xly6e 
as previously described (Section 3.5.4) and the response to IFN-y treatment (6h) 
analysed. The reporter construct was co-transfected with plasmids specifying for 
dominant negative mutants of CK2 and PKB (Section 2.4.5) or with the empty 
plasmid vectors pSG5 and pcDNA3 respectively. Results are presented as the 
mean fold induction (basal level assigned as 1) (±SD). A standard statistical T- 
test (Appendix IV) was performed on the data and changes in expression were 
found to be significant to the level indicated.
Co-transfection with the dominant negative inhibitor of CK2 (CK2a-K68A) resulted 
in an inhibition of the IFN-y-stimulated induction of reporter gene expression from 
the 3xly6e construct of approximately 39.4% in comparison to cells co-transfected 
with the empty vector pSG5 (Figure 4.5A). Co-transfection of a dominant negative 
mutant construct for PKB (AAA) with the 3xly6e construct also resulted in an 
inhibition of the IFN-y-stimulated induction in the reporter gene expression of 
approximately 57% in comparison to cells co-transfected with the empty vector 
pcDNA3 (Figure 4.5B). This suggests that both PKB and CK2 have a role in the 
regulation of transcriptional activation by STAT1 in response to IFN-y.
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Figure 4.5 Effect of dominant negative inhibitors of PKB and CK2 on the 
stimulation of 3xly6e promoter activity by IFN-y
Hep3B cells were transfected with 3xly6e and plasmid constructs specifying for a 
dominant negative form of CK2a (A) or PKB (B) and the vectors pSG5 and 
pcDNA3 respectively. Transfected cells were treated with IFN-y for 6h after which 
cell extracts were prepared for luciferase reporter activity assay. Relative counts 
were normalised to protein concentration and presented as the mean fold 
induction (±SD) in response to IFN-y, in relation to basal expression, from three 
independent experiments. **P<0.01.
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4.3.2 Co-immunoprecipitation of JAK2 and PI3K p85 subunit
Activation of PI3K often occurs in response to a range of cytokines and growth 
factors through phosphorylation by receptor-associated tyrosine kinases (e.g. IL-2 
and GM-CSF receptors). Several studies have demonstrated functional 
interactions between the p85 subunit of PI3K and JAK1 and JAK2, inducible by 
various cytokines in cardiac myocytes, hepatocytes, macrophages, and 
neutrophils (Okugawa et al. 2003, Al-Shami and Naccache 1999, Oh et al. 1998, 
Yamauchi etal. 1998) (Section 1.9.4). IFN-aR also associates with PI3K following 
stimulation with IFN-a leading to activation of the kinase (Thyrell et al. 2004, 
Uddin et al. 2000, Pfeffer et al. 1997). Co-immunoprecipitation analysis was 
used to determine whether an interaction exists between p85 and JAK2 in J774.2 
cells and if binding is increased by IFN-y treatment. If such an interaction existed 
it would provide a potential mechanistic link between JAK2 (that is essential for 
IFN-y-mediated upregulation of MCP-1) and PI3K.
Phosphatase-free whole cell extracts were prepared from untreated J774.2 cells 
or those stimulated with IFN-y for 3h. Extracts were subjected to 
immunoprecipitation as described in Section 2.6.6, using antibodies raised 
against JAK2 and p85 (included for comparative purposes) or with no antibody 
(No Ab), as a negative control for the procedure (Table 2.9). Western blot analysis 
carried out using an antibody for p85 (Section 2.6.7-2.6.8). As illustrated in 
Figure 4.6 western blot with anti-p85 revealed a protein band of the appropriate 
size in lysates subjected to immunoprecipitation with anti-JAK2, suggesting that 
an interaction occurs between the two molecules. This interaction was not 
increased by treatment with IFN-y.
IPJAK2____________ IP p85 No Ab
Figure 4.6 Constitutive interaction between JAK2 and p85 subunit of PI3K
J774.2 cells were treated with IFN-y for 3h and phosphatase-free whole cell protein 
extracts were prepared. Immunoprecipatation was carried out with anti-JAK2 and anti- 
p85 antibodies and western blot performed using an antibody specific for p85. No Ab 
denotes an extract immunoprecipitated with A/G agarose beads only (no antibody). 
Results are representative of four independent experiments.
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4.3.3 Time course for STAT1 phosphorylation by IFN-y at residues Tyrosine 701  
and Serine 727
STAT1 is activated in response to IFN-y through phosphorylation at Tyrosine 701  
by receptor-associated JAKs. This subsequently leads to STAT1 dimerisation and 
translocation to the nucleus. Maximal activation also requires phosphorylation at 
Serine 727 although the role and mechanism of phosphorylation at this site is 
less well understood. The phosphorylation of STAT1 at both tyrosine and serine 
was analysed in J774.2 cells in response to IFN-y.
Cells of the J774.2 cell line were stimulated with IFN-y for periods of 5min, 15min, 
30min, lh  and 3h and phosphatase-free whole cell extracts were subsequently 
prepared from treated cells and untreated controls (at Oh, 15min and 3h). 
Proteins (lOpg for total STAT1, 40pg for phospho-specific antibodies) were 
separated by SDS-PAGE and transferred to nitrocellulose membrane by 
immunoblotting (Section 2.6.7). Membranes were probed using antibodies 
against total STAT1 p84/p91, pSTATl (Tyr701) and pSTATl (Ser727) (Table 2.9). 
Following immunodetection, membranes were re-probed with antibodies specific 
for p-actin to ensure the equal loading of samples.
As shown in Figure 4.7 STAT1 (a and p isoforms, predominantly a) was 
phosphorylated at Tyrosine 701 after 5min stimulation with IFN-y and at 
subsequent time points. Phosphorylation of STAT1 at Serine 727 could also be 
observed after 5min reaching maximal levels after 30min and at subsequent time 
points. The amount of total STAT1 protein present did not vary. Densitometric 
analysis of the data was carried out as shown (Figure 4.7B).
4.3.4 Effect of LY294002 and apigenin on the phosphorylation of STAT1
Previous studies have investigated the effect of the PI3K inhibitor LY294002 on 
the phosphorylation of STAT1 in a variety of cell lines. LY294002 has been found, 
in fibroblasts, epithelial and mesangial cells, to inhibit the IFN-y-induced 
phosphorylation of STAT1 at Serine 727, so implicating PI3K in the regulation of
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Figure 4.7 Effect of IFN-y treatment on the phosphorylation of STAT1 at Tyrosine 
701 and Serine 727
J774.2 cells were treated with IFN-y for the times indicated and phosphatase-free 
whole cell protein extracts were prepared. Western blot analysis was carried out 
using antibodies specific for: pSTATl Tyr701; pSTATl Ser727; J3-Actin; STAT1 
p84/91 (A). Densitometric analysis was carried out (mean ±SD) from at least two 
independent experiments (B). *P<0.05
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STAT1 at this site (Choudhury et al. 2004, Kristof et a/. 2003, Nguyen et al. 
2001). Few studies have dealt with the potential role of CK2 in the regulation of 
STAT1 phosphorylation. To our knowledge only one study has analysed the effect 
of apigenin on the induction of STAT1 phosphorylation at Tyrosine 701 in 
fibroblasts. This did not indicate a requirement for CK2 in the mediation of this 
response (Higashi et al. 2003). To further investigate the function of PI3K and 
CK2 in the regulation of STAT1 activity in macrophages, the effect of LY294002 
and apigenin on the phosphorylation of STAT1 at both Tyrosine 701 and Serine 
727 was assessed.
J774.2 cells were pre-treated with LY294002 (20pM), apigenin (20pM) and 
AG490 (50|iM) or DMSO as a vehicle control. They were then cultured in the 
presence or absence of IFN-y for 3h after which phosphatase-free whole cell 
extracts were prepared. These concentrations and time point were chosen as 
those for which there was maximal MCP-1 mRNA induction with IFN-y, and this 
was prevented by pretreatment with these inhibitors Proteins (lOjig for total 
STAT1, 40pg for phospho-specific antibodies) were separated by SDS-PAGE and 
transferred to nitrocellulose membrane by immunoblotting. Membranes were 
probed using antibodies against total STAT1 p84/p91, pSTATl (Tyr701) and 
pSTATl (Ser727). Following immunodetection, membranes were re-probed with 
antibodies specific for p-actin to ensure the equal loading of samples.
In accordance with studies in other cell types (Choudhury et al. 2004, Higashi et 
al. 2003, Kristof et al. 2003, Nguyen et al. 2001), neither of the inhibitors 
LY294002 or apigenin reduced the IFN-y-induced phosphorylation of STAT1 at 
Tyrosine 701, in contrast to AG490. However the phosphorylation of Serine 727 
was inhibited by apigenin and AG490 and, to a slightly lesser extent, LY294002 
In two of three experiments, the control extract treated with AG490 alone, 
displayed an increased phosphorylation of Serine 727, the pathways involved in 
this are uncertain. The amount of total STAT1 protein did not vary (Figure 4.8A). 
Densitometric analysis was carried out as shown (Figure 4.8B). These findings 
correlate with the reduction in the activation of 3xly6e by IFN-y in co-transfections 
with dominant negative inhibitors of PKB and CK2 (Figure 4.5) and support a role 
for these kinases in the activation of STAT1 by the cytokine.
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Figure 4.8 Inhibition of IFN-y-induced phosphorylation of STAT1 at Serine 727 by 
LY294002 and Apigenin
J774.2 cells were pretreated with LY294002 (20pM), apigenin (20|iM), AG490 
(50pM) or DMSO as a vehicle control. They were then cultured in the presence or 
absence of IFN-y for 3h. Phosphatase-free whole cell protein extracts were 
prepared and western blot analysis was carried out using antibodies specific for: 
pSTATl Tyr701; pSTATl Ser727; P-Actin; STAT1 p84/91 (A). Densitometric 
analysis was carried out as shown and presented as the relative expression 
(mean ±SD) from at least three independent experiments (B). **P<0 0 r
***P<0.001.
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4.3.5 Stimulation of PKB activity by IFN^y
The use of the pharmacological inhibitor of PKB activity SH6, and a dominant negative 
construct demonstrated a role for PKB as a likely downstream effector of PI3K in the 
regulation of MCP-1 expression by IFN-y. PKB activity is controlled by phosphorylation of 
the residues Threonine 308 and Serine 473 by PDK-1 and the putative kinase PDK-2 
respectively (Bayascas and Alessi 2005, Yang et al. 2004). The enhanced 
phosphorylation of PKB at Serine 473 in response to IFN-y has been demonstrated in 
previous studies in fibroblasts, microglial cells and in primary monocytes. In all of these 
studies the phosphorylation of PKB was increased by IFN-y following less than 30min 
stimulation (Hwang et al. 2004, Navarro 2003, Nguyen et al. 2001). In human primary 
monocytes this effect was found to decline at later time points (Navarro et al. 2003). 
However, to our knowledge, no prior studies have been carried out in macrophages.
4.3.5.1 Time course for PKB phosphorylation by IFN-y at residues Threonine 308 and 
Serine 727
The change in PKB activation in response to stimulation by IFN-y was analysed in J774.2 
macrophages by studying both the phosphorylation at Threonine 308 and Serine 473  
and the kinase activity towards a downstream substrate (GSK-3). J774.2 cells were 
stimulated with IFN-y for periods of 5min, 15min, 30min, lh  and 3h and phosphatase- 
free whole cell extracts were subsequently prepared from treated cells and untreated 
controls (at Oh, 15min and 3h). Proteins (20pg for total PKB, 60pg for phospho-specific 
antibodies) were separated by SDS-PAGE and transferred to a nitrocellulose membrane 
by immunoblotting. Membranes were probed using antibodies against total PKB, pPKB 
(Thr308) and pPKB (Ser473) (Table 2.9). Following immunodetection, membranes were 
reprobed with an antibody specific for p-actin to ensure the equal loading of samples. As 
shown in Figure 4.9A PKB was phosphorylated maximally at both Thr308 and Ser473 
after approximately 15-30min stimulation with IFN-y and declined at subsequent time 
points. The amount of total PKB protein present does not vary. An assay of PKB kinase 
activity towards a recombinant substrate (Section 2.6.5) was carried out using 
phosphatase-free whole cell extracts prepared as above. The profile of PKB activation by 
IFN-y overtime correlated with that of the protein phosphorylation atThr308 and Ser473 
reaching maximal levels at 30min (Figure 4.9B). Densitometric analysis was carried out 
as shown.
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4.3.5.2 Effect of LY294002 and apigenin on the activation of PKB by IFN-y
In order to further elucidate the mechanism by which IFN-y induces the activation 
of PKB in macrophages, the effect of the pharmacological inhibitors LY294002, 
apigenin and AG490 on IFN-y-mediated activation of PKB was assessed. A recent 
study has implicated CK2 in the regulation of PKB activity in the Jurkat T-cell line 
(Di Maira etal. 2005).
J774.2 cells were pretreated with LY294002 (20pM), apigenin (20pM), AG490 
(50pM) or DMSO as a vehicle control. They were then cultured in the presence or 
absence of IFN-y for 30min (identified in Section 4.3.5.1 as stimulating the 
maximal induction in activity) after which phosphatase-free whole cell extracts 
were prepared. An assay of PKB kinase activity towards a recombinant substrate 
was carried out as in Section 4.3.6.1.
As expected the presence of LY294002 completely blocked the activation of PKB 
by IFN-y as well as decreasing basal kinase activity. The JAK2 inhibitor AG490 
also reduced the induction of PKB activity by the cytokine supporting the function 
of JAK2 in IFN-y-mediated activation of PI3K. The CK2 inhibitor apigenin had no 
effect on PKB activation by IFN-y in contrast to the findings of the previous study 
by Di Maira et al. (2005) in T-cells (Figure 4.10). Densitometric analysis was 
carried out as presented in Figure 4.10B.
As the activation of CK2 by IFN-y is unaffected by pretreatment with either AG490 
or LY294002 in J774.2 cells (Evans, S., personal communication) these results 
indicate that CK2 is involved in a IFN-y-stimulated pathway that is independent of 
either JAKs or PI3K.
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Figure 4 .10 Inhibition of IFN^y-induced activation of PKB by LY294002 and 
AG490 but not apigenin
J774.2 cells were pretreated with LY294002 (20pM), apigenin (20pM), AG490 
(50pM) or DMSO as a vehicle control. They were then cultured in the presence 
or absence of IFN-y for 30min after which phosphatase-free whole cell extracts 
were prepared. An assay of PKB kinase activity towards a recombinant 
substrate was performed (A). Densitometric analysis was carried out at shown 
and presented as relative expression (mean ±SD) from three independent 
experiments (B). *P<0.05; **P <0 .01 .
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4.4 Analysis o f MCP-1 Prom oter Binding
Analyses of the proximal promoter region of the human and mouse MCP-1 gene 
have revealed the presence of several putative c/'s-acting regulatory elements for 
transcription factors including S p l, STAT1, NF-kB, AP-1 and C/EBP-p as illustrated 
in Figure 3.11. In human astrocytoma cells lines, IFN-y-inducible binding for STAT1 
has been demonstrated to the GAS element at position -2 1 3  and S p l has been 
shown to bind constitutively to a GC box at position -125 (Zhou et al. 1998). 
Studies into the regulation of the ICAM-1 promoter in response to IFN-y have 
suggested an interaction between STAT1 and Spl, necessary for transcriptional 
activity (Look et al. 1995). The mouse promoter regions containing the GAS 
element at position -159 and the putative S p l binding site at position -51 were 
therefore selected for promoter binding analysis in order to further determine the 
role of STAT1 in the IFN-y-mediated upregulation of MCP-1 gene expression and to 
investigate the potential involvement of the transcription factor S p l in this 
response.
4.4.1 EMSA analysis of protein binding to the MCP-1 promoter
Nuclear protein extracts were prepared by the method detailed in Section 2.6.3, 
from untreated J774.2 cells and those stimulated for 30min or 3h with murine 
IFN-y. The EMSA probes MCPGC and MCPGAS (Table 2.11), containing the GC box 
(-51) and GAS element (-159) of the murine MCP-1 promoter respectively, were 
radiolabelled and incubated in a protein binding reaction with whole cell protein 
extracts as described in Section 2.7.1. The resulting DNA-protein complexes were 
resolved on a 6% (MCPGC) or 4% (MCPGAS) non-denaturing polyacrylamide gel 
and visualised by exposure to X-ray film (Section 2.7.1.5).
4.4.1.1 Constitutive binding of S p l/S p 3  to MCPGC
Protein binding to MCPGC, containing a GC box, gave rise to three distinct DNA- 
protein complexes (a-c) when resolved by electrophoresis as shown in Figure 
4.11. This binding was competed by an excess of the unlabelled probe and by the
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consensus sequence for S p l binding but not by a consensus sequence for AP-1 
(Section 2.7.1.4). Incubation with antibodies for S p l inhibited the formation of 
complex a and incubation with anti-Sp3 prevented the formation of complexes b 
and c. In addition, a DNA-protein-antibody supershift complex was obtained with 
these two antibodies which is particulary prominent with the Sp3 antibody 
(Section 2.7.1.4) (Figure 4.11A). The binding of S p l and Sp3 to MCP-GC was 
unaffected by IFN-y (Figure 4.11B). Densitometric analysis of this data is also 
presented.
4.4.1.2 IFN-y-mduced protein binding to MCPGAS
Figure 4.12 illustrates that protein binding to the GAS element of the proximal 
MCP-1 promoter is inducible by IFN-y after stimulation for 30min and declines at 
3h. Two DNA-protein complexes were present (a and b) the binding of which was 
competed by an excess of the unlabelled probe and a consensus STATl-binding 
site but not by a double stranded oligonucleotide for the NF-kB consensus 
element, indicating that the binding is sequence specific. Although further 
studies are required to confirm the identity of each band, band a is at a position 
consistent with that seen for STAT1 binding in previous studies (Zhou et al. 1998). 
A supershift antibody was unavailable in the laboratory for STAT1 at this time. 
Densitometric analysis of this data was carried out as shown (Figure 4.12B).
These findings confirm those of Zhou et al. (1998) who determined, in 
astrocytoma cells, that S p l bound constitutively to the MCP-1 promoter and the 
STAT1 binding was maximally induced at 30min and decreased by 5h. They also 
showed through mutation of the GAS and GC elements that the GAS element was 
necessary for the upregulation of MCP-1 expression from a reporter plasmid by 
IFN-y and that inactivation of the GC box reduced the basal expression from the 
promoter without affecting IFN-y-inducibility (Zhou et al. 1998).
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A. Competition Supershift
MCPGC S p l A PI S p l Sp3 NIS
ss Sp3
ss S p l
MCPGC
Figure 4.11 Constitutive binding of Spl/Sp3 to MCPGC
J774.2 cells were cultured in the presence or absence of IFNyfor 3h and nuclear 
extracts prepared. EMSA analysis was carried out for extracts using the 
radiolabelled probe MCPGC. Competition studies were carried out using 250x 
molar excess of unlabelled probe and unlabelled Spl and AP-1 consensus 
sequences. Supershift was performed using anti-Spl and anti-Sp3 antibodies. 
Results are representative of two independent experiments (A). Densitometric 
analysis shows the mean fold induction with IFN-y (±SD) from three experiments 
(B).
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Figure 4.12 IFN-y induces transient binding to MCPGAS
J774.2 cells were treated with IFNy for times of Oh, 30min and 3h and nuclear 
extracts prepared. EMSA analysis was carried out for extracts using the 
radiolabelled probe MCPGAS. Competition studies were carried out using 250x 
molar excess of unlabelled probe and unlabelled GAS and NF-kB consensus 
sequences (A). Densitometric analysis is presented as the mean fold induction 
with IFN-y (±SD) from three experiments (B). *P<0.05.
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4.4.2 ChIP analysis of protein binding to the MCP-1 promoter
In order to confirm that the in vitro findings from EMSA analysis occur in the cellular 
environment, ChIP analysis was carried out for S p l and STAT1 binding to the 
proximal MCP-1 promoter. Briefly, ChIP involves: the cross-linkage of proteins, 
including regulatory factors, to chromatin; chromatin fragmentation; 
immunoprecipitation of the protein of interest; reversal of crosslinking; followed by 
PCR analysis using primers specific for the section of DNA of interest (see Figure 
4.13). Protocols were carried out as specified using the Active Motif ChlP-IT™ Kit 
(Section 2.7.2). Positive and negative control primers supplied by Active Motif were 
specified for use in human cells and U937 monocytes have previously been used 
successfully in this protocol. This system was therefore employed in these 
experiments. Although the activation of MCP[213]Luc has been demonstrated by 
IFN-y in U937 cells (Section 3.5.3) the induction of endogenous mRNA has not been 
shown in this cell line. An initial experiment was therefore carried out to demonstrate 
a comparable induction in MCP-1 expression in response to IFN-y between these 
cells and J774.2 macrophages.
4.4.2.1 Validation of the use of U937 cells for use in studies of the induction of MCP- 
1 expression by IFN-y
U937 monocytes were incubated with the differentiating agent PMA for 24h and 
subsequently cultured in the presence or absence of human IFN-y for 3h, following 
which total RNA was extracted. For comparison, RNA was also prepared using cells 
cultured in the presence or absence of the cytokine that had not be preincubated 
with PMA. RT-PCR analysis was carried out as before using primers for human MCP-1 
and p-actin. PCR products were resolved by agarose gel electrophoresis as shown in 
Figure 4.14. The expression of MCP-1 was induced by IFN-y in both monocytes and 
cells differentiated in the presence of PMA. Notably, the overall level of MCP-1 
expression was dramatically increased by PMA treatment. This is consistent with 
other studies that have found that MCP-1 secretion in increased following the 
differentiation of human monocytes to macrophages (Fantuzzi et al. 1999) although 
a study by Gruss et al. (1994). has shown the opposite effect. These results indicate 
that U937 cells are suitable for use in the analysis of MCP-1 promoter binding in 
response to IFN-y.
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U937 monocytes were differentiated in the presence of PMA for 24h and 
subsequently treated with IFN-y for 30min. Cells were then subjected to ChIP 
analysis as follows:
1. Formaldehyde crosslinkage of proteins to chromatin
2. Sonication: chromatin fragmentation
3. Immunoprecipitation of the protein of interest
4. Reversal of protein-chromatin crosslinkage
5. PCR analysis using primers specific for promoter region of interest
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Figure 4.14 Induction of MCP-1 gene expression by IFN-y in U937 cells
U937 cells cultured in the presence or absence of PMA for 24h were then 
incubated in the presence or absence of human IFN-y for 3h. RNA was extracted 
and subjected to RT-PCR analysis using primers specific for human MCP-1 and p- 
actin. PCR products were resolved by agarose gel electrophoresis. The sizes of 
DNA markers are indicated. -RT represents a reaction for which no reverse 
transcriptase was included in the cDNA synthesis step (using untreated RNA).
4A .2.2 Optimisation of chromatin shearing
An important stage in the ChIP procedure is the shearing of chromatin by 
sonication (Section 2.7.2.3). Chromatin must be fragmented into sections of DNA 
in the range of 200-500bp. U937 cells were differentiated in the presence of 
PMA for 24h and subsequently fixed by the addition of formaldehyde to culture 
medium and subjected to lysis (Section 2.7.2.2). Individual aliquots of chromatin 
were subjected to 5, 10 or 15 pulses of sonication for 20s or 30s separated by 
pauses of 30s. Sheared chromatin was purified and separated by agarose gel 
electrophoresis as described in Section 2.7.2.3 (Figure 4.15A). From these 
results it was determined that optimal shearing would be achieved through 12 
periods of sonication for 30s.
To assess the effectiveness of this protocol, ChIP was carried out using the TFIIB 
antibody supplied by Active Motif for immunopreciptation, alongside a negative 
control antibody (also supplied). Immunoprecipitates were subjected to PCR 
analysis using primers for the GAPDH promoter and a region of gDNA between the 
GAPDH gene and the chromosome condensation-related SMC-associated protein 
(CNAP1) gene, which should not contain binding sites for any transcription factors, 
as a negative control PCR (Table 2.5). Products were resolved by agarose gel 
electrophoresis (Figure 4.15B). As expected the TFIIB antibody was
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immunoprecipitated with a greater quantity of DNA from the GAPDH promoter in 
comparison to the negative control antibody. The amount of non-promoter 
(negative) DNA present in each immunoprecipitate was equal, indicating that this 
is a sequence specific effect.
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Figure 4.15 Optimisation of ChIP protocol
Aliquots of chromatin were sheared by sonication for the periods indicated, purified 
and resolved by agarose gel electrophoresis (A). ChIP analysis was performed on 
chromatin subjected to 12 pulses of sonication of 30s. Immunoprecipitation was 
carried out using an antibody specific for TFIIB and a negative control IgG (NA) and 
PCR using primers for a region of the GAPDH promoter and a non-promoter section 
of gDNA (negative). PCR was also carried out using Input DNA (INP). Products were 
resolved by agarose gel electrophoresis (B).
4A .2.3 ChIP analysis of the effect of IFN-y on S p l and STAT1 binding to the MCP- 
1 promoter
In order to perform ChIP analysis for the binding of STAT1 and S p l to the human 
MCP-1 promoter, oligonucleotide primers (GC-GAS) were generated to amplify the 
region of the promoter between -289 and -95bp upstream of the transcriptional
166
C h ap ter fo u r :  M echanism s in  th e  R e g u la tio n  o f  M C P -1  Gene Expression b y  IFN -y
start site giving a 194bp product as illustrated in Figure 4.16. U937 cells, 
differentiated in presence of PMA for 24h, were treated with human IFN-y for 
30min (for which optimal GAS binding was observed in EMSA). ChIP analysis was 
carried out as in Section 4.4.2.2. Immunoprecipitation was performed using 
antibodies for S p l and STAT1 (Table 2.9) and PCR was carried out using the 
primers specified for the MCP-1 promoter and negative control primers as before 
(Table 2.5). Input DNA (diluted in a ratio of 1:10) was used as an indication of 
equal chromatin input. Products were resolved by agarose gel electrophoresis as 
shown in Figure 4.17A. Densitometry was carried out and relative levels of 
protein binding were assessed as follows: normalisation of GC-GAS and negative 
PCR values for each sample to the input value; normalisation of GC-GAS values to 
the negative PCR; and subtraction of the negative antibody value for each sample.
The mean (±SD) as calculated over three independent experiments is presented 
in Figure 4 .17B. A standard statistical t-test (Appendix IV) was performed on the 
data and the results were significant to the degree indicated. Consistent with the 
data from EMSA analysis the binding of STAT1 to GC-GAS was induced in 
response to IFN-y while S p l binding remained constant. Both EMSA and ChIP 
data suggests that STAT1 also binds constitutively to the MCP-1 promoter to some 
extent.
A.
Tgtttacacaatcctacagttctgctaggcttctatgatgctactattctgcatttgaatgagcaaatggatttaatgca
ttgtcagggagccggccaaagcttgagagctccttcctggctgggaggccccttggaatgtggcctgaaggtaagctggc
agcgagcctgacatgctttcatctagtttcctcgcttccttccttttctgcagttttcgcttcacagaaagcagaatcct
taaaaataaccctcttagttcacatctgtggtcagtctgggcttaatggcaccccatcctc
[-289]cccatttgctcatttggtct[For] .agcagtgaatggaaaaagtgtctcgtcctgaccccctgcttccctttc 
ctacttcctgigaaa[GAS] tccacaggatgctgcatttgctcagcagatttaacagcccacttatcactcatggaagatc 
cctcctcctgcttgactccgcrcc[GC] tctctc ^ S'tcfcqocegct't'tcaa'taag£-95] [Rev] aggcagagacagcagc 
cagaggaaccgagaggctgagactaacccagaaacatccaattctcaaactgaagctcgcactctcgcctccagcatg [-1]
B.
30 0  
200 
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Figure 4.16 Region of the human MCP-1 promoter amplified by PCR using the 
primers GC-GAS
The position of forward (For) and reverse (Rev) primers and the GC and GAS 
elements of interest are highlighted (A). gDNA was extracted from untreated 
U937 cells and subjected to PCR using the primers GC-GAS. The product was 
resolved by agarose gel electrophoresis (B).
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Figure 4.17 ChIP analysis of S p l and STAT1 binding to the MCP-1 promoter
U937 cells differentiated in the presence of PMA for 24h were treated with IFN-y for 
30min. Cells were fixed in the presence of formaldehyde and chromatin extracted. 
ChIP analysis was carried out using antibodies specific for Spl and STAT1 and a 
negative control IgG (NA). PCR primers were specific for a section of the human 
MCP-1 promoter (MCP-1 GC-GAS) and a region of non-promoter gDNA (negative). 
PCR was also carried out using Input DNA (INP). Products were resolved by agarose 
gel electrophoresis (A). Densitometric analysis was carried out and the relative 
levels of protein binding for S p l and STAT1 in comparison to NA (value assigned as 
0) are presented in Panel B as mean (±SD) from three experiments. **P<0.01.
4.4.3 Co-immunoprecipitation studies analysing the interactions between Spl, 
STAT1 and CK2 in response to stimulation with IFN-y
Constitutive binding of S p l to a GC box of the MCP-1 promoter was demonstrated 
by both EMSA and ChIP analysis in Sections 4.4.1-4.4.2. Co-immunoprecipitation 
studies were subsequently performed in order to establish whether an interaction 
exists between S p l and STAT1 that may play a part in the IFN-y response. Such 
an interaction has previously been demonstrated in relation to the regulation of 
the expression of the ICAM-1 gene by IFN-y in human epithelial cells (Look et al. 
1995) although other studies have failed to show binding between the two
Negative
Negative
168
Ch a p t e r  f o u r . M e c h a n is m s  in  t h e  R e g u l a t io n  o f  MCP-1 G e n e  Ex p r e s s io n  b y  IFN-y
transcription factors (Zhou et al. 1998). Work in our laboratory has previously 
found an interaction between CK2 and S p l (reproduced here as a positive control 
for the co-immunoprecipiation protocol) that suggests a role for CK2 in the 
regulation of S p l activity that may be relevant to the induction of MCP-1. Co- 
immunoprecipitation was also analysed between CK2 and STAT1 to determine 
whether CK2 regulates STAT1 in a similar mechanism.
Phosphatase-free whole cell extracts were prepared from untreated J774.2 cells, 
or those stimulated with IFN-y for 3h, according to the protocol detailed in Section 
2.6.2. Extracts were subjected to immunoprecipitation using antibodies raised 
against S p l and STAT1 (Table 2.9) as described in Section 2.6.5 and western blot 
analysis carried out using antibodies for Spl, STAT1, and CK2a, a ’, and p, in 
various combinations, as indicated in Figure 4.18. An interaction was observed, 
as expected, between S p l and all CK2 subunits. The interaction with CK2a was 
low in untreated cells and induced in IFN-y stimulated cells. For CK2a\ the 
constitutive interaction was found to be higher and induced to a lesser extent by 
IFN-y. CK2p appears to be constitutively bound to Spl. In contrast, no interaction 
was seen between CK2 and STAT1. An IFN-y inducible interaction was 
demonstrated between S pl and STAT1 as previously shown by Look etal. (1995) 
in epithelial cells. Densitometric analysis was carried out as shown for the fold 
induction of Spl-STATl by IFN-y (Figure 4.18B).
4.4.4 Role of other transcription factors in the regulation of MCP-1 expression by 
IFN-y
The MCP-1 promoter contains several putative c/s-acting regulatory elements for 
transcription factors including Spl, STAT1, NF-kB, AP-1 and C/EBP-p as illustrated 
in Figure 3.11. Previous studies have indicated a role for ail of these factors in 
the regulation of MCP-1 expression in response to cytokine stimulation (Table
1.7). The putative AP-1 element overlaps the S p l site in the proximal promoter 
and as indicated by EMSA analysis protein binding to this region is not competed 
by unlabelled double-stranded DNA encoding a consensus AP-1 site (Figure 4.11). 
A NF-kB binding site is also present in the MCP-GAS EMSA probe but protein 
binding was not inhibited by an unlabelled NF-kB consensus sequence (Figure
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4.12). However another putative kB binding site has been identified in the 
human MCP-1 promoter that may be responsive to IFN-y-stimulation. 
Transcriptional activation of both C/EBP-p and NF-kB has been linked to IFN-y 
signalling and may be regulated by both PI3K and CK2 (Section 1.8.2.1). The 
endogenous inhibitors of C/EBP-p and NF-kB activity, LIP and IkB respectively 
(Section 2.4.5), were overexpressed in co-transfection studies with MCP[213]Luc 
in order to assess the role of these transcription factors in the regulation of 
promoter activation by IFN-y.
A* IP S p l IP STATl No Ab
IFN-y + -  +
STATl 
S p l
CK2a
CK2a’
CK2P
4
3.6 
3
| ”3
I  2TJ 
£ 1.6
1
0.6
0
IFN-y - + +
No Ab
Figure 4.18 Co-immunoprecipitation studies to analyse interactions between Spl, CK2 and 
STATl
Phosphatase-free whole cell protein extracts were immunoprecipatated with anti-Spl and 
anti-STATl antibodies and western blot performed using antibodies specific for: CK2 (a, a ’ 
and p); Spl; STATl. No Ab denotes an extract immunoprecipitated using A/G Agarose beads 
only (no antibody) (A). Densitometric analysis was carried out and the results are presented 
as the mean fold induction with IFN-y (±SD) from four independent experiments (B). *P<0.05.
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4.4.4.1 Role of C/EBP-p in the induction of MCP-1 expression by IFN-y
The C/EBP-p transcript is translated into two major isoforms: liver-enriched 
activating protein (LAP) (C/EBP-p) and liver-enriched inhibitory protein (LIP). LIP 
lacks a section of the trans-activating domain but retains the ability to dimerise 
with other isoforms and to bind DNA. Hence LIP is able to act as an endogenous 
dominant negative repressor of C/EBP-p mediated gene expression (Ramji and 
Foka 2002). An expression plasmid encoding the Xenopus form of LIP was used 
to assess the role of C/EBP-p in the induction of MCP-1 expression by IFN-y.
As described previously in Section 3.5.4, Hep3B cells were transfected with the 
luciferase reporter construct MCP[213]Luc and the response to IFN-y treatment 
(6h) analysed. The reporter construct was co-transfected with an expression 
plasmid specifying for LIP or with the empty plasmid vector pCS2+. The LIP 
plasmid was also co-transfected with a reporter construct regulated by multiple 
C/EBP-p consensus elements (4xC/EBPLuc) (Section 2.4.5) to act as a positive 
control and to assess the level of inhibition achieved by overexpression of LIP in 
these cells. Transfections were carried out with samples in triplicate for three 
independent experiments. Results are presented as the mean fold induction 
(basal level assigned as 1) (±SD) except where stated otherwise. A standard 
statistical t-test (Appendix IV) was performed on the data and changes in 
expression were found to be significant to the level indicated.
The activity of the 4xC/EBPLuc promoter was increased marginally (approximately
1.5 fold) but significantly by treatment with IFN-y indicating that the cytokine does 
induce C/EBP-p binding activity in this system. However the induction of 
MCP[213]Luc by IFN-y was not affected by co-transfection with the LIP expression 
plasmid. The positive action of LIP was confirmed by its ability to inhibit basal 
transcription from the 4xC/EBPLuc construct (suppressed by 57%) (Figure 4.19). 
This suggests that although C/EBP-p binding activity can be increased in response 
to IFN-y this mechanism is not likely to be involved in the regulation of MCP-1 
expression by the cytokine.
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Figure 4.19 Role of C/EBP-p in the induction of MCP-1 expression by IFN-y
Hep3B cells were transfected with MCP[213]Luc (A) or 4xC/EBPLuc (B) and a 
plasmid construct expressing LIP or the empty vector pCS2+. Transfected cells 
were treated with IFN-y for 6h after which cell extracts were prepared for 
luciferase reporter activity assay. Relative counts were normalised to protein 
concentration and presented as the mean fold induction (±SD) in response to IFN- 
y, in relation to basal expression (assigned as 1), from three independent 
experiments. In the case of co-transfections for LIP and the 4xC/EBPLuc reporter, 
counts were normalised to the basal expression of 4xC/EBPLuc transfected with 
pCS2+. **P<0.01
4.4A .2 Role of NF-kB in the induction of MCP-1 expression by IFN-y
The function of Ik B as an inhibitor of NF-kB activation is discussed in Section 
1.8.2.1. As described previously in Section 3.5.4, Hep3B cells were transfected 
with the luciferase reporter construct MCP[213]Luc and the response to IFN-y 
treatment (6h) analysed. The reporter construct was co-transfected with an 
expression plasmid specifying for Ik B or with the empty plasmid vector pcDNA3. 
The IkB plasmid was also co-transfected with a reporter construct regulated by 
multiple NF-kB binding elements (4x NF-kBLuc) (Section 2.4.5) to assess the level 
of inhibition achieved by overexpression of IkB and act as a positive control. 
Results are presented as the mean fold induction (basal level assigned as 1) 
(±SD) except where stated otherwise. A standard statistical t-test (Appendix IV)
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was performed on the data and changes in expression were found to be 
significant to the level indicated.
The activity of the 4x NF-k BLuc promoter was increased marginally (approximately
1.5 fold) but significantly by treatment with IFN-y indicating that the cytokine does 
induce NF-k B binding activity in this system. However the induction of 
MCP[213]Luc by IFN-y was not affected by co-transfection with the Ik B expression 
plasmid. The positive action of IkB was confirmed by its ability to inhibit basal 
transcription from the 4xC/EBPLuc construct (suppressed by 57%) (Figure 4.20). 
This suggests that although NF-k B binding activity can be increased in response 
to IFN-y this mechanism is not involved in the regulation of MCP-1 expression by 
the cytokine.
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Figure 4.20 Role of NF-kB in the the induction of MCP-1 expression by IFN-y
Hep3B cells were transfected with MCP[2l3]Luc (A) or 4 x NF-k BLuc  (B) and a 
plasmid construct expressing Ik B or the empty vector pcDNA3. Transfected cells 
were treated with IFN-y for 6h after which cell extracts were prepared for 
luciferase reporter activity assay. Relative counts were normalised to protein 
concentration and presented as the mean fold induction (±SD) in response to IFN- 
y, in relation to basal expression (assigned as 1), from three independent 
experiments. In the case of co-transfections for Ik B and the 4 x NF-k BLuc  reporter, 
counts were normalised to the basal expression of 4 x NF-k BLuc transfected with 
pcDNA3. **P<0.01.
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4.5 Discussion
Due to the importance of MCP-1 in the progression of atherosclerosis and the 
potential to uncover a novel PI3K-dependent pathway in IFN-y-signalling, further 
studies were carried out of the regulation of MCP-1 expression by this cytokine. 
The action of PI3K either in cross-talk with classical JAK-STAT signalling or in 
STATl-independent induction of MCP-1 expression by IFN-y was of particular 
interest.
4.5.1 Role of STATl in the regulation of MCP-1 expression by IFN-y
Despite findings by Gil et al. (2001) that MCP-1 expression is inducible by IFN-y in 
both wild type and STATl-deficient macrophages previous studies have 
demonstrated a role for STATl in the IFN-y-mediated induction MCP-1 gene 
expression in astrocytes and osteoblasts (Zhou et al. 2001, Valente et al. 1998, 
Zhou et al. 1998). Co-transfection of dominant negative STATl with 
MCP[213]Luc, resulted in a decrease in the induction by IFN-y of approximately 
46.5%. Notably however, the upregulation of MCP-1 expression is only partially 
prevented by co-transfection with dominant negative STATl, in contrast to the 
reduction in luciferase expression regulated by tandem GAS elements, in the 
reporter 3xly6e, of approximately 89% (Figure 4.4). This suggests that an 
alternative, STATl-independent signalling pathway may operate alongside a 
STATl-dependent mechanism, or in its absence, in the regulation of MCP-1 
expression by IFN-y. Ramana et al. (2005) have recently demonstrated that 
STAT3 may function in place of STATl in STATl-deficient cells. This may provide a 
possible explanation for the finding of Gil et al. (2001) that the induction of MCP-1 
expression by IFN-y is unaffected in STATl-null macrophages while in the cellular 
systems used in this study, and others, STATl has been shown to be required. 
While in STATl knock-out cells STAT3 may act in place of STATl, a dominant 
negative inhibitor such as that used here may also sequester active STAT3 
through heterodimerisation and hence attenuate the response to IFN-y. However, 
we cannot exclude a potential role for alternative, STAT-independent 
mechanisms.
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The activation of STATl in J774.2 macrophages, through the phosphorylation at 
Tyrosine 701 and Serine 727 in response to IFN-y, was demonstrated to occur 
after 5min at both sites but not reach a maximal level until after 30min treatment 
in the case of Serine 727 phosphorylation (Figure 4.7). The phosphorylation of 
both sites after 3h stimulation with IFN-y, is inhibited by incubation with the JAK2 
inhibitor AG490 as expected. Notably, the basal level of STATl phosphorylation at 
Serine 727 was increased by AG490 treatment, suggesting that JAK2 may play a 
negative regulatory role in unstimulated cells (Figure 4.8).
Binding to a region of the human MCP-1 promoter containing a GAS element 
(-213) has been demonstrated previously by Zhou etal. (1998) to be inducible by 
IFN-y in astrocytoma cells. EMSA analysis showed a similar response in J774.2 
cells after 30min, declining after 3h treatment with IFN-y (Figure 4.12). ChIP 
analysis confirmed that STATl binds to this region of the proximal MCP-1 
promoter in the cellular environment and that this binding is increased by 
stimulation with IFN-y for 30min (Figure 4.17). The transient nature of STATl 
binding is different from the prolonged induction of MCP-1 mRNA expression by 
IFN-y. It is possible that the MCP-1 mRNA transcript, induced following short term 
IFN-y treatment, is stable over this period of time. Alternatively following STATl 
binding to the MCP-1 promoter, a secondary mechanism may be activated that 
does not require the presence of STATl.
4.5.2 Role of JAK1 and JAK2 in the regulation of MCP-1 experssion by IFN^y
Transfection of dominant negative forms of JAK1 and JAK2 in Hep3B cells led to a 
decrease in the IFN-y response of the MCP[213]Luc promoter of 75.8% and 
92.6% respectively (Figure 4.4). This indicates that JAK2 is essential for the 
upregulation of MCP-1 by IFN-y and that if two divergent pathways do exist, they 
must operate downstream of this Kinase. In confirmation of this role, the JAK2 
inhibitor AG490 also prevents the induction of both MCP-1 mRNA and protein 
expression in J774.2 cells by IFN-y (Figure 4.2 and 4.3). The inhibition of JAK1 
using a dominant negative construct appears to decrease the IFN-y response to a 
lesser degree than JAK2. Some difference in the degree of inhibition of the
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induction of expression from the construct 3xly6ef regulated by three tandem GAS 
elements, was also seen with dominant negative JAK1 and JAK2 (82% and 88.2% 
respectively) indicating that JAK2 may retain some ability to phosphorylate STATl 
in the absence of JAK1 kinase activity, or merely that the JAK2 mutant blocks 
kinase activity more efficiently than the mutant JAK1 (Figure 4.4). However, JAK2 
may also have a STATl-independent role that does not require the activation of 
JAK1.
4.5.3 Role of PI3K in the regulation of STATl in response to IFN-y-stimulation
Several previous studies have implicated PI3K in the regulation of STATl activity 
and suggest that the kinase functions in the phosphorylation of STATl on Serine 
727. These studies have shown that LY294002 has no effect on the 
phosphorylation of Tyrosine 701 in response to stimulation with IFN-y, but that the 
phosphorylation of Serine 727 is inhibited in fibroblasts, epithelial and mesangial 
cells (Choudhury 2004, Higashi et al. 2003, Nguyen et al. 2001). In contrast 
Hwang et al. (2004) found that LY294002 inhibited the IFN-y-mediated 
phosphorylation of STATl at Tyrosine 701 in microglial cells. The data shown 
here indicate that LY294002 affects the IFN-y-induced phosphorylation of STATl 
at Serine 727 in macrophages at a concentration that inhibits mRNA expression. 
Co-transfection of a dominant negative mutant of PKB with the reporter construct 
3xly6e reduces the stimulation of expression by IFN-y by approximately 57%, 
confirming an effect on STATl activation.
4.5.4 Activation of PI3K in response to IFN^y-stimulation potentially occurs 
through JAK activity
It has been suggested that phosphorylation of the IFN-y receptor may provide a 
docking site for PI3K recruitment and previous studies have demonstrated 
functional interactions between the p85 subunit of PI3K and JAK1 and JAK2, 
inducible by various cytokines (Okugawa et al. 2003, Rane and Reddy 2000, Al- 
Shami and Naccache 1999, Oh et al. 1998, Yamauchi et al. 1998). The 
transfection of dominant negative JAK1 and JAK2 mutants with MCP[213]Luc
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indicated that these kinases, in particular JAK2, are essential for the IFN-y- 
mediated induction of MCP-1. The possibility that PI3K activity may be induced 
through activated JAKs was therefore investigated.
Dominant negative and inhibitor studies previously indicated that PKB is a likely 
downstream effector of PI3K in the IFN-y-mediated induction of MCP-1 expression 
(Section 3.4). The phosphorylation and kinase activity of PKB were both found to 
be increased maximally in J774.2 cells by incubation with IFN-y for 30min. This 
corresponds to a maximal increase in STAT1 phosphorylation at Serine 727 
following 30min stimulation with IFN-y. The activation of PKB in response to the 
cytokine was inhibited by pretreatment with both LY294002 and AG490. This 
suggests that PI3K and its downstream effector PKB are activated by IFN-y 
through the action of JAK2.
Co-immunoprecipitation experiments showed a constitutive interaction between 
JAK2 and the PI3K p85 subunit that is not increased by IFN-y treatment. It 
remains to be determined if this is a direct interaction or occurs through the IFN-y 
receptor or another adaptor molecule. Al-Shami and Naccache (1999) have 
established that JAK2 is required for the phosphorylation of p85 in response to 
GM-CSF and showed that an interaction occurred between JAK2 and p85 
dependent on an unidentified adaptor protein. Yamauchi et al. (1998) 
demonstrated that JAK2 binds to p85 in response to GH and PRL through IRS-1. 
The constitutive nature of the interaction found here suggests that while PI3K 
may be constitutively recruited to JAKs and/or the IFN-y receptor, it is only 
activated when the kinases are activated by IFN-y. Future experiments will seek 
to determine whether a similar interaction is seen between p85 and JAK1 and 
how this coincides with the activation of JAKs by IFN-y and the phosphorylation of 
the IFN-y receptor. It is also worth noting that Nguyen et al. (2001) demonstrated 
that the activation of PI3K occurred in both JAK1 and JAK2-null cells although 
there may be a degree of functional redundancy involved.
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4.5.5 Role of CK2 in the regulation of STAT1 in response to IFN^stimulation
Previous studies have linked CK2 to the regulation of the activity of downstream 
effectors of PI3K including PTEN and PKB (Di Maira etal. 2005, Torres and Pulido 
2001). However in the cellular systems used in this work the activation of CK2 
appears to occur in a mechanism that is entirely independent of PI3K activation 
and may be independent of JAK signalling. IFN-y-induced activation of CK2 kinase 
activity is not inhibited by AG490 or LY294002 (Evans, S., personal 
communication), both of which attenuate the activation of PKB in response to the 
cytokine. On the other hand the activation of PKB in response to IFN-y is 
unaffected by the presence of apigenin (Figure 4.10).
To further investigate the role of CK2 in the IFN-y response, co-transfection and 
western blot experiments were carried out to determine a potential link between 
CK2 and the activation of STAT1. Co-transfection of dominant negative CK2 with 
the luciferase reporter construct 3xly6e indicated that CK2 does, to some extent, 
regulate the promoter binding activity of STAT1, IFN-y inducible expression being 
reduced by approximately 39.4% (Figure 4.5). Western blot experiments 
indicated that CK2 does not affect the phosphorylation of STAT1 at Tyrosine 701, 
as has previously been demonstrated in fibroblasts (Higashi et al. 2003), but may 
be involved in the phosphorylation of Serine 727, as the IFN-y-inducible 
phosphorylation of this residue is prevented by treatment with apigenin (Figure
4.8). Co-immunoprecipitation experiments suggest that STAT1 is not directly 
phosphorylated by CK2 as there is no interaction between the two molecules 
either in control or IFN-y stimulated cells (Figure 4.18). This suggests that a 
downstream STATl-kinase is potentially regulated through both CK2 and PKB.
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Table 4.1 summarises the effect of the dominant negative constructs used in this 
study on the activation of the MCP-1 promoter by IFN-y and the effect on the 
activity of a GAS-driven reporter.
Table 4.1 Relative inhibition of IFN-y-stimulated MCP-1 and GAS regulated 
promoter activity by dominant negative constructs
STATl (Tyr701) 46.5 89.0
STAT1 (Ser727) 36.5 42.8
JAK1 75.8 82.0
JAK2 92.6 88.2
CK2 45.1  (basal) 39.4
PKB 46.9 57.0
4.5.6 Role of S p l in the regulation of MCP-1 expression by IFN^ y
The transcription factor S p l is usually considered to have a role in constitutive 
gene expression although inducible regulation has also been demonstrated. Spl 
binds to a consensus promoter element known as a GC box, often found near 
binding sites for other transcription factors, suggesting that they may act to 
regulate gene expression in conjunction with other proteins (Section 1.8.2.1). 
Spl has been shown in our laboratory to be involved in the downregulation of LPL 
by IFN-y, whereby CK2 phosphorylates S p l leading to a decrease in promoter 
binding activity (Hughes et al. 2002, Armstrong et al. 1997, Evans, S., personal 
communication). An interaction has been shown by work in our laboratory, to 
exist between CK2 subunits and Spl, that is inducible by IFN-y for the a  and a ’ 
subunits and constitituve for CK20 (Evans, S., personal communication) and is 
reproduced in Figure 4.18. In the regulation of MCP-1 expression by IFN-y, Spl 
has previously been found to bind constitutively to the human MCP-1 promoter in 
astrocytoma cells, while STAT1 binding is increased by the cytokine. Mutation of 
the GC box in the human promoter also decreases basal activity of a luciferase 
reporter construct (Zhou et al. 1998). Constitutive binding of Spl to the GC box of 
the proximal promoter of the murine MCP-1 gene was demonstrated by EMSA in 
J774.2 macrophages (Figure 4.11) and by ChIP is U937 cells (Figure 4.17). It is 
possible to conceive a mechanism in which the phosphorylation of Spl by CK2 
may be involved in the constitutive expression of MCP-1, shown to be decreased
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by co-transfection with a dominant negative inhibitor of CK2. This may be 
mediated by an interaction with CK2p that is present in both control and IFN-y 
treated cells.
A study by Look etal. (1995) into the regulation of the ICAM-1 gene proposes that 
there is an IFN-y-inducible interaction between STAT1 and Spl, by which they 
work synergistically in the upregulation of ICAM-1 expression in human epithelial 
cells. Such an interaction was not found in a similar experiment by Zhou et al. 
(1998) in relation to the IFN-y-mediated regulation of MCP-1 in astrocytes. 
However, the co-immunoprecipitations described in this report have found that 
there is a marked increase in the binding of S p l and STAT1 by IFN-y (Figure 4.18). 
The role of this interaction in the transcriptional regulation of gene expression is 
unclear. S p l may have a function in the recruitment of STAT1 to the GAS site of 
the MCP-1 promoter or the binding of the two transcription factors may regulate 
the DNA conformation of the promoter region. The phosphorylation of S p l by CK2 
may also have role in mediating this interaction as may the phosphorylation of 
STAT1 at Serine 727 downstram of both CK2 and PI3K.
4.5.7 Role of other transcription factors in the regulation of MCP-1 expression by 
IFN-y
Figure 3.11 illustrates the presence of several putative c/s-acting regulatory 
elements in the MCP-1 promoter for transcription factors including Spl, STAT1, 
NF-kB, AP-1 and C/EBP-p. Previous studies have indicated a role for all of these 
factors in the regulation of MCP-1 expression in response to cytokine stimulation 
(Table 1.7). Competition studies in EMSA suggest that the AP-1 and NF-kB sites 
that overlap the GC-box and GAS element respectively are not involved in the 
regulation of MCP-1 expression. The role of C/EBP-p binding and binding to a 
second kB site in the human MCP-1 promoter in the response to IFN-y-stimulation 
had not been studied. Transcriptional activation of both C/EBP-p and NF-kB has 
also been linked to IFN-y-signalling and may be regulated by both PI3K and CK2 
(Section 1.82.1). The activity of promoters regulated by tandem C/EBP-p and NF- 
kB binding elements (4xC/EBPLuc and 4xNFkBLuc respectively) was upregulated
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by IFN-y. However the overexpression of the endogenous inhibitors of C/EBP-p 
and NF-k B activity, LIP and Ik B respectively, in co-transfection studies with 
MCP[213]Luc indicated that neither of these factors is necessary for the 
regulation of MCP-1 promoter activation in response to IFN-y. The efficacy of 
these inhibitors was confirmed by co-transfection with reporter constructs 
regulated by multimers of C/EBP-p and NF-k B elements, the activity of which was 
reduced by the presence of LIP and Ik B respectively. C/s-acting elements shown 
to bind these factors are also present in the distal region of the MCP-1 promoter 
however and the possibility remains that they may be able to enhance the IFN-y- 
inducible expression of the MCP-1 gene through these sites (Figure 3.11).
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CHAPTER 5. GENE-SPECIFIC FUNCTION OF PI3K IN IFN-y SIGNALLING
5.1 Introduction
The identification of PI3K as a signalling mediator in the regulation of MCP-1 gene 
expression by IFN-y, but not in the regulation of SOCS-1 or ICER (Figure 3.5), 
raised the possibility that a specific subset of ISGs are dependent on the 
activation of PI3K. If such a gene-specific pathway were to exist it may provide 
targets for the selective inhibiton of certain IFN-y responses in the treatment of 
atherosclerosis.
5.1.1 Experimental strategy
In order to investigate the gene-specific role of PI3K in IFN-y signalling further, a 
strategy was developed to study the regulation of groups of genes by the cytokine 
by RT-PCR analysis and using gene array technology. Experiments were carried 
out in J774.2 macrophages. Due to the difficulties with the efficient transfection 
of this cell line, the pharmacological agent LY294002 was used, as opposed to 
dominant negative mutants, in order to assess the requirement for PI3K. The role 
of CK2 and JAK2 in the regulation of selected genes by IFN-y was also to be 
investigated, using the inhibitors apigenin and AG490 respectively, in order to 
determine whether the regulatory mechanisms involved are comparable to those 
responsible for the induction of MCP-1. Additionally, key experiments were 
performed in endothelial cells to assess the possibility that findings might be 
relevant to IFN-y-mediated signalling in other cell types of the atherosclerotic 
plaque. The overall experimental strategy for work presented in this chapter is 
illustrated in Figure 5.1.
5.1.2 Regulation of chemokine gene expression by IFN^ y
Chemokines are important inflammatory mediators in the progression of 
atherosclerosis, discussed in detail in Section 1.5. Considering this role, and in 
order to investigate the possibility that a common mechanism may regulate a 
number of chemokines in addition to MCP-1, this group of genes was selected for
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Figure 5.1 Experimental strategy
In order to extend the previous findings with regards to the role of PI3K in IFN-y signalling, a 
broad strategy to identify a potential requirement for PI3K in the regulation of other 
atherosclerosis-associated genes by the cytokine was developed, involving the use of 
pharmacological inhibitors coupled with RT-PCR and microarray analyses. The investigation 
of the role of PI3K in the regulation of MCP-1 expression by IFN-y was also extended to 
studies in endothelial cells.
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further study of IFN-y-mediated mechanisms of transcriptional regulation. The 
expression of the CXC chemokines IP-10, Mig and l-TAC has been shown to be 
upregulated by stimulation with IFN-y in a variety of cell types (Cole et al. 1998, 
Farber 1997). The CC chemokines M IP-la and -lp  have also exhibited inducible 
expression in response to IFN-y in macrophage cell lines (Martin and Dorf 1991). 
The expression of the CC chemokine RANTES may also be regulated by IFN-y 
although it has more commonly been found to act in synergy with TNF-a and other 
cytokines (Wakugawa etal. 2001, Marfaing-Koka eta/. 1995). These genes were 
selected for initial investigations into the potential role of a common PI3K- 
dependent pathway in the IFN-y-induced expression of these genes in addition to 
MCP-1.
5.2 PI3K-Dependent Signalling in the Regulation of Chemokine Gene 
Expression by IFN^y
To establish whether IFN-y affects the expression of IP-10, Mig, l-TAC, MIP-la, 
MIP-lp and RANTES in J774.2 macrophages a time course analysis was 
performed. Subsequent experiments involved the use of the inhibitors 
LY294002, apigenin and AG490 to identify a potential role of PI3K, CK2 and JAK2 
in mediating the IFN-y response.
5.2.1 Effect of IFN-y on the expression of chemokines in macrophages
J774.2 cells were stimulated with murine IFN-y for periods of 0, 1, 3, 6, 12 and 
24h after which RNA was extracted. RT-PCR was carried out for murine IP-10, 
Mig, l-TAC, M IP-la, MIP-ip, RANTES and P-actin using the primers and conditions 
detailed in Table 2.5, generating products of the appropriate size. Figure 5.2 
summarises the change in mRNA levels for each species in response to IFN-y, 
over the duration of the time course. Figure 5.2A illustrates the PCR products 
fractionated by agarose gel electrophoresis. The band densities were normalised 
to the expression of p-actin and the fold induction in comparison to the mRNA 
expression at Oh (assigned as 1) was plotted in relation to time (h) (Figure 5.2B). 
Gene expression levels for the trio of CXC chemokines IP-10, Mig and l-TAC were 
highest following stimulation with IFN-y for between 3-6h (Figure 5.2). On the
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other hand, expression of the CC chemokines MIP-la, MIP-ip and RANTES were 
maximal after 24h treatment with the cytokine (Figure 5.2).
5 .2.2 Effect of pharmacological inhibitors on the IFN-y-mediated induction of 
chemokine expression
The data shown in Figure 5.2 indicated that the chemokines IP-10, Mig and l-TAC 
have a similar time-dependent expression profile, in response to IFN-y, to MCP-1. 
They are therefore of the most interest for a comparison of the mechanisms 
involved in this response. The expression of MIP-la, MIP-lp and RANTES was 
induced following a longer period of incubation with IFN-y and the mechanisms 
involved are likely to require de novo protein synthesis. Inhibitor studies were 
subsequently carried out in order to determine whether IP-10, Mig and l-TAC are 
regulated through a similar PI3K-dependent pathway to that responsible for the 
induction of MCP-1 expression by IFN-y.
J774.2 cells were pretreated with apigenin (IO jiM), LY294002 (5pM and 20pM) 
or AG490 (50pM) or DMSO as a vehicle control. They were then cultured in the 
presence or absence of IFN-y for 3h, after which RNA was extracted. RT-PCR was 
carried out for each gene as before using the primers specified in Table 2.5. 
Figures 5.3-5.5 show the PCR products using primers specific to each mRNA 
species and the band intensities in relation to p-actin expression. The IFN-y- 
mediated induction of all three chemokines was inhibited by apigenin (Figure 5.3), 
LY294002 (Figure 5.4) and AG490 (Figure 5.5) suggesting that the signalling 
mechanisms involved in the regulation of MCP-1 expression by the cytokine are 
also likely to be required to stimulate the expression of these chemokines.
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Figure 5.3 Effect of the CK2 inhibitor apigenin on the induction of chemokine 
expression by IFN^ y
J774.2 macrophages were pretreated with apigenin (lOpM) or DMSO as a vehicle 
control. They were then cultured in the presence or absence of IFN-y for 3h. 
Total RNA was isolated and subjected to RT-PCR using primers against: ITAC; Mig; 
IP-10; (3-actin. The amplification products were analysed by agarose gel 
electrophoresis (A). The size of the DNA markers are indicated. Panel B shows 
the relative expression (mean ±SD) normalised to the expresssion of p-actin as 
determined by densitometric analysis from at least three independent 
experiments. -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (using vehicle-treated RNA). ***P <0 .001.
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Figure 5.4 Effect of the PI3K inhibitor LY294002 on the induction of chemokine 
expression by IFN^ y
J774.2 macrophages were pretreated with LY294002 (5pM and 20pM)or DMSO 
as a vehicle control. They were then cultured in the presence or absence of IFN-y 
for 3h. Total RNA was isolated and subjected to RT-PCR using primers against: 
ITAC; Mig; IP-10; p-actin. The amplification products were analysed by agarose 
gel electrophoresis (A). The size of the DNA markers are indicated. Panel B 
shows the relative expression (mean ±SD) normalised to the expresssion of p- 
actin as determined by densitometric analysis from at least three independent 
experiments. -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (using vehicle-treated RNA). *P<0.05; 
**P<0.01; ***P <0.001.
189
Re
la
tiv
e 
E
xp
re
si
io
n
Chapter  five: Gen e -S pecific  Fun c tio n  o f  PI3K in  IFN-y S ig n a llin g
AG490
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AG490 AG490 AG490
Figure 5.5 Effect of the JAK2 inhibitor AG490 on the induction of chemokine 
expression by IFN^ y
J774.2 macrophages were pretreated with AG490 (50pM) or DMSO as a vehicle 
control. They were then cultured in the presence or absence of IFN-y for 3h. 
Total RNA was isolated and subjected to RT-PCR using primers against: ITAC; Mig; 
IP-10; p-actin. The amplification products were analysed by agarose gel 
electrophoresis (A). The size of the DNA markers are indicated. Panel B shows 
the relative expression (mean ±SD) normalised to the expresssion of p-actin as 
determined by densitometric analysis from at least three independent 
experiments. -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (using vehicle-treated RNA). *P<0.05; 
***P <0.001.
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5.3 PI3K-Dependent S ignalling in the Regulation o f CCR2 Gene 
Expression by IFN-y
The role of PI3K in the stimulation of chemokine expression by IFN-y may also 
extend to the regulation of chemokine receptor expression. Previous studies have 
presented conflicting data with regards to the regulation of the MCP-1 receptor, 
CCR2, by IFN-y in monocytes, corresponding to similar discrepancies in the effect 
of oxLDL on CCR2 expression (Section 1.6). Studies in monocytes have shown 
that CCR2 is downregulated in response to IFN-y (Penton-Roi et al. 1998, 
Tangirala et a/. 1997) while Schwarz et al. (2002) have demonstrated an 
induction in CCR2 expression by the cytokine in human mesangial cells. The 
expression of CCR2 has also been found to be downregulated upon the 
differentiation of monocytes to macrophages (Fantuzzi et al. 1999, Tangirala et 
al. 1997). RT-PCR analysis was carried out in order to determine the effect of IFN- 
y on the regulation of CCR2 gene expression in J774.2 macrophages.
5.3.1 Induction of CCR2 gene expression by IFN-y in macrophages
J774.2 cells were stimulated with murine IFN-y for periods of 0, 1, 3, 6, 12 and 
24h after which RNA was extracted. RT-PCR was carried out for murine CCR2 and 
P-actin using the primers and conditions detailed in Table 2.5, generating 
products of the appropriate size. Figure 5.6 illustrates the PCR products 
fractionated by agarose gel electrophoresis (Figure 5.6A). The band densities 
were normalised to the expression p-actin and the fold induction in comparison to 
the mRNA expression at Oh (assigned as 1) was plotted in relation to time (h) 
(Figure 5.6B). IFN-y was found to induce the expression of CCR2 mRNA, maximal 
levels being reached after 3-6h cytokine stimulation.
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Figure 5.6 Induction of CCR2 mRNA expression by IFN-y
J774.2 macrophages were exposed to IFN-y for the indicated time. Total RNA was 
isolated and subjected to RT-PCR using primers against CCR2 and p-actin. The 
amplification products were analysed by agarose gel electrophoresis (A). The 
position of the appropriate product and the size of the DNA markers are indicated. 
Panel B shows the fold induction (mean ±SD) in the expression of the appropriate 
gene normalised to the expression of p-actin as determined by densitometric 
analysis from three independent experimental series. -RT denotes a reaction in 
which no reverse transcriptase was included for the cDNA synthesis step (using 
untreated RNA). *P<0.05; **P <0.001.
5.3.2 IFN-y-mediated upregulation of CCR2 mRNA levels in macrophages is 
dependent on transcriptional activity but not mRNA stability
Notably, the increase of CCR2 mRNA levels was not as dramatic as for MCP-1 and 
the CXC chemokines, thereby suggesting the possibility that it may be mediated 
by a more moderate effect of IFN-y on mRNA stability and not transcriptional 
activation. In order to determine whether this was the case, the pharmacological 
inhibitor of transcription, actinomycin D was used. J774.2 cells were pretreated 
with actinomycin D (5pg/ml) or DMSO as a vehicle control. They were then
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cultured in the presence or absence of IFN-y for 3h. RNA was extracted and RT- 
PCR analysis carried out using murine CCR2 and p-actin primers (Table 2.5) as 
before. As shown in Figure 5.7, the presence of actinomycin D prevented the 
increase of CCR2 mRNA by IFN-y, demonstrating a requirement for increased 
transcriptional activity.
M Actinomycin D -RT
IFN-y + - +
5 0 0 /5 1 7
5 0 0 /5 1 7
CCR2 (2) 
P-Actin
Figure 5.7 Effect of actinomycin D on the induction of MCP-1 mRNA levels by IFN-7
J774.2 macrophages were pretreated with actinomycin D (5pg/ml) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h. Total RNA was isolated and subjected to RT-PCR using primers against CCR2 
and p-actin. The amplification products were analysed by agarose gel 
electrophoresis. The size of the DNA markers are indicated. -RT denotes a 
reaction in which no reverse transcriptase was included for the cDNA synthesis 
step (using vehicle-treated RNA). Results shown are representative of two 
independent experiments.
5.3.3 Effect of pharmacological inhibitors on the IFN-y-mediated induction of 
CCR2 gene expression
The action of the pharmacological inhibitors LY294002, apigenin and AG490 on 
the IFN-y-mediated induction of CCR2 gene expression was analysed in order to 
determine whether a similar PI3K-dependent pathway may be involved in the 
regulation of both MCP-1 and its receptor by the cytokine. J774.2 cells were 
pretreated with LY294002 (20pM), apigenin (20pM), AG490 (50pM) or DMSO as 
a vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h after which RNA was extracted. RT-PCR was carried out using primers 
specifying for CCR2 and p-actin as before. Figure 5.8 shows the PCR products 
resolved by agarose gel electrophoresis and the band intensities in relation to p- 
actin expression. The IFN-y-mediated induction of CCR2 expression was inhibited 
by LY294002, apigenin (Figure 5.8A) and AG490 (Figure 5.8B) suggesting that 
the signalling mechanisms involved in the regulation of MCP-1 expression by the 
cytokine may also be required to stimulate the expression of the receptor CCR2.
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Figure 5.8 Effect of inhibitors on the induction of CCR2 expression by IFN^y
J774.2 macrophages were pretreated with LY294002 (20pM), apigenin (20|iM) 
(A), AG490 (50pM) (B) or DMSO as a vehicle control. They were then cultured in 
the presence or absence of IFN-y for 3h. Total RNA was isolated and subjected 
to RT-PCR using primers against CCR2 and p-actin. The amplification products 
were analysed by agarose gel electrophoresis (A.i and B.ii). The size of the DNA 
markers are indicated. Panel A.ii and B.ii shows the relative expression (mean 
±SD) normalised to the expression of p-actin as determined by densitometric 
analysis from three independent experiments. -RT denotes a reaction in which 
no reverse transcriptase was included for the cDNA synthesis step (using 
vehicle-treated RNA). **P <0.01; * **P < 0 .0 0 1 .
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5.4 M icroarray Analysis of the Role of P I3K-D ependent S ignalling in the 
Regulation of M acrophage G ene Expression by IFN^y
Having established a subset of genes that are regulated by IFN-y in a PI3K- 
dependent manner, this study was extended to the global regulation of 
macrophage gene expression through the use of microarray analysis. Following a 
review of the gene array technology currently available, the system selected was 
the Nylon matrix based SuperArray Oligo GEArray™ DNA Microarray (Section
2.8.1). This system allows the use of pathway- and pathology-specific arrays. The 
Oligo GEArray™ Mouse Atherosclerosis Microarray used contains 113 
oligonucleotides specific to genes related to the pathogenesis of atherosclerosis 
as well as control genes and blank spots. The complete list and grid layout of 
these genes can be seen in Appendix V. Full information can be found at 
http.y/superarrav.com/OligoGEArrav.php. Figure 5.9 details the experimental 
strategy used for this series of experiments.
5.4.1 Optimisation of microarray procedures
To confirm the reliability of the array system selected, an initial experiment was 
carried out for which a pair of array membranes were each probed with labelled 
cRNA generated from the same RNA sample. Total RNA was prepared from 
untreated J774.2 macrophages incorporating a DNasel step into the usual 
protocol to minimise gDNA contamination (Section 2.5.2). Figure 5.10A illustrates 
the quality of the RNA used. RNA was converted to a labelled sample of cRNA as 
described in Section 2.8.3 and a fraction resolved by agarose electrophoresis. As 
shown in Figure 5.10B this produced a smear of between 400-1500bp. In order 
to assay the labelling efficiency, serial dilutions of labelled cRNA were prepared 
and subjected to dot blot analysis as described in Section 2.8.4. A signal was 
observed at dilutions of up to 1 /1 2 8 0  that indicates that labelled cRNA is of a 
sufficient quality to use in array hybridisation (Figure 5.10C). Hybridisation and 
chemiluminescent detection was carried out as detailed in Section 2.S.5-2.8.6. 
Both membranes displayed a comparable pattern of gene expression. The 
pattern of gene expression produced using an initial sample of RNA from 
untreated J774.2 macrophages is shown in Figure 5.11.
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Figure 5.10 Optimisation of microarray procedures
RNA was extracted from untreated J774.2 macrophages and resolved by agarose 
gel electrophoresis to determine the integrity (A) and converted to biotin-labelled 
cRNA. The success of this procedure was assessed by resolving cRNA by agarose 
gel electrophoresis (B) and by dot blot analysis (C).
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Kev: Blue, control genes; Red, genes visibly expressed at this exposure in untreated J774.2 macrophages. See Appendix V for gene 
abbreviations
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5.4.2 Microarray analysis of the effect of LY294002 on the IFN-y-mediated 
regulation of macrophage gene expression
J774 .2  cells were pretreated with L Y 29 4 00 2  (20p M ) or DMSO as a vehicle control.
They were then cultured in the presence or absence of IFN-y for 3h after which RNA 
was extracted. Microarray procedures were carried out as detailed in Section 5 .4 .1 . 
Relative expression levels were determ ined using GEArray™ Expression Analysis 
Software (SuperArray Bioscience Corporation). Statistical analysis of the data from  
three independent experiments was performed according to the methods described 
in Section 2 .8 .7  (see Figure 5 .9  for strategy). Table 5 .1  lists the genes that were 
consistently expressed in all three experiments and in the case of genes up- or 
downregulated in response to IFN-y, for which this effect was significant. Statistical 
analysis accurately represents visible data as illustrated in Figure 5 .1 2  for the 
induction of MCP-1 expression by IFN-y and the inhibition of this response in the 
presence of L Y 294002 . For the genes listed in Table 5 .1 : the relative level of 
expression; the fold change with IFN-y treatm ent; and (for those regulated by IFN-y) 
the inhibitory effect (%) of L Y 2 9 4 0 0 2  on the response, is shown. Relative 
expression is normalised to the expression of the LPL gene (100% ), which gave the 
highest signal of the genes listed. Of the 66  genes listed the expression of 50  was 
induced in response to IFN-y and 3  suppressed, while 6 were unaffected by the 
cytokine according the the criteria detailed in Section 2 .8 .7 . In the division of IFN-y- 
responsive genes according to the action of L Y 294002 , a lower limit of 55%  
inhibition of the response was set for classification as LY294002-sensitive. Of the 
50  genes induced by IFN-y in the study, the upregulation of 3 9  genes was inhibited 
by LY294002 by more than 55% .
LY294002  
IFN-y + - +
MCP-1 
GAPDH
Figure 5.12 Visible representation of the upregulation of MCP-1 gene expression by IFN-y 
and the inhibition of this response in the presence of LY294002
J774.2 cells were pretreated with L Y 29 4 00 2  (20 p M ) or DMSO as a vehicle control. They 
were then cultured in the presence or absence of IFN-y for 3h after which total RNA was 
extracted. RNA was converted to biotin-labelled cRNA that was hybridised to the Oligo 
GEArray™ Mouse Atherosclerosis Microarray and visualised by chemiluminescent detection. 
Results are representative of three independent experiments
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Table 5.1 Effect of LY294002 on IFN-y-mediated regulation of macrophage gene 
expression
M s rl 6 .2 8 1 0 .5 0 1.67 1 0 0
Ccl2 (MCP-1) 6 .2 3 11 9 .4 3 19 .17 96  6
1110 4 .6 2 14  49 3 .1 3 79 .2
Ccr2* 4 .4 2 1 0 .7 3 2 .43 98 .2
Bax 2 .6 4 1 0 . 0 2 3 8 0 1 0 0
Cd36 2 5 6 8 .31 3.24 89  7
Sell 2 .4 8 5 8 8 2.37 84 .0
Csf3 2 . 1 0 7 .15 3 .41 1 0 0
Ccl5 1 .7 0 1 1 .9 6 7.05 67 .8
Ccl20 1 .5 8 6 9 5 4 .38 63 9
Pdgfb 1 .3 3 1 1 .8 3 8.87 99 .3
Tnc 1 .1 8 3 9 8 3.37 62 .1
Itgb2 1 .1 3 4 .74 4 .21 1 0 0
Fabp3 1 .0 8 3 .8 6 3.57 83 .0
Itgax 1 .04 4 .2 2 4 .08 96 .1
Ppard 0 .9 9 4 .7 4 4 .79 97 .1
c Birc3 0 .9 5 1 0 .8 5 1 1 .3 9 72 .5
^  .2  o ' -t- 
•=
Serpinb2 0 .9 5 3 .6 5 3 .8 5 57.4
Mmp9 0.9 4 4 3 6 4 .65 7 1 6
U5 £iV 0^ Cxcll 0 .77 9 .0 5 1 1 7 6 6 8 .8A  £  
C Sele 0 .7 6 3 .8 6 5 .06 1 0 0
Ctgf 0 .7 5 4 4 3 5 .92 97 .5
Itgb3 0 .7 3 5 .94 8.08 94 .6
Ldlr 0 .7 3 4 3 2 5 .90 97 .5
Ifng 0 .7 3 9 9 2 13 .6 6 90 .9
T3 Lcat 0 .7 2 4  8 3 6 .71 92 .4
<£ t ) Ppara 0 .7 1 4 .1 2 5 .8 2 1 0 0w
3 Soat2 0 . 6 8 3 .4 2 5 .03 61 .6
'a Tgfb2 0.57 3 .4 7 6 . 1 0 59 .5
Pdgfrb 0 .44 3 .6 6 8 .31 1 0 0
114 0 .44 8 2 5 1 8 7 5 66.7
Lyplal 0 4 4 3 .0 1 6 .8 8 1 0 0
115 0 .4 3 3 6 8 8 4 6 1 0 0
Vcam l 0 .4 0 2 9 3 7.27 85.7
C c l l l 0 .37 2 .4 2 6.50 1 0 0
Cdh5 0 .3 1 2 .4 5 7.86 8 6 .2
I l ia 0 .2 7 2 6 6 9.85 9 3 9
112 0 .2 5 3 .7 1 14 .71 6 8 .6
Apoa2 0 .7 6 2 .7 3 3 .5 8 55 .6
Tnf 4 .3 0 1 5 .4 0 3 .5 9 45 .9
lea m2 3 .3 9 9 1 9 2 .71 0
Npy 2 .4 1 6 .1 9 2.57 30 .2
B cl2ala 1 .67 4 0 3 2 .41 0
c  
_ o lea m l 1 .5 8 1 2 .9 5 8.19 0
S? '£ N rlh 3 1 .4 1 4 8 9 3 .4 6 0
S  1 Fga 1 . 2 0 4 .27 3 .57 28 .8
V  £ 1113 0 . 8 8 9 0 3 10 .3 0 30 .4c C crl 0 .67 3 .6 3 5.39 0
F7 0 .5 5 3 .1 7 5.81 0
Fgb 0 .4 2 8 .26 19 .81 43 .6
X3 3?
0)H) IOU3 Lpl 1 0 0 60  0 4 0 .6 0 1 0 0
(A A
E
a
Q. IO Abcal 7 .39 5.72 0.77 40 .6
3 IO Scarbl 1 7 .9 7 1 2 .5 3 0 .70 28 .8
CO V
a>
o> Ptgsl 6 9 .1 2 77 .62 1 .1 23
c
(0 Apoal 4 2 .7 6 52 .57 1 .2 29
£ N fkb l 4 0 .6 0 5 5 .0 9 1 .357
o Cd44 14  6 6 16 .0 5 1 .095
O•» Adpf 6 . 2 1 7.10 1 .143
Tgfb3 5 .9 0 6 .0 6 1.0 27
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5.4.3 Validation of microarray data by RT-PCR analysis
Microarray data indicated an induction of almost 20-fold for MCP-1 expression in 
response to IFN-y and only 2.4-fold for CCR2, both of which were attenuated in 
the presence of LY294002. This is consistent with the RT-PCR data presented 
previously. In order to further validate the microarray data, RT-PCR analysis was 
carried out for selected genes from each category to confirm the responses to 
IFN-y and LY294002. J774.2 cells were pretreated with LY294002 (20jiM) or 
DMSO as a vehicle control. They were then cultured in the presence or absence 
of IFN-y for 3h after which RNA was extracted. RT-PCR analysis was performed 
using primers specific for: MCP-1; CD36; RANTES; MMP9; IL-10; TNF-a; ICAM-1; 
LPL; ABCA1; SR-B1; NF-kB; CD44; and GAPDH, as the control gene to which 
microarray data was normalised. PCR products were resolved by agarose gel 
electrophoresis and bands of the appropriate size were obtained.
For the majority of these genes the RT-PCR data was consistent with the 
microarray results shown in Table 5.1. However discrepancies were found 
concerning the genes IL-10 and LPL. RT-PCR analysis showed a marked 
suppression in the expression of IL-10 in response to IFN-y, in contrast to the 
induction reported in the microarray data. For LPL gene expression, the 
suppressive effect of IFN-y was consistent between the RT-PCR and microarray 
data as well as previous studies in our laboratory. Incubation with LY294002 
during 24h stimulation with IFN-y, has been found to prevent the inhibition in 
expression mediated by the cytokine in THP-l-derived macrophages (Evans, S., 
personal communication) consistent with the microarray data presented in Table 
5.1. RT-PCR analysis in J774.2 cells however, with 3h IFN-y treatment, does not 
show such a marked inhibition with LY294002 although densitometric analysis 
(data not shown) does indicate a small inhibition in the response due to a 
reduction in the basal level of LPL expression in cells treated with LY294002. RT- 
PCR data is summarised in Figure 5.13 and is representative of three 
independent experiments.
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LY294002 LY294002
IFN-y -RTIFN-y -RT
LY294002 LY294002
IFN-y -RT -RT
Anomalous  data
S uppressed  by IFN-y U naffected  by IFN-y
Induction inhibited by LY294002
Induced  by IFN-y
Induction unaffected by LY294002
LY294002  
IFN-y - +  -RT
Figure 5.13 Validation of microarray data by RT-PCR analysis
J774.2 cells were pretreated with LY294002 (20jiM) or DMSO as a vehicle 
control. They were then cultured in the presence or absence of IFN-y for 3h after 
which total RNA was extracted. RT-PCR analysis was carried out using primers 
specific for: MCP-1; CD36; RANTES; MMP9; IL-10; TNF-a; ICAM-1; LPL; ABCA1; SR- 
Bl; NF-kB; CD44; and GAPDH and the products resolved by agarose gel 
electrophoresis. -RT denotes a reaction for which no reverse transcriptase was 
included for cDNA synthesis (using vehicle-treated RNA). Results are 
representative of at least three independent experiments.
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5.5 Role o f  PI3K-Dependent Signalling in the Regulation o f MCP-1 Gene 
Expression by IFN-y in Endothelial C ells
It was of interest to determine whether PI3K is involved in the IFN-y-mediated 
regulation of gene expression specifically in macrophages or if future work may 
extend these findings into other cells of the atherosclerotic plaque. The arterial 
endothelium has an important role in the production of chemokines at the 
inflammatory site and is a target for the actions of cytokines such as IFN-y 
(Section 1.4.3). The effect of IFN-y on the expression of the MCP-1 gene in 
human endothelial cells was therefore analysed, and the dependence of this 
response on PI3K-mediated signalling.
Experiments were carried out in the human endothelial EA.hy926 cell line (Section
2.3.1). Cells of the EA.hy926 line closely represent functional ECs while providing 
a homogeneous system that allows for the extraction of a good yield of RNA or 
protein (Edgell et a l. 1983, Rieber et a/. 1993). Key data were also confirmed in 
primary HUVEC cells (Section 2.3.5) in order to establish that responses were not 
peculiar to the transformed cells.
5.5.1 Regulation of MCP-1 gene expression by IFN^y in endothelial cells
EA.hy926 cells were stimulated with human IFN-y for periods of 0 ,1 , 3, 6 ,1 2  and 
24h after which RNA was extracted. RNA was also extracted from untreated 
control cells at 24h. RT-PCR was carried out for human MCP-1 and GAPDH using 
the primers and conditions detailed in Table 2.5. Figure 5.14 summarises the 
change in mRNA levels for MCP-1 in response to IFN-y, over the duration of the 
time course. Figure 5.14A illustrates the PCR products fractionated by agarose 
gel electrophoresis. The band densities were normalised to the expression of 
GAPDH and the fold induction in comparison to the mRNA expression at Oh 
(assigned as 1) was plotted in relation to time (h) (Figure 5.14B). While maximal 
MCP-1 mRNA levels were observed following 3h stimulation with IFN-y as in 
macrophages, levels declined at 12h and 24h indicating the existence of a 
refractory mechanism in these cells that is not present in macrophages.
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A.
M -RT
IFN-y 0  1 3  6  12 24 -
5 0 0 /5 1 7
GAPDH
ifn-t
Treatment (h)
Figure 5.14 Regulation of MCP-1 gene expression by IFN-y in endothelial cells
EA.hy926 endothelial cells were exposed to human IFN-y for the indicated time. 
Total RNA was isolated and subjected to RT-PCR using primers against human 
MCP-1 and GAPDH. The amplification products were analysed by agarose gel 
electrophoresis (A). The position of the appropriate product and the size of the 
DNA markers are indicated. Panel B shows the fold induction (mean ±SD) in the 
expression of MCP-1 normalised to the expression of GAPDH as determined by 
densitometric analysis from three independent experimental series. -RT denotes 
a reaction in which no reverse transcriptase was included for the cDNA synthesis 
step (using untreated RNA). **P <0 .01
5.5.2 Effect of LY294002 on the IFN-y-mediated induction of MCP-1 gene 
expression
The effect of LY294002 on the IFN-y-mediated induction of MCP-1 gene 
expression was studied in both the EA.hy926 cell line and in HUVECs to ensure 
that responses are not a peculiar property of the EA.hy926 cell line. Cells were 
pretreated with LY294002 (5pM and 2 0 jliM ) or DMSO as a vehicle control. They 
were then cultured in the presence or absence of human IFN-y for 3h after which
204
Ch a p t e r  f iv e : G e n e -S p e c if ic  F u n c t io n  o f  PI3K in  IFN-y S ig n a l l in g
RNA was extracted. RT-PCR was carried out for human MCP-1 and GAPDH as
before.
Figure 5.15 shows the PCR products obtained using primers specific to each 
mRNA species and the band intensities in relation to GAPDH expression. Results 
were consistent between the EA.hy926 cell line (Figure 5.15A) and HUVECs 
(Figure 5.15B). Stimulation of MCP-1 gene expression following IFN-y treatment is 
inhibited by LY294002 in a concentration dependent manner.
A.i
M
Bi.
LY294002 -RT M LY294002 -RT
y - + + + - -  IFN^ yr - + + + _ .
^g|^ g9BS9HHi MCP-1
GAPDH m B H IH I
ii.
EA.hy926
ii
HIV EC
MCP-1
GAPDH
*  0.6
IFN-y -
LY 294002
1.2
1
1  0.8
g£ 0.6
2
|  0-4 
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0.2
0
IFN-y
i I
LY2 9 4 0 0 2
Figure 5.15 Effect of LY294002 on the IFN^-mediated induction of MCP-1 gene 
expression in endothelial cells
EA.hy926 (A) and HUVECs (B) were pretreated with LY294002 (5pM and 20pM) or 
DMSO as a vehicle control. They were then cultured in the presence or absence of 
human IFN-y for 3h after which total RNA was extracted. RT-PCR analysis was carried 
out using primers specific for human MCP-1 and GAPDH and the products resolved by 
agarose gel electrophoresis. -RT denotes a reaction for which no reverse transcriptase 
was included for cDNA synthesis (using vehicle-treated RNA). (A.i and B.i). 
Densitometric analysis was carried out and presented as the relative expression (mean 
±SD) normalised to the expression of GAPDH (A.ii and B.ii). Results are representative of 
three independent experiments in EA.hy926 cells and two in HUVECs. ***P<0.001.
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5.6 D iscussion
With the aim of expanding the findings regarding the role of PI3K in IFN-y- 
mediated regulation of gene expression, further studies were carried out into the 
regulation of subsets of genes by IFN^ y in macrophages. Initial investigations 
involved RT-PCR analysis of the regulation of the expression of chemokines and 
the receptor CCR2 by IFN-y. Gene array technology was then utilised to show a 
selective requirement for PI3K in the regulation of macrophage gene expression 
by IFN-y.
5.6.1 IFN^y-inducible expression of chemokines IP-10, Mig and l-TAC and the 
receptor CCR2 is regulated through a PI3K-dependent pathway
In addition to MCP-1 other chemokines also play an important role in the 
development of atherosclerosis (Section 1.5). The expression of the CXC 
chemokines IP-10, Mig and l-TAC were found to be regulated by IFN-y in J774.2 
macrophages, reaching maximal levels of mRNA expression at 3h. The CC 
chemokines M IP-la, M IP-lp and RANTES were also found to be induced in 
response to IFN-y but were not expressed maximally until after 24h cytokine 
treatment. The regulation of these genes was not investigated further as the 
mechanisms involved are likely to differ from those studied in relation to genes 
for which expression is induced more rapidly by IFN-y. The induction of IP-10, Mig 
and l-TAC expression by IFN-y was attenuated by the pharmacological inhibitors 
LY294002, apigenin and AG490. It is therefore feasible to assume that the 
expression of these chemokines is stimulated in response to IFN-y through the 
PI3K-dependent pathway responsible for the upregulation of MCP-1 gene 
expression.
The expression of the MCP-1 receptor, CCR2, was also found to be induced by 
IFN-y treatment in J774.2 macrophages. Pretreatment with the transcriptional 
ihibitor actinomycin D showed that this effect is due to increased transcription of 
the MCP-1 gene as opposed to increased mRNA stability. Previous studies have 
presented conflicting data with regards to the regulation of CCR2 by IFN-y in
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monocytes. While Schwarz et al. (2002) have demonstrated an induction in CCR2 
expression by the cytokine in human mesangial cells, studies in monocytes have 
shown that CCR2 is downregulated in response to IFN-y (Tangirala et al. 1997, 
Penton-Roi et al. 1998). The authors suggest that this enables the retention of 
monocytes recruited to an inflammatory site. Similarly the proinflammatory 
stimulus oxLDL has been found to mediate a decrease in CCR2 expression, in 
contrast to native LDL which upregulates expression of the receptor (Han et al. 
1998, Han et al. 2000). However following monocytic-differentiation, mature 
macrophages will not migrate from the inflammatory site. In this situation IFN-y 
may induce the expression of CCR2 in order to enhance other cellular responses 
to the chemokines present. The induction of CCR2 expression by IFN-y was 
attenuated by the pharmacological inhibitors LY294002, apigenin and AG490, 
suggesting that a pathway dependent on JAK2, CK2 and PI3K may be involved in 
both the regulation of chemokines and certain receptors in response to IFN-y.
A brief analysis of the promoter region approximately 400bp upstream of the 
transcriptional start site for the murine IP-10, Mig, l-TAC and CCR2 genes, 
revealed the presence of putative GAS elements for each of these genes 
(Appendix VI). Functional data has been obtained for the activation of the murine 
IP-10 and Mig promoters by IFN-y (Ohmori and Hamilton 1992, Wright and Farber 
1991). These genes are therefore all potentially regulated through STAT1 without 
the need for cfe novo protein synthesis. There are some variations in the 
expression profile in response to IFN-y between these genes, both in the degree of 
induction and the change in mRNA levels over time. This may be due to the initial 
conformation of the promoter or the necessity for different combinations of 
factors regulated through the same, or divergent pathways. Further promoter and 
biochemical studies are required to determine the precise mechanisms involved.
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5.6.2 Microarray analysis reveals a selective role for PI3K in the regulation of IFN- 
y-inducible gene expression in macrophages
This study was extended to the global regulation of macrophage gene expression 
through the use of microarray analysis. These experiments confirmed a selective 
role for PI3K in IFN-y-inducible gene expression. The commercial array 
(SuperArray Bioscience Oligo GEArray™ Mouse Atherosclerosis Microarray) 
chosen for use in this analysis contained a specifc selection of oligonucleotides 
representing genes for which a role has been demonstrated in atherosclerosis. 
As presented in Table 5.1, the expression of 50 of these genes was induced in 
response to IFN-y and 3 suppressed, while 6 were unaffected by the cytokine. 
The high proportion of genes that were found to be induced by IFN-y may be due 
to the selection of genes represented on the array. The cytokine is known to have 
an important role in the pathology of atherosclerosis and this is apparent in the 
high number of genes regulated by IFN-y in this study. A number of these genes 
have been discussed previously in relation to the role of IFN-y in the progression 
of atherosclerosis. For instance VCAM-1 and ICAM-1, the IFN-y-mediated 
induction of which is particularly notable on the surface of ECs (Cybulsky et al. 
1993, Chung et al. 2002) were shown to also be induced by the cytokine in 
macrophages (although the level of VCAM-1 expression is relatively low). LPL 
(Hughes et al. 2002) and ABCA1 (Panousis and Zuckerman 2000a), for which 
expression is suppressed, are also discussed in Section 1.4.6.
The expression of a number of cytokines was found to be induced including IL-4, 
IL-5, IL-la, IL-2, TNF-a, IL-13 and IL-10 (although this was not confirmed by PCR 
validation, see below) and several chemokines and receptors including CCL2 
(MCP-1), CCL5 (RANTES) (see below), CCL20 (MIP-3a), CXCL1 (GRO-a), CCL11 
(eotaxin), CCR2 and CCR1. Interestingly, the expression of lipoprotein receptors, 
including Msrl (SR-A), CD36, LDL-R and Scarbl (SR-B1), are shown in this study 
to be regulated by IFN-y in a contrasting manner to that described previously 
(Section 1.4.6). IFN-y is usually considered to act in an atheroprotective manner 
in the downregulation of the scavenger receptors SR-A and CD36 (Geng and 
Hansson 1992, Nakagawa et al. 1998). However this response is observed
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following prolonged stimulation with IFN-y for 24-36h and the effect of shorter 
term stimulation may be different. A study by Grewal et al. (2001) have proposed 
that scavenger receptor expression is differentially regulated over monocytic 
differentiation and also in response to long and short term treatment with IFN-y. 
They have shown an induction in SR-A expression in THP-1 cells cultured in the 
presence of PMA for up to 24h following a further 24h stimulation with IFN-y. This 
is mediated through binding to a GAS element in the promoter. Longer periods of 
treatment with IFN-y resulted in reduced levels of SR-A expression (Grewal et al.
2001). The results of microarray analysis indicated that IFN-y acts in a similarly 
atherogenic manner by suppressing the expression of the atheroprotective HDL- 
receptor SR-B1 (Huszar et al. 2000).
In the division of IFN-y-responsive genes according to the action of LY294002, an 
inhibition of the response of less than 55% was classed as unaffected. Of the 50 
genes induced by IFN-y in the study the upregulation of 39 of these was inhibited 
by LY294002 by more than 55%. Although the action of LY294002 in the 
inhibition of the IFN-y response is clearly selective, the majority of genes in this 
array are regulated by the cytokine in a PI3K-dependent manner. Again it is 
uncertain whether this is an accurate reflection of the proportion of genes 
regulated through this pathway or if the selection of genes involved in 
atherosclerotic changes has distorted these findings. If this were the case PI3K 
may preferentially function in the regulation of proinflammatory, proatherogenic 
mediators in response to IFN-y and as such would provide a potential therapeutic 
target for the treatment of atherosclerosis. For instance the IFN-y-inducible 
expression of the predominantly antiinflammatory cytokine IL-13 is not affected 
by LY294002 treatment, while that of the proinflammatory cytokines IL-5, IL-la, 
IL-2 and IL-4 (which has been shown to act in both a pro- and antiatherogenic 
manner) is inhibited in the presence of LY294002 (von der Thusen et al. 2003). 
This is not the case for all the genes for which the IFN-y response is unaffected by 
LY294002 treatment. For example the cell adhesion molecules ICAM-1 and 
VCAM-1 are both considered to have an equal impact on the development of 
atherosclerosis (although the function of these molecules is less well 
characterised in macrophages than in ECs) but the IFN-y-mediated induction is
209
Chapter  five: Ge n e -S pec if ic  F u n c tio n  o f  P I3 K  in  IF N - /S ig n a llin g
differentially responsive to LY294002. Further studies are clearly required before 
firm conclusions can be drawn in relation to the role of PI3K in the regulation of 
pro- and antiatherogenic genes in response to IFN-y.
Data from microarray experiments was consistent with previous findings from RT- 
PCR analysis, showing an induction of almost 20-fold for MCP-1 expression in 
response to IFN-y and only 2.4-fold for CCR2, both of which were attenuated in 
the presence of LY294002. However in order to further validate the microarray 
data, RT-PCR analysis was carried out for selected genes from each category to 
confirm the responses to IFN-y and LY294002. As shown in Figure 5.13, for the 
majority of these genes the RT-PCR data was consistent with the microarray 
results. The expression of RANTES was also found to be upregulated in response 
to only 3h stimulation with IFN-y in this experiment, an effect seen only marginally 
in the results presented in Figure 5.2. RT-PCR confirmed this response and the 
inhibitory effect of LY294002 at this time point. The discreprancy here may be 
due to the limitations of semi-quantitative RT-PCR in the analysis of genes that 
are not dramatically induced by the relevant stimulus.
As detailed in Section 5.4.3 anomalous data was presented with respect to the 
genes IL-10 and LPL. A literature review supports the finding that IFN-y inhibits 
the expression of IL-10 as shown in RT-PCR data (Li etal. 1997, Chromarat etal. 
1993). Interestingly, IL-10 expression has been shown to be regulated by the 
transcription factors S p l and Sp3 and IFN-y may mediate the suppression of gene 
expression through a mechanism similar to that involved in the regulation of the 
LPL gene (Hughes et al. 2002, Tone et al. 2000). The possibility must therefore 
be considered, that a second transcript that is upregulated by IFN-y also has the 
ability to bind to the oliogonucleotide sequence representing IL-10 on the array. 
For LPL gene expression, while the suppressive effect of IFN-y was consistent 
between the RT-PCR and microarray data, as well as previous studies in our 
laboratory (Hughes et al. 2002), a difference was observed in the level of 
inhibition of the IFN-y response following incubation with LY294002. It is 
uncertain from this data whether PI3K is involved in the suppression of LPL 
following 3h stimulation with IFN-y. However, LY294002 has been found to inhibit
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this response during 24h stimulation with the cytokine, the time point at which 
LPL is maximally suppressed by IFN-y in J774.2 cells. The results may differ here 
due to the difficulties of exact quantification of expression in either RT-PCR or 
microarray analysis.
These findings highlight the need for caution in the interpretation of microarray 
data and for independent confirmation by RT-PCR experiments. This does not 
mean that such experiments do not provide important information regarding the 
global role of mediators in signal transduction as well as indicating genes for 
which further mechanistic studies would be of interest. Further studies that may 
arise from the microarray data presented here include an analysis of the 
differential pathways regulating VCAM-1 and ICAM-1 expression and an extension 
of the investigation into the regulation of chemokine and chemokine receptor 
expression by IFN-y. Of particular interest may be the PI3K-independent induction 
of CCR1 by the cytokine in comparison to the induction of CCR2. Dominant 
negative or siRNA based experiments should also be carried out to confirm the 
role of PI3K in the regulation of genes of particular interest. Dependence of the 
regulation of these genes on the IFN-y-mediated activation of JAKs, STAT1 and 
CK2 should also be investigated by dominant negative or siRNA-based 
approaches.
5.6.3 A PI3K-dependent pathway regulates the IFN^y-mediated induction of MCP-1 
expression in endothelial cells
The arterial endothelium has an important role in the production of chemokines 
at the inflammatory site, and in atherosclerosis, and is a target for the actions of 
cytokines such as IFN-y (Section 1.4.3). In order to determine whether PI3K is 
involved in the IFN-y-mediated regulation of gene expression specifically in 
macrophages, or if future work may extend these findings into other cells of the 
atherosclerotic plaque, the effect of IFN-y on the expression of the MCP-1 gene in 
human ECs was analysed. For initial studies in these cells the human endothelial 
EA.hy926 cell line was utilised. As in macrophages maximal MCP-1 mRNA 
expression in these cells was observed following 3h stimulation with IFN-y.
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However mRNA levels declined at 12h and 24h indicating the existence of a 
refractory mechanism in these cells that is not present in J774.2 macrophages. 
This effect has been observed previously by Zhou et al. (2001) in human 
astrocytoma cells.
The dependence of this response on PI3K-mediated signalling was assessed by 
pretreatment of ECs with LY294002. This experiment was performed in both 
EA.hy926 cells and primary HUVECs. IFN-y induced the expression of MCP-1 
following 3h treatment in both cell types indicating that this was not a peculiar 
property of the EA.hy926 cell line. LY294002 was also shown to inhibit the IFN-y- 
mediated induction of MCP-1 expression in EA.hy926 cells and HUVECs in a dose 
dependent manner.
212
Chapter six
M echanism s  in the 
Regulation of ICER Gene
Expression  by iFN^y
Ch a p t e r  s ix  : M e c h a n is m s  in  t h e  R e g u l a t io n  o f  ICER G e n e  Ex p r e s s io n  b y  IFN-y
CHAPTER 6 . MECHANISMS IN THE REGULATION OF ICER GENE 
EXPRESSION BY IFN-y
6.1 Introduction
As discussed in Section 3.2-3.3, IFN-y was found to stimulate a dramatic increase 
in ICER expression in J774.2 macrophages, maximal levels resulting from 
between 2h and 6h of stimulation. The IFN-y-mediated induction of ICER was 
found to be attenuated by the CK2 inhibitor apigenin. The phosphorylation of 
CREB at Ser-133 (known to induce the trans-activation potential of this protein) 
was also shown to be increased by IFN-y treatment and this response was 
inhibited by apigenin. Although CK2 is considered to be a constitutively active 
kinase, the activity of the a-subunit was demonstrated to be increased by 
treatment with IFN-y, maximal activation being achieved after 2h stimulation 
(Mead et al. 2003).
6.1.1 Role of CK2 and the JAK-STAT pathway in the regulation of ICER expression 
by IFN-y
Although the use of apigenin indicated that CK2 may be involved in the regulation 
of MCP-1 and SOCS-1 expression in response to IFN-y, as well as ICER (Figure 
3.3), the induction of ICER expression was not found to be dependent on the 
activation of JAK2 as for MCP-1 and SOCS-1 (Figure 4.2). Nor was there a 
requrement for PI3K (Figure 3.5). This raises the possibility that ICER gene 
expression is regulated in response to IFN-y in a novel JAK-STAT-independent 
pathway. This chapter focuses on further studies carried out into the 
mechanisms involved in the IFN-y-stimulated upregulation of ICER expression with 
the aim of establishing the function of CK2, JAK-STAT signalling and other 
potential mediators in this response.
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6.1.2 Role of other mediators in the regulation of ICER expression by IFN-y
Previous work in our laboratory, regarding the expression of ICER in response to 
IFN-y, has utilised a number of inhibitors. These include: H89, an inhibitor of PKA; 
bisindoylmaleimide, a PKC inhibitor; SB202190, a p38 MAPK inhibitor; PD98059, 
an ERK inhibitor; W7, a calcium-calmodulin-dependent protein kinase inhibitor; 
and the JAK2 inhibitor, AG490. None of these compounds were found to affect 
signalling by IFN-y with respect to the expression of ICER (Mead et al. 2003). The 
c-Jun NH2-terminal kinase/stress activated protein kinase (JNK/SAPK) pathway 
has not been studied for a potential role in the regulation of ICER.
JNK is a member of the MAPK family of signal transducing proteins and is 
activated through MAPK signalling cascades. JNK/SAPK is activated by 
environmental stress, cytokines and other stimuli and regulates the activity of a 
variety of transcription factors including AP-1, Spl, NF-kB as well as ATF-2 and 
CREB. The pathway is required for the regulation of the inflammatory response, 
proliferation and apoptosis (Manning and Davis 2003, Wang et al 2000a, 
Sanchez et al. 1994). Several recent studies have linked the actions of CK2 to 
the activation of a JNK signalling cascade (Hilgard et al. 2004, Riga et al. 2004, 
Fleming etal. 2000).
6.1.3 Experimental strategy
The initial screen using a panel of pharmacological agents only revealed a role for 
CK2 in the IFN-y-mediated regulation of ICER gene expression. With the aim of 
identifying a further potential effector of the IFN-y response, a pharmacological 
inhibitor of JNK activity was used to establish whether this kinase is involved in 
the regulation of ICER expression by the cytokine. In order to confirm the role of 
CK2 in the induction of ICER expression by IFN-y a dominant negative mutant of 
the kinase was used in conjunction with RT-PCR analysis and the transfection of a 
luciferase reporter construct modelling the ICER promoter. Dominant negative 
mutants for JAK1, JAK2 and STAT1 were also employed to establish whether there 
is a requirement for the JAK-STAT pathway in this response (see Figure 6.1 for the 
overall experimental strategy).
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Figure 6.1 Experimental strategy
Pharmacological inhibitors were used with the aim of identifying further potential 
effectors in the IFN-y-mediated regulation of ICER expression. In order to confirm the 
role of CK2 in the induction of ICER expression by IFN-y a dominant negative mutant of 
the kinase was used in conjunction with RT-PCR analysis and the transfection of a 
luciferase reporter construct modelling the ICER promoter. Dominant negative mutants 
for JAK1, JAK2 and STAT1 were also employed to establish whether there is a 
requirement for the JAK-STAT pathway in this response
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6.2 E ffect o f Pharmacological Inhibitors on IFN-y-Stimulated Expression 
of ICER
In order to assess the role of the kinase JNK in the regulation of ICER expression 
by IFN-y, the pharmacological inhibitor of JNK activity SP600125, was used. 
SP600125 is an anthrapyrazolone compound that acts as a reversible ATP- 
competitive inhibitor for JNK (Bennett et al. 2001) (Table 2.2).
6.2.1 Effect of the pharmacological inhibitor of JNK activity SP600125 on the 
induction of ICER expression by IFN-y
J774.2 cells were pretreated with SP600125 (5pM and 20pM) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h, after which RNA was extracted. RT-PCR was carried out as before for ICER I/ll. 
A previous observation in our laboratory found that the induction of SOCS-1 by 
IFN-y is inhibited by SP600125 and this response was used as a positive control 
for the action of the inhibitor.
Figure 6.2 shows the PCR products resolved by agarose gel electrophoresis 
(Figure 6.2A) and band densities normalised to p-actin (Figure 6.2B). The level of 
ICER I/ll mRNA did not differ between IFN-y-stimulated samples and those treated 
with SP600125 in addition to IFN-y. In contrast the induction of SOCS-1 by IFN-y 
was inhibited by SP600125 in a concentration dependent manner. This is an 
interesting observation and suggests that JNK may also have a role in JAK-STAT 
signalling. However, due to time constraints, this was not persued in the current 
study.
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Figure 6.2 Effect of SP600125 on the induction of ICER expression by IFN^ y
J774.2 cells were pretreated with SP600125 (5pM and 20pM) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h. Total RNA was isolated and subjected to RT-PCR using primers against ICER, 
SOCS-1 and p-actin as indicated. The amplification products were analysed by 
agarose gel electrophoresis (A). The size of the DNA markers are indicated. Panel 
B shows the relative expression (mean +SD) normalised to the expression of p- 
actin as determined by densitometric analysis from three independent 
experiments. -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (using vehicle-treated RNA). ***P<0.001.
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6.2.2 Effect of apigenin on the induction of ICER expression by IFN-y in primary 
monocyte-derived macrophages
In order to rule out the possibility that the results obtained were peculiar to the 
J774.2 cell line, the effect of IFN-y and the CK2 inhibitor apigenin on ICER gene 
expression in human primary monocyte-derived macrophages was investigated. 
Primary monocytes were isolated from human blood and allowed to differentiate 
in culture over seven days (Section 2.3.4). Macrophages were pretreated with 
apigenin (20pM) or DMSO as a vehicle control. They were then cultured in the 
presence or absence of human IFN-y for 3h, after which RNA was extracted. RNA 
was extracted and RT-PCR was carried out using primers specific for human ICER 
I/ll and P-actin. Products were resolved by agarose gel electrophoresis (Figure 
6.3A). The density of the product bands as determined by densitometric analysis 
was normalised to those for p-actin as illustrated in Figure 6.3B. Apigenin was 
found to inhibit the IFN-y-induced expression of ICER I/ll mRNA as in J774.2 cells 
(Figure 3.3).
6.3 Activation o f the ICER Prom oter by IFN-y
As discussed in Section 1.11 the expression of all four isoforms of ICER (I, ly, II, 
lly) is controlled by an internal, alternative promoter (P2) in the CREM gene. This 
promoter region contains four tandem CRE-related sequences Known as cAMP 
autoregulatory elements (CAREs) as depicted in Figure 6.4.
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Figure 6.3 Effect of apigenin on the induction of ICER expression by IFN-y in 
primary monocyte-derived macrophages
Primary monocyte-derived macrophages were pretreated with apigenin (20jiM) or 
DMSO as a vehicle control. They were then cultured in the presence or absence 
of human IFN-y for 3h. Total RNA was isolated and subjected to RT-PCR using 
primers against hICER and p-actin. The amplification products were analysed by 
agarose gel electrophoresis (A). The size of DNA markers are indicated. Panel B 
shows the relative expession (mean ±SD) normalised to the expression of p-actin 
as determined by densitometric analysis from two independent experiments. -RT 
denotes a reaction in which no reverse transcriptase was included for the cDNA 
synthesis step (using vehicle treated RNA). **P<0.01.
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L5 Functional elements in the ICER promoter (P2)
Schematic representation of the alternative promoter (P2) of the CREM gene that regulates 
the expression of the ICER transcript showing the position of four tandem CRE-like 
elements known as CAREs (A). CARE3 and CARE4 conform to the consensus for classical 
CREs (Krueger et al. 1999). The luciferase reporter construct, pCRELuc (Stratagene) 
contains four tandem CRE consensus sites and was used to model the ICER promoter in 
transfection experiments (Section 6.3). Panel B illustrates a comparison of the sequence 
of the regulatory region of pCRELuc and the CAREs of the ICER promoter.
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6.3.1 IFN-y-mediated upregulation of ICER I/ll mRNA levels In macrophages is 
dependent on transcriptional activity but not mRNA stability
The chemical inhibitor of transcription, actinomycin D, was used to establish 
whether IFN-y increases the transcription of ICER I/ll mRNA in macrophages. 
J774.2 cells were pretreated with actinomycin D (5jig/ml) or DMSO as a vehicle 
control. They were then cultured in the presence or absence of IFN-y for 3h. RNA 
was extracted and RT-PCR analysis carried out using murine ICER I/ll and p-actin 
primers as before. As shown in Figure 6.5, the presence of actinomycin D 
prevented the increase of ICER l/H mRNA by IFN-y, demonstrating a requirement 
for increased transcriptional activity and not enhanced mRNA stability in response 
to the cytokine.
M Actinomycin D -RT
IFN-y + - +
I ICER10005 0 0 /5 1 7
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Figure 6.5 Effect of actinomycin D on the induction of ICER expression by IFN-y
J774.2 macrophages were pretreated with actinomycin D (5pg/ml) or DMSO as a 
vehicle control. They were then cultured in the presence or absence of IFN-y for 
3h. Total RNA was isolated and subjected to RT-PCR using primers against ICER 
I/ll and p-actin. The amplification products were analysed by agarose gel 
electrophoresis. The size of the DNA markers are indicated. -RT denotes a 
reaction in which no reverse transcriptase was included for the cDNA synthesis 
step (using vehicle-treated RNA). Results shown are representative of two 
independent experiments.
6.3.2 Expression from a reporter construct containing tandem CRE consensus 
sites is inducible by IFN^y
A luciferase reporter construct (pCRELuc) in which expression of the luciferase 
gene is controlled by a TATA box linked to four CRE consensus enhancer 
elements, as described in Section 2.4, was obtained from Stratagene and used to 
model the response of the P2 promoter regulating ICER expression. A comparison
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of the insert sequence containing the CREs to the sequence of the CAREs of the 
ICER promoter is given in Figure 6.4B. In order to investigate whether tandem 
CREs similar to those in the ICER promoter can support IFN-y-inducibility, pCRELuc 
was transfected into U937 cells, differentiated in the presence of PMA, and the 
regulatory effect of IFN-y treatment measured.
The pCRELuc plasmid was transfected into U937 cells by the SuperFect™ 
(Qiagen) transfection method and treated with IFN-y for 12h as described 
previously (Section 3.5). Tranfected cells were harvested and extracts prepared 
for assay of reporter gene activity. All transfections were carried out with samples 
in triplicate for at least three independent experiments. Results are presented as 
the mean fold induction (±SD) (basal level assigned as 1). A standard statistical t- 
test (Appendix IV) was performed on the data and changes in expression were 
found to be significant to the level indicated. Figure 6.6 shows that transcription 
of the luciferase gene from the pCRELuc reporter construct was increased by 
approximately 4-5 fold in cells treated with IFN-y.
pCRELuc
IFN-y - +
Figure 6.6 Activation of a promoter regulated by tandem CREs by IFN^ y in 
macrophages
U937 cells were transfected with the reporter construct pCRELuc and treated with 
IFN-y for 12h. Relative counts were normalised to protein concentration and 
presented as the mean fold induction (±SD) in response to IFN-y, in relation to basal 
expression. Results are representative of five independent experiments. 
***P<0.001.
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6.3.3 Generation of a reporter construct containing tandem CAREs
A reporter construct based on the pGL2-Promoter plasmid backbone and 
regulated by a 63bp region of the ICER promoter, containing four CAREs, was 
generated to determine if the regulation by IFN-y corresponds to that of pCRELuc. 
Sense and antisense oligonucleotides were synthesised (Sigma-Genosys, UK) and 
annealed (Section 2.7.2.1) to form double-stranded DNA representing the 
sequence of the four CAREs of the ICER promoter (P2) and containing Xhol and 
Xmal restriction sites at the 5 ’ and 3 ’ ends respectively (Appendix III). This 
sequence was cloned into the pGL2-Promoter luciferase reporter plasmid by the 
method described in Section 2.5.12 and the sequence of the insert was verified 
by sequencing (Lark, UK) (Section 2.5.12.5). Figure 6.7A shows the PCR product 
resulting from a reaction with the primers GL1 and GL2 (Table 2.5) of the 
ICER4xCARE plasmid, confirming the presence of an insert of the correct size 
(PCR product for empty vector, 135bp; plus insert, 172bp).
The ICER4xCARE construct, and the empty vector pGL2-Promoter, were 
transfected into cells of the U937 cell line by the SuperFect™ (Qiagen) 
transfection method and treated with IFN-y as for the pCRELuc reporter construct 
(Section 6.3.2). Results are presented as the mean fold induction (±SD) (basal 
level assigned as 1). As illustrated in Figure 6.7B, a small but significant increase 
was observed in reporter gene expression from the ICER 4xCARE plasmid in 
response to IFN-y. The empty pGL2-Promoter vector however, displayed reduced 
activation upon treatment with IFN-y. When counts were normalised to those for 
the empty vector the induction of ICER 4xCARE was comparable to that for 
pCRELuc, as indicated in Figure 6.6C. However the mechanisms involved in the 
regulation of the pGL2-promoter in response to IFN-y, and hence the impact on 
ICER 4xCARE, are not clear. This construct was not considered a useful model for 
further co-transfection experiments and instead pCRELuc was utilised.
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Cloning of a region of the ICER promoter into a luciferase reporter vector and the 
effect of IFN^ y
PCR was carried out using primers GL1 and GL2 on maxi prep DNA for empty pGL2-Promoter 
vector and the ICER 4xCARE construct. Products were resolved by agarose gel 
electrophoresis (A). U937 cells were transfected with the pGL2-Promoter expression vector 
and ICER4xCARE and treated with IFN-y for 6h after which cell extracts were prepared for 
luciferase reporter activity assay. Relative counts were normalised to protein concentration 
and presented as the mean (+SD) (B). Relative counts for ICER4xCARE were normalised to 
those for pGL2-promoter and presented as the mean fold induction (±SD) from four 
independent experiments. *P<0.05; **P<0.01.
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6.3.4 Validation of a hepatocyte transfection system for studies of ICER expression 
in response to IFN^y
As before, the transfection efficiency of U937 cells was not sufficient to observe a 
reproducible effect of dominant negative inhibitors on the induction of ICER 
expression by IFN-y (Section 3.5.4). Transfection based studies were 
subsequently carried out in the human hepatocyte cell line, Hep3B. In order to 
validate the use of this system, RT-PCR analysis was carried out to demonstrate 
the induction of ICER expression by IFN-y and the effect of LY294002 and 
apigenin on this response. Hep3B cells were pretreated with LY294002 (20pM) 
and apigenin (20pM) or DMSO as a vehicle control. They were then cultured in 
the presence or absence of human IFN-y for 3h, after which RNA was extracted. 
RT-PCR was carried out as before using primers specifying for human ICER I/ll 
and p-actin. The upregulation of ICER in response to IFN-y and the inhibitory 
effect of apigenin (and not LY294002) in these cells is shown in Figure 6.8 to be 
comparable to that in J774.2 cells.
ICER
P-Actin
Figure 6.8 Confirmation of induction of ICER expression by IFN-y and the effect of 
apigenin and LY294002 on this response in Hep3B cells
Hep3B cells were pretreated with LY294002 (20pM), apigenin (20pM) or DMSO 
as a vehicle control. They were then cultured in the presence or absence of IFN-y 
for 3h. Total RNA was isolated and subjected to RT-PCR using primers against 
human ICER I/ll and p-actin. The amplification products were analysed by 
agarose gel electrophoresis. The size of the DNA markers are indicated. -RT 
denotes a reaction in which no reverse transcriptase was included for the cDNA 
synthesis step (using vehicle-treated RNA). Results shown are representative of 
two independent experiments.
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6.3.5 Autoregulation of the ICER promoter
As previously reported, IFN-y induces the expression of ICER maximally following 
2-6h stimulation (Figure 3.2). For treatment periods longer than this, the levels of 
ICER mRNA decline. This corresponds to the role of ICER in the regulation of 
cyclic processes such as the mammalian circadian rhythm (Link et al. 2004, 
Maronde et al. 1999, Foulkes et al. 1997). As the ICER promoter is regulated 
through tandem CRE-like elements, it is likely that the cyclic nature of ICER 
expression is due to autoregulation of the promoter, demonstrated in several 
studies (De Cesare and Sassone-Corsi 2000, Shaywitz and Greenburg 1999, 
Della-Fazia et al. 1997, Molina et al. 1993). To demonstrate this mechanism in 
the regulation of pCRELuc, ICER I was overexpressed and the effect on expression 
from pCRELuc analysed.
As described in Section 3.5.4, Hep3B cells were transfected with the luciferase 
reporter construct pCRELuc and the response to IFN-y treatment (6h) analysed. 
The reporter construct was co-transfected with an expression plasmid encoding 
ICER I (Section 2.4.5) or the empty vector pcDNA3. Results are presented as the 
mean fold induction (±SD) (basal level assigned as 1). A standard statistical t-test 
(Appendix IV) was performed on the data and changes in expression were found 
to be significant to the level indicated. Overexpression of ICER prevented the IFN- 
y-mediated activation of the pCRE-Luc promoter (as well as reducing basal levels 
of reporter expression) as shown in Figure 6.9, confirming that ICER is involved in 
the suppression of CREB-mediated signalling and that ICER is also likely to 
downregulate its own expression.
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Figure 6.9 Inhibition of IFN^y-mediated induction of pCRELuc activity by 
overexpression of ICER I
Hep3B cells were co-transfected with pCRELuc and a expression plasmid for ICER 
I or the vector pcDNA3. Transfected cells were treated with IFN-y for 6h after 
which cell extracts were prepared for luciferase reporter activity assay. Relative 
counts were normalised to protein concentration and presented as the mean fold 
induction (±SD) in response to IFN-y, in relation to basal expression (assigned as 
1), from three independent experiments. * * *  P<0.001.
6.4  C o n firm atio n  o f  th e  In v o lv e m en t o f  CK2 in th e  Induction  o f  ICER 
Expression T h ro u g h  Use o f  a  D o m in an t Negative C o n s tru c t
While use of the inhibitor apigenin has indicated a role for CK2 in the regulation of 
ICER gene expression by IFN-y, a dominant negative construct specifying for a 
mutant form of CK2a was used to confirm the requirement for this kinase. Two 
approaches were used: the transfection of dominant negative CK2 followed by RT- 
PCR analysis of endogenous ICER I/ll mRNA expression; and the co-transfection 
of the dominant negative construct with pCRELuc.
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6.4.1 RT-PCR analysis of the effect of a dominant negative inhibitor of CK2 on the 
induction of ICER gene expression by IFN-y
Hep3B cells were transfected by the PEI method with either a plasmid encoding a 
dominant negative mutant for CK2, CK2aK68A, or the empty vector pSG5 Cells 
were then stimulated with human IFN-y for 3h after which RNA was extracted. RT- 
PCR was carried out using primers specific for human ICER I/ll and p-actin. The 
products were resolved by agarose gel electrophoresis as depicted in Figure 6.9A. 
Densitometric analysis was carried out for this data as shown (Figure 6.9B). 
Dominant negative CK2 inhibited the induction of ICER I/ll expression by IFN-y in 
comparison with the effect of the empty vector pSG5.
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Figure 6.10 Inhibition of IFN-y-mediated induction of ICER expression by dominant negative 
CK2
Hep3B cells were transfected with a dominant negative construct for CK2 or the vector 
pSG5. Transfected cells were incubated in the presence or absence of IFN-y for 3h. Total 
RNA was isolated and subjected to RT-PCR using primers against human ICER I/ll and p- 
actin. The amplification products were analysed by agarose gel electrophoresis (A). The size 
of DNA markers are indicated. Panel B shows the relative expression (mean ±SD) 
normalised to the expression of p-actin as determined by densitometric analysis from four 
independent experiments. -RT denotes a reaction in which no reverse transcriptase was 
included for the cDNA synthesis step (using untreated RNA). **P<0.01.
ICER
P-Actin
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6.4.2 Effect of a dominant negative inhibitor of CK2 on the activation of pCRELuc 
by IFN-y
Co-transfection of pCRELuc and a dominant negative inhibitor of CK2 (CK2a- 
K68A) or pSG5 in Hep3B cells was carried out by the PEI method as before 
(Section 3.5.4) and cells were treated with IFN-y for 6h. Results are presented as 
the mean fold induction (±SD) (basal level assigned as 1). A standard statistical t- 
test (Appendix IV) was performed on the data and changes in expression were 
found to be significant to the level indicated. Co-transfection with dominant 
negative CK2 led to an inhibition of the induction of reporter gene expression 
from pCRELuc by IFN-y compared with co-transfection with the empty plasmid 
vector only. This supports the hypothesis that CK2 is involved in the activation of 
a transcription factor(s), in response to IFN-y treatment, that binds to CAREs in the 
CREM ?2 promoter (Figure 6.11).
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Inhibition of IFN-y-mediated induction of ICER expression and 
pCRELuc activity by dominant negative CK2
Hep3B cells were co-transfected with pCRELuc and a plasmid construct specifying 
for a dominant negative mutant of CK2. Transfected cells were treated with IFN-y 
for 6h after which cell extracts were prepared for luciferase reporter activity 
assay. Relative counts were normalised to protein concentration and presented 
as the mean fold induction (±SD) in response to IFN-y, in relation to basal 
expression (assigned as 1) from four independent experiments. *P<0.05.
230
Ch a p t e r  s i x :  M e c h a n is m s  in  t h e  R e g u l a t io n  o f  ICER G e n e  Ex p r e s s io n  b y  IFN-y
6.5 Role of the JAK-STAT Pathway in the Regulation of ICER Gene 
Expression by IFN-y
Previous studies in our laboratory have found that the specific JAK2 inhibitor, 
AG490, does not suppress the stimulation of ICER gene expression by IFN-y 
(Figure 4.2) (Mead et al. 2003). The activation of CK2 by IFN-y, shown to be 
necessary for the induction of ICER expression in response to the cytokine, was 
also unaffected by pre-treatment with this inhibitor (Evans, S., personal 
communication).
To further investigate the role of the JAK-STAT pathway in the regulation of ICER, 
dominant negative forms of JAK1, JAK2 and STAT1 were transfected in Hep3B 
cells and the effect on the induction of ICER expression by IFN-y determined 
through RT-PCR analysis. Hep3B cells were transfected by the PEI method as 
before with plasmids encoding dominant negative mutants of JAK1 and JAK2 and 
a dominant negative form of STAT1 mutated at the phosphorylation site Tyrosine 
701. Due to the unavailability of the empty plasmid vectors used in these 
constructs (pRK5 and pRC/CMV), pcDNA3 was transfected in control cells. Cells 
were then stimulated with human IFN-y for 3h after which RNA was extracted. RT- 
PCR was carried out using primers specific for human ICER I/ll, p-actin and MCP-1 
as a positive control for the action of the dominant negative mutants (Table 2.5). 
The products were resolved by agarose gel electrophoresis as depicted in Figure 
6.12A. Densitometric analysis of the data was carried out as presented in Figure 
6.12B.
Inactivation of each of these components (JAK1, JAK2 and STAT1) did not inhibit 
the induced expression of ICER mRNA by IFN-y in comparison to an effect on the 
induction of MCP-1 by the cytokine. This suggests that the IFN-y-mediated 
regulation of ICER expression occurs through a CK2-dependent mechanism 
independent of the JAK-STAT pathway.
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Figure 6.12 Effect of a dominant negative inhibitors of STAT1 on the IFN^- 
mediated induction of ICER expression
Hep3B cells were transfected with DN-STAT1 (Y701F), WT-STAT and pcDNA3. 
Transfected cells were exposed to IFN-y for 3h. Total RNA was isolated and 
subjected to RT-PCR using primers against human ICER I/ll and p-actin. The 
amplification products were analysed by agarose gel electrophoresis (A). The size 
of DNA markers are indicated. Panel B shows the relative expression (mean ±SD) 
normalised to the expression of p-actin as determined by densitometric analysis 
from three independent experiments. -RT denotes a reaction in which no reverse 
transcriptase was included for the cDNA synthesis step (using pcDNA3- 
transfected RNA). ***P < 0 .0 0 1 .
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Effect of dominant negative inhibitors of JAK1 and JAK2 on the IFN-y- 
mediated induction of ICER expression
Hep3B cells were transfected with DN-JAK1, DN-JAK2 and pcDNA3. Transfected 
cells were exposed to human IFN-y for 3h. Total RNA was isolated and subjected 
to RT-PCR using primers against human ICER I/ll and p-actin. The amplification 
products were analysed by agarose gel electrophoresis (A). The size of DNA 
markers are indicated. Panel B shows the relative expression (mean ±SD) 
normalised to the expression of p-actin as determined by densitometric analysis 
from three independent experiments. -RT denotes a reaction in which no reverse 
transcriptase was included for the cDNA synthesis step (using pcDNA3- 
transfected RNA). **P <0.01; ***P < 0 .0 0 1 .
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6.6 D iscussion
ICER is an important transcriptional repressor of genes regulated through CREs. 
The dramatic induction of ICER mRNA expression by IFN-y leads to speculation 
that the action of ICER may be involved in the suppression of a number of genes 
in response to the cytokine. In particular, a number of genes involved in the 
progression of atherosclerosis are downregulated by IFN-y treatment such as SR- 
A, VLDL-R, and LRP (Schulz etal. 2003, Kosaka etal. 2001, LaMarre etal. 1993, 
Geng and Hansson 1992). The overexpression of ICER has been demonstrated to 
reduce the expression of LPL, known to be suppressed in response to IFN-y (Mead
2002). The mechanisms in the regulation of ICER expression by IFN-y are 
therefore of interest. ICER potentially also represents a category of ISG that is 
induced independently of both PI3K and JAK activation (Figures 3.2-3.4 and 4.2).
6.6.1 Activation of the ICER promoter by IFN^y
As discussed in Section 1.11 the expression of all four isoforms of ICER (I, ly, II, 
lly) is controlled by an internal, alternative promoter (P2) in the CREM gene. This 
promoter region contains four tandem CRE-related sequences known as CAREs as 
depicted in Figure 6.4. Use of the chemical inhibitor of transcription, actinomycin 
D, established that IFN-y increased the transcription of ICER I/ll mRNA in 
macrophages and that the response was not mediated by an increase in mRNA 
stability. A luciferase reporter construct (pCRELuc), in which expression of the 
luciferase gene is controlled by a TATA box linked to four CRE consensus 
enhancer elements, was used to model the response of the P2 promoter 
regulating ICER expression. Transfection of this construct in U937 cells, 
differentiated in the presence of PMA, demonstrated IFN-y-inducible regulation 
from a CRE-regulated promoter.
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A reporter construct based on the pGL2-Promoter plasmid and regulated by a 
63bp region of the ICER promoter containing four CAREs (ICER4xCARE), was 
generated to determine if the regulation by IFN-y corresponds to that of pCRELuc. 
The ICER4xCARE construct, and the empty vector pGL2-Promoter, were 
transfected into U937 cells treated with IFN-y as for the pCRELuc reporter 
construct. A statistically significant increase in reporter gene expression from 
ICER 4xCARE was stimulated by IFN-y despite a corresponding decrease in the 
activity of the empty pGL2-promoter. A comparble induction in reporter gene 
expression from ICER 4xCARE and pCRELuc was observed when counts were 
normalised to those for the empty vector.
It is possible that the difference in expression from pCRELuc and ICER 4xCARE is 
due to specific differences in the functional sequence elements within the two 
promoters. A comparison of the pCRELuc and ICER4xCARE sequence highlights 
these differences (Figure 6.4B). Of the four CAREs, only CARE3 matches the CRE 
consensus sequence and these differences may only be tolerated within the 
context of the ICER promoter, allowing for the maximal upregulation by IFN-y. The 
spacing between the four elements may also be crucial and only allow IFN-y- 
mediated regulation in a context specific manner. An additional element may be 
present in the full length promoter that is vital for maximal IFN-y-mediated 
upregulation from the CAREs but not the CRE consensus. Generation of a 
luciferase reporter containing a longer section of the ICER promoter may help to 
resolve this issue. It is likely however, that the nature of the minimal promoter 
elements in the vectors pLuc-MCS and pGL2-Promoter is responsible for the 
difference in pCRELuc and ICER 4xCARE activation by IFN-y. Cloning the ICER 
4xCARE promoter sequence into the pLuc-MCS plasmid may reduce this effect.
However for the purposes of this investigation the pCRELuc promoter was 
considered to be an adequate model for this response. Overexpression of ICER 
prevented the IFN-y-mediated activation of the pCRE-Luc promoter as well as 
reducing basal levels of reporter expression (Figure 6.9). This indicates that the 
cyclic nature of ICER mRNA expression in response to IFN-y, as demonstrated by 
RT-PCR analysis (Figure 3.2), is likely to be due to autoregulation of the promoter.
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The autoregulation of ICER is also important in the regulation of cyclic processes 
such the mammalian circadian rhythm (Link et al. 2004, Maronde et al. 1999, 
Foulkes et al. 1997). In the absence of the empty vector for the pCRELuc 
construct (pLuc-MCS) this also allowed confirmation that the effect of IFN-y on the 
activation of reporter gene expression is due to regulation through CREs and not 
an alternative element in the plasmid backbone. Together these studies suggest 
that CREs represent a novel class of IFN-y-responsive elements.
6.6.2 Role of CK2 in the regulation of ICER expression by IFN^y
Previous work in our laboratory, regarding the expression of ICER in response to 
IFN-y, utilised a number of pharmacological inhibitors. These included those 
acting on PKA, PKC, p38 MAPK, ERK, Ca-calmodulin-dependent protein kinase 
and JAK2. None of these compounds were found to affect signalling by IFN-y in 
respect to the expression of ICER (Mead et al. 2003). In this study it was also 
demonstrated that the specific inhibitor of JNK activity, SP600125 also failed to 
inhibit the induction of ICER by the cytokine (Figure 6.2). Thus far the IFN-y- 
mediated expression of ICER is unique in that only the CK2 inhibitor apigenin has 
been found to affect the reponse.
The activity of CK2 in J774.2 cells has been shown to be induced maximally 
following stimulation with IFN-y for 2h. A CK2-mediated increase in the 
phosphorylation of CREB is also observed in response to IFN-y treatment (Mead et 
al. 2003). Activated CREB, or another member of the CREB/CREM/ATF-2 
subfamily, is thought to subsequently bind to the alternative P2 promoter of the 
CREM gene to increase the production of the ICER transcript. The upregulation of 
ICER by IFN-y in isolated primary human monocyte-derived macrophages was 
observed to a similar level to that in J774.2 cells, and found to be inhibited by 
apigenin, indicating that these findings are not a peculiar property of the J774.2 
cell line (Figure 6.3).
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The involvement of CK2 in the IFN-y-mediated regulation of ICER was confirmed in 
this study by transfection of a dominant negative construct specifying for a 
mutant form of CK2a into cells of the human hepatoma cell line, Hep3B. Due to 
the difficulty of DNA transfection in macrophages with suitable efficiency, the 
Hep3B cell line was selected as a high efficiency transfection system for the work 
described. The use of this cell line was justified by the similarity of the IFN-y 
response for ICER expression in these cells shown by RT-PCR analysis (Figure 
6.8). Transfection of CK2aK68A reduced the induction of ICER by IFN-y in 
comparison to that in cells transfected with the empty plasmid expression vector 
pSG5 (Figure 6.10).
The construct CK2aK68A was also co-transfected with the luciferase reporter 
pCRELuc. This led to an inhibition of the induction of reporter gene expression 
from pCRELuc by IFN-y compared to co-transfection with the empty plasmid vector 
only (Figure 6.11). This supports the hypothesis that CK2 is involved in the 
activation of CREB, in response to IFN-y treatment, and this subsequently binds to 
CRE-like elements in the P2 promoter.
6.6.3 Role of the JAK-STAT pathway in the regulation of ICER expression by IFN-y
At present the upregulation of ICER expression by IFN-y has not been linked to the 
activation of STAT1 and no GAS sites are present in the ICER promoter. The JAK2 
inhibitor, AG490 was not shown to inhibit the IFN-y-mediated induction of ICER 
expression (Figure 4.2) or the activation of CK2 in response to the cytokine 
(Evans, S., personal communication). Inactivation of JAK1 and JAK2 by the 
transfection of dominant negative mutant constructs in Hep3B cells did not inhibit 
the induced expression of ICER mRNA by IFN-y, in comparison to an effect on the 
induction of MCP-1 by the cytokine (Figure 6.12). This supports the hypothesis 
that the IFN-y-mediated activation of CK2 occurs in a pathway independent of JAK 
signalling
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Similarly, transfection of a dominant negative construct encoding a mutant form 
of STATla in Hep3B cells did not prevent the induction of ICER expression by IFN- 
y (Figure 6.13). While CK2 was implicated in the regulation of STAT1 activity by 
co-transfection experiments (Section 4.3) and by analysis of STAT1 
phosphorylation, the role of CK2 in the expression of ICER, through 
phosphorylation of CREB, may be entirely STAT1-independent. The regulation of 
ICER expression by IFN-y may therefore provide a novel JAK-STAT-independent 
mechanism of IFN-y signalling.
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CHAPTER 7. GENERAL DISCUSSION
7.1 Mechanisms in the  Regulation o f Gene Expression by IFN-y
The pleiotropic cytokine IFN-y was among the first cytokines to be identified and 
the actions and downstream signalling mechanisms of this important 
inflammatory mediator have been extensively studied. Identification of the JAK- 
STAT pathway in relation to IFN-y signalling has provided a paradigm for 
intracellular cytokine-activated signalling pathways. However aspects of IFN-y- 
activated signalling remain unclear in relation to both JAK-STAT-dependent and 
independent mechanisms and warrant further study. IFN-y functions in the 
pathology of a number of diseases (Section 1.3.2) and has a complex role in the 
development of atherosclerosis (Section 1.4.6). The work detailed in this study 
has used several different approaches in order to elucidate novel mechanisms in 
the regulation of gene expression by IFN-y, with particular emphasis on identifying 
potential targets that may be of relevance to the treatment of atherosclerosis. 
The majority of this work was carried out in macrophages as these cells have a 
key role in the pathology of atherosclerosis and are an important target for the 
action of IFN-y. It is hoped that such studies will not only enhance our 
understanding of foam cell formation and atherosclerosis but, in the long term, 
may also lead to the identification of potentially novel targets for therapeutic 
intervention in the disease.
Experiments based around the use of pharmacological inhibitors of potential 
mediators of IFN-y signalling, identified a selective role for PI3K in the regulation 
of the expression of certain genes in response to the cytokine. This was 
subsequently supported through the use of kinase assays, co- 
immunoprecipitation and in studies using dominant negative mutants. The work 
was also extended to the IFN-y-mediated regulation of expression of a wider range 
of genes in macrophages through microarray analysis. In contrast to PI3K, CK2 
was found to have a common role in the IFN-y-mediated regulation of expression 
for all the genes selected for study. This role has also been supported by further 
experimentation. Two genes, MCP-1 and ICER, were chosen for extensive study
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into the mechanisms involved in the induction of expression by IFN-y with the aim 
of identifying pathways that may later be extended to the regulation of other 
genes by the cytokine.
7.1.1 Role of CK2 in IFN^y-mediated regulation of gene expression
The CK2 inhibitor apigenin prevented the IFN-y-mediated induction of all the 
genes initially selected for study (ICER, MCP-1 and SOCS-1) and of those 
subsequently investigated (IP-10, Mig, l-TAC and CCR2). This suggests that CK2 
may have a common role in the regulation of gene expression by IFN-y in 
macrophages. The activation of CK2 is maximal in response to 2h incubation with 
IFN-y consistent with a primary function in the regulation of gene expression 
following stimulation with the cytokine (Mead etal. 2003). Previous studies in our 
laboratory have shown that this response is not attenuated by the 
pharmacological inhibitors of JAK2 and PI3K, AG490 and LY294002 respectively 
(Evans, S., personal communication). The activation of PKB in response to IFN-y 
stimulation was also unaffected by apigenin indicating that distinct pathways 
function in the regulation of PI3K and CK2 activity by IFN-y.
Transfection based assays, in Hep3B cells, confirmed that CK2 is involved in the 
regulation of ICER expression by IFN-y and indicated that CK2 may be involved in 
both the basal and induced expression of MCP-1. An effect of apigenin and a 
dominant negative mutant of CK2 on basal expression can also be seen in some, 
but not all, RT-PCR experiments. CK2 is a constitutively active kinase and it is 
reasonable to suppose that it may have a role in constitutive gene expression. A 
role for CK2 in the regulation of basal transcriptional machinery has also been 
documented, for example in the activity of RNA polymerases II and III (Cabrigos et 
al. 2004, Hu etal. 2003, Llorens etal. 2003, Johnston etal. 2002).
An effect on the activity of STAT1 has also been demonstrated for CK2. Co­
transfection of dominant negative CK2 reduced the IFN-y-induced expression of a 
luciferase reporter construct regulated by tandem GAS elements (3xly6e). 
Apigenin also reduced the phosphorylation of STAT1 on Serine 727, necessary for
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maximal activation. Possibly CK2 has a dual role in the constitutive expression of 
the genes studied and in the IFN-y response. CRE-mediated effects of IFN-y (e.g. 
ICER gene transcription) appear to require CK2 and STATl-mediated responses 
may do also. In addition to cytokine-inducible activation, STAT1 has a role in the 
constitutive regulation of certain genes (Meyer et al. 2002, Chatterjee-Kishore et 
al. 2000). EMSA and ChIP analysis indicated that STAT1 binds constitutively to a 
GAS element in the proximal promoter of the MCP-1 gene, as well as being 
induced by IFN-y, that may maintain a low basal level of expression. CK2 may 
have a role in the constitutive regulation of STAT1 that is increased upon IFN-y- 
mediated activation of the kinase. CK2 is a pleiotropic kinase with a large 
number of identified and potential substrates, and is likely to have diverse roles in 
the regulation of many genes (Meggio and Pinna 2003). The possibility remains 
that CK2 is involved in a different mechanism for each of the genes studied.
7.1.2 Role of PI3K in IFN-y-mediated regulation of gene expression
In contrast to CK2, PI3K appears a have a selective role in the IFN-y-mediated 
regulation of gene expression in macrophages. Of the genes initially selected for 
investigation (MCP-1, SOCS-1 and ICER), the PI3K inhibitor LY294002 inhibited 
the induction of only MCP-1 gene expression by IFN-y. The role of PI3K was 
supported in the regulation of MCP-1 expression through the use of a second 
inhibitor, wortmannin, and a plasmid construct specifying for a dominant negative 
form of the downstream effector of PI3K, PKB.
Extension of this line of experiment to the regulation of global macrophage gene 
expression by IFN-y, through microarray analysis, also indicated a selective role 
for PI3K in these responses. Using a microarray representing genes associated 
with the progression of atherosclerosis, it was found that the expression of 50 of 
these genes was induced by IFN-y, while the expression of 3 was suppressed. The 
genes that were upregulated included a large number of cytokines and 
chemokines. The IFN-y-induced expression of 39 of the genes was inhibited in the 
presence of LY294002. It remains to be determined whether the large proportion 
of atherosclerosis-associated genes for which the regulation by IFN-y was affected 
by the inhibitor could have relevance to the disease and potential therapies.
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The induction of the chemokines IP-10, Mig and l-TAC, and the receptor CCR2 by 
IFN-y was also found to be mediated through a PI3K-dependent pathway. The 
mechanisms behind this selectivity have yet to be identified (discussed below). 
The function of PI3K in the induction of MCP-1 expression by IFN-y has also been 
indicated in ECs opening the possibility that these findings may be extended to 
other cells of the atherosclerotic plaque.
The downstream effector of PI3K, PKB, has been shown in previous studies to be 
activated in response to IFN-y treatment (Nguyen et al. 2001, Hwang et al. 2004, 
Navarro 2003). This was also demonstrated in this study in J774.2 macrophages. 
PKB was found to be involved in the induction of MCP-1 gene expression by IFN-y 
and is likely to act as a downstream effector of PI3K in this response. The 
induction of PKB activity by IFN-y was found to be dependent on JAK2. Co- 
immunoprecipitation experiments demonstrated an interaction between the PI3K 
subunit p85 and JAK2 suggesting that the activation of JAKs by IFN-y may be 
directly responsible for the activation of PI3K and PKB.
Several previous studies implicate the activation of PI3K in the regulation of 
STAT1 by IFN-y (Choudhury 2004, Hwang et al. 2004, Nguyen et al. 2001). This 
was supported, as a potential mechanism in macrophages, by the data 
presented. A dominant negative form of PKB reduced IFN-y-induced expression 
from the luciferase reporter construct 3xly6e and LY294002 inhibited the 
phosphorylation of STAT1 on Serine 727. Choudhury et al. (2004) have also 
presented data showing that LY294002 affected the stimulation of MCP-1 
expression by IFN-y in mesangial cells. They found that LY294002 reduced IFN-y- 
induced phosphorylation of STAT1 at Serine 727 and GAS-activity but that it did 
not affect IFN-y-induced binding to a consensus STAT1 element in vitro. This 
suggests that PI3K regulates the activation potential of STAT1 in a manner that 
does not alter the DNA binding activity. However, although PI3K is involved in the 
activation of STAT1, LY294002 does not inhibit all IFN-y-regulated genes including 
those known to be induced through the JAK-STAT pathway such as SOCS-1.
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An important factor in the selective requirement for PI3K in IFN-y-signalling may 
be in the control of the interaction of STAT1 with other factors such as Spl, shown 
to be inducible by IFN-y. The role of Serine 727 in the activity of STAT1 is unclear 
at present but appears to be involved in the recruitment of coactivators such as 
MCM5 and BRCA1 (Ouchi et al. 2000, Zhang et al. 1998). It is possible that it 
may also function in interactions with other transcription factors including S p l 
either directly or through such coactivators. Such interactions are likely to be 
specific to the regulation of particular genes and potentially mediated by the 
proximity of the appropriate binding sites in the promoter.
Alternatively the selective action of PI3K may be to alter the affinity of STAT1 for 
specific promoter sequences. Naik et al. (1997) have demonstrated that an IFN- 
y-activated STAT1 complex (gamma response factor (GRF)) binds to an element in 
the human ICAM-1 promoter but not to the classical GAS element. Interestingly, 
while dominant negative inhibition of PKB reduced the activation of a GAS- 
regulated promoter by IFN-y, the induction of ICAM-1 in response to the cytokine 
was not affected by the presence of LY294002. This may be due to a similar, 
sequence specific mechanism.
7.1.3 Regulation of MCP-1 gene expression by IFN^y
The expression of MCP-1 has been shown by Gil et al. (2001) to be induced by 
IFN-y in both wild type and STATl-deficient macrophages. However, STAT1 has 
been shown through several independent studies to be involved in the IFN-y- 
mediated upregulation of MCP-1 in a variety of cell types but not in macrophages 
(Zhou et al. 2001, Valente et al. 1998, Zhou et al. 1998). In this study, both 
potential STATl-dependent and -independent pathways in the regulation of MCP- 
1 expresssion by IFN-y were investigated.
Initial work identified a role for CK2 and PI3K through the use of the 
pharmacological inhibitors, apigenin and LY294002. The downstream effector of 
PI3K, PKB was subsequently found to also be necessary for the response 
confirmed with the use of a dominant negative construct. Transfection based
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studies using a dominant negative mutant of CK2a indicated that CK2 may have 
a role in both the constitutive and induced expression of MCP-1. Transfection of a 
dominant negative form of STAT1 inhibited the activation of the MCP-1 promoter 
by 46.5% in comparison to an inhibition of 89% of the GAS regulated construct 
3xly6e. CK2 and PKB dominant negative mutants inhibited the MCP-1 response 
to a similar degree. In contrast, a dominant negative form of JAK2 almost 
completely prevented the activation of the MCP-1 promoter in response to IFN-y 
and dominant negative JAK1 to a slightly lesser extent. It is possible that 
alternative IFN-y signalling pathways for the regulation of MCP-1 expression may 
exist, but that all mechanism are dependent on JAK kinase activity. Both CK2 and 
PI3K were shown to regulate the activity of STAT1 binding activity through the 
phosphorylation of STAT1 at Serine 727, however this does not rule out the 
possibility that one or both of these kinases is also involved in a STAT1- 
independent mechanism.
Promoter binding analysis revealed an increase in STAT1 binding to a GAS 
element of the MCP-1 promoter with IFN-y. However constitutive binding of STAT1 
was also observed. It is possible that CK2 may have a role in the constitutive 
activity of STAT1 and that this is responsible for the reduction in the basal activity 
of the MCP-1 promoter observed in co-transfection studies using dominant 
negative CK2. S p l was also shown to bind constitutively to a GC box in the 
proximal MCP-1 promoter. CK2 has been shown in our laboratory to 
immunoprecipitate with S p l and independent studies have demonstrated the 
phosphorylation of S p l by CK2 (Armstrong et al. 1997, Evans, S., personal 
communication). An IFN-y-inducible interaction was demonstrated between S p l 
and STAT1 and the two factors may co-operate to regulate the expression of MCP- 
1 as previously suggested by Look et al. (1995) in the regulation of ICAM-1. 
Although the phosphorylation of S p l by CK2 has previously been shown to 
decrease S p l binding to the LPL promoter (Hughes et al. 2002, Evans, S., 
personal communication), in the context of the MCP-1 promoter, this may also 
have a role in the IFN-y-inducible interaction with STAT1.
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7.1.4 Regulation of ICER gene expression by IFN^y
The expression of ICER is regulated through an internal promoter of the CREM 
gene (P2) that contains four tandem CRE-like elements known as CAREs. It has 
been shown previously in our laboratory that CK2 is activated by IFN-y and 
subsequently phosphorylates CREB. A luciferase reporter plasmid, pCRELuc, 
regulated by four CRE consensus sites and used to model the ICER promoter, was 
upregulated by IFN-y in U937 cells. This activity was inhibited by the 
overexpression of ICER I. A significant induction was also observed in the 
expression of a reporter gene regulated by a section of the CREM P2 promoter 
containing four CRE-like elements (CAREs). These studies identify CREs as a 
novel class of IFN-y responsive element that merits further investigation.
Thus far CK2 is the only signalling mediator for which a role has been established 
in the regulation of ICER expression by IFN-y. The IFN-y-mediated upregulation of 
ICER is not suppressed by the JAK2 inhibitor AG490 in J774.2 cells or by 
transfection of dominant negative forms of JAK1, JAK2 or STAT1 in Hep3B cells. 
The regulation of ICER expression by IFN-y therefore appears to represent a novel 
JAK-STAT independent signalling mechanism. However, it still remains to rule out 
the possibility that members of the JAK or STAT families of proteins are acting in a 
functionally redundant mechanism in the IFN-y-mediated induction of ICER 
expression. It is currently unclear which other effectors of IFN^ signalling may be 
involved in the regulation of ICER by IFN^y, if any.
7.1.5 Differential pathways in the IFN-y-mediated regulation of gene expression
In course of this study three differential pathways have been identified in the IFN- 
y-mediated regulation of macrophage gene expression. The regulation of the 
expression of the majority of genes by IFN-y appears to be dependent on the 
action of JAKs. The activation of PI3K and PKB is mediated through JAKs and has 
a role in the modulation of STAT1 activity through the phosphorylation of Serine 
727. However an important observation, made in this study and others (Hwang et 
al. 2004), is that not all genes that are regulated by IFN y^ require PI3K for this
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response. This suggests the division of ISGs, as depicted in Figure 7.1, into those 
for which the IFN-y response is “PI3K-dependent” (e.g. MCP-1) and those 
regulated through the classical “JAK-STAT” pathway (e.g. SOCS-1). Initial 
observations indicated an inverse relationship between STAT1- and PI3K- 
dependence in the induction of MCP-1 and SOCS-1 expression by IFN-y based on 
the findings by Gil et al. (2001). However there does not appear to be an obvious 
correlation between PI3K-dependence and STATl-dependence as the 
chemokines Mig and IP-10, the expression of which is regulated by IFN-y in a 
PI3K-dependent manner, have been shown by in the study by Gil et al. (2001) to 
be induced in wild type cells only (Gil et al. 2001, Ramana et al. 2002).
The third pathway is that involved in the stimulation of ICER expression in 
response to IFN-y. This requires the JAK-independent activation of CK2 that leads 
to the phosphorylation and activation of CREB. CREB, or other members of the 
CREB/CREM/ATF-2 subfamily, may also therefore be involved in the expression of 
other genes stimulated by IFN-y. The activation of CK2 may also lead to the 
activation of other transcription factors (e.g. NF-kB, AP-1) involved in the 
regulation of a diverse range of genes. CK2 may function in the constitutive and 
IFN-y-induced expression of many ISGs through regulation of STATl-binding 
potential or interaction with other factors such as Spl. Alternatively, it is possible 
that the role of CK2 in the regulation of the majority of these genes is mediated 
through actions on basal transcriptional machinery such as RNA polymerases 
(Cabrigos etal. 2004, Hu etal. 2003, Llorens etal. 2003, Johnston etal. 2002).
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Other
transcription
factors?
IFN-yR
STATs
e.g.
SOCS-1
e.g.
MCP-1
C K2-dependent PI3K-dependent JAK-STAT
Figure 7.1 Differential pathways in the IFN-y-mediated regulation of gene 
expression
The “CK2-dependent” pathway (red) responsible for the induction of ICER 
expression in response to IFN-y involves the JAK-independent activation of CK2 
leading to the phosphorylation of CREB or a related factor. Other transcription 
factors may also be activated by CK2-dependent phosphorylation and regulate 
the expression of other genes. The “PI3K-dependent” pathway (blue) potentially 
regulates the expression of a number of ISGs including MCP-1. JAK-dependent 
activation of PI3K leads to the activation of PKB and the DNA-binding of STATs. 
CK2 may also have a role in the regulation of these genes. The classical “JAK- 
STAT” pathway (green) illustrated is used to describe a mechanism in which 
STAT1 is activated through JAKs in a PI3K-independent manner, involved in the 
IFN-y-mediated regulation of genes such as SOCS-1. For simplicity, the potential 
role of CK2 in this pathway has been ommitted.
Abbreviations: CK2, casein kinase 2; CREB, CRE-binding protein; ICER, inducible cAMP early 
repressor; IFN-y, interferon-y; IFN-yR, IFN-y receptor; JAK, janus kinase; MCP-1, monocyte 
chemoattractant protein-1; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; SOCS-1, 
suppressor of cytokine signalling-1; STAT, signal transducer and activator of transcription
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7.2 Future W ork
A number of avenues for further investigation are highlighted by the results of this 
study. These can be divided into investigations of the general roles of PI3K and 
CK2 in the regulation of gene expression by IFN-y and the continued in depth 
analysis of the mechanisms involved in MCP-1 and ICER gene expression.
7.2.1 Future investigations of the roles of PI3K and CK2 in the regulation of gene 
expression by IFN-y
The initial stage in a continued investigation of the gene-specific role of PI3K in 
the regulation of IFN-y-mediated gene expression, is to extend the studies via the 
dominant negative approaches used for this work or by isoform specific knock­
down of PI3K subunits or PKB with siRNA. A study of the mechanisms involved in 
the regulation of specific genes or groups of genes, highlighted in this study, by 
IFN-y may help to determine the selective action of PI3K in these responses. In 
particular the regulation of chemokine and chemokine receptor expression by IFN- 
y is of interest due to the important function of these mediators in 
atherosclerosis.
PI3K-dependence may be dictated by the presence of certain elements in the 
promoter of target genes and require interactions such as that between S p l and 
STAT1. IFN-y-inducible interactions between these factors may be mediated 
through the action of PI3K or CK2. Further studies of protein-protein interactions, 
by co-immunoprecipitation or a mammalian two-hybrid assay, could be carried out 
in the presence of inhibitors for these kinases. Glutathione S-transferase (GST)- 
fusion proteins could be used to identify the domains required for interaction. 
The GST domain would be linked to domains of a mediator of interest and the 
fusion protein incubated with treated protein extracts. Complexes could then be 
easily purified and the interacting protein identified.
The function of PI3K and CK2 in the regulation of STAT1 activity should also be 
studied in more detail. PKB may potentially phosphorylate STAT1 at Serine 727
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analysis of the functional interactions between these proteins and demonstration 
of the ability of active PKB to phosphorylate STAT1 in an in vitro Kinase reaction. 
The role of Serine 727 in the regulation of STAT1 activity is unclear at present but 
appears to be involved in the recruitment of coactivators such as MCM5 and 
BRCA1 (Ouchi et al. 2000, Zhang et al. 1998). It is possible that it may also 
function in interactions with other transcription factors including S p l either 
directly or through such coactivators. Expression of a mutant form of STAT1 
lacking the Serine 727 phosphorylation site only partially inhibited the IFN-y- 
stimulated activation of the 3xly6e promoter. Phosphorylation of this site may not 
be required for the activation of all STATl-mediated gene expression. The use of 
a mutant form of STAT1 lacking this phosphorylation site could indicate a 
differential requirement for Serine 727 phosphorylation in the regulation of gene 
expression by IFN-y. Similarly, mice or cells with genetic mutations of this site 
could be generated to investigate these effects. PI3K and PKB may also be 
involved in the activation of STAT1 via the phosphorylation of other regulatory 
sites that are as yet undetermined.
CK2 similarly affected the phosphorylation of STAT1 at Serine 727. Co- 
immunoprecipitation did not show an interaction between CK2 and STAT1 in 
macrophages. This does not rule out the possibility that CK2 is involved in direct 
phosphorylation of STAT1 as this technique may not reveal reactions for which 
dimerisation is unstable or transient. Incubation of recombinant CK2 and STAT1 
in an in vitro kinase reaction could be used demonstrate this action.
The activity of CK2 is regulated in an independent manner to PKB but these 
pathways may converge to regulate a common STATl-kinase responsible for 
phosphorylation at Serine 727. Further studies should aim to identify a putative 
downstream effector. Other pathways that have been linked to the 
phosphorylation of STAT1 at Serine 727 in response to various mediators include 
those dependent on JNK, ERK, p38 and PKC (Kovarik etal. 1999). These kinases 
may also be involved in pathways mediated by PI3K or CK2. Preliminary studies 
have found that the induction of SOCS-1 expression by IFN-y is inhibited in the 
presence of the JNK inhibitor SP600125 (Figure 6.2). The activation of JNK has 
previously been linked to CK2 kinase activity (Hilgard et al. 2004, Riga et al.
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previously been linked to CK2 kinase activity (Hilgard et a/. 2004, Riga et a/. 
2004, Fleming et a/. 2000). Further studies may elucidate a common pathway 
involving these kinases in the cytokine-inducible regulation of STAT1.
The mechanism involved in the IFN-y-stimulated activation of CK2 is 
undetermined. While it has been shown that this response occurs independently 
of JAKs it is likely to require the activation of IFN-yR and the binding of an 
upstream kinase, or CK2 itself, to the receptor. The necessity of IFN-yR should be 
confirmed in cells lacking this receptor. Subsequently, mutational analyses could 
be carried out in order to determine which regions of the receptor are required to 
mediate the activation of CK2 by IFN-y. Co-immunoprecipitation or mammalian 
two-hybrid assays could be used to demonstrate the binding of either CK2 itself or 
putative upstream kinases to IFN-yR. Immunofluorescent staining could allow the 
determination of whether CK2 is recruited to the cell membrane upon stimulation 
with IFN-y. It is unclear whether cytokine-inducible CK2 activity is mediated 
through the phosphorylation and activation of individual subunits of CK2 or by 
promoting assembly of the CK2 heterotetramer. This issue should also be 
addressed in future studies through the use of phospho-peptide mapping of CK2 
subunits and analysing subunit interactions by co-immunoprecipitation and 
mammalian two-hybrid assays.
The common mechanism or mechanisms by which CK2 is involved in the IFN-y- 
inducible regulation of all the genes studied remains to be determined. While the 
activation of CK2 by IFN^y suggests that it does have a role in cytokine-induced 
gene expression, as CK2 is constutitvely active, part of its function may be in the 
maintenance of basal expression for certain genes, as may be the case for MCP- 
1. The effect of a dominant negative form of CK2 on the basal promoter 
expression for other ISGs should therefore be analysed. Genome wide arrays 
could be used to determine the function of CK2 in both basal and IFN-y-mediated 
transcriptional control.
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7.2.2 Future investigations of the mechanisms of the lFN^y-mediated induction of 
MCP-1 and ICER gene expression
One of the initial aims of this study was to investigate the potential role of a 
STATl-independent signalling pathway in the regulation of MCP-1 gene expression 
by IFN-y. Such a mechanism has not thus far been identified. However STAT3 
can also be activated by IFN-y and Ramana et al. (2005) have recently 
demonstrated that STAT3 may function in place of STAT1 in STATl-deficient cells, 
at least for the regulation of SOCS-3 expression (Ramana et al. 2005, Qing et a/. 
2004). This may explain the finding of Gil et al. (2001) that the induction of MCP- 
1 expression by IFN-y is unaffected in STATl-null macrophages while in the 
cellular systems used in this study and others, STAT1 has been shown to be 
required. While in STAT1 knock-out cells STAT3 may act in place of STAT1, a 
dominant negative inhibitor such as that used here may also sequester active 
STAT3 through heterodimerisation and hence attenuate the response to IFN-y 
(Ramana et al. 2005, Qing et al. 2004). Transfection based studies utilising a 
dominant negative mutant of STAT3, available in the laboratory, should help to 
resolve this issue.
Alternatively promoter elements in regions outside that studied (213bp upstream 
of transcriptional start site) may be involved in a STATl-independent response. 
The role of putative NF-k B and C/EBP-p binding sites in the distal MCP-1 promoter 
is worthy of investigation, particularly as IFN-y was shown to mediate a significant 
induction in the expression of a reporter gene regulated by consensus NF-k B and 
C/EBP-p binding elements. Other components of PI3K-dependent and CK2- 
dependent pathways in the IFN-y-mediated induction of MCP-1 expression may 
also be identified through the use of pharmacological inhibitors, dominant 
negative and siRNA based approaches, kinase activity assays, promoter 
dissection, EMSA and ChIP analysis.
The regulation of ICER expression by IFN-y is of particular interest as it represents 
a potentially novel mechanism of signalling in IFN-y-mediated responses. Initial 
studies should be performed in cells lacking functional JAK1, JAK2 and JAK3 in
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order to assess the possibility that these kinases are acting in a redundant 
manner in the regulation of ICER expression and CK2 activation by IFN-y. A 
functional dissection of the ICER promoter should be carried out to identify 
binding sites for other transcription factors that may be involved in the IFN-y 
response. EMSA and ChIP analysis could be used to confirm the binding of CREB, 
or related family members, to the region containing tandem CAREs and to show 
whether this is inhibited in the presence of apigenin. As CREB is likely to be 
phosphorylated directly by CK2 (Meggio and Pinna 2003) co-immunoprecipitation 
could be used to demonstrate an IFN-y-inducible interaction between these 
proteins. The domains required for interaction could subsequently be studied 
through the use of ‘pull-down’ assays with GST-fusion proteins. If an interaction 
were shown, in vitro kinase assays should be carried out using CREB as a 
substrate for CK2. The experiments detailed have so far failed to reveal 
components of this signalling pathway in addition to CK2. Future studies will aim 
to identify such components through the use of pharmacological inhibitors, 
dominant negative and siRNA based approaches and kinase activity assays.
7.3 Implications fo r  th e  Treatm ent o f  A therosclerosis
The chemokine MCP-1 is a proatherogenic factor (Section 1.6) and represents a 
good therapeutic target for the treatment of atherosclerosis. Previous studies 
have demonstrated that transfection of a N-terminal deletion mutant of the MCP- 
1 gene (7ND) in apoE-null mice inhibits both lesion formation and the progression 
of existing lesions, as well as increasing plaque stability (Inoue etal. 2002, Ni et 
al. 2001). The broad based inhibition of the action of chemokines has also been 
investigated as a potential treatment for inflammatory disease with some success 
(Johnson et al. 2004, Grainger and Reckless 2003). The findings in this study 
may highlight further mechanisms by which the inflammatory effects of MCP-1 
may be reduced.
The identification of a common PI3K-dependent pathway in the regulation of 
chemokine expression by IFN-y in macrophages suggests a beneficial, 
atheroprotective effect to the specific inhibition of PI3K signalling or the 
downstream effector PKB. This pathway may also function in ECs, which are
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important in the production and secretion of chemokines in inflammation. PI3K- 
dependent signalling mechanisms are often activated in response to chemokine 
stimulation, and as such, the inhibition of PI3K activity has previously been 
suggested as a potential therapeutic strategy in inflammatory disease (Johnson et 
al. 2004) In LDL-R-null mouse models of atherosclerosis, deficiency in the PI3K 
subunit p l l0 8  in bone marrow transplants, has been found to abrogate the 
development of the disease (Pinderski et al. 2005). Therapeutic strategies have 
been investigated for the treatment of certain tumors that involve the inhibition of 
PI3K-dependent signalling (Berrie 2001) and it is possible that these may be 
applied in atherosclerosis. The requirement of CK2 in IFN-y-stimulated responses 
indicates that signalling through this kinase may also provide a target for 
therapeutic intervention in atherosclerosis. The dominant negative inhibition of 
CK2 activity has been shown to reduce the progression of the inflammatory 
disease glomerulonephritis in rats and similar mechanisms may operate in the 
pathology of atherosclerosis (Yamada etal. 2005).
Both CK2 and PI3K are important biological mediators with a diverse range of 
actions in normal cellular function. In particular, the multitude of actions and 
targets of CK2 have yet to be studied comprehensively. PI3K also has beneficial 
effects on the development of diabetes (Cho et al. 2001, Shepherd et al. 1998). 
Direct inhibition of these kinases therefore, while a promising therapeutic 
strategy, is likely to affect a number of cellular systems. However the studies 
reported may lead to the identification of factors that are specific to the 
inflammatory pathways that are exacerbated in atherosclerosis and as such 
provide good targets for therapeutic intervention.
From the work presented in this thesis it is clear that the regulation of gene 
expression by IFN-y in macrophages is dependent on several signalling pathways. 
IFN-y-dependent signalling and the target genes studied have important functions 
in the pathogenesis of atherosclerosis. A complete understanding of the 
molecular mechanisms involved will hopefully lead to the development of new 
therapeutic strategies to combat this disease.
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APPENDIX II
DNA and protein molecular weight markers
NEB lOObp ladder Invitrogen lk b  ladder Gibco lkb  plus ladder
Base Pairs DMA Mass
-1,917
(nfl)
45
-1200 35
-1,000 95
- 900 27
- 800 24
- 700 21
- 600 18
- 500/517 97
- 400 38
- 300 29
-  200 25
- 100 48
bp
| r - 1 2 , 2 1  6
=±_1 1 .1 98
—  6 1 0 3
—  5C 9 3
—  4C 72
—  3C 54
—  2 0 3 5  
— 1 6 3 5
 1 Cl  8
—  0 0 5 , 5 1  7 
 396
—  3 4 4  
293
223  
201 
l 54  
134  
75
i£ d £19162
‘ 114 47126
Hinf  I f r ag men ts  
of  tne v e c to r
bp
12,000
5.000
z.ooo
1,650-
1,000
830
650
300
■100
300
200
100
1.3% agarose gel 
0.5pg/lane  
Cat No. N 3231S/N 3231L
0.9% agarose gel 
0.5pg/lane  
Cat No. 15615-016
0.9% agarose gel 
0.9pg/lane  
Cat No. 10787-018
Amersham Full-Range Rainbow™ 
Molecular Weight Markers
2 5 0
1 6 0
1 0 5
75
50
35
30
25
15
10
12% SDS-PAGE gel
\is \ nn\ionn
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APPENDIX 111
Sequence of ICER 4xCARE insert in the pGL2-Promoter vector
GL1[T GTATCTTATGGTACT GTAACT GA1GCTAACATAACCCGGGTTT CAGT GAGCT GCACATT GATGGCAGT GA 
TAGGCTGGTGACGTCACTGTGATGTCAGTGCTCCTCGAGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGT 
AAAA[T GGAAGACGCCAAAAACATAAAGAAJGL2
APPENDIX IV
t-Test
Mean 1 = lc± Standard deviation 1 = o i
Mean 2 = *2 Standard deviation 2 = 02
Variance = od2
2 2 
t  -  t71 +  172& d  ^ ------
n l n 2
t
t-Table
A difference between two means is significant (at the given probability level) if the 
calculated t value is greater than the value given in this table. A probability of p = 
0.05 (95% probability of making a correct statement) is usually acceptable for 
biological work.
When comparing two means, the number of degrees of freedom is (ni + n2)-2, 
where ni is the number of replicates of treatment 1, and n2 is the number of 
replicates of treatment 2 (adapted from
http://helios.bto.ed.ac. uk/bto/statistics/tress4a.html#Student's%20t-tesD.
¥
P-Value 0 .1 0 .05 0 .01 0 .0 0 1
1 6.31 12.71 63 .66 6 36 .62
2 2.92 4 .30 9 .93 3 1 .6 0
3 2.35 3 .18 5 .84 12.92
4 2.13 2 .78 4 .60 8 .61
5 2.02 2.57 4 .03 6 .87
6 1.94 2 .45 3 .71 5.96
7 1.89 2 3 7 3 .50 5 .41
8 1 .86 2.3JL 3 .36 5.04
9 1.83 2 .26 3 .25 4 .78
10  1 .81  2 .2 3  3 .17  4 .59
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APPENDIX V 
Layout of gene specific oligonucleotides in the Oligo GEArray™ Mouse 
Atherosclerosis Microarray
Gapdh A bcal Ace Adfp Apoal Apoa2 Apoa4 Apob
1 2 3 4 5 6 7 8
Apoe Bax Bcl2 Bel 2a la B cl2ll Bid Birc3 Cel 11
9 10 11 12 13 14 15 16
Ccl2 Ccl20 Ccl5 C crl Ccr2 Cd36 Cd44 Cdh5
17 18 19 20 21 22 23 24
Cflar C ol3a l Csfl Csf2 Csf3 Ctgf Cxcll Hbegf
25 26 27 28 29 30 31 32
Egrl Eln Eng F7 Fabp3 Fga Fgb Fgf2
33 3 4 35 36 37 38 39 40
F n l lea m l Icam2 Ifnar2 Ifng 1110 1113 Ilia
41 42 4 3 4 4 4 5 4 6 47 48
lllb l l l r l Illr2 l l l r l l 112 113 114 115
49 50 51 52 53 54 55 56
116 117 Itga2 Itga5 Itgax Itgb2 Itgb3 Itgb5
57 58 59 6 0 61 62 63 64
Itgb7 Kdr Klf2 L am al Lcat Ldlr Lif Lpl
65 66 67 68 6 9 70 71 72
Lyplal M m p l3 M m pla Mmp3 Mmp9 M srl N fkbl Npy
73 74 75 76 77 78 79 80
N rlh3 O lrl Pdgfa Pdgfb Pdgfrb Ppara Ppard Pparg
81 82 83 84 85 86 87 88
Ptgsl Ptgs2 Rxra Scarbl Sele Sell Selp Selpl
89 90 91 92 93 94 95 96
Serpinb2 Serpinel Snn Soat2 S od l Sod 2 Sppl Tgfbl
97 98 99 100 101 102 103 104
Tgfb2 Tgfb3 Thbs4 Tnc Tnf Tnfaip3 Fas Vcam l
105 106 107 108 109 110 111 112
Vegfa Vwf PUC18 Blank Blank AS1R2 AS1R1 AS1
113 114 115 116 117 118 119 120
Rps27a B2m Hspcb Hspcb Ppia Ppia BAS2C BAS2C
121 122 123 124 125 126 127 128
Appendix
Function of genes in the Oligo GEArray™ Mouse Atherosclerosis Microarray 
(adapted from http://superarrav.com/genetable.php?pcatn=QMM-038)
1 NM _008084 Gapdh Glyceraldehyde-3-
phosphate
dehydrogenase
Oxidoreductase
activity;Mitochondrion;Glyceraldehyde-3-phosphate 
dehydrogenase (phosphorylating) activity;Glucose 
metabolism;Glycolysis;Glyceraldehyde-3-phosphate 
dehydrogenase activity;
2 NM_013454 Abcal ATP-binding 
cassette, sub-family 
A (ABC1), member 1
ATP binding Integral to 
membrane;Membrane;lntegral to plasma 
membrane;Transpo rt; Cholesterol 
metabolism;Cholesterol transport Lipoprotein 
biosynthesis;
3 NM_009598 Ace Angiotensin 
converting enzyme
Hydrolase activity;Integral to membrane;Proteolysis 
and peptidolysis;Zinc ion 
bindingMembrane;Extracellular 
space; Metallopeptidase activity; Carboxypeptidase 
activity; Peptidyl-di peptidase A activity;
4 NM_007408 Adfp Adipose 
differentiation 
related protein
Plasma membrane;Nucleus;Protein 
bindingMembrane;Longchain fatty acid 
transport Lipid particle; Lipid storage;
5 N M .009692 Apoal Apolipoprotein A-l Protein bindingExtracellular space;Lipid transporter 
activity;Regulation of cholesterol absorption;
6 NM_013474 Apoa2 Apolipoprotein A-ll Extracellular space;TransportLipid transporter 
activity;Lipid transport;Regulation of cholesterol 
absorption;Lipid bindingLipoprotein 
metabolism;Extracellular region;
7 NM_007468 Apoa4 Apolipoprotein A-IV Extracellular;Extracellular space;Lipid transporter 
activity;Lipid transport;Regulation of cholesterol 
absorption;Lipid bindingLipoprotein metabolism;
8 XM_137955 Apob Apolipoprotein B Endoplasmic reticulum;Microsome;Lipid 
metabolism; Cholesterol transportTriacylglycerol 
mobilization;
9 N M .009696 Apoe Apolipoprotein E Extracellular; Extracellular space;Heparin 
bindingLipid transporter activity;Lipid 
transport Lipid bindingLipoprotein metabolism;
10 NM_007527 Bax Bcl2-associated X 
protein
Integral to membrane;Protein bindingApoptotic 
mitochondrial changes;Induction of 
apoptosis;Regulation of 
apoptosis;Apoptosis;lnduction of apoptosis by 
extracellular signals;Mitochondrial outer 
membrane;Cytosol;Response to woundinglnduction 
of apoptosis by intracellular signals;Caspase 
activation via cytochrome c;Release of cytochrome 
c from mitochondria;Response to DNA damage 
stimulus;Protein homooligomerization 
activity;Insertion of proteins into mitochondrial 
membranes during the induction of 
apoptosis;Negative regulation of fibroblast 
proliferation;Nuclear fragmentation;Regulation of
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A p p e n d ix
caspase activation;
11 N M _009741 Bcl2 B-cell
leukemia/lymphoma
2
Integral to membrane.Protein bindingRegulation of 
a poptosis; Apoptosis;Anti- 
apoptosis;Mitochondrion;Cytosol;Membrane;
12 N M _009742 Be 12a la B-cell
leukemia/lymphoma 
2 related protein 
A id
Regulation of apoptosis;Apoptosis;
13 N M _009743 B cl2ll RIKEN cDNA 
A 630035D 09 gene
Integral to membrane;Protein bindingRegulation of 
apoptosis;Apoptosis;Anti-
apoptosis;Mitochondrion;Membrane;Response to 
radiation;Negative regulation of apoptosis;
14 N M _007544 Bid BH3 interacting 
domain death 
agonist
Regulation of a poptosis; Apoptosis;
15 N M _007464 Birc3 Baculoviral IAP 
repeat-containing 3
Protein binding;Regulation of 
apoptosis;Apoptosis;Anti-apoptosis;Zinc ion 
bindingUbiquitin-protein ligase activity;Protein 
ubiquitination;Ubiquitin ligase complex;lntracellular;
16 N M _011330 C c l l l Small chemokine (C- 
C motif) ligand 11
Signal transduction;Extracellular;lmmune 
response;lnflammatory response;Extracellular 
space;Chemokine activity;Chemotaxis;Cytokine 
activity;
17 N M _011333 Cel 2 Chemokine (C-C 
motif) ligand 2
Signal transduction;Extracellular;lmmune 
response;Protein bindinglnflammatory 
response.Extracellular space;Chemokine 
activity; Chemotaxis;Cytokine activity; G-protein- 
coupled receptor binding
18 N M _016960 Ccl20 Chemokine (C-C 
motif) ligand 20
Signal transduction;Extracellular;lmmune 
response;Protein bindinglnflammatory 
response;Extracellular space;Chemokine 
activity;Chemotaxis;Cytokine activity;
19 NM _013653 Cel 5 Chemokine (C-C 
motif) ligand 5
Signal transduction;Extracellular;lmmune 
response; Inflammatory response;Extracellular 
space;Chemokine activity;Chemotaxis;Cytokine 
activity;
20 N M _009912 C crl Chemokine (C-C 
motif) receptor 1
Integral to membrane;Protein bindinglnflammatory 
response;G-protein coupled receptor protein 
signaling pathway;Receptor activity;Rhodopsin-Iike 
receptor activity.lmmune cell chemotaxis;C-C 
chemokine receptor activity;G-protein coupled 
receptor activity.Neuropeptide Y receptor 
activity;Purinergic nucleotide receptor activity, G- 
protein coupled;Myeloid blood cell differentiation;
21 N M _009915 Ccr2 Chemokine (C-C 
motif) receptor 2
Integral to membrane;lmmune response;Protein 
bindingHumoral immune response;Inflammatory 
response;G-protein coupled receptor protein 
signaling pathway;Chemotaxis;Defense 
response;Rhodopsin-like receptor 
activity;Hemopoiesis;C-C chemokine receptor 
activity;G-protein coupled receptor activity;Cytokine 
bindingCellular defense response (sensu 
Vertebrata); Perception of pain.Regulation of cell
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migration;
22 N M _007643 Cd36 CD36 antigen Plasma membrane;lntegral to membrane;Cell 
adhesion;Protein bindingReceptor 
activity;Membrane;Transport;
23 M 2 7 1 3 0 Cd44 CD44 antigen Integral to membrane;Cell adhesion;Protein 
binding Receptor activity;Membrane;Hyaluronic 
acid binding External side of plasma 
membrane;Ureteric bud branching
24 N M _009868 Cdh5 Cadherin 5 Integral to membrane;Calcium ion bindingCell 
adhesion;Protein bindingHomophilic cell 
adhesion;Membrane;Extracellular space;
25 N M _009805 Cflar CASP8 and FADD- 
like apoptosis 
regulator
Proteolysis and peptidolysis;Protein 
binding Induction of a poptosis; Regulation of 
apoptosis,Apoptosis.Caspase activity,
26 N M _009930 Col 3a 1 Procollagen, type III, 
alpha 1
Cell adhesion;Cytoplasm;Extracellular matrix 
structural constituent Phosphate 
transportCollagen;Extracellular matrix structural 
constituent conferring tensile strength;Extracellular 
matrix (sensu Metazoa);
27 N M _007778 Csfl Colony stimulating 
factor 1 
(macrophage)
Integral to membrane;Cell growth and/or 
maintenance;Extracellular space;Growth factor 
activity;Cytokine activity;Positive regulation of body 
size.Positive regulation of odontogenesis (sensu 
Vertebrata);Regulation of ossification;
28 NM _009969 Csf2 Colony stimulating 
factor 2 
(granulocyte- 
macrophage)
Extracellular;!mmune response;Extracellular 
space;Growth factor activity;Cytokine and 
chemokine mediated signaling pathway;Cytokine 
activity;Granulocyte macrophage colony-stimulating 
factor receptor bindingDendritic cell differentiation;
29 N M _009971 Csf3 Colony stimulating 
factor 3 
(granulocyte)
Extracellular;lmmune response;Extracellular 
space;Growth factor activity;Cytokine activity;
30 NM _010217 Ctgf Connective tissue 
growth factor
Cell adhesion;Regulation of cell 
growth;Extracellular;Protein bindingCell-matrix 
adhesion;Extracellular space;Heparin bindingCell 
migration;lntegrin-mediated signaling pathway;Cell 
differentiation;Angiogenesis;lnsulin-like growth 
factor bindingDNA metabolism;Fibroblast growth 
factor receptor signaling pathway;Integrin 
bi nd ing Ossification; Ca rti lage 
condensation;Extracellular matrix (sensu Metazoa);
31 NM _008176 Cxcll Chemokine (C-X-C 
motif) ligand 1
Extracellular;!mmune response;Cell growth and/or 
maintenance;Regulation of cell cycle;lnflammatory 
response;lntracellular; Extracellular space;Growth 
factor activity;Chemokine activity;Cytokine activity;
32 N M _010415 Hbegf Heparin-binding 
EGF-like growth 
factor
Integral to membrane;Extracellular space;Epidermal 
growth factor receptor signaling pathway;Heparin 
bindingGrowth factor activity;Regulation of heart 
contraction rate;
33 N M _007913 Egrl Early growth 
response 1
Nucleic acid bindingDNA bindingRegulation of 
transcription, DNA-
dependent.Nucleus,Transcription factor activity;Zinc
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ion bindingThymocyte differentiation;
34 N M _007925 Eln Elastin Structural molecule activity;Extracellular matrix 
structu ra 1 constituent; Myogenesis; Extracell ula r 
matrix (sensu Metazoa);Regulation of actin filament 
polymerization;Stress fiber formation;
35 N M _007932 Eng Endoglin Integral to membrane;Cell adhesion;Protein 
bindingExtracellular 
space;Angiogenesis;BindingHeart 
development;Regulation of transforming growth 
factor beta receptor signaling pathway;
36 NM JD10172 F7 Coagulation factor 
VII
Hydrolase activity;Calcium ion bindingProteolysis 
and peptidolysis;Oxidoreductase 
activity; Extracellular space;Metabolism;Blood 
coagulation;Chymotrypsin activity;Trypsin 
activity;Serine-type endopeptidase 
activity;Extracellular region;Coagulation factor Vila 
activity;
37 N M _010174 Fabp3 Fatty acid binding 
protein 3, muscle 
and heart
Transporter activity;Transport; Binding Lipid binding
38 N M _010196 Fga Fibrinogen, alpha 
polypeptide
Extracellular space;
39 N M _181849 Fgb Fibrinogen, B beta 
polypeptide
Extracellular space;Blood coagulation;
40 N M _008006 Fgf2 Fibroblast growth 
factor 2
Cell proliferation;Signal transduction;Protein 
bindingRegulation of cell cycle;Extracellular 
space.Heparin bindingGrowth factor 
activity;Angiogenesis;Positive regulation of cell 
differentiation;Regulation of retinal programmed 
cell death;Glial cell differentiation;Fibroblast growth 
factor receptor binding;
41 NM _01 0233 F n l Fibronectin 1 Cell adhesion;Extracellular;Protein 
bindingOxidoreductase activity; Extracellular 
space;Heparin bindingAcute-phase 
res ponse;Metabolism;Cell-substrate junction 
assembly;Wound healing Extracellular matrix 
(sensu Metazoa);
42 NM _010493 Icam l H I  histone family, 
member 0
Plasma membrane;lntegral to membrane;Cell 
adhesion;Protein bindingMembrane;Cell-cell 
adhesion;Defense response;
43 NM _010494 Icam2 Intercellular 
adhesion molecule 
2
Integral to membrane;Cell adhesion;Protein 
bindingMembrane;Cell-cell adhesion;Integral to 
plasma membrane;Uropod;
44 NM _010509 Ifnar2 Interferon (alpha 
and beta) receptor 2
Integral to membrane;Cell proliferation;Regulation 
of transcription from Pol II promoter;Receptor 
activity;Membrane;Extracellular 
space;Hematopoietin/interferon-class (D200- 
domain) cytokine receptor activity; Interferon- 
alpha/beta receptor activity;
45 N M _008337 Ifng Interferon gamma Regulation of cell growth;Extracellular;lmmune 
response;Transcriptional activator 
activity;Extracellular space; Defense 
response;Regulation of transcription;Cytokine 
activity; Interferon-gamma receptor
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bindingNeutrophil chemotaxis;Positive regulation 
of transcription, DNA-dependent;Positive regulation 
of MHC class II biosynthesis;Positive regulation of 
isotype switching to IgG isotypes;Regulation of 
immune response;Programmed cell death, 
neutrophils;Positive regulation of interleukin-12 
biosynthesis;Positive regulation of interleukin-6 
biosynthesis;Positive regulation of chemokine 
biosynthesis;Positive regulation of interleukin-1 
beta secretion;Programmed cell death, 
inflammatory cells;
46 N M _010548 1110 Interleukin 10 Extrace 11 ula r; 1 m mu ne response; Extracel 1 u 1 a r 
space;Cytokine activity;Positive regulation of MHC 
class II biosynthesis;
47 N M _008355 1113 Interleukin 13 Extracel 1 ular; 1 m mune response; Extracel 1 ula r 
space; Cytokine activity; Interleu kin-13 receptor 
bindingHematopoietin/interferon-class (D200- 
domain) cytokine receptor binding
48 NM _010554 Ilia Interleukin 1 alpha Cell proliferation;Extracellular;lmmune 
response;Regulation of cell cycle;lnflammatory 
response;Signal transducer activity;Growth factor 
activity; Interleu kin-1 receptor bindingCytokine and 
chemokine mediated signaling pathway;Cytokine 
activity;
49 NM _008361 lllb Interleukin 1 beta Cell proliferation;Extracellular;lmmune 
response.Regulation of cell cycle;lnfiammatory 
response;Signal transducer activity;Growth factor 
activity; Interleu kin-1 receptor bindingCytokine and 
chemokine mediated signaling pathway;Cytokine 
activity;Neutrophil chemotaxis;Positive regulation of 
interleukin-6 biosynthesis;Positive regulation of 
chemokine biosynthesis;
50 N M _008362 l l l r l Interleukin 1 
receptor, type 1
Integral to membrane;Signal transducer activity;Cell 
surface receptor linked signal 
tra nsduction; Receptor activity; Membra ne; 1 ntegra 1 
to plasma membrane;Extracellular 
space;Transmembrane receptor activity; Interleu kin- 
1, Type 1, activating receptor activity,Cytokine and 
chemokine mediated signaling pathway; Inter leu kin- 
1 receptor activity;lnterleukin receptor activity;
51 NM_010555 Illr2 Interleukin 1 
receptor, type II
ATP binding Integral to membrane;Cell surface 
receptor linked signal transduction;Receptor 
activity;Membrane;Integral to plasma 
membrane;Extracellular space; Interleu kin-1, Type II, 
blocking receptor activity;Transport;ATP-binding 
cassette (ABC) transporter activity;lnterleukin-1 
receptor activity; Interleu kin receptor activity;
52 NM_010743 l l l r l l Interleukin 1 
receptor-like 1
Plasma membrane;lntegral to membrane;DNA 
bindingDNA methylation.Receptor 
activity;Membrane;Extracellular 
space;Transmembrane receptor activity;Defense 
response; Interleu kin-1 receptor activity; N- 
methyltransferase activity;
53 N M _008366 112 Interleukin 2 Cell proliferation;Extracellular;lmmune 
response; 1 nfla mmatory response; Extracel 1 u lar
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space;Growth factor activity; Hormone
activity;Defense response;Cytokine activity;Cellular
defense response; Interleu kin-2 receptor binding
54 N M _01 0556 113 Interleukin 3 Extracellular;lmmune response;Extracellular 
space;Growth factor activity;Cytokine 
activity; Interleu kin-3 receptor binding
55 N M _021283 114 Interleukin 4 Extracellular;lmmune response;Extracellular 
space;Growth factor activity;Cytokine 
activity; Interleu kin-4 receptor 
bindingHematopoietin/interferon-class (D200- 
domain) cytokine receptor binding B-cell 
activation;Negative regulation of osteoclast 
differentiation;Positive regulation of MHC class II 
biosynthesis;Positive regulation of isotype switching 
to IgG isotypes;Regulation of immune 
response;Regulation of phosphorylation;
56 N M _010558 115 Interleukin 5 Extracellular;lmmune response;Extracellular 
space.Growth factor activity;Cytokine 
activity; Interleu kin-5 receptor binding
57 N M _031168 116 Interleukin 6 Extracellular.lmmune response.Protein 
binding Extracellular space;Aeute-phase 
response;Growth factor activity;Cytokine 
activity; Interleu kin-6 receptor bindingNegative 
regulation of chemokine biosynthesis;Programmed 
cell death, neutrophils;
58 N M _008371 117 Interleukin 7 Extracellular;lmmune response;Growth factor 
activity;Positive regulation of T-cell 
differentiation;Cytokine activity;lnterleukin-7 
receptor bindingHematopoietin/interferon-class 
(D20O<Jomain) cytokine receptor binding Bone 
resorption;Positive regulation of B-cell proliferation;
59 N M _008396 Itga2 Integrin alpha 2 Integral to membrane;Cell adhesion;Protein 
binding Receptor activity;Cell-matrix 
adhesion;Extracellular space.lntegrin-mediated 
signaling pathway;Integrin complex;Magnesium ion 
binding
60 N M _010577 Itga5 Integrin alpha 5 
(fibronectin receptor 
alpha)
Integral to membrane;Cell adhesion;Protein 
binding Receptor activity; Cel l-matrix 
adhesion;Extracellular space;lntegrin-mediated 
signaling pathway;!ntegrin complex;Cell-substrate 
junction assembly;Synaptosome;Memory;
61 NM _021334 Itgax Integrin alpha X Integral to membrane;Cell adhesion;Protein 
binding Receptor activity; Cel l-matrix 
adhesion;lntegrin-mediated signaling 
pathway;!ntegrin complex;Magnesium ion 
binding External side of plasma membrane;
62 NM _008404 Itgb2 Integrin beta 2 Integral to membrane;Cell adhesion;Protein 
bi nd i ng Development; Receptor activity; Cel l-matrix 
adhesion;Extracellular space;Integrin-mediated 
signaling pathway;Integrin complex;Neutrophil 
chemotaxis;Cellular extravasation;
63 NM_016780 Itgb3 Integrin beta 3 Integral to membrane;Cell adhesion;Protein 
bindingOxidoreductase activity;Receptor
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activity; Cel l-matrix adhesion;Extracellular 
space;Metabolism;lntegrin-mediated signaling 
pathway;Integrin complex;Cell-substrate junction 
assembly;External side of plasma membrane;
64 N M _010580 Itgb5 Integrin beta 5 Integral to membrane;Cell adhesion;Protein 
bindingDevelopment;Receptor activity;Cel l-matrix 
adhesion;Extracellular space;lntegrin-mediated 
signaling pathway;Integrin complex;
65 NM _013566 Itgb7 Integrin beta 7 Integral to membrane;Cell adhesion;Protein 
binding Receptor activity;Cell-matrix 
adhesion;Extracellular space;Electron 
transport'lntegrin-mediated signaling 
pathway;Integrin complex;Electron carrier activity;
66 N M _010612 Kdr Kinase insert 
domain protein 
receptor
ATP bindingTransferase activity;Protein amino acid 
phosphorylation integral to membrane; Protein 
serine/threonine kinase activity;Protein-tyrosine 
kinase activity;Receptor activity;Transmembrane 
receptor protein tyrosine kinase 
activity;Membrane;Protein kinase 
activity; Extracellular space;Transmembrane 
receptor protein tyrosine kinase signaling 
pathway;Kinase activity;Vascular endothelial growth 
factor receptor activity;Angiogenesis;Cell fate 
commitment;Endothelial cell differentiation;
67 N M _008452 Klf2 Kruppel-like factor 2 
(lung)
Nucleic acid bindingDNA bindingRegulation of 
transcription, DNA-
dependent;Nucleus;Transcription factor activity;Zinc 
ion bindingPositive regulation of 
transcription;Transcription regulator activity;
68 N M _008480 Lam al Laminin, alpha 1 Receptor bindingStructural molecule activity;Cell 
adhesion;Protein bindingCell surface receptor 
linked signal transduction;Extracellular matrix 
structural constituent;Regulation of cell 
adhesion;Regulation of cell 
migration;Morphogenesis of an epithelial 
sheet;Basal lamina;Basement 
membrane;Histogenesis;Extracellular matrix (sensu 
Metazoa);Regulation of embryonic 
development; Laminin-1;
69 N M _008490 Lcat Lecithin cholesterol 
acyltransferase
Transferase activity;Extracellular space;Lipid 
meta bol ism; Cholesterol 
metabolism;Acyltransferase activity;Catalytic 
activity;Phosphatidylcholine-sterol O-acyltransferase 
activity;
70 NM_010700 Ldlr Low density 
lipoprotein receptor
Integral to membrane;Calcium ion bindingProtein 
bindingReceptor activity;Membrane;Extracellular 
space; Endosome; Cholesterol 
metabolism;Endocytosis;Lipid transporter 
activity;Lipid transport;Low-density lipoprotein 
receptor activity;Coated pit; Cholesterol 
homeostasis;
71 N M _008501 Lif Leukemia inhibitory 
factor
Extracellular;lmmune response;Extracellular 
space;Growth factor activity;Cytokine 
activity.Leukemia inhibitory factor receptor binding;
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72 N M _008509 Lpl Lipoprotein lipase Hydrolase activity;Extracellular space.Heparin 
bindingLipid metabolism;Lipid transporter 
activity;Catalytic activity;Lipid 
catabolism.Lipoprotein lipase activity;
73 N M _008866 Lyplal Lysophosphol i pase 
1
Hyd rolase activity;M itochond rion; Li pid 
metabolism;Fatty acid metabolism;Catalytic 
activity;Lysophospholipase activity;
74 N M _008607 M m p l3 Matrix
metalloproteinase
13
Hydrolase activity;Calcium ion bindingProteolysis
and peptidolysis;Zinc ion bindinglnterstitial
collagenase activity;Collagen
catabolism;Extracellular
space; Meta 1 loendopeptidase
activity; Meta llopeptidase activity; Extracellular
matrix (sensu Metazoa);
75 N M _032006 M m pla Matrix
metalloproteinase 
la  (interstitial 
collagenase)
Collagenase activity;
76 NM _010809 Mmp3 Matrix
metalloproteinase 3
Hydrolase activity;Calcium ion 
binding Extracellular; Proteolysis and 
peptidolysis;Zinc ion binding Collagen 
catabolism;Extracellular 
space; Meta 1 loendopeptidase 
activity;Metallopeptidase activity; Stromelysin 1 
activity;Extracellular matrix (sensu Metazoa);
77 NM _013599 Mmp9 Matrix
metalloproteinase 9
Hydrolase activity;Proteolysis and peptidolysis;Zinc 
ion bindingCollagen catabolism;Extracellular 
space; Metalloendopeptidase 
activity;Metallopeptidase activity;Gelatinase B 
activity;Extracellular matrix (sensu Metazoa);
78 N M _031195 M srl Macrophage 
scavenger receptor 
1
Integral to membrane;Cytoplasm;Receptor 
activity;Membrane;Scavenger receptor 
activity;Receptor mediated
endocytosis; Endocytosis; Phosphate transport; Li pid 
transporter activity;
79 N M _008689 N fkbl Ubiquitin-
conjugating enzyme 
E2D 3 (UBC4/5 
homolog yeast)
Signal transduction;DNA bindingRegulation of 
transcription, DNA-dependent;Nucleus;Protein 
bindingApoptosis;Transcription factor 
activity;Lymph gland development;Specific 
transcriptional repressor activity;Negative 
regulation of interleukin-12 biosynthesis;Negative 
regulation of transcription, DNA-dependent;
80 N M _023456 Npy Neuropeptide Y Extracellular;Extracellular space;Hormone activity;G- 
protein-coupled receptor bindingRegulation of 
blood pressure;Neuropeptide signaling pathway;
81 NM _013839 N rlh3 Nuclear receptor 
subfamily 1, group 
H, member 3
DNA bindingRegulation of transcription, DNA- 
dependent; N ucleus; Electron transporter 
activity;Transcription factor activity;Receptor 
activity;Electron transport;Copper ion 
bindingSteroid hormone receptor activity,Ligand- 
dependent nuclear receptor activity;Transcription 
regulator activity,Negative regulation of 
transcription;
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82 NM_13 8 6 4 8 01 n Oxidized low density 
lipoprotein (lectin­
like) receptor 1
Integral to membrane;Receptor activity;Sugar 
bindingLow-density lipoprotein receptor 
activity;Extrinsic to plasma membrane;
83 N M _008808 Pdgfa Platelet derived 
growth factor, alpha
Cell proliferation;Cell growth and/or 
maintenance;Regulation of cell 
cycle; Mem bra ne; Extracell ula r 
space;Organogenesis;Growth factor 
activity;Regulation of peptidyl-tyrosine 
phosphorylation,Actin cytoskeleton organization 
and biogenesis;Cell projection biogenesis;
84 N M _011057 Pdgfb Platelet derived 
growth factor, B 
polypeptide
Cell proliferation;Cell growth and/or 
maintenance;Regulation of cell 
cycle;Membrane;Extracellular space.Growth factor 
activity;Substrate-bound cell migration;Regulation 
of peptidyl-tyrosine phosphorylation,Actin 
cytoskeleton organization and biogenesis;Cell 
projection biogenesis;
85 N M _008809 Pdgfrb Platelet derived 
growth factor 
receptor, beta 
polypeptide
ATP bindingTransferase activity;Protein amino acid 
phosphorylation;Integral to membrane;Signal 
transduction;Protein serine/threonine kinase 
activity;Protein-tyrosine kinase activity;Signal 
transducer activity;Receptor 
activity;Transmembrane receptor protein tyrosine 
kinase activity;Membrane;Protein kinase 
activity; Extracel 1 ula r space;T ra nsmembrane 
receptor protein tyrosine kinase signaling 
pathway;Kinase activity;Vascular endothelial growth 
factor receptor activity;Regulation of peptidyl- 
tyrosine phosphorylation;
86 N M _011144 Ppara Peroxisome 
prol iterator 
activated receptor 
alpha
DNA bindingRegulation of transcription, DNA- 
dependent,Nucleus;Transcription factor 
activity;Receptor activity,Glucose 
metabolism;Steroid hormone receptor activity; Li pid 
metabolism;Epidermis development; Ligand- 
dependent nuclear receptor activity;Fatty acid 
metabolism;Regulation of fatty acid metabolism;
87 N M _011145 Ppard Peroxisome 
proliferator activator 
receptor delta
Cell proliferation;DNA bindingRegulation of 
transcription, DNA-dependent;Nucleus;Cell growth 
and/or maintenance;Transcription factor 
activity;Negative regulation of transcription from Pol 
II promoter, Receptor activity,Steroid hormone 
receptor activity; Li pid metabolism; Epidermis 
development;Ligand-dependent nuclear receptor 
activity;Transcriptional repressor activity;Nerve 
ensheathment;
88 N M _011146 Pparg Peroxisome 
proliferator 
activated receptor 
gamma
DNA bindingRegulation of transcription, DNA- 
dependent; N ucleus;T ra nscri ption factor 
activity; 1 nf la m matory
response;Cytosol;Transcriptional activator 
activity;Receptor activity;Regulation of 
transcription;Steroid hormone receptor 
activity.Adipocyte differentiation;Ligand-dependent 
nuclear receptor activity;
89 N M _008969 Ptgsl Prostaglandin- 
endoperoxide 
synthase 1
Cytoplasm;Oxidoreductase activity; Peroxidase 
activity;Membrane;Extracellular
3 1 2
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space;Microsome;Oxidoreductase activity, acting on 
single donors with incorporation of molecular 
oxygen, incorporation of two atoms of 
oxygen;Prostaglandin-endoperoxide synthase 
activity;Prostaglandin biosynthesis;Regulation of 
blood pressure;NOT nucleus;
90 N M _011198 Ptgs2 Prostaglandin- 
endoperoxide 
synthase 2
Cytoplasm;Oxidoreductase activity; Peroxidase 
activity;Membrane;Extracellular 
space;Oxidoreductase activity, acting on single 
donors with incorporation of molecular oxygen, 
incorporation of two atoms of oxygen;Prostaglandin- 
endoperoxide synthase activity;Prostaglandin 
biosynthesis;Regulation of blood pressure;NOT 
nucleus;
91 N M _011305 Rxra Retinoid X receptor 
alpha
DNA bindingRegulation of transcription, DNA- 
dependent; N ucleus;Tra nscri ption factor 
activity;Receptor activity;Steroid hormone receptor 
activity;Ligand-dependent nuclear receptor 
activity;Steroid binding
92 N M _016741 Scarbl Scavenger receptor 
class B, member 1
Integral to membrane;Cell adhesion;Receptor 
activity;Membrane;
93 N M _011345 Sele Selectin, endothelial 
cell
Integral to membrane;Cell adhesion;Protein 
bindingMembrane;Extracellular space;Sugar 
bindingHeterophilic cell adhesion;
94 N M _011346 Sell Selectin, lymphocyte Integral to membrane;Cell adhesion,Protein 
binding Membrane; Extracellular space;Defense 
response;Sugar bindingHeterophilic cell 
adhesion;External side of plasma membrane;
95 N M _011347 Selp Selectin, platelet Integral to membrane;Cell adhesion;Protein 
bindinglnflammatory
response;Membrane; Extracellular space;Sugar 
binding
96 N M _009151 Selpl Selectin, platelet (p- 
selectin) ligand
Integral to membrane;Cell adhesion;Protein 
bindingExtracellular space;Sugar binding
97 N M _011111 Serpinb2 Serine (or cysteine) 
proteinase inhibitor, 
clade B, member 2
Serine-type endopeptidase inhibitor 
activity;Plasminogen activator activity;
98 N M _008871 Serpinel Serine (or cysteine) 
proteinase inhibitor, 
clade E, member 1
Protein bindingExtracellular space;Serine-type 
endopeptidase inhibitor activity;Plasminogen 
activator activity;Regulation of angiogenesis;
99 N M _009223 Snn Stannin Integral to membrane;Molecular_function 
unknown; Biological_process unknown;
100 N M _146064 Soat2 Sterol 0-
acyltransferase 2
Transferase activity;!ntegral to 
membrane;Endoplasmic reticulum;Cholesterol 
metabolism;Acyltransferase activity;Protein 
prenyltransferase activity;Protein amino acid 
prenylation;
101 XM _128337 Sodl Superoxide 
dismutase 1, 
soluble
Cytoplasm;Oxidoreductase activity;Response to 
oxidative stress;Mitochondrion;Antioxidant 
activity;Copper, zinc superoxide dismutase 
activity;Metal ion bindingSuperoxide 
metabolism;Removal of superoxide
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radicals;Activation o f MAPK;DNA fragmentation;
102 NM _013671 Sod 2 Superoxide 
dismutase 2, 
mitochondrial
Oxidoreductase activity;Mitochondrion;Metal ion 
bindingSuperoxide metabolism;Manganese ion 
binding Manganese superoxide dismutase 
activity;Superoxide dism utase activity;
103 N M _009263 S ppl Secreted
phosphoprotein 1
Cell adhesion;Protein bindingExtracellular 
space;Cytokine activity; Ossification;
104 N M _011577 Tgfbl Transforming growth 
factor, beta 1
Protein amino acid phosphorylation;Cell 
proliferation; Protein b inding Negative regulation of 
cell proliferation;Regulation of cell 
cycle;lnflammatory response;Extracellular 
matrix;Extracellular space;Organogenesis;Growth 
factor activity;Skeletal development;Defense 
response;Regulation o f cell 
proliferation;Necrosis;Transforminggrowth factor 
beta receptor signaling pathway;Transforming 
growth factor beta receptor bindingCell 
growth;Lymph gland
development; Growth; Myogenesis; Regu lation of 
myogpnesis;Regulation o f protein-nucleus import;
105 NM _009367 Tgfb2 T ra nsformi ng growth 
factor, beta 2
Cell proliferation;Regulation of cell 
cycle;Extracellular space;Growth factor 
activity;Transforming growth factor beta receptor 
bindingCell growth;Growth;Extracellular matrix 
organization and biogenesis;
106 N M _009368 Tgfb3 Transforming growth 
factor, beta 3
Cell proliferation;Negative regulation of cell 
proliferation; Regu lation o f cell cycle;Extracellular 
space;0rganogenesis;Growth factor 
activity;Transforming growth factor beta receptor 
bindingCell growth;Growth;Embryonic development 
(sensu Mammalia);Embryonic morphogenesis;
107 NM _011582 Thbs4 Thrombospondin 4 Calcium ion bindingStructural molecule activity;Cell 
adhesion;Extracellular;Protein bindingExtracellular 
space;
108 N M _011607 Tnc Tenascin C Extracellular space;
109 NM _013693 Tnf Tumor necrosis 
factor
Plasma membrane;Cell proliferation;lmmune 
response;Cell growth a n d /o r maintenance;Humoral 
immune response;Inflammatory response;Positive 
regulation of cell proliferation;lnduction of 
apoptosis via death dom ain receptors;Signal 
transducer activity; Developm ent Positive regulation 
of 1-kappaB kinase/NF-kappaB cascade;Integral to 
plasma membrane;Organogenesis;Tumor necrosis 
factor receptor b ind ing  Defense response;Secretory 
granule;Regulation o f cell proliferation;Cytokine and 
chemokine mediated signaling pathway;Cellular 
defense response;Lymph gland 
development,Cellu 1 ar extravasation; Positive 
regulation of osteoclast differentiation;Programmed 
cell death, transformed cells;Regulation of 
osteoclast differentiation;
110 N M _009397 Tnfaip3 Tumor necrosis 
factor, alpha- 
induced protein 3
Hydrolase activity;DNA bindingNucleus;Protein 
bindingCytoplasm;Apoptosis;Zinc ion
314
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binding Cysteine-type peptidase activity;
111 NM 0 0 7 9 8 7 Fas Fas (TNF receptor 
superfamily 
member)
Integral to membrane;Sigpal transduction;Immune 
response;Apoptosis;Induction of apoptosis via 
death domain receptors;Receptor 
activity;Membrane;Transmembrane receptor 
activity;Programmed cell death, transformed 
cel Is; Programmed cell death, inflammatory 
cells;External side of plasma 
membrane;Programmed cell death, activated T- 
cells;
112 N M _011693 Vcam l Vascular cell 
adhesion molecule 
1
Plasma membrane;lntegral to membrane;Cell 
adhesion;Protein bindingMembrane;Cell-cell 
adhesion;Extracellular space;
113 N M _009505 Vegfa Vascular endothelial 
growth factor A
Cell proliferation;Cell growth and/or 
maintenance;Anti-apoptosis;Regulation of cell 
cycle; Mesoderm
development;Membrane;Extracellular 
space;Heparin bindingGrowth factor 
activity.Angiogenesis;
114 N M _011708 Vwf Von Willebrand 
factor homolog
Cell adhesion;Protein bindingExtracellular 
space; Hemostasis; Blood coagulation;Extracellular 
matrix (sensu Metazoa);
115 L08752 PUC18 PUC18 Plasmid DNA
116
117
118 SA_00005 AS1R2 Artificial Sequence 1 
Related 2 (80%  
identity)(48/60)
119 SA_00004 AS1R1 Artificial Sequence 1 
Related 1 (90%  
identity)(5 4 /6 0 )
120 SA 0 0 0 0 3 AS1 Artificial Sequence 1
121 N M _024277 Rps27a Ribosomal protein 
S27a
lntracellular;Protein biosynthesis;Ribosome;
122 N M _009735 B2m Beta-2 microglobulin Plasma membrane;Integral to plasma 
membrane;Extracellular space;Defense 
response;Cellular defense response;Antigen 
processing endogenous antigen via MHC class 
l;MHC class 1 receptor activity;Antigen presentation, 
endogenous antigen;
123 N M _008302 Hspcb Heat shock protein 
1, beta
ATP bindingProtein
bindingMitochondrion;Response to heafProtein 
foldingUnfolded protein binding Response to 
unfolded protein;ATP bindingProtein 
bindingMitochondrion;Response to heat;Protein 
foldingUnfolded protein binding Response to 
unfolded protein;
124 N M _008302 Hspcb Heat shock protein 
1, beta
ATP bindingProtein
bindingMitochondrion;Response to heat;Protein
folding Unfolded protein binding Response to 
unfolded protein;ATP bindingProtein 
bindingMitochondrion;Response to heafProtein 
folding Unfolded protein binding Response to 
unfolded protein;
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125 N M _008907 Ppia Peptidyl prolyl 
isomerase A
Cytosol;Protein foldinglsomerase activity; Peptidyl- 
prolyl cis-trans isomerase activity;Cytosol;Protein 
folding Isomerase activity;Peptidyl-prolyl cis-trans 
isomerase activity;
126 N M _008907 Ppia Peptidyl prolyl 
isomerase A
Cytosol; Protein foldinglsomerase activity; Peptidyl- 
prolyl cis-trans isomerase activity;Cytosol;Protein 
foldinglsomerase activity;Peptidyl-prolyl cis-trans 
isomerase activity;
127 SA_00007 BAS2C Biotinylated Artificial 
Sequence 2 
Complementary 
sequence
128 SA_00007 BAS2C Biotinylated Artificial 
Sequence 2 
Complementary 
sequence
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Appendix
APPENDIX VI
Sequence of region upstream of the transcriptional start site for murine IP-10,
Mig, l-TAC and CCR2 genes.
IFN-y-responsiveness for the IP-10 and Mig promoters has been mapped to the sequences 
shown (Ohmori and Hamilton 1992, Wright and Farber 1991). Putative GAS elements are 
ISREs are highlighted.
IP-10 promoter (mouse)
[-369]caaatgtaaaaaccatggttagaacctgacttagatatcagctctgtgttttatttatgagagaaggaagatga
gaattaaagccatttccagacttattctgcaaggcactcatctgaf-2501tttctcaaa[GAS1cagctcacgcttt
[-228]|ggaaagtgaaaccl[ISRE]tacctcactcgttaaaaattaaaaggagcacaagaggggagagggaaattccaagt
tcatgggtcacaataaacacaagcaatgccctcggtttacaggggacttccctcgggttgcggagccttgctgagtcatctccaaagt
cagccaatcaggactcagggagggaaactctttgcagataaatactcctcagcagccggcactcgag[-l]aagcgcttc
Mig promoter (mouse)
[-358]Agctttgacttgtgaggaaaggcagtttgagtcgccatatagtgtcatgtcccacgtgggaagtacatctcc
Aaccttcattgtacagcattaatatagtcattgtataatctattccacatccaggtagcaactttgcctggggg
[-212]|tggtttcacatccc[ISRE]^H m M H B iJ ic tc cccgtttatgtgaaatggaagtagaacatgca
gaaattccctgggatctgagagtagggttttccccaggacgatcaatttgtggttagtttagttcttctaggtcagctgaggagaccag
ccaatcagagacgggaaggaaaagggatttcctaaataaatatgatccccaagaacatgctctc[-l]taaagacattct
ITAC promoter (mouse)
[-396]gaaattggaaggaaaaaaaaaagtaaagatagatgaaggtcacctggtatgtataatatatgccttatccatatat
gtgtggttatgtgagggaggcaggatgagctgcctggaactgggaccatcttcctgagttggtgggactctgcccagaatccctaca
caatcaaagca[-222]tttctaggaaIGAS]aagccacctgctgagcagctgctgagtgctttcaccttccagtggcttc
ttaactccacagaggggacagtcacagcgctgacttaaggacaaaagagaaactccaggaggcaagaaagctacgtgagtca
aggaggggaattcctgatactgcctgaagattgctggtctataaatgctcctcagactcctcaggttcagccttcctgcct[-l]
CCR2 promoter (mouse)
[-552]Taagcatataggagagtaaaaatcctgagatcagctgatataattcagataaaaatctgaattagaagaattttga
agcaagaataaaaagaaaaaaaggcaaaagttggcaaaagccaaatacagtgccttgaggttttatgaagtttgcagggatat
gtcacagaaatattaataagcagccacgtaggtgtc|^HBMfiHlBM^8ctaaaagcaatatttttaagatttatc
tgtttttttattttgtgtaagtatctgtgccttaagtcacatatagtttatgtgacttaagtgtgtgcaggtgccaatggagttcaaaaagt
gatagatccactaaaactggaattacaggtggttatgagctccctgctgtgggtataggaaatcaacttgggttctatgcaagaaa
agtaagtgcctttgacccctgagccatctctaatcccttcaaaagagttttaaatgggggaaattcatgctcaatgaaaagaatttg
gaatgacattaaggtatttgaacattaaattaacattgcaaccttatcaaaagtg[-l]tgagtgagagcaagggg
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